

Please type a plus (+) inside this box → ☐

PTO/SB/29 (12/97)

Approved for use through 09/30/00. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. 8535-027-999 Total Pages 197

First Named Inventor or Application Identifier

Michael Nehls

Express Mail Label No. EL 452 479 937

APPLICATION ELEMENTS
See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. ☒ Fee Transmittal Form
Submit an original, and a duplicate for fee processing)
2. ☒ Specification [Total Pages 84]
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R&D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings *(if filed)*
 - Detailed Description of the Invention (including drawings, *if filed*)
 - Claim(s)
 - Abstract of the Disclosure
- ☒ Drawing(s) (35 USC 113) [Total Sheets 1]
- ☒ Oath or Declaration (unexecuted) [Total Sheets 2]
 - a. ☐ Newly executed (original or copy)
 - b. ☐ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)
[Note Box 5 below]
 - i. ☐ DELETION OF INVENTORS(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33 (b).
- ☐ Incorporation By Reference *(useable if Box 4b is checked)*
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

6. ☐ Microfiche Computer Program *(Appendix)*
7. ☒ Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
 - a. ☐ Computer Readable Copy
 - b. ☒ Paper Copy (109 pages)
 - c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)
10. ☐ English Translation Document *(if applicable)*
11. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
14. ☐ Small Entity Statement filed in prior application, Statement(s) Status still proper and desired
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☐ Other:

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:

☐ Continuation ☐ Divisional ☒ Continuation-in-part (CIP) of prior application No: 60/104,292 filed 10/14/98.

18. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label 20583
(Insert Customer No. or Attach bar code label here) or ☐ Correspondence address below

NAME					
ADDRESS					
CITY	STATE	ZIP CODE			
COUNTRY	TELEPHONE	FAX			

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

**NOVEL HUMAN POLYNUCLEOTIDES AND THE
POLYPEPTIDES ENCODED THEREBY**

This application claims priority to United States Provisional Application No.
5 60/104,292, filed October 14, 1998, which is also incorporated herein by reference for any
purpose.

1. FIELD OF THE INVENTION

The present invention is in the field of molecular genetics. The application discloses
10 novel nucleic acid sequences that partially define the scope of human exons that can be
trapped and identified by the disclosed vectors/methods, and which are useful, *inter alia*, for
identifying the organization of the coding regions and of the human genome.

2. BACKGROUND OF THE INVENTION

15 The Human Genome Project and privately financed ventures are currently sequencing
the human genome, and the substantial completion of this milestone is expected before the
year 2003. The hope is that, at the conclusion of the sequencing phase, a comprehensive
representation of the human genome will be available for biomedical analysis. However, the
data resulting from such efforts will largely comprise human genomic sequence of which
20 only a fraction actually encodes expressed sequence information. Although sophisticated
computer-assisted exon identification programs can be applied to such genomic sequence
data, the computer predictions require verification by laboratory analysis to actually identify
the coding regions of the genome. Consequently, the availability of cDNA information will
significantly contribute to the value of the human genomic sequence since cDNA sequence
25 provides a direct indication of the presence of transcribed sequences as well as the location of
splice junctions. Thus, the sequencing of cDNA libraries to obtain expressed sequence tags
(or ESTs) that identify exons expressed within a given tissue, cell, or cell line is currently in
progress. As a consequence of these efforts, a large number of EST sequences are presently
compiled in public and privately held databases. However, the present EST paradigm is
30 inherently limited by the levels and extent of mRNA production within a given cell. A
related problem is the lack of cDNA sources from specific tissue and developmental

expression profiles. In addition, some genes are typically only active under certain physiological conditions or are generally expressed at levels below or near the threshold necessary for cDNA cloning and detection and are therefore not effectively represented in current cDNA libraries.

5 Researchers have partially addressed these issues by using phage vectors to clone genomic sequences such that internal exons are trapped (Nehls, *et al.*, 1994, *Current Biology*, 4(1):983-989, and Nehls, *et al.*, 1994, *Oncogene*, 9:2169-2175). However, such libraries require the random cloning of genomic DNA into a suitable cloning vector *in vitro*, followed by reintroduction of the cloned DNA *in vivo* in order to express and splice the cloned genes
10 prior to producing the cDNA library. Additionally, such methods can only "trap" the internal exons of genes. Consequently, genes containing a single exon or a single intron are typically not trapped by traditional methods of exon trapping.

3. SUMMARY OF THE INVENTION

15 The subject invention provides numerous isolated and purified novel human cDNAs produced using gene trap technology. The novel human gene trapped sequences (GTSs) of the subject invention are disclosed as SEQ ID NOS:9-503 in the appended Sequence Listing.

The subject invention further contemplates the use of one or more of the subject GTSs, or portions thereof, to isolate cDNAs, genomic clones, or full-length
20 genes/polynucleotides, or homologs, heterologs, paralogs, or orthologs thereof, that are capable of hybridizing to one or more of the disclosed GTSs or their complementary sequences under stringent conditions.

The subject invention additionally contemplates methods of analyzing biopolymer (*e.g.*, oligonucleotides, polynucleotides, oligopeptides, peptides, polypeptides, proteins, etc.)
25 sequence information comprising the steps of loading a first biopolymer sequence into or onto an electronic data storage medium (*e.g.*, digital or analogue versions of electronic, magnetic, or optical memory, and the like) and comparing said first sequence to at least a portion of one of the polynucleotide sequences, or amino acid sequence encoded thereby, that is first disclosed in, or otherwise unique to, SEQ ID NOS:9-503. Typically, the
30 polynucleotide sequences, or amino acid sequences encoded thereby, will also be present on,

or loaded into or onto a form of electronic data storage medium, or transferred therefrom, concurrent with or prior to comparison with the first polynucleotide.

Another embodiment of the invention is the use of an oligonucleotide or polynucleotide sequence first disclosed in at least a portion of at least one of the GTS sequences of SEQ ID NOS:9-503 as a hybridization probe. Of particular interest is the use of such sequences in conjunction with a solid support matrix/substrate (resins, beads, membranes, plastics, polymers, metal or metallized substrates, crystalline or polycrystalline substrates, etc.). Of particular note are spatially addressable arrays (*i.e.*, gene chips, microtiter plates, etc.) of polynucleotides wherein at least one of the polynucleotides on the spatially addressable array comprises an oligonucleotide or polynucleotide sequence first disclosed in at least one of the GTS sequences of SEQ ID NOS:9-503.

Similarly, one or more oligonucleotide probes based on, or otherwise incorporating, sequences first disclosed in any one of SEQ ID NOS:9-503, can be used in methods of obtaining novel gene sequence via the polymerase chain reaction or by cycle sequencing. Similar oligonucleotide hybridization probes can also comprise sequence that is complementary to a portion of a sequence that is first disclosed in, or preferably unique to, at least one of the GTS polynucleotides in the sequence listing. The oligonucleotide probes will generally comprise between about 8 nucleotides and about 80 nucleotides, preferably between about 15 and about 40 nucleotides, and more preferably between about 20 and about 35 nucleotides.

Moreover, an oligonucleotide or polynucleotide sequence first disclosed in at least one of the GTS sequences of SEQ ID NOS:9-503 can be incorporated into a phage display system that can be used to screen for proteins, or other ligands, that are capable of binding an amino acid sequence encoded by an oligonucleotide or polynucleotide sequence first disclosed in at least one of the GTS sequences of SEQ ID NOS:9-503.

An additional embodiment of the present invention is a library comprising individually isolated linear DNA molecules corresponding to at least a portion of the described human GTSS which are useful for synthesizing physically contiguous sequences of overlapping GTSS by, for example, the polymerase chain reaction (PCR).

The subject invention also provides for an antisense molecule which comprises at least a portion of sequence that is first disclosed in, or preferably unique to, at least one of the GTS polynucleotides.

The subject invention also contemplates a purified polypeptide in which at least a portion of the polypeptide is encoded by, and thus first disclosed by, at least a portion of a GTS of the present invention. The invention also relates to naturally occurring polynucleotides comprising the disclosed GTSs that are expressed by promoter elements other than the promoter elements that normally express the GTSs in human cells (*i.e.*, gene activated GTSs). Such promoter elements can be directly incorporated into the cellular genome or recombinantly engineered upstream from at least a portion of a GTS (preferably at least about 50, more preferably at least about 75, and most preferably at least about 100 to 130 base in length) of the present invention, or a complement thereof. A particularly preferred embodiment includes recombinantly engineered expression vectors that similarly have or incorporate at least a, preferably unique, portion of the disclosed GTSs or complement thereof.

4. DESCRIPTION OF THE SEQUENCE LISTING AND FIGURES

The Sequence Listing is a compilation of nucleotide sequences obtained by sequencing a human gene trap library that at least partially identifies the genes in the target cell genome that can be trapped by the described gene trap vectors (*i.e.*, the repertoire of genes that are active or have not been inactivated).

Figures 1A-1D. Figure 1A illustrates a retroviral vector that can be used to practice the described invention. Figure 1B shows a schematic of how a typical cellular genomic locus is effected by the integration of the retroviral construct into intronic sequences of the cellular gene. Figure 1C shows the chimeric transcripts produced by the gene trap event as well as the locations of the binding sites for PCR primers. Figure 1D shows how the PCR amplified cDNAs are directionally cloned into a suitable GTS vector.

5. DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to novel human polynucleotide sequences obtained from cDNA libraries generated by the normalized expression of genomic exons using gene trap technology. In particular, the disclosed novel polynucleotides were generated using a modified reverse-orientation retroviral gene trap vector that was nonspecifically integrated into the target cell genome, although other polynucleotide (DNA or RNA) gene trap vectors could have been introduced to the target cells by, for example, transfection, electroporation, or retrotransposition. Preferred retroviral vectors that can be used to practice the present invention (as well as methods and recombinant tools for making and using the described GTSSs) are disclosed in, *inter alia*, U.S. Application Ser. No. 09/276,533, filed March 25, 1999 which is herein incorporated by reference in its entirety.

After integration, the exogenous promoter of the sequence acquisition, or 3' gene trap, component of the vector was used to express and splice a chimeric mRNA that was subsequently reverse transcribed, amplified, and subject to DNA sequence analysis. Unlike conventional cDNA libraries, the presently disclosed libraries are largely unaffected by the bias inherent in cDNA libraries that rely solely on endogenous mRNA expression. Additionally, by integrating a vector into the target cell genes, a chimeric mRNA is produced that allows for the specific expansion and isolation of cDNAs corresponding to the chimeric mRNAs using vector specific primers.

As used herein the term "gene trapped sequence", or "GTS", refers to nucleotide sequences that correspond to naturally occurring endogenously encoded human exons that have been expressed as part of a chimeric "gene trapped" mRNA. Typically, the chimeric mRNA incorporates at least a portion of sequence that has been engineered into the sequence acquisition exon of a gene trap vector which, *inter alia*, facilitates cDNA production by reverse transcriptase and amplification of the cDNA by PCR to produce an isolated linear DNA molecule. The disclosed GTSSs do not include vector encoded sequences.

The term "GTS" not only refers to polynucleotides that are exactly complementary to naturally occurring human mRNA, but also refers to "GTS derivatives". The term "GTS derivative" also refers to heterologs, paralogs, orthologs, and allelic variants of the specific

GTSs described herein. In addition, a GTS may include the complete coding region for a naturally occurring peptide or polypeptide. A GTS may also include a complete open reading frame.

The term "GTS peptide" as used herein includes oligopeptides or polypeptides sharing biological activity and/or immunogenicity (or immunological cross-reactivity) with an amino acid sequence encoded by at least one of the disclosed GTSs or complement thereof. The terms "biological activity" (or "biological characteristics") of a polypeptide refers to the structural or biochemical function of the polypeptide in the normal biological processes of the organism in which the polypeptide naturally occurs. Examples of such characteristics include protein structure and/or conformation, which can be determined biochemically by reaction with appropriate ligands or receptors or by suitable biological assays.

A GTS peptide may also correspond to a full-length naturally occurring peptide or polypeptide. GTS peptides can have amino acid sequences that directly correspond to naturally occurring polypeptides or amino acid sequences or can comprise minor variations. Such variations can include amino acid substitutions that are the result of the replacement of one amino acid with another amino acid having a similar structural and/or chemical properties, such as the substitution of a leucine with an isoleucine or valine, an aspartate with a glutamate, or a threonine with a serine, *i.e.*, conservative amino acid replacements. Additional variations include minor amino acid deletions and/or insertions, typically in the range of about 1 to 6 amino acids, and can also include one or more amino acid substitutions. Guidance in determining which GTS peptide amino acid residues can be replaced or deleted without abolishing the biological activity of interest may be determined empirically, or by using computer amino acid sequence databases to identify polypeptides that are homologous to a given GTS peptide and trying to avoid amino acid substitutions in conserved regions of homology.

"Homology" refers to the similarity or the degree of similarity between a reference, or known polynucleotide and/or polypeptide and a test nucleotide sequence and/or its corresponding amino acid sequence. As used herein, "homology" is defined by sequence similarity between a reference sequence and at least a portion of the newly sequenced

nucleotide. Typically, a corresponding amino acid sequence similarity should exist between the peptides encoded by such homologous sequences.

To determine whether proteins are homologous, the GTS sequence is translated into the corresponding amino acid sequence. The amino acid sequence is then compared with reference polypeptide sequences. A short string of matching amino acid sequence can constitute good evidence of homology (for example, repeating Gly-Pro-X sequence, or the presence of an RGD motif). However, typically a larger number of similar amino acids is required to label two sequences homologous. Generally, the match needs to be at least about 7 or 8 amino acids, among which perhaps one mismatch is allowed. These criteria allow good sensitivity in finding all relevant sequences while providing a threshold amount of selectivity.

After peptide homology has been found, the respective nucleotide sequences are compared. An alignment of the reference and new sequences should show at least about 60%, and preferably at least about 65%, agreement over the minimum of 21 nucleotides which correspond to the 6 matching amino acids. Generally, a low percentage of agreement is acceptable if the differences are in the "wobble" position (or third nucleotide of the triplet coding for an amino acid).

As used herein, a "mutated" polypeptide has an altered primary structure typically resulting from corresponding mutations in the nucleotide sequence encoding the protein or polypeptide. As such, the term "mutated" polypeptides can include allelic variants. Mutational changes in the primary structure of a polypeptide result from deletions, additions or substitutions. A "deletion" is defined as a change in a polypeptide sequence in which one or more internal amino acid residues are absent. An "addition" is defined as a change in a polypeptide sequence which has resulted in one or more additional internal amino acid residues as compared to the wild type. A "substitution" results from the replacement of one or more amino acid residues by other residues. A polypeptide "fragment" is a polypeptide consisting of a primary amino acid sequence which is identical to a portion of the primary sequence of the polypeptide to which the polypeptide is related.

A host cell "expresses" a gene or DNA when the gene or DNA is transcribed into RNA that may optionally be translated to produce a polypeptide.

The subject invention also includes GTSs which are incorporated into expression vectors and transformed into host cells which subsequently express the polynucleotides and/or polypeptides encoded by the GTSs.

5 The subject invention also includes antibodies capable of specifically binding to GTS peptides, as well as methods of detecting a GTS peptides or the corresponding protein by combining a sample for analysis with an antibody capable of specifically binding to a GTS peptide and detecting the formation of antibody complexes present in the sample.

10 The subject invention also includes a method of isolating a GTS peptide, or its corresponding protein comprising the step of separating the GTS peptide, or its corresponding protein, from a solution utilizing an antibody capable of specifically binding to the GTS peptide or its corresponding protein.

The subject invention also provides for markers for use in detecting diseases, biological events, cell types and tissues which comprise at least a portion of a GTS sequence.

15 Further, the subject invention provides polynucleotide markers useful for physical and genetic mapping of the human, and/or certain model organism, genome(s). In particular, the nucleotide sequences in the Sequence Listing provide sequence tagged sites (STS), that will be useful in completing an STS-based physical map of the human genome, a goal of the human genome project (Collins, F. and Galas, D. (1993) Science 262:43-46). Additionally, some of these sequences will identify new genes. These new genes will be useful in
20 completing physical and genetic maps of all the genes in the human genome, another goal of the human genome project.

25 The exons contained in the disclosed GTSs contain open reading frames (present in one of the three reading frames in either orientation of the sequence). Typically, the gene trap strategy employed to generate the GTS sequences allows for the directional cloning and identification of the sense strand. However, it is possible that occasional sequencing errors or random reverse transcription, or PCR aberrations will mask the presence of the appropriate open reading frame. In such cases of sequencing error, it is possible to determine the corresponding GTS sequence by expressing the GTS in an appropriate expression system and determining the amino acid sequence by standard peptide mapping and sequencing
30 techniques (Current Protocols in Molecular Biology, John Wiley & Sons, Vol. 2, Sec 16,

1989). Additionally, the actual reading frame and amino acid sequence of a given nucleotide sequence may be determined by *in vitro* synthesis of a portion of an oligopeptide comprising a possible amino acid sequence and preparing antibodies to the oligopeptide. If the antibodies react with cells from which the GTS of interest was derived, the reading frame is likely correct. Alternatively, codon usage analysis can be used to track and correct reading frame shifts in gene sequence data.

The correct amino acid sequence of a GTS protein is largely a function of the DNA sequence and the correct amino acid sequence can be readily determined using routine techniques. For example, by providing independent three fold sequencing coverage of the GTS library, random sequencing/RT/PCR errors can be identified and corrected by selecting the sequence represented by the majority of gene trap sequences covering a given nucleotide.

The nucleotide sequences of the Sequence Listing may contain some sequencing errors and several of the nucleotide sequences of the Sequence Listing may contain nucleotides that have not been precisely identified, typically designated by an N, rather than A, T, C, or G. Since each of the nucleotide sequences presented in the Sequence Listing is believed to uniquely identify a novel GTS, any sequencing errors or N's in the nucleotide sequences of the Sequence Listing do not present a problem in practicing the subject invention. Several methods employing standard recombinant methodology, for example, as described in Molecular Cloning: Laboratory Manual 2nd ed., Sambrook *et al.* (1989), Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (or periodic updates thereof), may be used to correct errors and complete the missing sequence information. For example, a nucleotide and/or oligonucleotide corresponding to a portion of a nucleotide sequence of GTS of interest, can be chemically or biochemically synthesized *in vitro*, and used as a hybridization probe to screen a cDNA library in order to identify and obtain library isolates comprising recombinant DNA sequences containing the GTS cDNA sequence of interest. The library isolate may then be independently subjected to nucleotide sequencing using one or more standard sequencing procedures so as to obtain a complete and accurate nucleotide sequence.

For the purposes of this disclosure, the term "isolated and purified polynucleotide" comprises a polynucleotide purified from a natural cell or tissue as well as polynucleotides

which are complementary to the polynucleotides isolated from the natural cell or tissue. One example of an isolated or purified polynucleotide, or a substantially isolated preparation thereof, is a preparation where the polynucleotide of interest represents at least about 80 percent, preferably at least about 85 percent, and more preferably at least about 90 to 95 percent or more of the net product(s) that can be visualized on a DNA agarose gel stained with ethidium bromide.

The described GTSSs were obtained from isolates of a cDNA library. Clones isolated from cDNA libraries generated by 3' gene trapping typically contain only a portion of the mature RNA transcript that has been spliced to a vector encoded sequence acquisition exon, and therefore such clones may only encode a portion of the polypeptide of interest (however, it should be appreciated that a number of the disclosed GTSSs may encode full-length ORFs). To obtain the remainder of the sequence, the GTSSs can be used as hybridization probes to re-screen the same or a different cDNA library, and additional clones isolated by the re-screening can be purified and characterized using standard methods (Benton and Davis, 1977, Science, 196:180-183). Once sufficiently purified, the size of the DNA insert can be approximated by agarose gel electrophoresis and the larger clones can be analyzed to determine the exact number of bases by DNA sequencing. Frequently, the use of a library different from the one which contained the original clone is useful for this purpose, and particularly a library that has been prepared with extra care to extend cDNA synthesis to full-length, or a library that has been intentionally primed with random primers in order to "jump over" particularly difficult regions of the transcript sequence.

Missing upstream DNA sequence can also be obtained by "primer extension" of the cDNA isolate, a practice common in the art (Sambrook *et al.* (1989), Molecular Cloning: Laboratory Manual 2nd ed. pg 7.79-7.83, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY), whereby a sequence-specific oligonucleotide is used to prime reverse-transcription near the 5'-end of the cDNA clone and the resulting product is either cloned into a bacterial vector or is analyzed directly by DNA sequencing. Finally, newer methods to extend clones in either direction employ oligonucleotide-directed thermocyclic DNA amplification of the missing sequences, wherein a combination of a cDNA-specific primer and a degenerate, vector-specific, or oligo-dT-binding second oligonucleotide can be used to

prime strand synthesis. In any of the above methods or other methods of detecting additional cDNA sequence, two or more resulting clones containing the partial cDNA sequence can be recombined to form a single full-length cDNA by standard cloning methods. The resulting full-length cDNA may subsequently be transferred into any of a number of appropriate expression vectors.

In many instances, the sequencing of clones resulting from independent nonspecific gene trap events will result in a natural redundancy of sequencing more than one cDNA from a particular gene. As discussed above, this feature is a built in form of error detection and correction. These independent gene trap events can also be combined using the various overlapping regions of sequence into an entire contiguous sequence ("contig") containing the complete nucleotide sequence of the full length cDNA. Similar methodology can be used to combine one or more GTSs with one or more publicly available, or proprietary, ESTs to synthesize, electronically or chemically, a contiguous sequence.

The ABI Assembler application, part of the INHERITS DNA analysis system (Applied Biosystems, Inc., Foster City, CA), creates and manages sequence assembly projects by assembling data from selected sequence fragments into a larger sequence. The Assembler combines two advanced computer technologies which maximize the ability to assemble sequenced DNA fragments into Assemblages, a special grouping of data where the relationships between sequences are shown by graphic overlap, alignment and statistical views. The process is based on the Meyers-Kececioglu model of fragment assembly (INHERITS™ Assembler User's Manual, Applied Biosystems, Inc., Foster City, CA), and uses graph theory as the foundation of a very rigorous multiple sequence alignment program for assembling DNA sequence fragments. Additional methods of using GTSs and obtaining full length versions thereof are discussed in U.S. Patent No. 5,817,479, herein incorporated by reference.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code (see, for example, Table 4-1 at page 109 of "Molecular Cell Biology", 1986, J. Darnell *et al.* eds., Scientific American Books, New York, NY, herein incorporated by reference) a multitude of GTS nucleotide sequences, some bearing minimal nucleotide sequence homology to the nucleotide sequence of genes naturally encoding GTS peptides,

can be produced. The invention has specifically contemplated each and every possible variation of nucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the nucleotide sequence of naturally occurring human GTS

5 nucleotide sequences and all such variations are to be considered as being specifically disclosed. Once the triplet codons are "translated" (which can be done electronically) into their amino acid counterparts, the amino acid sequences encoded by the GTS ORFs effectively represent a generic representation of the various nucleotide sequences that can encode the amino acid sequence (*i.e.*, each amino acid is generic for the various nucleotide
10 codons that correspond to that amino acid).

The presently described novel human GTSs provide unique tools for diagnostic gene expression analysis, for cross species hybridization analysis, for genetic manipulations using a variety of techniques, like, for example, antisense inhibition, gene targeting, the identification or generation of full-length cDNA, mapping exons in the human genome,
15 identifying exon splice junctions, gene therapy, gene delivery, chromosome mapping, etc. Furthermore, the expression-based detection and isolation of the described novel polynucleotides verifies that the genes encoding these sequences have not been inactivated by, for example, the covalent modification (methylation, acetylation, glycosylation, etc.) of the target cell genome, or inhibiting the function of transcriptional control elements. The fact
20 that the genes have not been inactivated in the target cell genome can indicate an involvement in cellular metabolism, catabolism, homeostasis, or any of a wide variety of developmental and cell differentiation processes or the regulation of physiological or endocrine functions in the body, etc. (although treating the target cell with, for example, histone deacetylators can partially compensate for such inactivation and expand the target size of a given trapping
25 construct). These data are especially useful when correlated with cDNA data from differentiated tissues and/or cells or cell lines in order to determine whether the absence of expression is regulated at the level of transcription or gene inactivation.

5.1 POLYNUCLEOTIDES OF THE PRESENT INVENTION

The nucleotide sequences of the various isolated human GTSs of the present invention appear in the Sequence Listing as SEQ ID NOS:9-503. Additional embodiments of the present invention are GTS variants, or homologs, paralogs, orthologs, etc., which include

5 isolated polynucleotides, or complements thereof, that hybridize to one or more of the disclosed GTSs of SEQ ID NOS:9-503 under stringent, or preferably highly stringent, conditions. By way of example and not limitation, high stringency hybridization conditions can be defined as follows: Prehybridization of filters containing DNA to be screened is carried out for 8 h to overnight at 65°C in a buffer containing 6X SSC, 50mM Tris-HCl (pH
10 7.5), 1mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 µg/ml denatured salmon sperm DNA. Filters are hybridized for 48 h at 65°C in prehybridization mixture containing 100µg/ml denatured salmon sperm DNA and 5-20 x 10⁶ cpm of ³²P-labeled probe (alternatively, as in all hybridizations described herein, approximately 42, 44, 46, 48, 50, 52, 54, 56, 58, 62, 64, 66, 68, 70, or about 72 degrees or more can be used). The filters are then
15 washed in approximately 1X wash mix (10X wash mix contains 3M NaCl, 0.6M Tris base, and 0.02M EDTA, alternatively, as with all washes described herein, 2X, 3X, 4X, 5X, 6X wash mix, or more, can be used) twice for 5 minutes each at room temperature, then in 1X wash mix containing 1% SDS at 60°C (alternatively, as in all washes described herein, approximately 42, 44, 46, 48, 50, 52, 54, 56, 58, 62, 64, 66, 68, 70, or about 72 degrees or
20 more can be used) for about 30 min, and finally in 0.3X wash mix (alternatively, as in all final washes described herein, approximately, 0.2X, 0.4X, 0.6X, 0.8X, 1X, or any concentration between about 2X and about 6X can be used in conjunction with a suitable wash temperature) containing 0.1% SDS at 60°C (alternatively, approximately 42, 44, 46, 48, 50, 52, 54, 56, 58, 62, 64, 66, 68, 70, or about 72 degrees or more can be used) for about 30
25 min. The filters are then air dried and exposed to x-ray film for autoradiography. In an alternative protocol, washing of filters is done at 37°C for 1 h in a solution containing 2X SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA. This is followed by a wash in 0.1X SSC at 50°C for 45 min before autoradiography. Another example of hybridization under highly stringent conditions is hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% sodium
30 dodecyl sulfate (SDS), 1 mM EDTA at 65°C, and washing in 0.1xSSC/0.1% SDS at 68°C

(Ausubel F.M. *et al.*, eds., 1989, Current Protocols in Molecular Biology, Vol. I, Green Publishing Associates, Inc., and John Wiley & sons, Inc., New York, at p. 2.10.3).

Preferably, such GTS variants will encode at least a portion or domain of a, preferably naturally occurring, protein or polypeptide that encodes a functional equivalent to a protein or polypeptide, or portion or domain thereof, encoded by the disclosed GTSs. Additional examples of GTS variants include polynucleotides, or complements thereof, that are capable of binding to the disclosed GTSs under less stringent conditions, such as moderately stringent conditions, (*e.g.*, washing in 0.2xSSC/0.1% SDS at 42° C (Ausubel *et al.*, 1989, *supra*).

Moderately stringent conditions can be additionally defined, for example, as follows: Filters containing DNA are pretreated for 6 h at 55°C in a solution containing 6X SSC, 5X Denhart's solution, 0.5% SDS and 100 µg/ml denatured salmon sperm DNA. Hybridizations are carried out in the same solution and 5-20 x 10⁶ cpm ³²P-labeled probe is used. Filters are incubated in hybridization mixture for 18-20 h at 55°C (alternatively, as in all hybridizations described herein, approximately 42, 44, 46, 48, 50, 52, 54, 56, 58, 62, 64, 66, 68, 70, or about 72 degrees or more can be used in combination with a suitable concentration of salt). The filters are then washed in approximately 1X wash mix (10X wash mix contains 3M NaCl, 0.6M Tris base, and 0.02M EDTA, alternatively, as with all washes described herein, 2X, 3X, 4X, 5X, 6X wash mix, or more, can be used) twice for 5 minutes each at room temperature, then in 1X wash mix containing 1% SDS at 60°C (alternatively, as in all washes described herein, approximately, 42, 44, 46, 48, 50, 52, 54, 56, 58, 62, 64, 66, 68, 70, or about 72 degrees or more can be used) for about 30 min, and finally in 0.3X wash mix (alternatively, as in all final washes described herein approximately 0.2X, 0.4X, 0.6X, 0.8X, 1X, or any concentration between about 2X and about 6X can be used in conjunction with a suitable wash temperature) containing 0.1% SDS at 60°C (alternatively, approximately 42, 44, 45, 48, 50, 52, 54, 56, 58, 62, 64, 66, 68, 70, or about 72 degrees or more can be used) for about 30 min. The filters are then air dried and exposed to x-ray film for autoradiography.

In an alternative protocol, washing of filters is done twice for 30 minutes at 60°C in a solution containing 1X SSC and 0.1% SDS. Filters are blotted dry and exposed for autoradiography.

Other conditions of moderate stringency which may be used are well-known in the art.

For example, washing of filters can be done at 37°C for 1 h in a solution containing 2X SSC, 0.1% SDS. Another example of hybridization under moderately stringent conditions is washing in 0.2xSSC/0.1% SDS at 42°C (Ausubel et al., 1989, *supra*). Such less stringent conditions may also be, for example, low stringency hybridization conditions. By way of example and not limitation, procedures using such conditions of low stringency are as follows (see also Shilo and Weinberg, 1981, Proc. Natl. Acad. Sci. USA 78:6789-6792): Filters containing DNA are pretreated for 6 h at 40°C in a solution containing 35% formamide, 5X SSC, 50mM Tris-HCl (pH 7.5), 5mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500 µg/ml denatured salmon sperm DNA. Hybridizations are carried out in the same solution with the following modifications: 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100µg/ml salmon sperm DNA, 10% (wt/vol) dextran sulfate, and 5-20 X 10⁶ cpm ³²P-labeled probe is used. Filters are incubated in hybridization mixture for 18-20 h at 40°C (alternatively, as in all hybridizations described herein, approximately 42, 44, 46, 48, 50, 52, 54, 56, 58, 62, 64, 66, 68, 70, or about 72 degrees or more can be used). The filters are then washed in approximately 1X wash mix (10x wash mix contains 3M NaCl, 0.6M Tris base, and 0.02M EDTA, alternatively, as with all washes described herein, 2X, 3X, 4X, 5X, 6X wash mix, or more, can be used) twice for five minutes each at room temperature, then in 1X wash mix containing 1% SDS at 60°C (alternatively, as in all washes described herein, approximately 42, 44, 46, 48, 50, 52, 54, 56, 58, 62, 64, 66, 68, 70, or about 72 degrees or more can be used) for about 30 min, and finally in 0.3X wash mix (alternatively, as in all final washes described herein, approximately, 0.2X, 0.4X, 0.6X, 0.8X, 1X, or any concentration between about 2X and about 6X can be used in conjunction with a suitable wash temperature) containing 0.1% SDS at 60°C (alternatively, approximately 42, 44, 46, 48, 50, 52, 54, 56, 58, 62, 64, 66, 68, 70, or about 72 degrees or more can be used) for about 30 min. The filters are then air dried and exposed to x-ray film for autoradiography. In yet another alternative protocol, washing of filters is done for 1.5 h at 55°C in a solution containing 2X SSC, 25mM Tris-HCl (pH 7.4), 5mM EDTA, and 0.1% SDS. The wash solution is replaced with fresh solution and incubated an additional 1.5 h at 60°C. Filters are then blotted dry and exposed for autoradiography. If necessary, filters are washed for a third time at 65-68°C and reexposed to film. Other conditions of low stringency which may be used are well known in the art (*e.g.*,

as employed for cross-species hybridizations). Preferably, GTS variants identified or isolated using the above methods will also encode a functionally equivalent gene product (*i.e.*, protein, polypeptide, or domain thereof, encoding or otherwise associated with a function or structure at least partially encoded by the complementary GTS).

5 Additional embodiments contemplated by the present invention include any polynucleotide sequence comprising a continuous stretch of nucleotide sequence originally disclosed in, or otherwise unique to, any of the GTSs of SEQ ID NOS:9-503 that are at least 8, or at least 10, or at least 14, or at least 20, or at least 30, or at least about 40, and preferably at least about 60 consecutive nucleotides up to about several hundred bases of nucleotide
10 sequence or an entire GTS sequence. Functional equivalents of the gene products of SEQ ID NOS:9-503 include naturally occurring variants of SEQ ID NOS:9-503 present in other species, and mutant variants, both naturally occurring and engineered, which retain at least some of the functional activities of the gene products of SEQ ID NOS:9-503.

The invention also includes degenerate variants of the claimed GTS sequences, and
15 products encoded thereby. Such variants may be 80% identical to any one of SEQ ID NOS: 9-503, more preferably 85%, more preferably 90%, more preferably 95% and most preferably 98% identical. The degree of identity (or the degree of homology) of a polynucleotide sequence to any one of SEQ ID NOS: 9-503 may be determined using any sequence analysis program known in the art, for example, the University of Wisconsin GCG sequence analysis
20 package, SEQUENCHER 3.0, Gene Codes Corp., Ann Arbor, MI. The invention further includes GTS derivatives wherein any of the disclosed GTSs, or GTS variants, is linked to another polynucleotide molecule, or a fragment thereof, wherein the link may be either directly or through other polynucleotides of any sequence and of a length of about 1,000 base pairs, or about 500 base pairs, or about 300 base pairs, or about 200 base pairs, or about 150
25 base pairs, or about 100 base pairs or about 50 base pairs, or less.

The invention also particularly includes polynucleotide molecules, including DNA, that hybridize to, and are therefore the complements of, the nucleotide sequences of the disclosed GTSs. Such hybridization conditions may be highly stringent or less highly stringent, as described above. In instances wherein the nucleic acid molecules are
30 deoxyoligonucleotides ("DNA oligos"), highly stringent conditions may refer to, for example,

washing in 6xSSC/0.05% sodium pyrophosphate at 37° C (for oligos having 14-base DNA oligos), 48° C (for 17-base DNA oligos), 55° C (for 20-base DNA oligos), and 60°C (for 23-base oligos). Similar conditions are contemplated for RNA oligos corresponding to a portion of the disclosed GTS sequences.

5 These nucleic acid molecules may encode or act as antisense molecules to polynucleotides comprising at least a portion of the sequences shown in SEQ ID NOS:9-503 that are useful, for example, to regulate the expression of genes comprising a nucleotide sequence of any of SEQ ID NOS:9-503, and can also be used, for example, as antisense primers in amplification reactions of gene sequences. With respect to gene regulation, such techniques can be used to regulate, for example, developmental processes by modulating the expression of genes in embryonic stem cells. Further, such sequences may be used as part of ribozyme and/or triple helix sequences that can be used to regulate gene expression. Still further, such molecules may be used as components of diagnostic methods whereby, for example, the presence of a particular allele, of a gene that contains any of the sequences of SEQ ID NOS:9-503 may be detected. Of particular interest is the use of the disclosed GTSs to conduct analysis of single nucleotide polymorphisms (SNPs), and particularly coding region SNPs or “cSNPs”, in the human genome, or as general or individual-specific forensic markers. When so applied, a collection of GTSs is obtained from an individual, and screened against a control database of cSNPs (or other genetic markers) that have previously been associated with disease, suitability or susceptibility (or sensitivity) to specific drugs or therapies, or virtually any other human trait that correlates with a given cSNP or genetic marker, or assortment thereof. In addition to disease/diagnostic testing, the described GTSs are also useful as genetic markers for the prenatal analysis of congenital traits or defects.

 In addition to the nucleotide sequences described above, full length cDNA or gene sequences that contain any of SEQ ID NOS:9-503 present in the same species and/or homologs of any of those genes present in other species can be identified and isolated by using molecular biological techniques known in the art.

 In order to clone the full length cDNA sequence from any species encoding the cDNA corresponding to the entire messenger RNA or to clone variant or heterologous forms of the molecule, labeled DNA probes made from nucleic acid fragments corresponding to any of the

partial cDNA disclosed herein may be used to screen a cDNA library. For example, oligonucleotides corresponding to either the 5' or 3' terminus of the cDNA sequence may be used to obtain longer nucleotide sequences. Briefly, the library may be plated out to yield a maximum of about 30,000 pfu for each 150 mm plate. Approximately 40 plates may be

5 screened. The plates are incubated at 37° C until the plaques reach a diameter of 0.25 mm or are just beginning to make contact with one another (3-8 hours). Nylon filters are placed onto the soft top agarose and after 60 seconds, the filters are peeled off and floated on a DNA denaturing solution consisting of 0.4N sodium hydroxide. The filters are then immersed in neutralizing solution consisting of 1 M Tris HCl, pH 7.5, before being allowed to air dry.

10 The filters are prehybridized in casein hybridization buffer containing 10% dextran sulfate, 0.5 M NaCl, 50 mM Tris HCL, pH 7.5, 0.1% sodium pyrophosphate, 1% casein, 1% SDS, and denatured salmon sperm DNA at 0.5 mg/ml for 6 hours at 60° C. The radiolabelled probe is then denatured by heating to 95° C for 2 minutes and then added to the prehybridization solution containing the filters. The filters are hybridized at 60° C

15 (alternatively, as in all hybridizations described herein, approximately 42, 44, 46, 48, 50. 52, 54, 56, 58, 62, 64, 66, 68, 70, or about 72 degrees or more can be used) for about 16 hours. The filters are then washed in approximately 1X wash mix (10X wash mix contains 3M NaCl, 0.6M Tris base, and 0.02M EDTA, alternatively, as with all washes described herein, 2X, 3X, 4X, 5X, 6X wash mix, or more, can be used) twice for 5 minutes each at room

20 temperature, then in 1X wash mix containing 1% SDS at 60° C (alternatively, as in all washes described herein, approximately 42, 44, 46, 48, 50. 52, 54, 56, 58, 62, 64, 66, 68, 70, or about 72 degrees or more can be used) for about 30 min, and finally in 0.3X wash mix (alternatively, as in all final washes described herein, approximately, 0.2X, 0.4X, 0.6X, 0.8X, 1X, or any concentration between about 2X and about 6X can be used in conjunction with a

25 suitable wash temperature) containing 0.1% SDS at 60° C (alternatively, approximately 42, 44, 46, 48, 50. 52, 54, 56, 58, 62, 64, 66, 68, 70, or about 72 degrees or more can be used) for about 30 min. The filters are then air dried and exposed to x-ray film for autoradiography. After developing, the film is aligned with the filters to select a positive plaque. If a single, isolated positive plaque cannot be obtained, the agar plug containing the plaques will be

30 removed and placed in lambda dilution buffer containing 0.1M NaCl, 0.01M magnesium

sulfate, 0.035M Tris HCl, pH 7.5, 0.01% gelatin. The phage may then be replated and rescreened to obtain single, well isolated positive plaques. Positive plaques may be isolated and the cDNA clones sequenced using primers based on the known cDNA sequence. This step may be repeated until a full length cDNA is obtained.

5 It may be necessary to screen multiple cDNA libraries from different sources/tissues to obtain a full length cDNA. In the event that it is difficult to identify cDNA clones encoding the complete 5' terminal coding region, an often encountered situation in cDNA cloning, the RACE (Rapid Amplification of cDNA Ends) technique may be used. RACE is a proven PCR-based strategy for amplifying the 5' end of incomplete cDNAs. 5'-RACE-Ready
10 cDNA synthesized from human fetal liver containing a unique anchor sequence is commercially available (Clontech). To obtain the 5' end of the cDNA, PCR is carried out, for example, on 5'-RACE-Ready cDNA using the provided anchor primer and the 3' primer. A secondary PCR reaction is then carried out using the anchored primer and a nested 3' primer according to the manufacturer's instructions.

15 Once obtained, the full length cDNA sequence may be translated into amino acid sequence and examined for certain landmarks found in the amino acid sequences encoded by SEQ ID NOS:9-503, or any structural similarities to these disclosed sequences.

The identification of homologs, heterologs, or paralogs of SEQ ID NOS:9-503 in other, preferably related, species can be useful for developing additional animal model
20 systems that are closely related to humans for purposes of drug discovery. Genes at other genetic loci within the genome that encode proteins which have extensive homology to one or more domains of the gene products encoded by SEQ ID NOS:9-503 can also be identified via similar techniques. In the case of cDNA libraries, such screening techniques can identify clones derived from alternatively spliced transcripts in the same or different species.

25 Screening can be done using filter hybridization with duplicate filters. The labeled probe can contain at least 15-30 base pairs of the nucleotide sequence presented in SEQ ID NOS:9-503. The hybridization washing conditions used should be of a lower stringency when the cDNA library is derived from an organism different from, or heterologous to, the type of organism from which the labeled sequence was derived. With respect to the cloning
30 of a mammalian homolog, heterolog, ortholog, or paralog, using probes derived from any of

the sequences of SEQ ID NOS:9-503, for example, hybridization can, for example, be performed at 65° C overnight in Church's buffer (7% SDS, 250 mM NaHPO₄, 2 mM EDTA, 1% BSA). Washes can be done with 2XSSC, 0.1% SDS at 65° C and then at 0.1XSSC, 0.1% SDS at 65° C.

5 Low stringency conditions are well known to those of skill in the art, and will vary predictably depending on the specific organisms from which the library and the labeled sequences are derived. For guidance regarding such conditions see, for example, Sambrook *et al.*, 1989, Molecular Cloning, A Laboratory Manual, Cold Springs Harbor Press, N.Y.; and Ausubel *et al.*, 1989, Current Protocols in Molecular Biology, Green Publishing Associates
10 and Wiley Interscience, N.Y.

Alternatively, the labeled nucleotide probe of a sequence of any of SEQ ID NOS:9-503 may be used to screen a genomic library derived from the organism of interest, again, using appropriately stringent conditions. The identification and characterization of human
15 genomic clones is helpful for designing diagnostic tests and clinical protocols for treating disorders in human patients that are known or suspected to be linked to disease or other developmental or cell differentiation disorders and abnormalities. For example, sequences derived from regions adjacent to the intron/exon boundaries of the human gene can be used to design primers for use in amplification assays to detect mutations within the exons, introns,
20 splice sites (*e.g.*, splice acceptor and/or donor sites), etc., that can be used in diagnostics.

Further, gene homologs can also be isolated from nucleic acid of the organism of interest by performing PCR using two oligonucleotide primers derived from SEQ ID NOS:9-503 or two degenerate oligonucleotide primer pools designed on the basis of amino acid
25 sequences within the gene products encoded by SEQ ID NOS:9-503. The template for the reaction may be cDNA obtained by reverse transcription of mRNA prepared from, for example, human or non-human cell lines, cell types, or tissues, like, for example, ES cells from the organism of interest.

The PCR product may be subcloned or sequenced directly or subcloned and sequenced to ensure that the amplified sequences represent the sequences of the gene corresponding to the sequence of SEQ ID NOS:9-503 of interest. The PCR fragment may
30 then be used to isolate a full length cDNA clone by a variety of methods. For example, the

amplified fragment may be labeled and used to screen a cDNA library, such as a bacteriophage cDNA library. Alternatively, the labeled fragment may be used to isolate genomic clones via the screening of a genomic library.

PCR technology may also be utilized to isolate full length cDNA sequences. For example, RNA can be isolated using standard procedures from an appropriate cellular source (*i.e.*, one known, or suspected, to express the gene corresponding to the sequence of SEQ ID NOS:9-503 of interest, such as, for example, ES cells). A reverse transcription reaction may be performed on the RNA using an oligonucleotide primer specific for the most 5' end of the amplified fragment for the priming of first strand synthesis. The resulting RNA/DNA hybrid may then be "tailed" with guanines, for example, using a standard terminal transferase reaction, the hybrid may be digested with RNase H, and second strand synthesis may then be primed with a poly-C primer. Thus, cDNA sequences upstream from the amplified fragment may easily be isolated. For a review of cloning strategies which may be used, see *e.g.*, Sambrook *et al.*, 1989, supra. Alternatively, cDNA or genomic libraries can be screened using 5' PCR primers that hybridize to vector sequences and 3' PCR primers specific to the gene of interest. Typically, such primers comprise oligonucleotide "priming" sequences first disclosed in, or otherwise unique to, one of the GTSSs of SEQ ID NOS:9-503.

The sequence of a gene corresponding to any of the sequences of SEQ ID NOS:9-503 can also be used to isolate mutant alleles of that gene. Such mutant alleles may be isolated from individuals either known or suspected to have a genotype which contributes to the disease of interest or other symptoms of developmental and cell differentiation and/or proliferation disorders and abnormalities. Mutant alleles and mutant allele products may then be utilized in the therapeutic and diagnostic programs described below. Additionally, such sequences of any of the genes corresponding to SEQ ID NOS:9-503 can be used to detect gene regulatory (*e.g.*, promoter or promoter/enhancer) defects which can affect development or cell differentiation.

A cDNA of a mutant gene corresponding to any of the sequences of SEQ ID NOS:9-503 can be isolated as discussed above, or, for example, by using PCR. In this case, the first cDNA strand may be synthesized by hybridizing an oligo-dT oligonucleotide to mRNA isolated from cells derived from an individual suspected of carrying a mutant gene

corresponding to any of the sequences of SEQ ID NOS:9-503 by extending the new strand with reverse transcriptase. The second strand of the cDNA is then synthesized using an oligonucleotide that hybridizes specifically to the 5' region of the normal gene. The amplified product can be directly sequenced or cloned into a suitable vector and subsequently subjected to DNA sequence analysis. By comparing the DNA sequence of the mutant allele to that of the normal allele, the mutation(s) responsible for the loss or alteration of function of the mutant gene product can be ascertained.

Alternatively, a genomic library can be constructed using DNA obtained from one or more individuals suspected of carrying, or known to carry, a mutant allele corresponding to any of SEQ ID NOS:9-503. Corresponding mutant cDNA libraries can be also constructed using RNA from cell types known, or suspected, to express such mutant alleles. The corresponding normal gene, or any suitable fragment thereof, may then be labeled and used as a probe to identify the corresponding mutant allele in such libraries. Clones containing the mutant gene sequences may then be identified and analyzed by DNA sequence analysis.

Additionally, a protein expression library can be constructed utilizing cDNA synthesized from, for example, RNA isolated from a cell type known, or suspected, to express a mutant allele corresponding to any of the sequences of SEQ ID NOS:9-503 from an individual suspected of, carrying or known to carry, such a mutant allele. In this manner, gene products made by the putatively mutant cell type may be expressed and screened using standard antibody screening techniques in conjunction with antibodies raised against the corresponding normal gene product or a portion thereof, as described below in Section 5.4 (For screening techniques, see, for example, Harlow, E. and Lane, eds., 1988, "Antibodies: A Laboratory Manual", Cold Spring Harbor Press, Cold Spring Harbor.) Additionally, screening can be accomplished by screening with labeled fusion proteins. In cases where a mutation results in an expressed gene product with altered function (*e.g.*, as a result of a missense or a frame shift mutation), a polyclonal set of antibodies to the wild-type gene product are likely to cross-react with the mutant gene product. Library clones detected via their reaction with such labeled antibodies can be purified and subjected to sequence analysis according to methods well known to those of skill in the art.

The invention also encompasses nucleotide sequences that encode mutant isoforms of any of the amino acid sequences encoded by the GTSSs of SEQ ID NOS:9-503, peptide fragments thereof, truncated versions thereof, and fusion proteins including any of the above. Examples of such fusion proteins can include, but not limited to, an epitope tag which aids in purification or detection of the resulting fusion protein; or an enzyme, fluorescent protein, luminescent protein which can be used as a marker.

The present invention additionally encompasses (a) RNA or DNA vectors that contain any portion of SEQ ID NOS:9-503 and/or their complements as well as any of the peptides or proteins encoded thereby; (b) DNA vectors that contain a cDNA that substantially spans the entire open reading frame corresponding to any of the sequences of SEQ ID NOS:9-503 and/or their complements; (c) DNA expression vectors that have or contain any of the foregoing sequences, or a portion thereof, operatively associated with a (d) genetically engineered host cells that contain a cDNA that spans the entire open reading frame, or any portion thereof, corresponding to any of the sequences of SEQ ID NOS:9-503 operatively associated with a regulatory element, generally recombinantly positioned either *in vivo* (such as in gene activation) or *in vitro* that directs the expression of the coding sequences in the host cell. As used herein, regulatory elements include, but are not limited to, inducible and non-inducible promoters, enhancers, operators and other elements known to those skilled in the art that drive and regulate expression. Such regulatory elements include, but are not limited to, the baculovirus promoter, cytomegalovirus hCMV immediate early gene promoter, the early or late promoters of SV40 adenovirus, the *lac* system, the *trp* system, the *TAC* system, the *TRC* system, the major operator and promoter regions of phage A, the control regions of fd coat protein, acid phosphatase promoters, phosphoglycerate kinase (PGK) and especially 3-phosphoglycerate kinase promoters, and yeast alpha mating factors.

An additional application of the described novel human polynucleotide sequences is their use in the molecular mutagenesis/evolution of proteins that are at least partially encoded by the described novel sequences using, for example, polynucleotide shuffling or related methodologies. Such approaches are described in U.S. Patents Nos. 5,830,721 and 5,837,458 which are herein incorporated by reference in their entirety.

5.2 **PROTEINS AND POLYPEPTIDES ENCODED BY POLYNUCLEOTIDES EXPRESSED IN MODIFIED HUMAN CELLS**

Peptides and proteins encoded by the open reading frame of mRNAs corresponding to
5 SEQ ID NOS:9-503, polypeptides and peptide fragments, mutated, truncated or deleted forms
of those peptides and proteins, fusion proteins containing any of those peptides and proteins
can be prepared for a variety of uses, including, but not limited to, the generation of
antibodies, as reagents in diagnostic assays, the identification of other cellular gene products
involved in the regulation of development and cellular differentiation of various cell types,
10 like, for example, ES cells, as reagents in assays for screening for compounds that can be
used in the treatment of disorders affecting development and cell differentiation, and as
pharmaceutical reagents useful in the treatment of disorders affecting development and cell
differentiation.

The invention also encompasses proteins, peptides, and polypeptides that are
15 functionally equivalent to those encoded by SEQ ID NOS:9-503. Such functionally
equivalent products include, but are not limited to, additions or substitutions of amino acid
residues within the amino acid sequence encoded by the nucleotide sequences described
above, but which result in a silent change, thus producing a functionally equivalent gene
product. Amino acid substitutions can be made on the basis of similarity in polarity, charge,
20 solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues
involved. For example, nonpolar (hydrophobic) amino acids include alanine, leucine,
isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; polar neutral amino
acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine;
positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively
25 charged (acidic) amino acids include aspartic acid and glutamic acid.

While random mutations can be introduced into DNA encoding peptides and proteins
of the current invention (using random mutagenesis techniques well known to those skilled in
the art), and the resulting mutant peptides and proteins tested for activity, site-directed
mutations of the coding sequence can be engineered (using standard site-directed mutagenesis
30 techniques) to generate mutant peptides and proteins of the current invention having
increased functionality.

03417522 101399
SECRET

For example, the amino acid sequence of peptides and proteins of the current invention can be aligned with homologs from different species. Mutant peptides and proteins can be engineered so that regions of interspecies identity are maintained, whereas the variable residues are altered, *e.g.*, by deletion or insertion of an amino acid residue(s) or by

- 5 substitution of one or more different amino acid residues. Conservative alterations at the variable positions can be engineered in order to produce a mutant form of a peptide or protein of the current invention that retains function. Non-conservative changes can be engineered at these variable positions to alter function. Alternatively, where alteration of function is desired, deletion or non-conservative alterations of the conserved regions can be engineered.
- 10 One of skill in the art may easily test such mutant or deleted form of a peptide or protein of the current invention for these alterations in function using the teachings presented herein.

- Other mutations to the coding sequences described above can be made to generate peptides and proteins that are better suited for expression, scale up, etc. in the host cells chosen. For example, the triplet code for each amino acid can be modified to conform more
- 15 closely to the preferential codon usage of the host cell's translational machinery, or, for example, to yield a messenger RNA molecule with a longer half-life. Those skilled in the art would readily know what modifications of the nucleotide sequence would be desirable to conform the nucleotide sequence to preferential codon usage or to make the messenger RNA more stable. Such information would be obtainable, for example, through use of computer
- 20 programs, through review of available research data on codon usage and messenger RNA stability, and through other means known to those of skill in the art.

- Peptides corresponding to one or more domains (or a portion of a domain) of one of the proteins described above, truncated or deleted proteins, as well as fusion proteins in which the full length protein described above, a subunit peptide or truncated version is fused to an
- 25 unrelated protein are also within the scope of the invention and can be designed by those of skill in the art on the basis of experimental or functional considerations. Such fusion proteins include, but are not limited to, fusions to an epitope tag; or fusions to an enzyme, fluorescent protein, or luminescent protein which provide a marker function.

- While the peptides and proteins of the current invention can be chemically
- 30 synthesized (*e.g.*, see Creighton, 1983, *Proteins: Structures and Molecular Principles*, W.H.

Freeman & Co., N.Y.), large polypeptides derived from any of the polynucleotides described above may advantageously be produced by recombinant DNA technology using techniques well known in the art for expressing genes and/or coding sequences. These methods include, for example, *in vitro* recombinant DNA techniques, synthetic techniques, and *in vivo* genetic recombination. See, for example, the techniques described in Sambrook *et al.*, 1989, *supra*, and Ausubel *et al.*, 1989, *supra*. Alternatively, RNA capable of encoding any of the nucleotide sequences described above may be chemically synthesized using, for example, synthesizers. See, for example, the techniques described in "Oligonucleotide Synthesis", 1984, Gait, M.J. ed., IRL Press, Oxford, which is incorporated by reference herein in its entirety.

A variety of host-expression vector systems may be utilized to express the nucleotide sequences of the invention. Where the peptide or protein to be synthesized is a soluble derivative, the peptide or polypeptide can be recovered from the culture, *i.e.*, from the host cell in cases where the peptide or polypeptide is not secreted, and from the culture media in cases where the peptide or polypeptide is secreted by the cells. However, such engineered host cells themselves may be used in situations where it is important not only to retain the structural and functional characteristics of the expressed peptide or protein, but to assess biological activity, *e.g.*, in drug screening assays.

The expression systems that may be used for purposes of the invention include, but are not limited to, microorganisms such as bacteria (*e.g.*, *E. coli*, *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing a nucleotide sequence of the current invention; yeast (*e.g.*, *Saccharomyces*, *Pichia*) transformed with recombinant yeast expression vectors containing a nucleotide sequence of the current invention; insect cell systems infected with recombinant virus expression vectors (*e.g.*, baculovirus) containing a nucleotide sequence of the current invention; plant cell systems infected with recombinant virus expression vectors (*e.g.*, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (*e.g.*, Ti plasmid) containing a nucleotide sequence of the current invention; or mammalian cell systems (*e.g.*, COS, CHO, BHK, 293, 3T3, U937) harboring recombinant expression constructs containing promoters derived from the genome of

mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter).

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the gene product being expressed. For example, when large quantities of such a protein are to be produced for the generation of pharmaceutical compositions of a protein or for raising antibodies to the protein to be expressed, for example, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited to, the *E. coli* expression vector pUR278 (Ruther *et al.*, 1983, EMBO J. 2:1791), in which the coding sequence of the polynucleotide to be expressed may be ligated individually into the vector in frame with the *lacZ* coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, 1985, Nucleic Acids Res. 13:3101-3109; Van Heeke & Schuster, 1989, J. Biol. Chem. 264:5503-5509); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). If the inserted sequence encodes a relatively small polypeptide (less than 25 kD), such fusion proteins are generally soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety. Alternatively, if the resulting fusion protein is insoluble and forms inclusion bodies in the host cell, the inclusion bodies may be purified and the recombinant protein solubilized using techniques well known to one of skill in the art.

In an insect system, *Autographa californica* nuclear polyhidrosis virus (AcNPV) may be used as a vector to express foreign genes. (e.g., see Smith *et al.*, 1983, J. Virol. 46: 584; Smith, U.S. Patent No. 4,215,051). In one embodiment of the current invention, Sf9 insect cells are infected with a baculovirus vector expressing a peptide or protein of the current invention.

In mammalian host cells, a number of viral-based expression systems may be utilized. Specific embodiments (described more fully below) include the gene trap cDNA sequences of the current invention that are expressed by a CMV promoter to transiently express recombinant protein in U937 cells or in Cos-7 cells. Alternatively, retroviral vector systems

well known in the art may be used to insert the recombinant expression construct into host cells, or vaccinia virus-based expression systems may be employed.

In yeast, a number of vectors containing constitutive or inducible promoters may be used. For a review, see Current Protocols in Molecular Biology, Vol. 2, 1988, Ed. Ausubel *et al.*, Greene Publish. Assoc. & Wiley Interscience, Ch. 13; Grant *et al.*, 1987, Expression and Secretion Vectors for Yeast, *in* Methods in Enzymology, Eds. Wu & Grossman, 1987, Acad. Press, N.Y., Vol. 153, pp. 516-544; Glover, 1986, DNA Cloning, Vol. II, IRL Press, Wash., D.C., Ch. 3; and Bitter, 1987, Heterologous Gene Expression in Yeast, Methods in Enzymology, Eds. Berger & Kimmel, Acad. Press, N.Y., Vol. 152, pp. 673-684; and The Molecular Biology of the Yeast *Saccharomyces*, 1982, Eds. Strathern *et al.*, Cold Spring Harbor Press, Vols. I and II.

In cases where plant expression vectors are used, the expression of the coding sequence may be driven by any of a number of promoters. For example, viral promoters such as the 35S RNA and 19S RNA promoters of CaMV (Brisson *et al.*, 1984, Nature, 310:511-514), or the coat protein promoter of TMV (Takamatsu *et al.*, 1987, EMBO J. 6:307-311) may be used; alternatively, plant promoters such as the small subunit of RUBISCO (Coruzzi *et al.*, 1984, EMBO J. 3:1671-1680; Broglie *et al.*, 1984, Science 224:838-843); or heat shock promoters, *e.g.*, soybean hsp17.5-E or hsp17.3-B (Gurley *et al.*, 1986, Mol. Cell. Biol. 6:559-565) may be used. These constructs can be introduced into plant cells using Ti plasmids, Ri plasmids, plant virus vectors, direct DNA transformation, microinjection, electroporation, etc. For reviews of such techniques see, for example, Weissbach & Weissbach, 1988, Methods for Plant Molecular Biology, Academic Press, NY, Section VIII, pp. 421-463; and Grierson & Corey, 1988, Plant Molecular Biology, 2d Ed., Blackie, London, Ch. 7-9.

In cases where an adenovirus is used as an expression vector, the nucleotide sequence of interest may be ligated to an adenovirus transcription/translation control complex, *e.g.*, the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by *in vitro* or *in vivo* recombination. Insertion in a non-essential region of the viral genome (*e.g.*, region E1 or E3) will result in a recombinant virus that is viable and capable of expressing the gene product of interest in infected hosts. (*e.g.*, See Logan & Shenk, 1984, Proc. Natl. Acad. Sci. USA 81:3655-3659). Specific initiation signals may also

be required for efficient translation of inserted nucleotide sequences of interest. These signals include the ATG initiation codon and adjacent sequences. In cases where an entire gene or cDNA, including its own initiation codon and adjacent sequences, is inserted into the appropriate expression vector, no additional translational control signals may be needed.

- 5 However, in cases where only a portion of a coding sequence of interest is inserted, exogenous translational control signals, including, perhaps, the ATG initiation codon, must be provided. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (See Bittner *et al.*, 1987, Methods in Enzymol. 153:516-544).

- 15 In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (*e.g.*, glycosylation) and processing (*e.g.*, cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, 20 eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript may be used. Such mammalian host cells include, but are not limited to, CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, WI38, and U937 cells.

- For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the sequences of interest described 25 above may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (*e.g.*, promoter, enhancer sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, 30 and then are switched to a selective media. The selectable marker in the recombinant plasmid

confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the gene product of interest. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that affect the endogenous activity of the gene product of interest.

A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler *et al.*, 1977, Cell 11:223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, 1962, Proc. Natl. Acad. Sci. USA 48:2026), and adenine phosphoribosyltransferase (Lowy *et al.*, 1980, Cell 22:817) genes can be employed in tk⁻, hgp^rt⁻ or ap^rt⁻ cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler *et al.*, 1980, Natl. Acad. Sci. USA 77:3567; O'Hare *et al.*, 1981, Proc. Natl. Acad. Sci. USA 78:1527); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, 1981, Proc. Natl. Acad. Sci. USA 78:2072); neo, which confers resistance to the aminoglycoside G-418 (Colberre-Garapin *et al.*, 1981, J. Mol. Biol. 150:1); and hyg^r, which confers resistance to hygromycin (Santerre *et al.*, 1984, Gene 30:147).

The gene products of interest can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, guinea pigs, pigs, micro-pigs, goats, and non-human primates, *e.g.*, baboons, monkeys, and chimpanzees may be used to generate transgenic animals carrying the polynucleotide of interest of the current invention.

Any technique known in the art may be used to introduce the transgene of interest into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to pronuclear microinjection (Hoppe, P.C. and Wagner, T.E., 1989, U.S. Pat. No. 4,873,191); retrovirus mediated gene transfer into germ lines (Van der Putten *et al.*, 1985, Proc. Natl. Acad. Sci., USA 82:6148-6152); gene targeting in embryonic stem cells (Thompson *et al.*, 1989, Cell 56:313-321); electroporation of embryos (Lo, 1983, Mol Cell Biol. 3:1803-1814); sperm-mediated gene transfer (Lavitrano *et al.*, 1989, Cell 57:717-723); positive-negative selection as described in U.S. Patent No. 5,464,764 herein incorporated by reference. For a review of such techniques, see Gordon, 1989, Transgenic Animals, Intl. Rev. Cytol. 115:171-229, which is incorporated by reference herein in its entirety.

The present invention provides for transgenic animals that carry the transgene of interest in all their cells, as well as animals which carry the transgene in some, but not all their cells, *i.e.*, mosaic animals. The transgene may be integrated as a single transgene or in concatamers, *e.g.*, head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko *et al.* (Lasko, M. *et al.*, 1992, Proc. Natl. Acad. Sci. USA 89:6232-6236). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the transgene of interest be integrated into the chromosomal site of the endogenous copy of that same gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene of interest are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene of interest. In this way, the expression of the endogenous gene may also be eliminated by inserting non-functional sequences into the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene of interest in only that cell type, by following, for example, the teaching of Gu *et al.* (Gu *et al.*, 1994, Science 265: 103-106). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant gene of interest may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to assay whether integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of cell type samples obtained from the animal, *in situ* hybridization analysis, and RT-PCR. Samples of gene-expressing tissue, may also be evaluated immunocytochemically using antibodies specific for the transgene product, as described below.

5.3 CELLS THAT CONTAIN A DISRUPTED ALLELE OF A GENE ENCODING A POLYNUCLEOTIDE OF THE CURRENT INVENTION

Another aspect of the current invention are cells which contain a gene that encodes a polynucleotide of the current invention and that has been disrupted. Those of skill in the art would know how to disrupt a gene in a cell using techniques known in the art. Also, techniques useful to disrupt a gene in a cell and especially an ES cell, that may already be disrupted, as disclosed in copending US patent applications Nos. 08/726,867; 08/728,963; 08/907,598; and 08/942,806, all of which are hereby incorporated herein by reference in their entirety, are within the scope of the current invention to disrupt a gene that encodes a polynucleotide of the current invention.

5.3.1 IDENTIFICATION OF CELLS THAT EXPRESS GENES ENCODING POLYNUCLEOTIDES OF THE CURRENT INVENTION

Host cells that contain coding sequence and/or express a biologically active gene product, or fragment thereof, encoded by a gene corresponding to a GTS present invention may be identified by at least four general approaches; (a) DNA-DNA or DNA-RNA hybridization; (b) the presence or absence of "marker" gene functions; (c) assessing the level of transcription as measured by the expression of mRNA transcripts in the host cell; and (d) detection of the gene product as measured by immunoassay, enzymatic assay, chemical assay, or by its biological activity. Prior to screening for gene expression, the host cells can first be treated in an effort to increase the level of expression of genes encoding polynucleotides of the current invention, especially in cell lines that produce low amounts of the mRNAs and/or peptides and proteins of the current invention.

In the first approach, the presence of the coding sequence for peptides and proteins of the current invention inserted in the expression vector can be detected by DNA-DNA or DNA-RNA hybridization using probes comprising nucleotide sequences that are homologous to the coding sequence for peptides and proteins of the current invention, respectively, or portions or derivatives thereof.

In the second approach, the recombinant expression vector/host system can be identified and selected based upon the presence or absence of certain "marker" gene functions

(e.g., thymidine kinase activity, resistance to antibiotics, resistance to methotrexate, transformation phenotype, occlusion body formation in baculovirus, etc.). For example, if the coding sequence for the peptide or protein of the current invention is inserted within a marker gene sequence of the vector, recombinants containing the coding sequence for the peptide or protein of the current invention can be identified by the absence of the marker gene function. Alternatively, a marker gene can be placed in tandem with the sequence for the peptide or protein of the current invention under the control of the same or different promoter used to control the expression of the coding sequence for the peptide or protein of the current invention. Expression of the marker in response to induction or selection indicates expression of the coding sequence for the peptide or protein of the current invention.

In the third approach, transcriptional activity for the coding region of genes specific for peptides and proteins of the current invention can be assessed by hybridization assays. For example, RNA can be isolated and analyzed by Northern blot using a probe derived from a GTS, or any portion thereof. Alternatively, total nucleic acids of the host cell may be extracted and assayed for hybridization to such probes. Additionally, RT-PCR (using GTS specific oligos/products) may be used to detect low levels of gene expression in a sample, or in RNA isolated from a spectrum of different tissues, or PCR can be used to screen a variety of cDNA libraries derived from different tissues to determine which tissues express a given GTS.

In the fourth approach, the expression of the peptides and proteins of the current invention can be assessed immunologically, for example by Western blots, immunoassays such as radioimmuno-precipitation, enzyme-linked immunoassays and the like. This can be achieved by using an antibody and a binding partner specific to a peptide or protein of the current invention.

5.4 ANTIBODIES TO PROTEINS OF THE CURRENT INVENTION

Antibodies that specifically recognize one or more epitopes of a peptide or protein of the current invention, or epitopes of conserved variants of a peptide or protein at least partially encoded by a GTS of the present invention, or any and all peptide fragments thereof, are also encompassed by the invention. Such antibodies include, but are not limited

to, polyclonal antibodies, monoclonal antibodies (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab')₂ fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above.

5 The antibodies of the invention may be used, for example, in the detection of the peptide or protein of interest of the current invention in a biological sample and may, therefore, be utilized as part of a diagnostic or prognostic technique whereby patients may be tested for abnormal amounts of these proteins. Such antibodies may also be utilized in conjunction with, for example, compound screening schemes as described, below in Section 10 5.6 for the evaluation of the effect of test compounds on expression and/or activity of the gene products of interest of the current invention. Additionally, such antibodies can be used in conjunction with the gene therapy and gene delivery techniques described below to, for example, evaluate the normal and/or engineered peptide- or protein-expressing cells prior to their introduction into the patient. Such antibodies may additionally be used as a method for 15 inhibiting the abnormal activity of a peptide or protein of interest at least partially encoded by a GTS of the present invention. Thus, such antibodies may, for example, be utilized as part of treatment methods for development and cell differentiation disorders.

For the production of antibodies, various host animals may be immunized by injection with the peptide or protein of interest, a subunit peptide of such protein, a truncated 20 polypeptide, functional equivalents of the peptide or protein, mutants of the peptide or protein, or denatured forms of the above. Such host animals may include, but are not limited to, rabbits, mice, and rats, to name but a few. Various adjuvants can be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active 25 substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and *Corynebacterium parvum*. Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of the immunized animals.

Monoclonal antibodies, which are homogeneous populations of antibodies to a particular antigen, may be obtained by any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique of Kohler and Milstein, (1975, *Nature* 256:495-497; and U.S. Patent No. 4,376,110), the human B-cell hybridoma technique (Kosbor *et al.*, 1983, *Immunology Today* 4:72; Cole *et al.*, 1983, *Proc. Natl. Acad. Sci. USA* 80:2026-2030), and the EBV-hybridoma technique (Cole *et al.*, 1985, *Monoclonal Antibodies And Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96). Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof. The hybridoma producing the mAb of this invention may be cultivated *in vitro* or *in vivo*. Production of high titers of mAbs *in vivo* makes this the presently preferred method of production.

In addition, techniques developed for the production of "chimeric antibodies" (Morrison *et al.*, 1984, *Proc. Natl. Acad. Sci. USA*, 81:6851-6855; Neuberger *et al.*, 1984, *Nature*, 312:604-608; Takeda *et al.*, 1985, *Nature*, 314:452-454) by splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a porcine mAb and a human immunoglobulin constant region.

Alternatively, techniques described for the production of single chain antibodies (U.S. Patent 4,946,778; Bird, 1988, *Science* 242:423-426; Huston *et al.*, 1988, *Proc. Natl. Acad. Sci. USA* 85:5879-5883; and Ward *et al.*, 1989, *Nature* 334:544-546) can be adapted to produce single chain antibodies against gene products of interest. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide.

Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, such fragments include, but are not limited to: the F(ab')₂ fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab')₂ fragments.

Alternatively, Fab expression libraries may be constructed (Huse *et al.*, 1989, *Science*,

246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.

Antibodies to peptides and proteins that are fully or at least partially encoded by the described GTSs, or fragments or truncated versions thereof, can in turn be utilized to generate anti-idiotypic antibodies that "mimic" an epitope of the peptide or protein of interest, using techniques well known to those skilled in the art. (See, *e.g.*, Greenspan & Bona, 1993, FASEB J 7(5):437-444; and Nissinoff, 1991, J. Immunol. 147(8):2429-2438). For example antibodies that bind to a regulatory peptide or protein of interest of the current invention and competitively inhibit the binding of such peptide or protein to any of its binding partners in the cell can be used to generate anti-idiotypes that "mimic" the peptide or protein of interest and, therefore, bind and neutralize the particular binding partner of the peptide or protein of interest. Such neutralizing antibodies, anti-idiotypes, Fab fragments of such antibodies, or humanized derivatives thereof, can be used in therapeutic regimens to mimic or neutralize (depending on the antibody) the effect of a particular peptide of interest, or a binding partner of a peptide or protein of interest.

5.5 DIAGNOSIS OF DISORDERS AFFECTING DEVELOPMENT AND CELL DIFFERENTIATION

A variety of methods can be employed for the diagnostic and prognostic evaluation of disorders involving developmental and differentiation processes, and for the identification of subjects having a predisposition to such disorders.

Such methods may, for example, utilize reagents such as the nucleotide sequences described above, and antibodies to peptides and proteins of the current invention, as described, in Section 5.4. Specifically, such reagents may be used, for example, for: (1) the detection of the presence of gene mutations, or the detection of either over- or under-expression of the respective mRNAs relative to the non-disorder state; (2) the detection of either an over- or an under-abundance of the respective gene product relative to the non-disorder state; and (3) the detection of perturbations or abnormalities in the intra- and inter-cellular processes mediated by the respective peptides or proteins of the current invention.

The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one specific nucleotide sequence of the current invention or antibody reagent described herein, which may be conveniently used, *e.g.*, in clinical settings, to diagnose patients exhibiting developmental or cell differentiation disorder abnormalities.

For the detection of mutations in any of the genes described above, any nucleated cell can be used as a starting source for genomic nucleic acid. For the detection of gene expression or gene products, any cell type or tissue in which the gene of interest is expressed, such as, for example, ES cells, may be utilized. Specific examples of cells and tissues that can be analyzed using the claimed polynucleotides include, but are not limited to, endothelial cells, epithelial cells, islets, neurons or neural tissue, mesothelial cells, osteocytes, lymphocytes, chondrocytes, hematopoietic cells, immune cells, cells of the major glands or organs (*e.g.*, lung, heart, stomach, pancreas, kidney, skin, etc.), exocrine and/or endocrine cells, embryonic and other stem cells, fibroblasts, and culture adapted and/or transformed versions of the above. Diseases or natural processes that can also be correlated with the expression of mutant, or normal, variants of the disclosed GTSs include, but are not limited to, aging, cancer, autoimmune disease, lupus, scleroderma, Crohn's disease, multiple sclerosis, inflammatory bowel disease, immune disorders, schizophrenia, psychosis, alopecia, glandular disorders, inflammatory disorders, ataxia telangiectasia, diabetes, skin disorders such as acne, eczema, and the like, osteo and rheumatoid arthritis, high blood pressure, atherosclerosis, cardiovascular disease, pulmonary disease, degenerative diseases of the neural or skeletal systems, Alzheimer's disease, Parkinson's disease, osteoporosis, asthma, developmental disorders or abnormalities, genetic birth defects, infertility, epithelial ulcerations, and viral, parasitic, fungal, yeast, or bacterial infection.

Primary, secondary, or culture-adapted variants of cancer cells/tissues can also be analyzed using the claimed polynucleotides. Examples of such cancers include, but are not limited to, Cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma; Lung: bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous

- hamartoma, mesothelioma; Gastrointestinal: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma, carcinoid tumors,
- 5 Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma); Genitourinary tract: kidney (adenocarcinoma, Wilm's tumor [nephroblastoma], lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma,
- 10 teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma); Liver: hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma; Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple
- 15 myeloma, malignant giant cell tumor, chordoma, osteochondroma (osteochondrogenous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors; Nervous system: skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma [pinealoma], glioblastoma
- 20 multiforme, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal cord (neurofibroma, meningioma, glioma, sarcoma); Gynecological: uterus (endometrial carcinoma), cervix (cervical carcinoma, pre-tumor cervical dysplasia), ovaries (ovarian carcinoma [serous cystadenocarcinoma, mucinous cystadenocarcinoma, endometrioid tumors, celioblastoma, clear cell carcinoma, unclassified carcinoma], granulosa-thecal cell tumors,
- 25 Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma [embryonal rhabdomyosarcoma], fallopian tubes (carcinoma); Hematologic: blood (myeloid leukemia [acute and chronic], acute lymphoblastic leukemia, chronic lymphocytic leukemia,
- 30 myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome), Hodgkin's

disease, non-Hodgkin's lymphoma [malignant lymphoma]; Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, moles, dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis; Breast: carcinoma and sarcoma, and Adrenal glands: neuroblastoma.

- 5 Nucleic acid-based detection techniques and peptide detection techniques that can be used to conduct the above analyses are described below.

5.5.1. DETECTION OF THE GENES OF THE CURRENT INVENTION AND THEIR RESPECTIVE TRANSCRIPTS

10 Mutations within the genes of the current invention can be detected by utilizing a number of techniques. Nucleic acid from any nucleated cell can be used as the starting point for such assay techniques, and may be isolated according to standard nucleic acid preparation procedures which are well known to those of skill in the art.

15 DNA may be used in hybridization or amplification assays of biological samples to detect abnormalities involving gene structure, including point mutations, insertions, deletions and chromosomal rearrangements. Such assays may include, but are not limited to, Southern analyses, single stranded conformational polymorphism analyses (SSCP), and PCR analyses.

Such diagnostic methods for the detection of gene-specific mutations can involve for
20 example, contacting and incubating nucleic acids including recombinant DNA molecules, cloned genes or degenerate variants thereof, obtained from a sample, *e.g.*, derived from a patient sample or other appropriate cellular source, with one or more labeled nucleic acid reagents including recombinant DNA molecules, cloned genes or degenerate variants thereof, as described above, under conditions favorable for the specific annealing of these reagents to
25 their complementary sequences within the gene of interest of the current invention.

Preferably, the lengths of these nucleic acid reagents are at least 15 to 30 nucleotides. After incubation, all non-annealed nucleic acids are removed from the nucleic acid molecule hybrid. The presence of nucleic acids which have hybridized, if any such molecules exist, is then detected. Using such a detection scheme, the nucleic acid from the cell type or tissue of
30 interest can be immobilized, for example, to a solid support such as a membrane, or a plastic surface such as that on a microtiter plate or polystyrene beads. In this case, after incubation,

non-annealed, labeled nucleic acid reagents of the type described above are easily removed. Detection of the remaining, annealed, labeled nucleic acid reagents is accomplished using standard techniques well-known to those in the art. The gene sequences to which the nucleic acid reagents have annealed can be compared to the annealing pattern expected from a normal gene sequence in order to determine whether a gene mutation is present.

Alternative diagnostic methods for the detection of gene specific nucleic acid molecules, in patient samples or other appropriate cell sources, may involve their amplification, *e.g.*, by PCR (the experimental embodiment set forth in Mullis, K.B., 1987, U.S. Patent No. 4,683,202), followed by the detection of the amplified molecules using techniques well known to those of skill in the art. The resulting amplified sequences can be compared to those which would be expected if the nucleic acid being amplified contained only normal copies of the respective gene in order to determine whether a gene mutation exists.

Additionally, well-known genotyping techniques can be performed to identify individuals carrying mutations in any of the genes of the current invention. Such techniques include, for example, the use of restriction fragment length polymorphisms (RFLPs), which involve sequence variations in one of the recognition sites for the specific restriction enzyme used.

Furthermore, the polynucleotide sequences of the current invention may be mapped to chromosomes and specific regions of chromosomes using well known genetic and/or chromosomal mapping techniques. These techniques include *in situ* hybridization, linkage analysis against known chromosomal markers, hybridization screening with libraries or flow-sorted chromosomal preparations specific to known chromosomes, and the like. The technique of fluorescent *in situ* hybridization of chromosome spreads has been described, for example, in Verma *et al.* (1988) Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York. Fluorescent *in situ* hybridization of chromosomal preparations and other physical chromosome mapping techniques may be correlated with additional genetic map data. Examples of genetic map data can be found, for example, in Genetic Maps: Locus Maps of Complex Genomes, Book 5: Human Maps, O'Brien, editor, Cold

Spring Harbor Laboratory Press (1990). Comparisons of physical chromosomal map data may be of particular interest in detecting genetic diseases in carrier states.

The level of expression of genes can also be assayed by detecting and measuring the transcription of such genes. For example, RNA from a cell type or tissue known, or suspected to express any of the genes of the current invention can be isolated and tested utilizing hybridization or PCR techniques (e.g., northern or RT PCR) such as those described, above. Such analyses may reveal both quantitative and qualitative aspects of the expression pattern of the respective gene, including activation or inactivation of gene expression. *In situ* hybridization using suitable radioactive labels, enzymatic labels, or chemically tagged forms of the described polynucleotide sequences can also be used to assess expression patterns *in vivo*.

Additionally, an oligonucleotide or polynucleotide sequence first disclosed in at least a portion of one of the GTS sequences of SEQ ID NOS:9-503 can be used as a hybridization probe in conjunction with a solid support matrix/substrate (resins, beads, membranes, plastics, polymers, metal or metallized substrates, crystalline or polycrystalline substrates, etc.). Of particular note are spatially addressable arrays (*i.e.*, gene chips, microtiter plates, etc.) of oligonucleotides and polynucleotides, or corresponding oligopeptides and polypeptides, wherein at least one of the biopolymers present on the spatially addressable array comprises an oligonucleotide or polynucleotide sequence first disclosed in at least one of the GTS sequences of SEQ ID NOS:9-503, or an amino acid sequence encoded thereby. Methods for attaching biopolymers to, or synthesizing biopolymers on, solid support matrices, and conducting binding studies thereon are disclosed in, *inter alia*, U.S. Patent Nos. 5,556,752, 5,744,305, 4,631,211, 5,445,934, 5,252,743, 4,713,326, 5,424,186, and 4,689,405 the disclosures of which are herein incorporated by reference in their entirety.

Oligonucleotides corresponding to the described GTSs can be used as hybridization probes either singly or in chip format. For example, a series of such GTS oligonucleotide sequences, or the complements thereof, can be used to represent all or a portion of the described GTS sequences. The oligonucleotides, typically between about 16 to about 40 (or any whole number within the stated range) nucleotides in length, may partially overlap each other and/or the NHP sequence may be represented using oligonucleotides that do not

overlap. Accordingly, the described NHP polynucleotide sequences shall typically comprise at least about two or three distinct oligonucleotide sequences of at least about 18, and preferably about 25, nucleotides in length that are first disclosed in the described Sequence Listing. Such oligonucleotide sequences may begin at any nucleotide present within a
5 sequence in the Sequence Listing and proceed in either a sense (5'-to-3') orientation vis-a-vis the described sequence or in an antisense orientation.

Although the presently described GTSs have been specifically described using nucleotide sequence, it should be appreciated that each of the GTSs can uniquely be described using any of a wide variety of additional structural attributes, or combinations
10 thereof. For example, a given GTS can be described by the net composition of the nucleotides present within a given region of the GTS in conjunction with the presence of one or more specific oligonucleotide sequence(s) first disclosed in the GTS. Alternatively, a restriction map specifying the relative positions of restriction endonuclease digestion sites, or various palindromic or other specific oligonucleotide sequences can be used to structurally
15 describe a given GTS. Such restriction maps, which are typically generated by widely available computer programs (*e.g.*, the University of Wisconsin GCG sequence analysis package, SEQUENCHER 3.0, Gene Codes Corp., Ann Arbor, MI, etc.), can optionally be used in conjunction with one or more discrete nucleotide sequence(s) present in the GTS that can be described by the relative position of the sequence relative to one or more additional
20 sequence(s) or one or more restriction sites present in the GTS.

5.5.2 DETECTION OF THE GENE PRODUCTS OF THE CURRENT INVENTION

25 Antibodies directed against wild type or mutant gene products of the current invention or conserved variants or peptide fragments thereof, which are discussed above in Section 5.4 may also be used as diagnostics and prognostics for disorders affecting development and cellular differentiation, as described herein. Such diagnostic methods, may be used to detect abnormalities in the level of gene expression, or abnormalities in the structure and/or
30 temporal, tissue, cellular, or subcellular location of the respective gene product, and may be performed *in vivo* or *in vitro*, such as, for example, on biopsy tissue.

The tissue or cell type to be analyzed will generally include those which are known, or suspected, to contain cells that express the respective gene. The protein isolation methods employed herein may, for example, be such as those described in Harlow and Lane (Harlow, E. and Lane, D., 1988, "Antibodies: A Laboratory Manual", Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York), which is incorporated herein by reference in its entirety. The isolated cells can be derived from cell culture or from a patient. The analysis of cells taken from culture may be a necessary step in the assessment of cells that could be used as part of a cell-based gene therapy technique or, alternatively, to test the effect of compounds on the expression of the respective gene.

For example, antibodies, or fragments of antibodies, such as those described above in Section 5.4 are also useful in the present invention to quantitatively or qualitatively detect the presence of gene products of the current invention or conserved variants or peptide fragments thereof. This can be accomplished, for example, by immunofluorescence techniques employing a fluorescently labeled antibody (see below, this Section) coupled with light microscopic, flow cytometric, or fluorimetric detection.

The antibodies (or fragments thereof) or fusion or conjugated proteins useful in the present invention may, additionally, be employed histologically, as in immunofluorescence, immunoelectron microscopy or non-immuno assays, for *in situ* detection of gene products of the current invention or conserved variants or peptide fragments thereof, or for catalytic subunit binding (in the case of labeled catalytic subunit fusion protein).

In situ detection may be accomplished by removing a histological specimen from a patient, and applying thereto a labeled antibody or fusion protein of the present invention. The antibody (or fragment) or fusion protein is preferably applied by overlaying the labeled antibody (or fragment) onto a biological sample. Through the use of such a procedure, it is possible to determine not only the presence of the gene product of the current invention, or conserved variants or peptide fragments, but also its distribution in the examined tissue. Using the present invention, those of ordinary skill will readily perceive that any of a wide variety of histological methods (such as staining procedures) can be modified in order to achieve such *in situ* detection.

Immunoassays and non-immunoassays for gene products of the current invention or conserved variants or peptide fragments thereof will typically comprise incubating a sample, such as a biological fluid, a tissue extract, freshly harvested cells, or lysates of cells which have been incubated in cell culture, in the presence of a detectably labeled antibody capable of identifying the respective gene products of interest or conserved variants or peptide fragments thereof, and detecting the bound antibody by any of a number of techniques well-known in the art.

The biological sample may be brought in contact with and immobilized onto a solid phase support or carrier such as nitrocellulose, or other solid support which is capable of immobilizing cells, cell particles or soluble proteins. The support may then be washed with suitable buffers followed by treatment with the detectably labeled antibody specific to the peptide or protein of interest of the current invention or with fusion protein. The solid phase support may then be washed with the buffer a second time to remove unbound antibody or fusion protein. The amount of bound label on solid support may then be detected by conventional means.

"Solid phase support or carrier" is intended to encompass any support capable of binding an antigen or an antibody. Well-known supports or carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, gabbros, and magnetite. The nature of the carrier can be either soluble to some extent or insoluble for the purposes of the present invention. The support material may have virtually any possible structural configuration so long as the coupled molecule is capable of binding to an antigen or antibody. Thus, the support configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube, or the external surface of a rod. Alternatively, the surface may be flat such as a sheet, test strip, etc. Preferred supports include polystyrene beads. Those skilled in the art will know many other suitable carriers for binding antibody or antigen, or will be able to ascertain the same by use of routine experimentation.

The binding activity of a given lot of antibody or fusion protein may be determined according to well known methods. Those skilled in the art will be able to determine operative and optimal assay conditions for each determination by employing routine experimentation.

With respect to antibodies, one of the ways in which the antibody can be detectably labeled is by linking the same to an enzyme and use in an enzyme immunoassay (EIA) (Voller, "The Enzyme Linked Immunosorbent Assay (ELISA)", 1978, Diagnostic Horizons 2:1-7, Microbiological Associates Quarterly Publication, Walkersville, MD); Voller *et al.*, 1978, J. Clin. Pathol. 31:507-520; Butler, 1981, Meth. Enzymol. 73:482-523; Maggio (ed.), 1980, Enzyme Immunoassay, CRC Press, Boca Raton, FL.; Ishikawa *et al.*, (eds.), 1981, Enzyme Immunoassay, Kigaku Shoin, Tokyo). The enzyme which is bound to the antibody will react with an appropriate substrate, preferably a chromogenic substrate, in such a manner as to produce a chemical moiety which can be detected, for example, by spectrophotometric, fluorimetric or by visual means. Enzymes which can be used to detectably label the antibody include, but are not limited to, malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate, dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase and acetylcholinesterase. The detection can be accomplished by colorimetric methods which employ a chromogenic substrate for the enzyme. Detection may also be accomplished by visual comparison of the extent of enzymatic reaction of a substrate in comparison with similarly prepared standards.

Detection may also be accomplished using any of a variety of other immunoassays. For example, by radioactively labeling the antibodies or antibody fragments, it is possible to detect the peptide or protein of interest through the use of a radioimmunoassay (RIA) (see, for example, Weintraub, B., Principles of Radioimmunoassays, Seventh Training Course on Radioligand Assay Techniques, The Endocrine Society, March, 1986, which is incorporated by reference herein). The radioactive isotope can be detected by such means as the use of a gamma counter or a scintillation counter or by autoradiography.

It is also possible to label the antibody with a fluorescent compound. When the fluorescently labeled antibody is exposed to light of the proper wave length, its presence can then be detected due to fluorescence. Among the most commonly used fluorescent labeling compounds are fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin and fluorescamine.

The antibody can also be detectably labeled using fluorescence emitting metals such as ¹⁵²Eu, or others of the lanthanide series. These metals can be attached to the antibody using such metal chelating groups as diethylenetriaminepentacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA).

5 The antibody also can be detectably labeled by coupling it to a chemiluminescent compound. The presence of the chemiluminescent-tagged antibody is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples of particularly useful chemiluminescent labeling compounds are luminol, isoluminol, thromatic acridinium ester, imidazole, acridinium salt and oxalate ester.

10 Likewise, a bioluminescent compound may be used to label the antibody of the present invention. Bioluminescence is a type of chemiluminescence found in biological systems in, which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Important bioluminescent compounds for labeling purposes include, but are
15 not limited to, luciferin, luciferase and aequorin.

 An additional use of a peptide or polypeptide encoded by an oligonucleotide or polynucleotide sequence first disclosed in at least one of the GTS sequences of SEQ ID NOS:9-503 is by incorporating the sequence into a phage display, or other peptide library/binding, system that can be used to screen for proteins, or other ligands, that are
20 capable of binding to an amino acid sequence encoded by an oligonucleotide or polynucleotide sequence first disclosed in at least one of the GTS sequences of SEQ ID NOS:9-503 (see U.S. Patents Nos. 5,270,170, and 5,432,018, herein incorporated by reference in their entirety). Moreover, peptide arrays comprising a novel amino acid sequence corresponding to a portion of at least one of the polynucleotide sequences first
25 disclosed in SEQ ID NOS:9-503 can be generated and screened essentially as described in U.S. Patents Nos. 5,143,854, 5,405,783, and 5,252,743, the complete disclosures of which are herein incorporated by references.

 Additionally, the presently described GTSSs, or primers derived therefrom, can be used to screen spatially addressable arrays, or pools therefrom, of clones present in a full-length
30 human cDNA library. The 96 well microtiter plate format is especially well-suited to the

screening, by PCR for example, of pooled subfractions of cDNA clones.

5.6 SCREENING ASSAYS FOR COMPOUNDS THAT MODULATE THE EXPRESSION OR ACTIVITY OF PEPTIDES AND PROTEINS OF THE CURRENT INVENTION

The following assays are designed to identify compounds that interact with (*e.g.*, bind to) peptides and proteins at least partially encoded by one of SEQ ID NOS:9-503 (*i.e.*, peptides or proteins of the current invention) compounds that interact with (*e.g.*, bind to) intracellular proteins that interact with peptides and proteins of the current invention, compounds that interfere with the interaction of peptides and proteins of the current invention with each other and with other intracellular proteins involved in developmental and cell differentiation processes, and to compounds which modulate the activity of genes of the current invention (*i.e.*, modulate the level of expression of genes of the current invention) or modulate the level of gene products of the current invention. Assays may additionally be utilized which identify compounds which bind to gene regulatory sequences (*e.g.*, promoter sequences) and which may modulate the expression of genes of the current invention. See *e.g.*, Platt, K.A., 1994, J. Biol. Chem. 269:28558-28562, which is incorporated herein by reference in its entirety.

Compounds that can be screened in accordance with the invention include, but are not limited to, peptides, antibodies and fragments thereof, prostaglandins, lipids and other organic compounds (*e.g.*, terpenes, peptidomimetics) that bind to the peptide or protein of interest of the current invention and either mimic the activity triggered by the natural ligand (*i.e.*, agonists) or inhibit the activity triggered by the natural ligand (*i.e.*, antagonists); as well as peptides, antibodies or fragments thereof, and other organic compounds that mimic the peptide or protein of interest of the current invention (or a portion thereof) and bind to and "neutralize" natural ligand.

Such compounds may include, but are not limited to, peptides such as, for example, soluble peptides, including but not limited to members of random peptide libraries (see, *e.g.*, Lam, K.S. *et al.*, 1991, Nature 354:82-84; Houghten, R. *et al.*, 1991, Nature 354:84-86), and combinatorial chemistry-derived molecular library peptides made of D- and/or L-configuration amino acids, phosphopeptides (including, but not limited to, members of

random or partially degenerate, directed phosphopeptide libraries; see, *e.g.*, Songyang, Z. *et al.*, 1993, Cell 72:767-778); antibodies (including, but not limited to, polyclonal, monoclonal, humanized, anti-idiotypic, chimeric or single chain antibodies, and Fab, F(ab')₂ and Fab expression library fragments, and epitope-binding fragments thereof); and small organic or inorganic molecules.

Other compounds that can be screened in accordance with the invention include, but are not limited to, small organic molecules that are able to gain entry into an appropriate cell (*e.g.*, in ES cells) and affect the expression of a gene of the current invention or some other gene involved in development and cell differentiation (*e.g.*, by interacting with the regulatory region or transcription factors involved in gene expression); or such compounds that affect the activity of the peptide or protein of interest of the current invention, *e.g.*, by inhibiting or enhancing the binding of such peptide or protein to another cellular peptide or protein, or other factor, necessary for catalysis, signal transduction, or the like, that is involved in developmental or cell differentiation processes.

Computer modeling and searching technologies permit the identification of compounds, or the improvement of already identified compounds, that can modulate the expression or activity of peptides or proteins of interest of the current invention. Having identified such a compound or composition, the active sites or regions are identified. Such active sites might typically be the binding partner sites, such as, for example, the interaction domains of the peptides and proteins of the current invention with their respective binding partners. The active site can be identified using methods known in the art including, for example, from study of the amino acid sequences of peptides, from the nucleotide sequences of nucleic acids, or from study of complexes of the relevant compound or composition with its natural ligand. In the latter case, chemical or X-ray crystallographic methods can be used to find the active site by finding where on the factor the complexed ligand is found.

Next, the three dimensional geometric structure of the active site is determined. This can be done by known methods, including X-ray crystallography, which can determine a complete molecular structure. On the other hand, solid or liquid phase NMR can be used to determine certain intra-molecular distances. Any other experimental method of structure determination can be used to obtain partial or complete geometric structures. The geometric

structures may be measured with a complexed ligand, natural or artificial, which may increase the accuracy of the active site structure determined.

If an incomplete or insufficiently accurate structure is determined, the methods of computer based numerical modeling can be used to complete the structure or improve its accuracy. Any recognized modeling method may be used, including parameterized models specific to particular biopolymers such as proteins or nucleic acids, molecular dynamics models based on computing molecular motions, statistical mechanics models based on thermal ensembles, or combined models. For most types of models, standard molecular force fields, representing the forces between constituent atoms and groups, are necessary, and can be selected from force fields known in physical chemistry. The incomplete or less accurate experimental structures can serve as constraints on the complete and more accurate structures computed by these modeling methods.

Finally, having determined the structure of the active site, either experimentally, by modeling, or by a combination, candidate modulating compounds can be identified by searching databases containing compounds along with information on their molecular structure. Such a search seeks compounds having structures that match the determined active site structure and that interact with the groups defining the active site. Such a search can be manual, but is preferably computer assisted. These compounds found from this search are potential modulating compounds of the peptides and proteins of interest of the current invention.

Alternatively, these methods can be used to identify improved modulating compounds from an already known modulating compound or ligand. The composition of the known compound can be modified and the structural effects of modification can be determined using the experimental and computer modeling methods described above applied to the new composition. The altered structure is then compared to the active site structure of the compound to determine if an improved fit or interaction results. In this manner, systematic variations in composition, such as by varying side groups, can be quickly evaluated to obtain modified modulating compounds or ligands of improved specificity or activity.

Further experimental and computer modeling methods useful to identify modulating compounds based upon identification of the active sites of peptides and proteins of interest of

the current invention, and related factors involved in development, cellular differentiation, and other cellular processes will be apparent to those of skill in the art.

Examples of molecular modeling systems are the CHARM and QUANTA programs (Polygon Corporation, Waltham, MA). CHARM performs the energy minimization and molecular dynamics functions. QUANTA performs the construction, graphic modeling and analysis of molecular structure. QUANTA allows interactive construction, modification, visualization, and analysis of the behavior of molecules with each other.

A number of articles review computer modeling of drugs interactive with specific proteins, such as Rotivinen *et al.*, 1988, *Acta Pharmaceutica Fennica* 97:159-166; Ripka, New Scientist 54-57 (June 16, 1988); McKinaly and Rossmann, 1989, *Annu. Rev. Pharmacol. Toxicol.* 29:111-122; Perry and Davies, OSAR: Quantitative Structure-Activity Relationships in Drug Design pp. 189-193 (Alan R. Liss, Inc. 1989); Lewis and Dean, 1989, *Proc. R. Soc. Lond.* 236:125-140 and 141-162; and, with respect to a model receptor for nucleic acid components, Askew *et al.*, 1989, *J. Am. Chem. Soc.* 111:1082-1090. Other computer programs that screen and graphically depict chemicals are available from companies such as BioDesign, Inc. (Pasadena, CA.), Allelix, Inc. (Mississauga, Ontario, Canada), and Hypercube, Inc. (Cambridge, Ontario). Although these are primarily designed for application to drugs specific to particular proteins, they can be adapted to the design of drugs specific to regions of DNA or RNA, once that region is identified.

Although described above with reference to design and generation of compounds which could alter binding, one could also screen libraries of known compounds, including natural products or synthetic chemicals, and biologically active materials, including proteins, for compounds which are inhibitors or activators.

Compounds identified via assays such as those described herein may be useful, for example, in elaborating the biological function of the gene products of interest of the current invention and for ameliorating disorders affecting development and cell differentiation. Assays for testing the effectiveness of compounds, identified by, for example, techniques such as those described below.

5.6.1. **IN VITRO SCREENING ASSAYS FOR COMPOUNDS THAT BIND TO PEPTIDES AND PROTEINS OF THE CURRENT INVENTION**

In vitro systems may be designed to identify compounds capable of interacting with (e.g., binding to) peptides and proteins of interest of the current invention, fragments thereof, and variants thereof. The identified compounds can be useful, for example, in modulating the activity of wild type and/or mutant gene products of the current invention; may be utilized in screens for identifying compounds that disrupt normal interactions of the peptides and proteins of the current invention with other factors, like, for example, other peptides and proteins; or may in themselves disrupt such interactions.

The principle of the assays used to identify compounds that bind to the peptides and proteins of the current invention involves preparing a reaction mixture of the peptides and proteins of interest that are disclosed by the current invention and a test compound under conditions and for a time sufficient to allow the two components to interact and bind, thus forming a complex that can be removed from and/or detected in the reaction mixture. The peptides and proteins of the current invention used can vary depending upon the goal of the screening assay. For example, where agonists of the natural ligand are sought, the full length peptide or protein of interest, or a fusion protein containing the subunit of interest fused to a protein or polypeptide that affords advantages in the assay system (e.g., labeling, isolation of the resulting complex, etc.) can be utilized.

The screening assays can be conducted in a variety of ways. For example, one method of conducting such an assay involves anchoring the peptide or protein of interest, or a fragment or fusion protein thereof, or the test substance onto a solid phase and detecting peptide or protein of interest/test compound complexes anchored on the solid phase at the end of the reaction. In one embodiment of such a method, the peptide or protein of interest may be anchored onto a solid surface, and the test compound, which is not anchored, may be labeled, either directly or indirectly. In another embodiment of the method, a peptide or protein of interest of the current invention anchored on the solid phase is complexed with a natural ligand of such peptide or protein of interest. Then, a test compound could be assayed for its ability to disrupt the association of the complex.

In practice, microtiter plates may conveniently be utilized as the solid phase. The anchored component may be immobilized by non-covalent or covalent attachments. Non-covalent attachment may be accomplished by simply coating the solid surface with a solution of the protein and drying. Alternatively, an immobilized antibody, preferably a monoclonal antibody, specific for the peptide or protein to be immobilized may be used to anchor the peptide or protein to the solid surface. The surfaces may be prepared in advance and stored.

In order to conduct the assay, the nonimmobilized component is added to the coated surface containing the anchored component. After the reaction is complete, unreacted components are removed (*e.g.*, by washing) under conditions such that any complexes formed will remain immobilized on the solid surface. The detection of complexes anchored on the solid surface can be accomplished in a number of ways. Where the previously nonimmobilized component is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the previously nonimmobilized component is not pre-labeled, an indirect label can be used to detect complexes anchored on the surface; *e.g.*, using a labeled antibody specific for the previously nonimmobilized component (the antibody, in turn, may be directly labeled or indirectly labeled with a labeled anti-Ig antibody).

Alternatively, a reaction can be conducted in a liquid phase, the reaction products separated from unreacted components, and complexes detected; *e.g.*, using an immobilized antibody specific for one component of complexes formed, like, for example, the peptide or protein of interest of the current invention or the test compound to anchor any complexes formed in solution, and a labeled antibody specific for the other component of the possible complex to detect anchored complexes.

5.6.2 ASSAYS FOR INTRACELLULAR PROTEINS THAT INTERACT WITH THE PEPTIDES AND PROTEINS OF THE CURRENT INVENTION

Any method suitable for detecting protein-protein interactions may be employed for identifying intracellular peptides and proteins that interact with peptides and proteins of the current invention. Among the traditional methods which may be employed are co-immunoprecipitation, crosslinking and co-purification through gradients or

chromatographic columns of cell lysates or proteins obtained from cell lysates and the peptides and proteins of the current invention to identify proteins in the lysate that interact with those peptides and proteins of the current invention. For these assays, the peptides and proteins of the current invention may be used in full length, or in truncated or modified forms or as fusion-proteins. Similarly, the component may be a complex of two or more of the peptides and proteins of the current invention. Once isolated, such an intracellular protein can be identified and can, in turn, be used in conjunction with standard techniques to identify proteins with which it interacts. For example, at least a portion of the amino acid sequence of an intracellular protein which interacts with a peptide or protein of the current invention, can be ascertained using techniques well known to those of skill in the art, such as via the Edman degradation technique. (See, *e.g.*, Creighton, 1983, "Proteins: Structures and Molecular Principles", W.H. Freeman & Co., N.Y., pp.34-49). The amino acid sequence obtained may be used as a guide for the generation of oligonucleotide mixtures that can be used to screen for gene sequences encoding such intracellular proteins. Screening may be accomplished, for example, by standard hybridization or PCR techniques. Techniques for the generation of oligonucleotide mixtures and the screening are well-known. (See, *e.g.*, Ausubel, supra., and PCR Protocols: A Guide to Methods and Applications, 1990, Innis, M. *et al.*, eds. Academic Press, Inc., New York).

Additionally, methods may be employed which result in the simultaneous identification of genes which encode the intracellular proteins interacting with peptides and proteins of the current invention. These methods include, for example, probing expression libraries, in a manner similar to the well known technique of antibody probing of cDNA libraries, using a labeled form of a peptide or protein of the current invention, or a fusion protein, *e.g.*, a peptide or protein at least partially encoded by a GTS of the present invention fused to a marker (*e.g.*, an enzyme, fluor, luminescent protein, or dye), or an Ig-Fc domain.

One method that detects protein interactions *in vivo*, the two-hybrid system, is described in detail for illustration only and not by way of limitation. One version of this system has been described (Chien *et al.*, 1991, Proc. Natl. Acad. Sci. USA, 88:9578-9582) and is commercially available from Clontech (Palo Alto, CA).

Briefly, utilizing such a system, plasmids are constructed that encode two hybrid proteins: one plasmid consists of nucleotides encoding the DNA-binding domain of a transcription activator protein fused to a nucleotide sequence of the current invention encoding a peptide or protein of the current invention, a modified or truncated form or a fusion protein, and the other plasmid consists of nucleotides encoding the transcription activator protein's activation domain fused to a cDNA encoding an unknown protein which has been recombined into this plasmid as part of a cDNA library. The DNA-binding domain fusion plasmid and the cDNA library are transformed into a strain of the yeast *Saccharomyces cerevisiae* that contains a reporter gene (*e.g.*, HBS or *lacZ*) whose regulatory region contains the transcription activator's binding site. Either hybrid protein alone cannot activate transcription of the reporter gene; the DNA-binding domain hybrid cannot because it does not provide activation function, and the activation domain hybrid cannot because it cannot localize to the activator's binding sites. Interaction of the two hybrid proteins reconstitutes the functional activator protein and results in expression of the reporter gene, which is detected by an assay for the reporter gene product.

The two-hybrid system or related methodology may be used to screen activation domain libraries for proteins that interact with the "bait" gene product. By way of example, and not by way of limitation, a peptide or protein of the current invention may be used as the bait gene product. Total genomic or cDNA sequences are fused to the DNA encoding an activation domain. This library and a plasmid encoding a hybrid of a bait gene product of the current invention fused to the DNA-binding domain are cotransformed into a yeast reporter strain, and the resulting transformants are screened for those that express the reporter gene. For example, and not by way of limitation, a bait gene sequence of the current invention can be cloned into a vector such that it is translationally fused to the DNA encoding the DNA-binding domain of the GAL4 protein. These colonies are purified and the library plasmids responsible for reporter gene expression are isolated. DNA sequencing is then used to identify the proteins encoded by the library plasmids.

A cDNA library of the cell line from which proteins that interact with bait gene product of the current invention are to be detected can be made using methods routinely practiced in the art. According to the particular system described herein, for example, the

cDNA fragments can be inserted into a vector such that they are translationally fused to the transcriptional activation domain of GAL4. This library can be co-transfected along with the bait gene-GAL4 fusion plasmid into a yeast strain which contains a lacZ gene driven by a promoter which contains GAL4 activation sequence. A cDNA encoded protein, fused to GAL4 transcriptional activation domain, that interacts with bait gene product will reconstitute an active GAL4 protein and thereby drive expression of the HIS3 gene. Colonies which express HIS3 can be detected by their growth on petri dishes containing semi-solid agar based media lacking histidine. The cDNA can then be purified from these strains, and used to produce and isolate the bait gene-interacting protein using techniques routinely practiced in the art.

5.6.3 ASSAYS FOR COMPOUNDS THAT INTERFERE WITH INTERACTIONS OF THE PEPTIDES AND PROTEINS OF THE CURRENT INVENTION WITH INTRACELLULAR MACROMOLECULES

The macromolecules that interact with the peptides and proteins of the current invention are referred to, for purposes of this discussion, as "binding partners". These binding partners are likely to be involved in catalytic reactions or signal transduction pathways, and therefore, in the role of the peptides and proteins of the current invention in development and cell differentiation. It is also desirable to identify compounds that interfere with or disrupt the interaction of such binding partners with the peptides and proteins of the current invention which may be useful in regulating the activity of the peptides and proteins of the current invention and thus control development and cell differentiation disorders associated with the activity of the peptides and proteins of the current invention.

The basic principle of the assay systems used to identify compounds that interfere with the interaction between the peptides and proteins of the current invention and its binding partner or partners involves preparing a reaction mixture containing the peptides or proteins of the current invention of interest, modified or truncated version thereof, or fusion proteins thereof as described above, and the binding partner under conditions and for a time sufficient to allow the two to interact and bind, thus forming a complex. In order to test a compound for inhibitory activity, the reaction mixture is prepared in the presence and absence of the test

compound. The test compound may be initially included in the reaction mixture, or may be added at a time subsequent to the addition of the peptide or protein of the current invention and its binding partner. Control reaction mixtures are incubated without the test compound or with a placebo. The formation of any complexes between the peptide or protein of the current invention and the binding partner is then detected. The formation of a complex in the control reaction, but not in the reaction mixture containing the test compound, indicates that the compound interferes with the interaction of the peptide or protein at least partially encoded by a GTS of the present invention and the interactive binding partner. Additionally, complex formation within reaction mixtures containing the test compound and normal peptide or protein of the current invention may also be compared to complex formation within reaction mixtures containing the test compound and a mutant peptide or protein of the current invention. This comparison can be important in those cases wherein it is desirable to identify compounds that disrupt interactions of mutant but not normal forms of a peptide or protein of the current invention.

The assay for compounds that interfere with the interaction of a peptide or protein of the current invention and binding partners can be conducted in a heterogeneous or homogeneous format. Heterogeneous assays involve anchoring either the peptide or protein of the current invention or the binding partner onto a solid phase and detecting complexes anchored on the solid phase at the end of the reaction. In homogeneous assays, the entire reaction is carried out in a liquid phase. In either approach, the order of addition of reactants can be varied to obtain different information about the compounds being tested. For example, test compounds that interfere with the interaction by competition can be identified by conducting the reaction in the presence of the test substance; *i.e.*, by adding the test substance to the reaction mixture prior to or simultaneously with the peptide or protein of the current invention and interactive binding partner. Alternatively, test compounds that disrupt preformed complexes, *e.g.* compounds with higher binding constants that displace one of the components from the complex, can be tested by adding the test compound to the reaction mixture after complexes have been formed. The various formats are described briefly below.

In a heterogeneous assay system, either the peptide or protein of the current invention or the interactive binding partner, is anchored onto a solid surface, while the non-anchored

species is labeled either directly or indirectly. In practice, microtiter plates are conveniently utilized. The anchored species may be immobilized by non-covalent or covalent attachments. Non-covalent attachment may be accomplished simply by coating the solid surface with a solution of the peptide or protein of the current invention or binding partner and drying.

- 5 Alternatively, an immobilized antibody specific for the species to be anchored may be used to anchor the species to the solid surface. The surfaces may be prepared in advance and stored.

In order to conduct the assay, the partner of the immobilized species is exposed to the coated surface with or without the test compound. After the reaction is complete, unreacted components are removed (*e.g.*, by washing) and any complexes formed will remain

- 10 immobilized on the solid surface. The detection of complexes anchored on the solid surface can be accomplished in a number of ways. Where the non-immobilized species is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the non-immobilized species is not pre-labeled, an indirect label can be used to detect complexes anchored on the surface; *e.g.*, using a labeled antibody specific for the
- 15 initially non-immobilized species (the antibody, in turn, may be directly labeled or indirectly labeled with a labeled anti-Ig antibody). Depending upon the order of addition of reaction components, test compounds which inhibit complex formation or which disrupt preformed complexes can be detected.

- Alternatively, the reaction can be conducted in a liquid phase in the presence or
- 20 absence of the test compound, the reaction products separated from unreacted components, and complexes detected; *e.g.*, using an immobilized antibody specific for one of the binding components to anchor any complexes formed in solution, and a labeled antibody specific for the other partner to detect anchored complexes. Again, depending upon the order of addition of reactants to the liquid phase, test compounds which inhibit complex or which disrupt
- 25 preformed complexes can be identified.

- In an alternate embodiment of the invention, a homogeneous assay can be used. In this approach, a preformed complex of the peptide or protein of the current invention and the interactive binding partner is prepared in which either the peptide or protein of the current invention or its binding partner is labeled, but the signal generated by the label is quenched
- 30 due to formation of the complex (see, *e.g.*, U.S. Patent No. 4,109,496 by Rubenstein which

utilizes this approach for immunoassays). The addition of a test substance that competes with and displaces one of the species from the preformed complex will result in the generation of a signal above background. In this way, test substances which disrupt peptide or protein of the current invention/intracellular binding partner interaction can be identified.

5 In a particular embodiment, a peptide or protein of the current invention can be prepared for immobilization. For example, the peptide or protein of the current invention or a fragment thereof can be fused to a glutathione-S-transferase (GST) gene using a fusion vector, such as pGEX-5X-1, in such a manner that its binding activity is maintained in the resulting fusion protein. The interactive binding partner can be purified and used to raise a
10 monoclonal antibody, using methods routinely practiced in the art and described above. This antibody can be labeled with the radioactive isotope ^{125}I , for example, by methods routinely practiced in the art. In a heterogeneous assay, *e.g.*, the GST-peptide or protein of the current invention fusion protein can be anchored to glutathione-agarose beads. The interactive binding partner can then be added in the presence or absence of the test compound in a
15 manner that allows interaction and binding to occur. At the end of the reaction period, unbound material can be washed away, and the labeled monoclonal antibody can be added to the system and allowed to bind to the complexed components. The interaction between the peptide or protein of the current invention and the interactive binding partner can be detected by measuring the amount of radioactivity that remains associated with the glutathione-
20 agarose beads. A successful inhibition of the interaction by the test compound will result in a decrease in measured radioactivity.

Alternatively, the GST-peptide or protein of the current invention fusion protein and the interactive binding partner can be mixed together in liquid in the absence of the solid glutathione-agarose beads. The test compound can be added either during or after the species
25 are allowed to interact. This mixture can then be added to the glutathione-agarose beads and unbound material is washed away. Again the extent of inhibition of the peptide or protein of the current invention/binding partner interaction can be detected by adding the labeled antibody and measuring the radioactivity associated with the beads.

In another embodiment of the invention, these same techniques can be employed
30 using peptide fragments that correspond to the binding domains of a peptide or protein of the

current invention and/or the interactive or binding partner (in cases where the binding partner is a protein) in place of one or both of the full length proteins. Any number of methods routinely practiced in the art can be used to identify and isolate the binding sites. These methods include, but are not limited to, mutagenesis of the gene encoding one of the proteins and screening for disruption of binding in a co-immunoprecipitation assay. Compensating mutations in the gene encoding the second species in the complex can then be selected. Sequence analysis of the genes encoding the respective proteins will reveal the mutations that correspond to the region of the protein involved in interactive binding. Alternatively, one protein can be anchored to a solid surface using methods described above, and allowed to interact with and bind to its labeled binding partner, which has been treated with a proteolytic enzyme, such as trypsin. After washing, a short, labeled peptide comprising the binding domain may remain associated with the solid material, which can be isolated and identified by amino acid sequencing. Also, once the gene coding for the intracellular binding partner is obtained, short gene segments can be engineered to express peptide fragments of the protein, which can then be tested for binding activity and purified or synthesized.

For example, and not by way of limitation, a peptide or protein of the current invention can be anchored to a solid material as described, above, by making a GST-peptide or protein of the current invention fusion protein and allowing it to bind to glutathione agarose beads. The interactive binding partner can be labeled with a radioactive isotope, such as ^{35}S , and cleaved with a proteolytic enzyme such as trypsin. Cleavage products can then be added to the anchored GST-peptide or protein of the current invention fusion protein and allowed to bind. After washing away unbound peptides, labeled bound material, representing the intracellular binding partner binding domain, can be eluted, purified, and analyzed for amino acid sequence by well-known methods. Peptides so identified can be produced synthetically or fused to appropriate facilitative proteins using recombinant DNA technology.

5.6.4 ASSAYS FOR IDENTIFICATION OF COMPOUNDS THAT AMELIORATE DISORDERS AFFECTING DEVELOPMENT AND CELL DIFFERENTIATION

Compounds including, but not limited to, binding compounds identified via assay techniques such as those described above, can be tested for the ability to ameliorate

development and cell differentiation disorder symptoms. The assays described above can identify compounds which affect the activity of peptides and proteins of the current invention (*e.g.*, compounds that bind to the peptides and proteins of the current invention, inhibit binding of their natural ligands, and compounds that bind to a natural ligand of the peptides and proteins of the current invention and neutralize the ligand activity); or compounds that affect the activity of genes encoding peptides and proteins of the current invention (by affecting the expression of those genes, including molecules, *e.g.*, proteins or small organic molecules, that affect or interfere with splicing events so that expression of the genes of interest can be modulated). However, it should be noted that the assays described herein can also identify compounds that modulate signal transduction or catalytic events that the peptides and proteins of the current invention are involved in. The identification and use of such compounds which affect a step in, for example, signal transduction pathways or catalytic events in which any of the peptides and proteins of the current invention are involved in, may modulate the effect of the peptides and proteins of the current invention on developmental or cell differentiation disorders. Such identification and use of such compounds are within the scope of the invention. Such compounds can be used as part of a therapeutic method for the treatment of developmental and cell differentiation disorders.

The invention encompasses cell-based and animal model-based assays for the identification of compounds exhibiting such an ability to ameliorate developmental and cell differentiation disorder symptoms. Such cell-based assay systems can also be used as the standard to assay for purity and potency of the natural ligand, catalytic subunit, including recombinantly or synthetically produced catalytic subunit and catalytic subunit mutants.

Cell-based systems can be used to identify compounds which may act to ameliorate developmental or cell differentiation disorder symptoms. Such cell systems can include, for example, recombinant or non-recombinant cells, such as cell lines, which express the gene encoding the peptide or protein of interest of the current invention. For example ES cells, or cell lines derived from ES cells can be used. In addition, expression host cells (*e.g.*, COS cells, CHO cells, fibroblasts, Sf9 cells) genetically engineered to express a functional peptide or protein of the current invention in addition to factors necessary for the peptide or protein of

the current invention to fulfil its physiological role of, for example, signal transduction or catalyses, can be used as an end point in the assay.

In utilizing such cell systems, cells may be exposed to a compound suspected of exhibiting an ability to ameliorate developmental or cell differentiation disorder symptoms, at a sufficient concentration and for a time sufficient to elicit such an amelioration of such disorder symptoms in the exposed cells. After exposure, the cells can be assayed to measure alterations in the expression of the gene encoding the peptide or protein of interest of the current invention, *e.g.*, by assaying cell lysates for the appropriate mRNA transcripts (*e.g.*, by Northern analysis) or for expression of the peptide or protein of interest of the current invention in the cell; compounds which regulate or modulate expression of the gene encoding the peptide or protein of interest of the current invention are valuable candidates as therapeutics. Alternatively, the cells are examined to determine whether one or more developmental or cell differentiation disorder-like cellular phenotypes has been altered to resemble a more normal or more wild type phenotype, or a phenotype more likely to produce a lower incidence or severity of disorder symptoms. Still further, the expression and/or activity of components of pathways or functionally or physiologically connected peptides or proteins of which the peptide or protein of interest of the current invention is a part, can be assayed.

For example, after exposure of the cells, cell lysates can be assayed for the presence of increased levels of the test compound as compared to lysates derived from unexposed control cells. The ability of a test compound to inhibit production of the assay compound such systems indicates that the test compound inhibits signal transduction initiated by the peptide or protein of interest of the current invention. Finally, a change in cellular morphology of intact cells may be assayed using techniques well known to those of skill in the art.

In addition, animal-based development or cell differentiation disorder systems, which may include, for example, mice, may be used to identify compounds capable of ameliorating development or cell differentiation disorder-like symptoms. Such animal models may be used as test systems for the identification of drugs, pharmaceuticals, therapies and interventions which may be effective in treating such disorders. For example, animal models may be exposed to a compound, suspected of exhibiting an ability to ameliorate development

or cell differentiation disorder symptoms, at a sufficient concentration and for a time sufficient to elicit such an amelioration of development and/or cell differentiation disorder symptoms in the exposed animals. The response of the animals to the exposure may be monitored by assessing the reversal of disorders associated with development and/or cell differentiation disorders. With regard to intervention, any treatments which reverse any aspect of development or cell differentiation disorder-like symptoms should be considered as candidates for human development and/or cell differentiation disorder therapeutic intervention. Dosages of test agents may be determined by deriving dose-response curves, as discussed below.

5.7 THE TREATMENT OF DISORDERS ASSOCIATED WITH STIMULATION OF PEPTIDES AND PROTEINS OF THE CURRENT INVENTION

The invention also encompasses methods and compositions for modifying development and cell differentiation and treating development and cell differentiation disorders. For example, one may decrease the level of expression of one or more genes of the current invention, and/or downregulate activity of one or more of the peptides or proteins of interest of the current invention. Thereby, the response of cells, like, for example, ES cells, to factors which activate the physiological responses that enhance the pathological processes leading to developmental and cell differentiation disorders may be reduced and the symptoms ameliorated. Conversely, the response of cells, like, for example, ES cells, to physiological stimuli involving any of the peptides or proteins of the current invention and necessary for proper developmental and cell differentiation processes may be augmented by increasing the activity of one or several of the peptides or proteins of interest of the current invention. Different approaches are discussed below.

5.7.1 INHIBITION OF PEPTIDES AND PROTEINS OF THE CURRENT INVENTION TO REDUCE DEVELOPMENT AND CELL DIFFERENTIATION DISORDERS

Any method which neutralizes the catalytic or signal transduction activity of the peptides and proteins of the current invention or which inhibits expression of the genes

encoding peptides and proteins (either transcription or translation) can be used to reduce symptoms associated with developmental and cell differentiation disorders.

In one embodiment, immuno therapy can be designed to reduce the level of endogenous gene expression for the peptides and proteins of the current invention, *e.g.*, using antisense or ribozyme approaches to inhibit or prevent translation of mRNA transcripts; triple helix approaches to inhibit transcription of the genes; or targeted homologous recombination to inactivate or "knock out" the genes or its endogenous promoter.

Antisense approaches involve the design of oligonucleotides (either DNA or RNA) that are complementary to mRNA specific for peptides and proteins of interest of the current invention. The antisense oligonucleotides will bind to the complementary mRNA transcripts and prevent translation. Absolute complementarity, although preferred, is not required. A sequence "complementary" to a portion of an RNA, as referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex. In the case of double-stranded antisense nucleic acids, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the longer the hybridizing nucleic acid, the more base mismatches with an RNA it may contain and still form a stable duplex (or triplex, as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

Oligonucleotides that are complementary to the 5' end of the message, *e.g.*, the 5' untranslated sequence up to and including the AUG initiation codon, should work most efficiently at inhibiting translation. However, sequences complementary to the 3' untranslated sequences of mRNAs have recently shown to be effective at inhibiting translation of mRNAs as well. See generally, Wagner, R., 1994, *Nature* 372:333-335. Thus, oligonucleotides complementary to either the 5'- or 3'- non- translated, non-coding regions of the mRNAs specific for the peptides and proteins of the current invention could be used in an antisense approach to inhibit translation of those endogenous mRNAs. Oligonucleotides complementary to the 5' untranslated region of the mRNA should include the complement of the AUG start codon. Antisense oligonucleotides complementary to mRNA coding regions

are less efficient inhibitors of translation but could be used in accordance with the invention. Whether designed to hybridize to the 5'-, 3'- or coding region of an mRNA, antisense nucleic acids should be at least six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects the oligonucleotide is at least 10
5 nucleotides, at least 17 nucleotides, at least 25 nucleotides or at least 50 nucleotides.

Regardless of the choice of target sequence, it is preferred that *in vitro* studies are first performed to quantitate the ability of the antisense oligonucleotide to inhibit gene expression. It is preferred that these studies utilize controls that distinguish between antisense gene inhibition and nonspecific biological effects of oligonucleotides. It is also preferred that these
10 studies compare levels of the target RNA or protein with that of an internal control RNA or protein. Additionally, it is envisioned that results obtained using the antisense oligonucleotide are compared with those obtained using a control oligonucleotide. It is preferred that the control oligonucleotide is of approximately the same length as the test oligonucleotide and that the nucleotide sequence of the oligonucleotide differs from the
15 antisense sequence no more than is necessary to prevent specific hybridization to the target sequence.

The oligonucleotides can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve
20 stability of the molecule, hybridization, etc. The oligonucleotide may include other appended groups such as peptides (*e.g.*, for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, *e.g.*, Letsinger *et al.*, 1989, Proc. Natl. Acad. Sci. U.S.A. 86:6553-6556; Lemaitre *et al.*, 1987, Proc. Natl. Acad. Sci. 84:648-652; PCT Publication No. WO88/09810, published December 15, 1988), or hybridization-triggered
25 cleavage agents. (See, *e.g.*, Krol *et al.*, 1988, BioTechniques 6:958-976) or intercalating agents. (See, *e.g.*, Zon, 1988, Pharm. Res. 5:539-549). To this end, the oligonucleotide may be conjugated to another molecule, *e.g.*, a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

The antisense oligonucleotide may comprise at least one modified base moiety which
30 is selected from the group including, but not limited to, 5-fluorouracil, 5-bromouracil,

- 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine,
 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine,
 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine,
 N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine,
 5 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine,
 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-
 D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-
 isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine,
 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-
 10 5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-
 3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including, but not limited to, arabinose, 2-fluoroarabinose, xylulose, and hexose.

- 15 In another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

- In yet another embodiment, the antisense oligonucleotide is an alpha-anomeric
 20 oligonucleotide. An alpha-anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual alpha-units, the strands run parallel to each other (Gautier *et al.*, 1987, Nucl. Acids Res. 15:6625-6641). The oligonucleotide is a 2'-O-methylribonucleotide (Inoue *et al.*, 1987, Nucl. Acids Res. 15:6131-6148), or a chimeric RNA-DNA analogue (Inoue *et al.*, 1987, FEBS Lett. 215:327-330).

- 25 Oligonucleotides of the invention may be synthesized by standard methods known in the art, *e.g.* by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein *et al.*, 1988, Nucl. Acids Res. 16:3209.

- Methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer
 30 supports (Sarin *et al.*, 1988, Proc. Natl. Acad. Sci. U.S.A. 85:7448-7451).

While antisense nucleotides complementary to the coding region sequence specific for the peptides and proteins of the current invention could be used, those complementary to the transcribed untranslated region are most preferred.

The antisense molecules should be delivered to cells which express the peptides and proteins of interest of the current invention *in vivo*, like, for example, ES cells. A number of methods have been developed for delivering antisense DNA or RNA to cells; *e.g.*, antisense molecules can be injected directly into the tissue or cell derivation site, or modified antisense molecules, designed to target the desired cells (*e.g.*, antisense linked to peptides or antibodies that specifically bind receptors or antigens expressed on the target cell surface) can be administered systemically.

However, it is often difficult to achieve intracellular concentrations of antisense molecules that are sufficient to suppress translation of endogenous mRNAs. Therefore a preferred approach utilizes a recombinant DNA construct in which the antisense oligonucleotide is placed under the control of a strong pol III or pol II promoter. The use of such a construct to transfect target cells in the patient will result in the transcription of sufficient amounts of single stranded RNAs that will form complementary base pairs with the endogenous transcripts specific for the peptides and proteins of interest of the current invention and thereby prevent translation of the respective mRNAs. For example, a vector can be introduced *in vivo* such that it is taken up by a cell and directs the transcription of an antisense RNA. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in mammalian cells. Expression of the sequence encoding the antisense RNA can be by any promoter known in the art to act in mammalian, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include, but are not limited to: the SV40 early promoter region (Bernoist and Chambon, 1981, Nature 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto *et al.*, 1980, Cell 22:787-797), the herpes thymidine kinase promoter (Wagner *et al.*, 1981, Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster *et al.*,

1982, Nature 296:39-42), etc. Any type of plasmid, cosmid, YAC or viral vector can be used to prepare the recombinant DNA construct which can be introduced directly into the tissue or cell derivation site; *e.g.*, the bone marrow. Alternatively, viral vectors can be used which selectively infect the desired tissue or cell type; (*e.g.*, viruses which infect cells of

5 hematopoietic lineage), in which case administration may be accomplished by another route (*e.g.*, systemically).

Ribozyme molecules designed to catalytically cleave mRNA transcripts specific for the peptides and proteins of interest of the current invention can also be used to prevent translation of the mRNAs of interest and expression of the peptides and proteins encoded by those mRNAs. (See, *e.g.*, PCT International Publication WO90/11364, published October 4, 10 1990; Sarver *et al.*, 1990, Science 247:1222-1225). While ribozymes that cleave mRNA at site specific recognition sequences can be used to destroy mRNAs, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole 15 requirement is that the target mRNA have the following sequence of two bases: 5'-UG-3'. The construction and production of hammerhead ribozymes is well known in the art and is described more fully in Haseloff and Gerlach, 1988, Nature, 334:585-591. Preferably the ribozyme is engineered so that the cleavage recognition site is located near the 5' end of the mRNA of interest; *i.e.*, to increase efficiency and minimize the intracellular accumulation of 20 non-functional mRNA transcripts.

The ribozymes of the present invention also include RNA endoribonucleases (hereinafter "Cech-type ribozymes") such as the one which occurs naturally in Tetrahymena Thermophila (known as the IVS, or L-19 IVS RNA) and which has been extensively described by Thomas Cech and collaborators (Zaug *et al.*, 1984, Science, 224:574-578; Zaug 25 and Cech, 1986, Science, 231:470-475; Zaug *et al.*, 1986, Nature, 324:429-433; published International Patent Application No. WO 88/04300 by University Patents Inc.; Been and Cech, 1986, Cell, 47:207-216). The Cech-type ribozymes have an eight base pair active site which hybridizes to a target RNA sequence where after cleavage of the target RNA takes place. The invention encompasses those Cech-type ribozymes which target eight base-pair

active site sequences that are present in the mRNAs specific for the peptides and proteins of interest of the current invention.

As in the antisense approach, the ribozymes can be composed of modified oligonucleotides (*e.g.* for improved stability, targeting, etc.) and should be delivered to cells which express the peptides and proteins of interest of the current invention *in vivo*, like, for example, ES cells. A preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy the endogenous messages specific for the peptides and proteins of interest of the current invention and inhibit translation. Because ribozymes unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene of interest specific for a peptide or protein of the current invention or its promoter using targeted homologous recombination. (*e.g.*, see Smithies *et al.*, 1985, Nature 317:230-234; Thomas & Capecchi, 1987, Cell 51:503-512; Thompson *et al.*, 1989 Cell 5:313-321; each of which is incorporated by reference herein in its entirety). For example, a mutant, non-functional peptide or protein of interest of the current invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous gene encoding said peptide or protein of interest of the current invention (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express said peptide or protein of interest of the current invention *in vivo*. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted endogenous gene. Such approaches are particularly suited in the agricultural field where modifications to ES cells can be used to generate animal offspring with an inactive copy of a gene encoding a peptide or protein of interest of the current invention (*e.g.*, see Thomas & Capecchi 1987 and Thompson 1989, supra). However this approach can be adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors.

Alternatively, endogenous expression of a gene of interest can be reduced by targeting deoxyribonucleotide sequences complementary to the regulatory region of said gene (*i.e.*, the promoter and/or enhancers) to form triple helical structures that prevent transcription of the gene of interest in target cells in the body. (See generally, Helene, C. 1991, Anticancer Drug Des., 6(6):569-84; Helene, C. *et al.*, 1992, Ann, N.Y. Acad. Sci., 660:27-36; and Maher, L.J., 1992, Bioassays 14(12):807-15).

In yet another embodiment of the invention, the activity of a peptide or protein of interest of the current invention can be reduced using a "dominant negative" approach. A dominant negative approach takes advantage of the interaction of the peptides or proteins of interest with other peptides or proteins to form complexes, the formation of which is a prerequisite for the peptide or protein of interest of the current invention to exert its physiological activity. To this end, constructs which encode a defective form of the peptide or protein of interest of the current invention can be used in gene therapy approaches to diminish the activity of said peptide or protein of interest in appropriate target cells.

Alternatively, targeted homologous recombination can be utilized to introduce such deletions or mutations into the subject's endogenous gene encoding the peptide or protein of interest of the current invention in the appropriate tissue. The engineered cells will express non-functional copies of the peptide or protein of interest of the current invention, thereby downregulating its activity *in vivo*. Such engineered cells should demonstrate a diminished response to physiological stimuli of the activity of the affected peptide or protein of interest of the current invention, resulting in reduction of the development or cell differentiation disorder phenotype.

5.7.2 RESTORATION OR INCREASE IN EXPRESSION OR ACTIVITY OF A PEPTIDE OR PROTEIN OF THE CURRENT INVENTION TO PROMOTE DEVELOPMENT OR CELL DIFFERENTIATION

With respect to an increase in the level of normal gene expression and/or gene product activity specific for any of the peptides and proteins of interest of the current invention, the respective nucleic acid sequences can be utilized for the treatment of development and cell differentiation disorders. Where the cause of the development or cell differentiation

dysfunction is a defective peptide or protein of the current invention, treatment can be administered, for example, in the form of gene delivery or gene therapy. Specifically, one or more copies of a normal gene or a portion of the gene that directs the production of a gene product exhibiting normal function of the appropriate peptide or protein of the current invention, may be inserted into the appropriate cells within a patient or animal subject, optionally using suitable vectors. Recombinant retroviruses have been widely used in gene transfer or gene delivery experiments and even human clinical trials (see generally, Mulligan, R.C., Chapter 8, In: Experimental Manipulation of Gene Expression, Academic Press, pp. 155-173 (1983); Coffin, J., In: RNA Tumor Viruses, Weiss, R. *et al.* (eds.), Cold Spring Harbor Laboratory, Vol. 2, pp. 36-38 (1985). Other eucaryotic viruses which have been used as vectors to transduce mammalian cells include adenovirus, papilloma virus, herpes virus, adeno-associated virus, vaccinia virus, rabies virus, and the like (See generally, Sambrook *et al.*, Molecular Cloning, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, Vol. 3:16.1-16.89 (1989). Alternatively, cationic or other lipids may be employed to deliver polynucleotides comprising (or including) the described GTS sequences to patients. Additionally, naked DNA comprising one or more GTS sequences, optionally modified by the addition of one or more of, in operable combination and orientation, a promoter, an enhancer, a ribosome entry or ribosome binding site, and/or an in-frame translation initiation codon can be employed to deliver GTSs to a patient. Another use of the above constructs includes "naked" DNA vaccines that can be introduced *in vivo* alone, or in conjunction with excipients, or microcarrier spheres, nanoparticles or other supporting or dosaging compounds or molecules.

The gene replacement/delivery therapies described above should be capable of delivering gene sequences to the cell types within patients which express the peptide or protein of interest of the current invention. Alternatively, targeted homologous recombination can be utilized to correct the defective endogenous gene in the appropriate cell type. In animals, targeted homologous recombination can be used to correct the defect in ES cells in order to generate offspring with a corrected trait.

Finally, compounds identified in the assays described above that stimulate, enhance, or modify the activity of the peptides and proteins of the current invention can be used to

achieve proper development and cell differentiation. The formulation and mode of administration will depend upon the physico-chemical properties of the compound.

5.8 PHARMACEUTICAL PREPARATIONS AND METHODS OF ADMINISTRATION

Compounds that are determined to affect gene expression of the peptides and proteins of the current invention, comprise nucleotide sequence information that is at least partially first disclosed in the Sequence Listing (*i.e.*, sequences used in antisense, gene therapy, dsRNA, or ribozyme applications), or the interaction of such peptides and proteins with any of their binding partners, can be administered to a patient at therapeutically effective doses to treat or ameliorate development and cell differentiation disorders. A therapeutically effective dose refers to that amount of the compound sufficient to result in any amelioration or retardation of disease symptoms, or development and cell differentiation or proliferation disorders.

5.8.1 EFFECTIVE DOSE

Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.*, for determining the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD₅₀/ED₅₀. Compounds which exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the

invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC₅₀ (*i.e.*, the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

When the therapeutic treatment of disease is contemplated, the appropriate dosage may also be determined using animal studies to determine the maximal tolerable dose, or MTD, of a bioactive agent per kilogram weight of the test subject. In general, at least one animal species tested is mammalian. Those skilled in the art regularly extrapolate doses for efficacy and avoiding toxicity to other species, including human. Before human studies of efficacy are undertaken, Phase I clinical studies in normal subjects help establish safe doses.

Additionally, the bioactive agent may be complexed with a variety of well established compounds or structures that, for instance, enhance the stability of the bioactive agent, or otherwise enhance its pharmacological properties (*e.g.*, increase *in vivo* half-life, reduce toxicity, etc.).

The above therapeutic agents will be administered by any number of methods known to those of ordinary skill in the art including, but not limited to, administration by inhalation; by subcutaneous (sub-q), intravenous (I.V.), intraperitoneal (I.P.), intramuscular (I.M.), or intrathecal injection; or as a topically applied agent (transderm, ointments, creams, salves, eye drops, and the like).

5.8.2 FORMULATIONS AND USE

Pharmaceutical compositions for use in accordance with the present invention may be formulated in conventional manner using one or more physiologically acceptable carriers or excipients.

Thus, the compounds and their physiologically acceptable salts and solvates may be formulated for administration by inhalation or insufflation (either through the mouth or the nose) or oral, buccal, parenteral or rectal administration.

For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (*e.g.*, pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (*e.g.*, lactose,

5 microcrystalline cellulose or calcium hydrogen phosphate); lubricants (*e.g.*, magnesium stearate, talc or silica); disintegrants (*e.g.*, potato starch or sodium starch glycolate); or wetting agents (*e.g.*, sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for
10 constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (*e.g.*, sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (*e.g.*, lecithin or acacia); non-aqueous vehicles (*e.g.*, almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (*e.g.*, methyl or propyl-
15 p-hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, flavoring, coloring and sweetening agents as appropriate.

Preparations for oral administration may be suitably formulated to give controlled release of the active compound.

For buccal administration the compositions may take the form of tablets or lozenges
20 formulated in conventional manner.

For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, *e.g.*,
dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide
25 or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of *e.g.* gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

The compounds may be formulated for parenteral administration by injection, *e.g.*, by
30 bolus injection or continuous infusion. Formulations for injection may be presented in unit

dosage form, *e.g.*, in ampules or in multi-dose containers, with an added preservative. The compositions

may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

- 5 Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, *e.g.*, sterile pyrogen-free water, before use.

The compounds may also be formulated as compositions for rectal administration such as suppositories or retention enemas, *e.g.*, containing conventional suppository bases such as cocoa butter or other glycerides.

- 10 In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange
15 resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt. The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may, for example, comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration.

- 20 The examples below are provided to illustrate the subject invention. These examples are provided by way of illustration and are not included for the purpose of limiting the invention in any way whatsoever.

6. EXAMPLES

25

6.1 CONSTRUCTION OF TRAPPED cDNA LIBRARIES

- The GTSs represented in SEQ ID NOS:9-503 were generated using normalized cDNA libraries produced as described in U.S. application Ser. No. 60/095,989, filed August 10, 1998 entitled "Construction of Normalized cDNA Libraries From Animal Cells" (also
30 identified as attorney docket no. 8535-021-888), by Nehls *et al.*, the disclosure of which is herein incorporated by reference in its entirety.

Figure 1A provides a representative illustration of the retroviral vector used to produce the described polynucleotides. In brief, pools of modified human PA-1 teratocarcinoma cells (*e.g.*, PA-2, PA-1 that has been transfected to express the murine ecotropic retrovirus receptor) were typically infected at an m.o.i. between about 0.01 and about 0.1 (although much higher m.o.i.'s such as 1 to more than 10 could have been used). Figure 1B schematically shows how the target cell genomic locus is presumably mutated by the integration of the retroviral construct into intronic sequences of the cellular gene. The integrated retrovirus results in the generation of two chimeric transcripts. As illustrated in Figure 1C, the first chimeric transcript is a fusion between the coding region of the resistance marker (*neo* was used to produce the presently described GTSSs) carried within the transgenic construct and the downstream exon(s) from the cellular gene. A mature transcript is generated when the indicated splice donor (SD) and splice acceptor (SA) sites are spliced. Translation of this fusion transcript produces the protein encoded by the resistance marker and allows for selection of gene trapped target cells, although selection is not required to produce the described polynucleotides.

Another chimeric transcript is shown in Figure 1C. This transcript is a fusion between the first exon of the transgenic construct (EXON1- the first exon of the murine *btk* gene was used as the sequence acquisition component for the described GTSSs) and downstream exons from the cellular genome. Unlike the transcript encoding the selectable marker exon, the transcript encoding EXON1 is transcribed under the control of a vector encoded, and hence exogenously added, promoter (such as the PGK promoter), and the corresponding mRNA is generated by splicing between the indicated SD and SA sites. The region encoding the sequence acquisition exon (EXON1) has also been engineered to incorporate a unique sequence that permits the selective enrichment of the fusion transcript using molecular biological methods such as, for example, the polymerase chain reaction (PCR). These sequences serve as unique primer binding sites for EXON1-specific PCR amplification of the transcript and can additionally incorporate one or several rare-cutter endonuclease restriction sites to allow site-specific cloning. These features allow for the efficient and preferential cloning of transgene expressed fusion transcripts from pools of target cells relative to the background of cellularly encoded transcripts.

Based on the unique sequence present in EXON1, that is schematically indicated as a rare-cutter (A) restriction site in Figure 1B, selective cloning of the fusion transcript is achieved as shown in Figure 1D. cDNA was generated by reverse transcribing isolated RNA from pools of cells that have undergone independent gene trap events using, for example, RTT-1 as a deoxyoligonucleotide primer. The 3' end of the RTT-1 primer consisted of a homopolymeric stretch of deoxythymidine residues that bound to the polyadenylated end of the mRNA. At its 5' end, the oligonucleotide contained a sequence that can serve as a binding site for a second and a third primer (GET-2 and GET-2N). In the center, RTT-1 contains the sequence of a second rare-cutter (B) restriction site. Depending on the size of the pool and the transcriptional levels of the fusion transcript, second strand synthesis was carried out either with deoxyoligonucleotide primer BTK-1 using Klenow polymerase or by a polymerase chain reaction (PCR) in the presence of primers BTK-1 and GET-2.

The second strand reaction products that were generated by PCR were digested with restriction endonucleases that recognize their corresponding restriction site (*e.g.*, A and B). Additionally, PCR conditions were suitably modified using a variety of established procedures for enhancing the size of the PCR products. Such methods are described, *inter alia*, in U.S. Patent No. 5,556,772, and/or the PanVera (Madison, WI) New Technologies for Biomedical Research catalog (1997/98) both of which are herein incorporated by reference.

Prior to cloning, the PCR cDNA fragments were size-selected using conventional methods such as, for example, chromatography, gel-electrophoresis, and the like. Alternatively or in addition to this size selection, the PCR templates could have been previously size selected into separate template pools.

After digestion with suitable restriction enzymes, and size selection as described above, the cleaved cDNAs were directionally cloned into phage vectors (see Figure 1D), although any other cloning vector/vehicle could have been used. Such vectors are generically referred to as gene trapped sequence vectors, or "GTS vectors" in Figure 1D), preferably incorporating a multiple cloning site with restriction sites corresponding to those incorporated into the amplified cDNAs (*e.g.*, *Sfi* I, which allows for directional cloning of the cDNAs).

After cloning, the resulting phage were handled as a conventional cDNA library using

standard procedures. Individual colonies and/or plaques were picked and used to generate PCR derived (using the primers indicated below) templates for DNA sequencing reactions.

A more detailed description of the above follows. The *btk* gene trap vector was introduced into human PA-2 cells using standard techniques. In brief, vector/virus containing supernatant from GP+E or AM12 packaging cells was added to approximately 50,000 cells (at an input ratio between about 0.1 and about 0.1 virus/target cell) for between about 16 to about 24 hours, and the cells were subsequently selected with G418 at active concentration of about 400 micrograms/ml for about 10 days. Between about 600 and about 3,000 G418 resistant colonies were subsequently pooled, and subjected to RNA isolation, reverse transcription, PCR, restriction digestion, size selection, and subcloning into lambda phage vectors. Individual phage plaques were directly amplified, purified, and sequenced to obtain the corresponding GTS.

When selection is not used, about 1×10^6 cells (PA-2, Hela, HepG2, or Jurkatt cells) per 100 mm dish were plated and infected with AM12 packaged *btk* retrovirus at an m.o.i. of approximately .01. After a 16 h incubation, the cells were washed in PBS and grown in culture media for four days. RNA from each plate was extracted, reverse transcribed, and the resulting cDNA was subject to two rounds of PCR, each for 25 cycles. The resulting PCR products were digested with Sfi and separated by gel electrophoresis. Six size fractions (between about 300 and about 4,000 bp) were recovered and each fraction was ligated into lambdaGT10Sfi arms, *in vitro* packaged, and plated for lysis. Individual plaques were picked from the plates, subject to an additional round of PCR, and subsequently sequenced to obtain the described GTSs. The particulars are described in greater detail below.

Figure 1 shows the chimeric fusion transcript that is formed when the first exon of the transgenic construct (EXON1- the first exon of the murine *btk* gene was used as the sequence acquisition component for the described GTSs) is spliced to downstream exons from the cellular genome. Unlike the transcript encoding the selectable marker exon, the transcript encoding EXON1 is transcribed under the control of a vector encoded, and hence exogenously added, promoter (such as the PGK promoter), and the corresponding mRNA is generated by splicing between the indicated SD and SA sites. The region encoding the sequence acquisition exon (EXON1) has also been engineered to incorporate a unique

sequence that permits the selective enrichment of the fusion transcript using molecular biological methods such as, for example, the polymerase chain reaction (PCR). These sequences serve as unique primer binding sites for EXON1-specific PCR amplification of the transcript and can additionally incorporate one or several rare-cutter endonuclease restriction sites to allow site-specific cloning. These features allow for the efficient and preferential cloning of transgene expressed fusion transcripts from pools of target cells relative to the background of cellularly encoded transcripts.

Based on the unique sequence present in EXON1, that is schematically indicated as a rare-cutter (A) restriction site in Figure 1B, selective cloning of the fusion transcript is achieved as shown in Figure 1D. cDNA was generated by reverse transcribing isolated RNA from pools of cells that have undergone independent gene trap events using, for example, RTT-1 as a deoxyoligonucleotide primer. The 3' end of the RTT-1 primer consisted of a homopolymeric stretch of deoxythymidine residues that bound to the polyadenylated end of the mRNA. At its 5' end, the oligonucleotide contained a sequence that can serve as a binding site for a second and a third primer (GET-2 and GET-2N). In the center, RTT-1 contains the sequence of a second rare-cutter (B) restriction site. Depending on the size of the pool and the transcriptional levels of the fusion transcript, second strand synthesis was carried out either with deoxyoligonucleotide primer BTK-1 using Klenow polymerase or by a polymerase chain reaction (PCR) in the presence of primers BTK-1 and GET-2.

The second strand reaction products that were generated by PCR were digested with restriction endonucleases that recognize their corresponding restriction site (*e.g.*, A and B). Additionally, PCR conditions were suitably modified using a variety of established procedures for enhancing the size of the PCR products. Such methods are described, *inter alia*, in U.S. Patent No. 5,556,772, and/or the PanVera (Madison, WI) New Technologies for Biomedical Research catalog (1997/98) both of which are herein incorporated by reference.

Prior to cloning, the PCR cDNA fragments were size-selected using conventional methods such as, for example, chromatography, gel-electrophoresis, and the like. Alternatively or in addition to this size selection, the PCR templates could have been previously size selected into separate template pools.

After digestion with suitable restriction enzymes, and size selection as described above, the cleaved cDNAs were directionally cloned into phage vectors (see Figure 1D), although any other cloning vector/vehicle could have been used. Such vectors are generically referred to as gene trapped sequence vectors, or "GTS vectors" in Figure 1D), preferably incorporating a multiple cloning site with restriction sites corresponding to those incorporated into the amplified cDNAs (e.g., *Sfi* I, which allows for directional cloning of the cDNAs). After cloning, the resulting phage were handled as a conventional cDNA library using standard procedures. Individual colonies and/or plaques were picked and used to generate PCR derived (using the primers indicated below) templates for DNA sequencing reactions.

Total cell RNA isolation was conducted using RNazol (Friendswood, TX, 77546) per the manufacturer's specifications. An RT premix containing 2X First Strand buffer, 100mM Tris-HCl, pH 8.3, 150mM KCl, 6mM MgCl₂, 2mM dNTPs, RNAGuard (1.5 units/reaction, Pharmacia), 20mM DTT, RTT-1 primer (3pmol/rxn, GenoSys Biotechnologies, sequence: 5' tggctaggccccaggataggcctcgctggcctttttttttttt 3', SEQ ID NO:1) and Superscript II enzyme (200 units/rxn, Life Technologies) was added. The plate/tube was transferred to a thermal cycler for the RT reaction (37° C for 5 min. 42° C for 30 min. and 55° C for 10 min).

The cDNA was amplified using two distinct, and preferably nested, stages of PCR. The PCR premix contained: 1.1X MGBII buffer (74 mM Tris pH 8.8, 18.3mM Ammonium Sulfate, 7.4mM MgCl₂, 5.5mM 2ME, 0.011% Gelatin), 11.1% DMSO (Sigma), 1.67mM dNTPS, Taq (5 units/rxn), water and primers. The sequences of the first round primers are: BTK-1 5' gccatggctccggtaggtccagag 3', SEQ ID NO:2 (GET-2, 5' tggctaggccccaggatag 3', SEQ ID NO:3), (about 7 pmol/rxn). The sequences of the second round primers are BTK-4 5' gtccagagatggccatagc 3', SEQ ID NO:4 (GET-2N 5' ccaggataggcctcgctg 3', SEQ ID NO:5), (used at about 20 pmol/rxn). The outer premix was added to an aliquot of cDNA and run for 20 cycles (94° C for 45 sec., 56° C for 60 sec 72° C for 2-4 min). An aliquot of this product was added to the inner premix and cycled at the same temperatures 20 times.

The PCR products of the second amplification series were extracted using phenol/chloroform, chloroform, and isopropanol precipitated in the presence of glycogen/sodium acetate. After centrifugation, the nucleic acid pellets were washed with 70 percent ethanol and were resuspended in TE, pH 8. After digestion with *Sfi* I at 55° C, the

digested products were loaded onto 0.8% agarose gels and size-selected using DEAE membranes as described (Sambrook *et al.*, 1989, *supra*). Generally, six approximate size-fractions (<700 bp, 700-900 bp, 900-1,300 bp, 1,300-1,600 bp, 1,600-2,000 bp, >2,000 bp) were separately ligated into GTS vector arms that were engineered to contain the

5 corresponding *Sfi* I "A" and "B" specific overhangs (*i.e.*, TAG and GCG, respectively). The ligation products were packaged using commercially available lambda packaging extracts (Promega), and plated using *E. coli* strain C600 using conventional procedures (Sambrook *et al.*, 1989, *supra*). Individual plaques were directly picked into 40 microliters of PCR buffer and subjected to 35 cycles of PCR [at 94° C for 45 sec., 56° C for 60 sec 72° C for 1-3 min
10 (depending on the size fraction)] using 12 pmol of the primers SEQ-4, 5' tacagtttttctgtgaagattg 3', SEQ ID NO:6 and SEQ-5, 5' gggtagtcctccacctttg 3', SEQ ID NO:7, per PCR reaction. The cloned 3' RACE products were purified using an S300 column equilibrated in STE essentially as described in Nehls *et al.*, 1993, TIG,9:336-337, and the products were recovered by centrifugation at 1,200 x g for 5 min. This step removes
15 unincorporated nucleotides, oligonucleotides, and primer-dimers. The PCR products were subsequently applied to a 0.25 ml bed of Sephadex® G-50 (DNA Grade, Pharmacia Biotech AB) that was equilibrated in MilliQ H₂O, and recovered by centrifugation as described above. Purified PCR products were quantified by fluorescence using PicoGreen (Molecular Probes, Inc., Eugene, OR) as per the manufacturer's instructions.

20 Dye terminator cycle sequencing reactions with AmpliTaq® FS DNA polymerase (Perkin Elmer Applied Biosystems, Foster City, CA) were carried out using 7 pmoles of primer (Oligonucleotide BTK-3; 5' tccaagtctggcatctcac 3', SEQ ID NO:8) and approximately 30-120 ng of 3' template. Unincorporated dye terminators were removed from the completed sequencing reactions using G-50 columns as described above. The reactions were dried
25 under vacuum, resuspended in loading buffer, and electrophoresed through a 6% Long Ranger acrylamide gel (FMC BioProducts, Rockland, ME) on an ABI Prism® 377 with XL upgrade as per the manufacturer's instructions. The sequences of the amplicons, or GTSSs, are described in SEQ ID NOS:9-503.

All publications and patents mentioned in the above specification are herein
30 incorporated by reference. Various modifications and variations of the described method and

system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the above-described modes for carrying out the invention which are obvious to those skilled in the field of molecular biology or related fields are intended to be within the scope of the following claims.

CLAIMS

WHAT IS CLAIMED IS:

1. An oligonucleotide comprising a contiguous stretch of at least about 15 nucleotides
5 first disclosed in at least one of SEQ ID NOS:9-503.

2. An isolated cDNA polynucleotide derived from the genome of a human that is
capable of hybridizing to a sequence first disclosed in at least one of SEQ ID NOS:9-503
under stringent conditions.

3. An isolated polynucleotide comprising a contiguous stretch of at least about 60
nucleotides first disclosed in at least one of SEQ ID NOS:9-503.

4. The isolated polynucleotide according to Claim 3, wherein said polynucleotide
15 sequence comprises at least one of SEQ ID NOS:9-503.

5. An *in vitro* process for producing a polynucleotide comprising the steps of:
a) obtaining a polynucleotide template encoding a sequence capable of
hybridizing to a GTS of SEQ ID NOS:9-503;
20 b) combining said template with a synthetic oligonucleotide sequence of about 14
to about 80 bases in length that comprises a contiguous sequence of at least
about 12 nucleotides disclosed in one of SEQ ID NOS:9-503; and
c) processing the combined oligonucleotide and template preparation such that
said oligonucleotide sequence hybridizes to said template in the presence of a
25 DNA polymerase molecule and a sufficient concentration of dNTPs for said
oligonucleotide sequence to prime DNA synthesis by said polymerase,
wherein a polynucleotide is produced that encodes at least about 50 contiguous
nucleotides first disclosed in one of SEQ ID NOS:9-503.

6. The process of Claim 5 wherein said template is mammalian cDNA.

7. The process of Claim 5 wherein said template is mammalian genomic DNA.

8. The process according to Claim 6 wherein said templates are of human origin.

5

9. The process according to Claim 7 wherein said templates are of human origin.

10


15

ABSTRACT


Novel human polynucleotides are disclosed that correspond to human gene trapped sequences, or GTSs. The disclosed GTSs are useful for gene discovery and as markers for, *inter alia*, gene expression analysis, forensic analysis, and determining the genetic basis of human disease.

10

1 A)




1 B)




1 C)

chimeric transcripts/cDNA synthesis



1 D)

TST vector
(e.g. lambdaPhage)



DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below at 201 et seq. underneath my name.

I believe I am the original, first and sole inventor if only one name is listed at 201 below, or an original, first and joint inventor if plural names are listed at 201 et seq. below, of the subject matter which is claimed and for which a patent is sought on the invention entitled

NOVEL HUMAN POLYNUCLEOTIDES AND THE POLYPEPTIDES ENCODED THEREBY

and for which a patent application:

- ☒ is attached hereto and includes amendment(s) filed on *(if applicable)*
☐ was filed in the United States on as Application No. *(for declaration not accompanying application)*
 with amendment(s) filed on *(if applicable)*
☐ was filed as PCT international Application No. on and was amended under PCT Article 19 on *(if applicable)*

I hereby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

EARLIEST FOREIGN APPLICATION(S), IF ANY, FILED PRIOR TO THE FILING DATE OF THE APPLICATION			
APPLICATION NUMBER	COUNTRY	DATE OF FILING (day, month, year)	PRIORITY CLAIMED
			YES <input type="checkbox"/> NO <input type="checkbox"/>
			YES <input type="checkbox"/> NO <input type="checkbox"/>

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

APPLICATION NUMBER	FILING DATE
60/104,292	October 14, 1998

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL NO.	FILING DATE	STATUS		
		PATENTED	PENDING	ABANDONED

POWER OF ATTORNEY As a named inventor, I hereby appoint S. Leslie Misrock (Reg. No. 18872), Harry C. Jones, III (Reg. No. 20280), Berj A. Terzian (Reg. No. 20060), Gerald J. Flintoft (Reg. No. 20823), David Weild, III (Reg. No. 21094), Jonathan A. Marshall (Reg. No. 24614), Barry D. Rein (Reg. No. 22411), Stanton T. Lawrence, III (Reg. No. 25736), Charles E. McKenney (Reg. No. 22795), Philip T. Shannon (Reg. No. 24278), Francis E. Morris (Reg. No. 24615), Charles E. Miller (Reg. No. 24576), Gidon D. Stern (Reg. No. 27469), John J. Lauter, Jr. (Reg. No. 27814), Brian M. Poissant (Reg. No. 28462), Brian D. Coggio (Reg. No. 27624), Rory J. Radding (Reg. No. 28749), Stephen J. Harbulak (Reg. No. 29166), Donald J. Goodell (Reg. No. 19766), James N. Palik (Reg. No. 25510), Thomas E. Friebe (Reg. No. 29258), Laura A. Coruzzi (Reg. No. 30742), Jennifer Gordon (Reg. No. 30753), Jon R. Stark (Reg. No. 30111), Allan A. Fanucci (Reg. No. 30256), Geraldine F. Baldwin (Reg. No. 31232), Victor N. Balancia (Reg. No. 31231), Samuel B. Abrams (Reg. No. 30605), Steven I. Wallach (Reg. No. 35402), Marcia H. Sundeen (Reg. No. 30893), Paul J. Zegger (Reg. No. 33821), Edmond R. Bannon (Reg. No. 32110), Bruce J. Barker (Reg. No. 33291), Adriane M. Antler (Reg. No. 32605), Thomas G. Rowan (Reg. No. 34419), James G. Markey (Reg. No. 31636), Thomas D. Kohler (Reg. No. 32797), Scott D. Stimpson (Reg. No. 33607), Gary S. Williams (Reg. No. 31066), William S. Galliani (Reg. No. 33885), Ann L. Gisolfi (Reg. No. 31956), Todd A. Wagner (Reg. No. 35399), Scott B. Familant (Reg. No. 35504), Warren S. Heit (Reg. No. 36828), Kelly D. Talcott (Reg. No. 39582), and Mark A. Farley (Reg. No. 33170) and, all of Pennie & Edmonds LLP, whose addresses are 1155 Avenue of the Americas, New York, New York 10036, 1667 K Street N.W., Washington, DC 20006 and 3300 Hillview Avenue, Palo Alto, CA 94304, and each of them, my attorneys, to prosecute this application, and to transact all business in the Patent and Trademark Office connected therewith.

SEND CORRESPONDENCE TO:		PENNIE & EDMONDS LLP 1155 Avenue of the Americas New York, N Y 10036-2711		DIRECT TELEPHONE CALLS TO: PENNIE & EDMONDS LLP DOCKETING (212) 790-2803	
201	FULL NAME OF INVENTOR	LAST NAME Nehls	FIRST NAME Michael	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY The Woodlands	STATE OR FOREIGN COUNTRY Texas	COUNTRY OF CITIZENSHIP Germany	
	POST OFFICE ADDRESS	STREET 178 S. Cochran's Green Cir.	CITY The Woodlands	STATE OR COUNTRY Texas	ZIP CODE 77381
202	FULL NAME OF INVENTOR	LAST NAME Zambrowicz	FIRST NAME Brian	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY The Woodlands	STATE OR FOREIGN COUNTRY Texas	COUNTRY OF CITIZENSHIP USA	
	POST OFFICE ADDRESS	STREET 18 Firethorne Place	CITY The Woodlands	STATE OR COUNTRY Texas	ZIP CODE 77382
203	FULL NAME OF INVENTOR	LAST NAME Sands	FIRST NAME Arthur	MIDDLE NAME T.	
	RESIDENCE & CITIZENSHIP	CITY The Woodlands	STATE OR FOREIGN COUNTRY Texas	COUNTRY OF CITIZENSHIP USA	
	POST OFFICE ADDRESS	STREET 163 Bristol Bend Circle	CITY The Woodlands	STATE OR COUNTRY Texas	ZIP CODE 77382

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF MICHAEL NEHLS (201)	SIGNATURE OF BRIAN ZAMBROWICZ (202)	SIGNATURE OF ARTHUR T SANDS (203)
DATE	DATE	DATE

SEQUENCE LISTING

<110> Nehls, Michael
Zambrowicz, Brian
Sands, Arthur T.

<120> Novel Human Polynucleotides and the Polypeptides
Encoded Thereby

<130> 008535-0027-999

<160> 503

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 40

<212> DNA

<213> Synthetic

<400> 1

tggttaggcc ccaggatagg cctcgctggc cttttttttt

40

<210> 2

<211> 24

<212> DNA

<213> Synthetic

<400> 2

gccatggctc cggtagggtcc agag

24

<210> 3

<211> 19

<212> DNA

<213> Rattus Norvegicus

<400> 3

tggttaggcc ccaggatag

19

<210> 4

<211> 19

<212> DNA

<213> Synthetic

<400> 4

gtccagagat ggccatagc

19

<210> 5

<211> 18

<212> DNA

<213> Synthetic

<400> 5

ccaggatagg cctcgctg

18

<210> 6

<211> 23

<212> DNA

<213> Bacteria Phage Lambda

<400> 6

094753 10139

tacagttttt cttgtgaaga ttg 23

<210> 7
<211> 19
<212> DNA
<213> Bacteria Phage Lambda

<400> 7
gggtagtccc caccttttg 19

<210> 8
<211> 20
<212> DNA
<213> Mus Musculus

<400> 8
tccaagtcct ggcattctcac 20

<210> 9
<211> 277
<212> DNA
<213> Homo sapiens

<400> 9
gtgttgtgct gatgcaggag acaaccgcga agatggggac agaattcagta acatcgacgt 60
aagggaattg aagcagaaga tcacgctgcc tgcagacacc aggaaacgcc aagacccccc 120
ttccacgaac caacattctt ccaccctctc caactttttt ctggaacccc ttcacttcca 180
accgccactc aatgtacact tcactttctc gtgctcttcc taagagagta gtgttttctt 240
cctccccacc gagaaaaaaa ataaaagcaa caactgg 277

<210> 10
<211> 434
<212> DNA
<213> Homo sapiens

<400> 10
cgtcatgttc ctgcaaagag aaaaataagg aaaaaatctg caaaacattg aagactcatg 60
accacttta aaaacataac tggatacatc acatgaactc aagaccatga ctatggagga 120
agatttaaca cttggcaact cttacaacaa caacaacagc aacagggaaa aacaacaaca 180
acaacaaccg aagagtgcaa aaagaactaa tgcattctct aggttaagcct ggatggagcc 240
tctaagacct aacaggatgt ctgagattcc agggaagtgg cctgtgatct gtcagtaaac 300
aaataagaag ctaatacagc tttgttgtgt tttctgattg gcatggttct tgaactatct 360
cctacttgta gttgcagaca aagaaacagg agatgaatta ccatgttcta ggactttgtg 420
ttcctttcca attc 434

<210> 11
<211> 407
<212> DNA
<213> Homo sapiens

<400> 11
gttcacaaca gtgttatggc gggagcaggg aggcacctac atccattgga cccatcctga 60
cagctgggaa ggatgtgtcc agccaccag ggatgtgcat ctggcaccca cctcacaaca 120
gctgttctaa ccacgtaaga agcacaaggg tcaccggtta ctctccatga gaacaaaagg 180
ccaaggatgc agagataatt gcatcaaagg gattcaactt cctggatgac ctcatccaa 240
agatctgcag agcccagata agcatcccag ggttctggca gagggcccct ccagggacag 300
gaaggggaca ggaagccggc tttcogtgtc tgtaccgct tccttgggaa ggataggaca 360
cctgtggcca tcaagtcatg atgccccatc tttctgaaac gaaaaca 407

<210> 12
<211> 200
<212> DNA

```

<213> Homo sapiens

<400> 12
gaggagaact ggtggccttta taagaagagg aagagagacc aaagcatagc atgtcagcat      60
gccacgtccc ctctccacgc tataccctgt gccacctcca gacacttcag agaccaggaa      120
taaggccctc accagaagtg cccctcaat cttggacttc ctatcctcca tggctgtaag      180
gaataaattc cttttctttc                                     200

<210> 13
<211> 128
<212> DNA
<213> Homo sapiens

<400> 13
atgaaggaaa agagggagaa gaaaccagct gcctggaaga ctgaccctct gagatgctct      60
ggagccgtgc agttgtttct actggcagat cagtcctgtc cctccaataa aagagagggt      120
gatcttgg                                     128

<210> 14
<211> 142
<212> DNA
<213> Homo sapiens

<400> 14
ctgaaagcaa agaactcttt agatagtggg gtcacactgg aaaaagcaca gacccttgag      60
tgtactgctt ggaggagagc taccctggag catttgctcc agattctgca tgagcaaaaa      120
ataaactttt gctgcataaa gt                                     142

<210> 15
<211> 149
<212> DNA
<213> Homo sapiens

<400> 15
acacttaatc tgggtgttct gaggctgacc tattggaata tcttgctgaa gaccacgtat      60
acaagatgtg aacattcatc attatgaggc tgaatgtaaa atacttcatt ttataatgaa      120
gaaagtcagt aaaacaattt ccagcccag                                     149

<210> 16
<211> 166
<212> DNA
<213> Homo sapiens

<400> 16
gaagaagaan ctcncctcnn catgagaccg ctgtggggat ctggcactgt ggttcctgna      60
tgcaaacant ggtctggncg tgctgggcn gacaataccc ctttccgtgt cncgggaaan      120
gccncctta aaaaaactga ngngttgaa aaaccagtaa accctc                                     166

<210> 17
<211> 113
<212> DNA
<213> Homo sapiens

<400> 17
accctgatna ngagaccagc tgaggcgaat tatgagtcaa ctaaaattat ccaaagatc      60
attttaccgt aaagtagttg ctgaatgtac acgaaatgtt tagaaattaa att                                     113

<210> 18
<211> 250
<212> DNA
<213> Homo sapiens

```

<400> 18
 cttctnctga agaattgagaa cacttgccag ccctttgcct atgttatcac ctggaataaaa 60
 ctggatgtgt ctnaatggaa cctgcctcct ttggggagcg catactcccg ccaggtcacc 120
 acagccacca tgaccacctc atgcctccca tccacctgtt tcattaattt gtgcctggac 180
 cattttcagt tttctggatg acatgggtga ggaggaggaa actcaggtaa atgataaagt 240
 ttcgactatc 250

<210> 19
 <211> 387
 <212> DNA
 <213> Homo sapiens

<400> 19
 aagacagctg aatgggttcca gtctttcagt cctgctcctg gccaacactg gacctctcaa 60
 agtctagcca actcctcttc cagcgccttg ataaacaacc ccctcatgct gggaaccaca 120
 gcagtgggct gtttttctcc ctcatgcacc ccaggaagcc tctcctcttt gcctgggctt 180
 tcttcccaag gccttagctg ccaacccatt ttacacccat gcgaagccca gtcagtcacc 240
 tgaagaaaag gagactcaca gaaggcccaa gatgaaagac tctttaatcc tgtggctttt 300
 tgagttttgt ttttagcagg aagaccttat tttcaaaaca aattgttaca cagaatttgc 360
 cagtttacag aacagatgaa taaagac 387

<210> 20
 <211> 216
 <212> DNA
 <213> Homo sapiens

<400> 20
 gcctaactgn tncaggagtg tctgcttgca tggacaccat tgtggaaacc ttcctccgca 60
 cctgtgccag gctcttgtgg atgccatcaa caaacccctc tgacacctct gacgggagca 120
 tgtgaataac accgaataat cacaacaaat cctcctcatc ataaagcctt gcgnggactg 180
 gcactcgcaa atatttaa atantattaaa acactg 216

<210> 21
 <211> 541
 <212> DNA
 <213> Homo sapiens

<400> 21
 ngtaatnnag gnggangccc cctggtgagg gaactgacca gcagactcca gcagctgtgg 60
 gaaaactcta ctgatgacag gcaagaagcc agactgctca gacctagagc tataaggaaa 120
 cctgagtaag ctcgggatga agttatcccc aatcaaccca ccaggtgatt ctgaagccaa 180
 taatttggtc cttggaagt tgtgctgtat ggaaaaaat cacccttctt ggctgacatc 240
 tgttttgctg gtaacacaaa tgcaacttat taatcatctc tgggtaagca agaaatgtaa 300
 tcctgaaaat ggcttacaag agaaaatctt ggaagataag accgtaacac taaaacgcct 360
 ctccagatgc cttaggaaca tccccaaagca gtaacagata aagtcctctc ataggattct 420
 tggctatgtt taagtttctc atagaaaaaa ataaaataac naaacncnaa aaaaaaagg 480
 gcccnggggg ccaattcagn ttggacttaa ccaggctgaa ctngttaaaa aggggggggg 540
 g 541

<210> 22
 <211> 492
 <212> DNA
 <213> Homo sapiens

<400> 22
 gacgtctggg gagctcctgc nttaagtnaa acnngaggtt ttngtnngcc cccagnaaan 60
 nngantcggc canaccnnaa aaaatcccan cctcaccaag agatgacacg tgacctgggtg 120
 ggctcacc agggcataca gctttcccag ctagcaaca aacaagccct ggctacagcg 180
 gttatagctg gctcatggtc gctcacagac actctgggca tgcattcccg tgacttanaa 240
 aagaggaggc ctttggaacc tgccagtgt gtctgtgat tgtgaggtgt ctggaacctg 300
 gggcccatg gccctccac accagcatgg tgctctgcaa aggccagctg ctcttcatcc 360
 tgtctcaatg atacacagtt tttttcccca aaactttagt agcgccactc tccctatcac 420

tcgtctttta attttgcccc ttattgntcc ttanattaaa aaatatcctc ctttcatngg 480
agggttggac ct 492

<210> 23
<211> 273
<212> DNA
<213> Homo sapiens

<400> 23
gctctgagtc aatacaagta ggaaggttca actggttccc tgggtgttca ttcctgggtg 60
gagagctgtt tgggaggctg ggaaggtcca ttagaagcat aattctattc cagaggtggc 120
ttggcagatg gagcatatca tgggttaatt tctcagcatg tcacagaaag caattcctac 180
tagacctgaa gaaagtggct tctctcttaa cagaatgtta tctttttcta gagagtaata 240
tgttttttatt aaataaaaaag catctaatag tac 273

<210> 24
<211> 495
<212> DNA
<213> Homo sapiens

<400> 24
attgcaagcc cccacctatg ttggttaatt ctgcttcaca tggaagagac agccattggg 60
ccagccctga acaaagatcc ctgtcaccaa gatccactgc tcctgctgtg gtcaggcaaaa 120
gagaagggtta tgtctcctga gttctagtcc tccgtcctga agtccatgta atgtgagtta 180
caagccgtct gcagagggtga gcattcgact ctggccagct caagtatttc ggcaagggtg 240
gattgtccag tcttgaggct gtttgctggg agaagcacga cataggctat tgccagtggc 300
aaggagaaca atcctaataa gactgacagc cctgcccata tgacatggca ttgaaaatga 360
cacctgactg aatgaanctg acccttgagg taggcacttg ancttnttca aaaaanaagg 420
gagggaccag ccncaganga ggcattggatc caaacttttg ggatcctcan aaatgtgtga 480
agtgactcct tctttt 495

<210> 25
<211> 468
<212> DNA
<213> Homo sapiens

<400> 25
attttcctgt agagtttagga aactgacaac tagaagacat aaatatctgt tccaactggc 60
tgctgtactt ctgtgtatga ataaattaat gttctgtttg aaacatcagt ctaagggaga 120
agagaatgta catgcagata gcctttctat cgacctctat aaccaagacg gcaagcttta 180
tgaaggagga gatgctgtct catttacaag agccaaaagc agtgttccct aactcctggc 240
tgagggattt gccatgcagg ataactcata tactatcatg tccttagaga agacatcata 300
ttcattttgtg ttttctcgga gtaaatTTTA gtgccgtgat accatttggg tattcattaa 360
tatttatcac acnaaggaat taaatgggtc tcccgaacct ggcnttaacc tccttgctaa 420
cctaataattc attcaacaaa tattaactgg gcatcttcaa tggggcag 468

<210> 26
<211> 176
<212> DNA
<213> Homo sapiens

<400> 26
gatcatgaat ggaatgacac actctgaacc gaagagacct tacagatcat ctagttctcc 60
agccttgaag atggggaaac tgaggctcaa ggaaggcatg taaacagcaa cctcgggatt 120
ccattttaat tctgcctctc tggatctgct tcctgatata taaaatggta ataacc 176

<210> 27
<211> 104
<212> DNA
<213> Homo sapiens

<400> 27

actggcatga aatgacagat atacagagga cccttgaaca acctggggttt gaactcctca	60
acatggacac ttatacacgg atttttctca ataaaaagtg cacc	104

<210> 28
 <211> 472
 <212> DNA
 <213> Homo sapiens

<400> 28	
gggggggctt ccttncttta gttccgaact ggggggggagg aaacccccc ananttaaggg	60
gtgggtttgn ggaacttggc agcccntttt ttttaccac taaataaaaa aatctggtat	120
tncaaaaaaca tggaccttna ttgnggccnc ccnttttnct tnattaaaaa aaccaaaagg	180
ggggccnttg gaccttaaag gnactaaaat ggncaagggg gtggggacca anaaatccaa	240
agtttgnccn ngteccacc aggttttttg ntttttaaaa taaaccccaa atttggnca	300
aaaaaatctt tccttcaaaa agaccacaaa ancncgattg aaagggggga aaaaatggcc	360
ccnttttggg gtttaaaaat tttaaaaacc aggnaggacc tnccctttt gngtcctttt	420
ttcaaggggt tcaaaataaa ataaaaaccn atttccttag tggattttaa gg	472

<210> 29
 <211> 443
 <212> DNA
 <213> Homo sapiens

<400> 29	
atctcactga agagttcttc tgtgcctgga agacttattt tcagtctgag aagaatgatt	60
tttcaatggt tctgttgaac atgcaattct cactgaaagc accagatttc cgcgtaggag	120
ggactcgggg gcaacgatgc aattggaaga actgcaccga aaatgacgat gtcttctcat	180
gcatatgaat tatccaaagt gtgggaagat gcgccccac tggagtacgc tgaagccttt	240
aacccaagta catttaatgc tgcgaagccc cgagtgaggc aaagggtgtc ttttatttta	300
gaagacattt aggacagttc atgtcactct gcacagatgc actgaaattg attgnggggg	360
caaactntaa agagagctta tgctcccaa atctgtttcc gagccaggta ggatgatgaa	420
ttctgaggtg ggactggagg ggt	443

<210> 30
 <211> 254
 <212> DNA
 <213> Homo sapiens

<400> 30	
tctctcctct ggatctgagc taaaagaatt cctgccttac tggaaaaaga gtacagcaga	60
gtgggtagaa gatcctgaag ttggtccttg ctcttttca gacccaacg ntctcagtct	120
ccctctttcc tggctagtgc attacaggca cactaaatat tgttggtggt gatgatgaca	180
gaaattacct tttcctaata tttcctatag gtaattatta gaaaattaaa agtagccact	240
tgcaaattaa aaag	254

<210> 31
 <211> 120
 <212> DNA
 <213> Homo sapiens

<400> 31	
aatatataac tgcagctcgt gttcctgtcc caggagagag agatgaccct cttcttggtg	60
ctttcccact ttagttttca tcttcataa tttacgaata aatgcataaa atggaaatgg	120

<210> 32
 <211> 124
 <212> DNA
 <213> Homo sapiens

<400> 32	
atctcggaga gaaacgcac tatcagattt ttactgatac cgaggaagaa gtatctccct	60
cttcgaattg tattgtacat ttgcattgat gtggttattt tcatctaaat aaagtcaaac	120

aggt

124

<210> 33
<211> 373
<212> DNA
<213> Homo sapiens

<400> 33
gtggggtctt tcaagatgaa atcagagtaa ccccatggag gtcctgagtc acggtggcac 60
cttgccctgc ttgcctaaca aagacctcct gggaggaggga cccagaagag ggcagggctg 120
aagaagagtc acagctgaag aatgtgactg tttgccagga aagccacttt ctttctgcag 180
caggattaga attcctacaa ctccagccaa aggaactggg ttgggaagcg atactgcaag 240
cattcatgtg cttccatcct ggtcttcagc ttagccacgg tcctgcgggg acagtgagtc 300
cctctctgag tggccaggac ctncacctgg cccacaggaa gcctttacca gcaggaagcg 360
aaacgggatg ggg 373

<210> 34
<211> 480
<212> DNA
<213> Homo sapiens

<400> 34
tgtcattgag gagaatttgc ctaggagatg caaagagaga gaagcccata ctttgagggt 60
ggaagccct ccaacaggca acatgactgc agcacaatca actatggctt tgctgatctc 120
gtgtatcatc atcctcatca tctcatccc cgcaattgca gcaaacgtcc agttgtgcac 180
ttgctgctga tgatgaataa atgtatagaa caggaaaaaa tgtatctcac cttcagacag 240
aagatctctg ccatcatgtg agagagagcc tgagttagcc tgctggatgg tcaaagatga 300
gtggtgcagc taagtgaag cctgctgact tgtagacata tgagtaaggc catgcttgat 360
cacctggctg ccagctggcc tgccaactaa ttggagggnac ttggaaagan tcnacnaaan 420
atcaccccc cagggtcaaat aaaccccagc cccctcctng agaattgatga actaaataat 480

<210> 35
<211> 100
<212> DNA
<213> Homo sapiens

<400> 35
aaagatgaca gaagaacaaa gatgaaggag gaggccactg gtttacagga agggtaaagg 60
acaacgacta tccagatttt tcttccaact ttactttaag 100

<210> 36
<211> 183
<212> DNA
<213> Homo sapiens

<400> 36
gcagcaacca cggctcgtaat gggatctgtg actgtcacca gaagaaatca ccaacagttt 60
cgtatcacgt gagagttttg cagggtgcctc caaatgccgt ccatgctcat caacactgtg 120
acatcagctg cggttcttta atgcatgtga taaggaagca cgtatattag aagtttgggt 180
ttt 183

<210> 37
<211> 144
<212> DNA
<213> Homo sapiens

<400> 37
aaaggacttg tacctcccag aagttcacgg aagtgtcag gacaacagaa tattgtgagg 60
ccaacacagc aaacagagca acgatgagca gccacttttg actttggttt ccttattcag 120
gaaataaaac agatgatctg acag 144

<210> 38

[illegible]

```
<210> 39
<211> 442
<212> DNA
<213> Homo sapiens
```

```
<210> 40
<211> 414
<212> DNA
<213> Homo sapiens
```

```
<210> 41
<211> 271
<212> DNA
<213> Homo sapiens
```

```
<210> 42
<211> 111
<212> DNA
<213> Homo sapiens
```

<210> 43
<211> 473
<212> DNA

[illegible]

aaaccgagac	agtaccact	gccagcagca	gatgggaagt	ctaaacagga	gagactgaat	60
aaagctgaca	actgaggcag	gataaagaag	agaaggaaca	aagaaggagg	gggcaggaaa	120
agaagccaag	cagaacatgc	tagcctgtcg	at tt t g t c t t	ccattaaggc	ttcagcagaa	180
gataagaaaa	gctaagccac	gtcagtgaag	ggaggacagc	aggaaggctt	tcaggggaag	240
at tt t g t g t g	tg g a t t c a c t	c g g c a t t g a t	g a g a g c a g c t	c c c c a g a c a g	a t a c c g a g a a	300
t g a a a a a c c a	a a c c a g t g a c	c a g g a a g a g a	a g a t a t g a a g	a a a a a t a t a a	g t a c a t c t t t	360
t a t t g t a a a a	a t g a a t a a c t	a t a g g c t a t a	g a c t g g a t n n	g g g a a n c c t a	a t c c c t a a t n	420
q n g a t g q a a t	t q q q a q n q q	q q c t t t q q q a	t q c c a t t a t t	t a a t a q r t c a	a q a	473

<213> Homo sapiens

gtgggggtctt	tcacagtcac	cagcatcaaa	ggagcagtag	tggcagcaga	gtctcaaccc	60
tacagaaacc	tgagcgggtc	anaacgttca	tcttcatcta	gccaaagtg	aagcaccag	120
aaaccaagga	cagacagntg	tgagagcaag	ctggcagcaa	agggtgagc	tctgaatttc	180
agtctggtag	agcaaaatga	ttttctcctt	cagcaatgtc	agaagaacca	tcccttattt	240
caagacatcc	ttacacatct	gctgtgtgca	aaacctgcac	acaggacgtg	gttctgaact	300
gcttcttcaa	aacaaagtaa	atgaaaattt	cagtggctcc	agcagtcggg	actgttaggc	360
atgaacaat	gagaagtacg	aaataaatct	tatatgcttt	tttataaatt	agtaacccat	420
taaaaatcc						429

<213> Homo sapiens

gagcatatcc	tccgttggaa	ggaagaaaga	agacaaacag	cagcctgcat	gcttttgaag	60
ctggactatc	aacaaaggat	cttctcaatc	aattcaccac	tagcaacaga	atgcaggcgg	120
ttctcagaaa	tggctcacia	agaaacacaa	aaaaaggntg	tctgaangna	aaancnagaa	180
aaggttccct	tcnnnaaaan	gnaaatggan	cnttnancnt	ttttnngggn	gcagaagtgc	240
cacggnctn	tnantgcggg	taattnaaan	agggncanaa	cactttcttc	aggccaccen	300
agggangttt	tatattnccc	atataaagan	acaaattccc	acantgtgcc	ttccttgngg	360
tnntccaac	tctttgccaa	caagaggcca	accggggng	ggccccncc	aggggaaaaa	420
aaccttttgg	gngganccc	cctttgggca	ntgccaan	ccttttgaca	tttcaccggc	480
gqgaagaga						489

<213> Homo sapiens

ggatttcaga	cnaaattcag	ggattcttcc	ccncccaaga	ctgtggttca	gaccacggtg	60
acgtcttcca	ggcaccagga	agaaatacga	ccaacctccg	taacaaatga	gagaaacttc	120
acctgactgt	gttttgtgca	tttggnttat	gagncgtttt	aaaaacgtgt	actttttactg	180
ctgcggttcag	gttttcagcg	atagaatatt	ctagaaaaaa	atagtataa	cattttatttc	240
accgctataa	ccttgaatgt	gtagctgtgt	tttttaaaaa	aacatttttt	tacaatttga	300
gaatatgtaa	catgcctcca	gaacgtgcc	ctaaacacaa	atatataatt	tggcaaat	358

<213> Homo sapiens

<400> 47

gaaaagctga	agatgggtcag	acctgggtggc	acacacctgt	aatgccagca	cctttgtgag	60
gccaaaggcag	gtggatcgct	tgagcccagg	aattcaagac	aggcctgggc	aacacagcaa	120
gaccttgtct	ctataaaaaa	ataaaaaata	aaaataaaaa	taaaaaaaag	atcagtc	177

<210> 48
 <211> 536
 <212> DNA
 <213> Homo sapiens

<400> 48						
gacgtctggg	gagctcctgc	nnntanntnac	actctggnag	aacccatggc	tcatgaatca	60
cccccttggc	ccaaggatga	gtaccacacag	cagcaagctc	ttccattgga	aaccacgctg	120
aggaagacat	ggtcaagctc	tggcagcaga	tcaagctgtt	atggcaagaa	ttcctggttc	180
tgcgtcccca	gcatgtaata	tagaagatct	gggagtgggg	tcttgggtct	gtaatgtctg	240
tgatatggct	cctcacatct	tcttgtgtag	agtgtcatgg	ccaaaacagg	aataaccgtg	300
tttgcccttc	tgaattcccc	agtaatgagt	ctgaagctag	tctgaagcta	ccacagtcta	360
ttttaagggg	ttccataaca	tgtttgaatt	atatctatat	ggnagggact	ttcaatcagt	420
agccaagatc	tgntactaaa	attaaatncn	caatttaatt	tccacaagct	acatacctcc	480
cttcanaggc	ctgccaaaat	tnttaatgga	ggacaatgaa	agttcgtaac	cttctt	536

<210> 49
 <211> 374
 <212> DNA
 <213> Homo sapiens

<400> 49						
gtgaggaact	gaaattgagc	acttgaatgc	ctggaaccac	atatccaacc	aatggcagcc	60
attgtcctct	caaagccggg	tcacttggtc	tcaagacact	ttatgtcgag	ccacagctac	120
ttcatgtact	gggagcacca	ctcctgaaga	agctgactca	gcttcaatgc	aaggaagaaa	180
gtctgactag	ttaggtggaa	catgggatct	gtaaagcatg	gtgctgtgcg	agaggtggtg	240
gaatgcatgg	gcaaattgatc	tctgggagact	ctagcaatca	ttccgaagtc	tgtgttcaag	300
cagtaaacaa	acagcacact	cagtaaccag	tattcttcta	aagatggagg	atggtaatta	360
cattctgtga	ctag					374

<210> 50
 <211> 595
 <212> DNA
 <213> Homo sapiens

<400> 50						
aggaaaggcc	acatgaagac	acacctagaa	tgtgcccgtc	tgagccaag	aagaaaggcc	60
tcaccagaaa	ccaaccctta	ctggcacctt	aatcttggac	ttccagtctc	cagaactgat	120
gcagtagaaa	tgaggccatg	tgactctcca	cgctggagga	ggacaggcac	tgaggcttcc	180
gccagctcgc	tcttgccttg	gtgatgcctg	cccttgggaa	ccagccaccg	taccgtgagg	240
aagccaagca	gccacgtgga	aaggccatta	caggtgttcc	agccacagtt	ctcatggagg	300
ttccagctaa	tagctggcat	cagctgccag	acatcacacg	gtgagggaga	ctgcacaaga	360
ttctagcctc	cgcccctgga	tgctccaact	ttgaaccagc	ccacctcact	tgagtgccgc	420
agagagaatt	gagtattatt	gctgaactct	gccc aaagtg	cagtttgtat	gcaaaatact	480
tcttccctta	ttttaaagtg	ataacttttt	ggagagactt	ttttacacaa	caagtagata	540
atggaacaaa	tactacttat	gatttttgcg	gagtaaatcg	gcttctcgct	tttcc	595

<210> 51
 <211> 268
 <212> DNA
 <213> Homo sapiens

<400> 51						
gagattttta	aacctcagta	tgactgaaaa	tatacttcag	aaagtcaaga	cctgggccta	60
ggagtctgca	ttaaaaacac	tactctgggt	agagataaag	aaagggactc	tctgagatga	120
gggaaaagca	gtgggtttcta	atctgtgggt	cagagatctc	tgctgggatg	aagaatatgg	180
agggagaaac	aagagttatt	gtaaaggggt	tacaaagctc	tacgtatgca	aagcactatc	240
tatagactga	ataaataagt	cttgact				268

```

<210> 52
<211> 60
<212> DNA
<213> Homo sapiens

<400> 52
atattttcgct ctgaagaaac atcattagaa ataaataaat aaaattaaca tataatacct      60

<210> 53
<211> 419
<212> DNA
<213> Homo sapiens

<400> 53
tctcaatacc ttcacagagg tgaagaagca gcaaccaaat gaattagaca gcaacatgat      60
tcctagagaa tggcaagacc aattcttcaa ctacttcttc agcatttctg aaacatatgg      120
aagatggccc attgtgctct cttaattctt tgataatctg gacattgact tttccattat      180
atgacctggg cttgtgggca tcatgtcata atgcacctgt tcagacatct ccctgtacca      240
atatggatca cttgaagaga ctcttttgcc tccatcaaaa aggatacagn tgtgtatctc      300
ttccattttt gnttacagng cctaaaatta tttgagcagg ttttcacctc ttctctgaat      360
aaacacctta ttagtcctta aaangaaang aaaaagggaa aataaaactt ttaaatgca      419

<210> 54
<211> 450
<212> DNA
<213> Homo sapiens

<400> 54
ggncgaggca gaaccaaacc atggatacgg gtccttttgct caaattcttc tcaatgaaga      60
ctctgtgatg aagaggccac ttccatttaa aggcagcgac acttagaaaa tcacaggcat      120
taaaacttag aagaggtcac cttatccaac gtcccagcca gcacagccat ctttcacag      180
catccatgac attcagcctc ctctcagaca tgggaagatc acctcttcat gaaacagcag      240
attcttcaag gataaggaaa tggaggaaca aagcagtga gtaatctgtc caaagcccaa      300
aagttgaatt gttgaaactg acatctgaaa gcaagtagcc tggcttcaga gtatatgctt      360
ttaatcgctg tgttatatac tgctctctta tatgtgataa tatagtatat ttattaagtt      420
attaaaagaa acataagttt ctttgttgtc      450

<210> 55
<211> 172
<212> DNA
<213> Homo sapiens

<400> 55
ggactaagga ccactaaca cagatccaag aacacatgta atgcaaacca ggtattcata      60
tgctctgac attttcaagc ctaaagatca agagccatca tcttttaca gagttgcagt      120
ttggtcttaa cctccaaaaa agaaacttct aataaatact atttccttct gt      172

<210> 56
<211> 211
<212> DNA
<213> Homo sapiens

<400> 56
agagtttggt gctaaacatt taccagcaca ccctaaagag aggagaaaaa aatatgtgaa      60
gaaaaagaaa aaaggagaaa tcaaagaaag agaaagcaaa aagagcatat ttggatgtgg      120
aagaagaaaa agacaagttg aactgtctta aattccagcc catgaaagcc ttcccttttt      180
taaataaagt ttttggtttg ttttggtctg g      211

<210> 57
<211> 328
<212> DNA
<213> Homo sapiens

```

<400> 57
taccatgggtg tnttgaatnc agcttngctt tcaccaaaac cccgatcatgc tnggcaccct 60
aatttcaaat ttccagcctc cagaactgct ccaagaaatg gaattttatt aaaagatgga 120
agaggaggat atttgagaga aggggaacta cctaatactg aaaactaata cagtccagga 180
tacatagaag atgatcaata acacttattc aatctaaatt accctatcag caagtggaga 240
gttctctctc gggagtgtcg ttttctttcc tgccagtcag ctctgtcagg ttgaatagaa 300
agcgataaat aaagaggaaa agaattcc 328

<210> 58
<211> 208
<212> DNA
<213> Homo sapiens

<400> 58
gagttgggtg ttaaaaagag cctggaatct ccccgctctt ctctggcttc ctctctcact 60
catgtgatat ctgcacttgg aggcctcctt tctctttctg ccatgaatga aagcagcttg 120
agaccctcac cagatacaga tgctgggtgc atgctctctg tacagcctgt agaccatgag 180
ccaaataaac ctgttttctt cacaatt 208

<210> 59
<211> 334
<212> DNA
<213> Homo sapiens

<400> 59
catatctcaa aaatcaagat gaanccttaa gctttctacc cagatgttgt gggaacttga 60
agacaaagtc tcaaagagac tccgttttgg tcaacaatta gcccttcac atttggatcc 120
tgggccacat gtggaaataa agagttccag aagaattctc ccatgaagc attggaatgc 180
ttcaatacat agttttgtgc caaatctaca ataatcttcc caaaagaaag actcttcagt 240
gttctggatt tttcgggact tntcttattt tcttgtgcaa catcttaaca caaactagaa 300
taaagatgac atataatcat ctgcattcat gaat 334

<210> 60
<211> 177
<212> DNA
<213> Homo sapiens

<400> 60
aaagctgggtc gttaaacatt tactaaaaca ccactggata caagtgacat catacaagat 60
ccagtccttg caaccactga tctgcctcct ccctctatgg cgtcacctgt ttggaacatt 120
tcatgtaaat ggaaccatac aagatgtgac cttttgtgac tggcttctct cacttgg 177

<210> 61
<211> 381
<212> DNA
<213> Homo sapiens

<400> 61
ctgcaatgtt cctagagaga agccagcact cgccagatct ttggccaccc cgagggtgtcg 60
tgtgcataag ggaagatgag aggcctgggtg acgcccaccc ttcaccagtt ttgtaaataa 120
caagctggcg cccagaacc catccacagc agctttttca gtggcattat gcattcgtgg 180
tgcaagcatc cttactgtgc ttcaatcagt ggcttcagtc gtggccggcg cacactgatg 240
gagtttcttc ctgcgcgcg gtcatattt cctctttgca tgtctgatga cttttgatta 300
gatgcaggcg ttgttcactt tccctgttga gttctgagta tatttgcatt cctattaaat 360
atccctgngt tttgctctgg g 381

<210> 62
<211> 141
<212> DNA
<213> Homo sapiens

<400> 62

gaaataagggg	accctggcat	ggatggagca	tgtgaaacta	tcaagaacag	tgaaatgttt	60
cagatTTTTg	ctatTTGCCA	gtttcgTTTT	atgaatgctg	gcagaagacg	cctgaatcaa	120
agataaagggc	tgTTTTtact	c				141

<210> 63
 <211> 581
 <212> DNA
 <213> Homo sapiens

<400> 63						
atgtgcagcc	tgTcaccaac	accaggaagc	tCagagacgt	gccacctgga	aaggaaatca	60
gacaggagag	ctcagggTcg	aagtCggccc	ggccgcctgg	agctccaagg	ggacaaatgg	120
agcccaggTt	caaccgcagc	cagggaggca	acgtctgtgc	acctgcaact	tcccatggca	180
ttgcccact	caatggctca	agaacctgcc	ctgtcctgct	tcgggcccag	cattccatcc	240
tctgaaagaa	cacgagcgTc	cccacatgct	ccgtagggac	catcctgcct	ctgccctccc	300
cactTcacca	gaagaactcc	tctcatcct	tctggggccaa	cttggcagca	actcctccgg	360
gaagcctTcc	ttgctctccc	aagacacgga	caggcacccc	tcgtacgtgc	caatagcatt	420
cccacagca	gtTgtcacac	acacaaggct	catgacctcc	ctccccacct	gtgccccag	480
gggaggggct	tncttggggg	cagggccatt	tcgtcgtcat	cttccagcac	cacacacact	540
cggTttgctg	aatgcttnct	aaataaatTc	ctgccaaatg	c		581

<210> 64
 <211> 244
 <212> DNA
 <213> Homo sapiens

<400> 64						
atgtcatgtt	ggagcattgc	agactgctct	tctcccttct	gcctttacat	acaagatgcc	60
tgTtgctgag	aacacttgTt	cccactTctc	tagcaggcaa	ggatctgggc	aggacaacaa	120
ccacaggcat	gtgctTtctc	atcatgtgat	gtcatctgcc	aggTcatgat	gcagcaagaa	180
ggccctcacc	agatgccacc	cctccagaac	catgagccaa	ataaatgtct	gttctttata	240
aatg						244

<210> 65
 <211> 362
 <212> DNA
 <213> Homo sapiens

<400> 65						
gaaactctcg	aagggtcctg	cctcagggTt	gttttatcca	ctagctgctc	tagacacagt	60
gcctgtggcc	ttccagctat	tCagtcaaca	gcatatgaaa	atgcagttca	ttaaaagtaa	120
accatccaag	tcacctgtTc	actgtggctt	cctgtcagga	gggacagTtt	agatgactTc	180
ttggagcctg	tcaactcgTa	ctgcactgat	ggTatcagat	gcaagctggg	gaatttggaa	240
tgctatctgc	aatagtGaca	tctggTggct	tctaagTtct	actgcacctc	cttaaggcag	300
gaaagcaagc	ctggctTtTa	agcagtattt	gtgaaaaaat	aaaggaatta	catgagTtct	360
gg						362

<210> 66
 <211> 418
 <212> DNA
 <213> Homo sapiens

<400> 66						
ggTctatgct	acaccacTt	ntgctTcac	cgaacaaaaa	gcggmtggag	ggagctgagc	60
ccagagaggg	atgatgcagg	ctcttccaga	acctgtgtcc	tatgcctcaa	gccttctTtc	120
cctcctgctc	gctgacaact	gctgaagcag	aaactaagat	tacgacacta	ggTggcagca	180
tnatcccacg	ggaagacaac	ttgagTttgg	ggagaccacc	ccccgccaaa	ctcaacacaa	240
tttggagagg	ctccacgaaa	aagaccagcc	cccaaataac	agggagactc	tgcaatgctt	300
ggTttccagt	gatgatcaac	actTtaaggg	ccaatggaat	tcacctTtac	aggggaaagg	360
ggaccgtTga	antancctgg	ggnnggggagg	ggcatgctcg	agaaacccta	cctaatgc	418

<210> 67

<211> 322
<212> DNA
<213> Homo sapiens

<400> 67
catggagcct agtacaaaga aaatatccaa tgaactgaat ctctactctt ctctgaaaac 60
tcaaaagatg agtaaaggaa agtctgctat ttccagagtc cacttgctct gagctggttt 120
tcttctaaac cacatcacia aagagcacga tgctgtgaac ctctcctttg gactcaagtg 180
tactaatggg gaggaatggc aagttacatg cattatttct ggattctata aaaatgaaag 240
tgatgggaat taaaaataag ttcattaata ttgtaattta tagttctgaa gagctttagc 300
aaataaacta aacattccaa at 322

<210> 68
<211> 317
<212> DNA
<213> Homo sapiens

<400> 68
ggtgctttac gtcccaccca aggcaagagg aacgccagcg aggaagacaa agaggcccg 60
ggtggggcgc atgcccgcga ctggactgaa agctgagtca caggaaatcgt acccctgcag 120
cgggccaggc cctccaggga gggacaccgc gcccttggtg ggagatgtcc acagtagaca 180
aaggcagttt cgaaataaaa gaatgcctgt caccgccagg gccacccga cccttagtta 240
ttatgcactg gtccccaaga gcaatttctg cgctgctggt gcaaaaattc atcgtaatga 300
aataaacgta aaagggg 317

<210> 69
<211> 678
<212> DNA
<213> Homo sapiens

<400> 69
gactctgggg agctcctgca ttanatnana nntgnngata tcnactctaa nagacatnaa 60
ggaggcacia aagtcccatg ccgagagaga agtcggtaac tacgcctgtg accgggagag 120
gccggacttg ctctccttcg cctaggtttg cactcagagc aagagagaat ataggagaga 180
ggaagagaga aaggtagcgt cctgacaggt actttcctgg ctatcacaga aagaacaagc 240
ctttcatggt ttattgggaa ccaagctcag gtgtccctgg aggcagagct acgtggaccc 300
agcaggcaga agagaaaaaga gccctgaacg ggaagtgtga gacctgtgtt ctattttgag 360
ctttgcccc actgttaaga ggactgacca ttttaacaagg gggagctggt gagatgactg 420
gacactttga agtgacaccg ggacccaagg gttctcaagt tcattatttg tgaagaaatg 480
gngcttgntt ctgtgatctt tctctgctct gaaatactac aggccttaan ctatagtgccc 540
tttggaggnc tttcctggat caacagatgg aggcactttc aaaagcagac gaaagtgaat 600
gggatcactc acacctctgc ttcggacaca gngaagccca gatggagaag aaagaaaact 660
tggncaaaagc tatacttg 678

<210> 70
<211> 257
<212> DNA
<213> Homo sapiens

<400> 70
gacacaaatc caggagccat tccttctgcc tgggaggagg gagtgatgaa gaccagagga 60
atcccagagg agaagccatc tgagatcggg agggaggagaa atggaacatc aggcggagga 120
aacagcccag acaatcgcac tgggacgtga aaacccttgg gctgcatgag gggagaaaac 180
cagaattggg gatgggttagg gttttggagg gaaacacagg gacatgtgac caaaaataat 240
aataactact gttactt 257

<210> 71
<211> 491
<212> DNA
<213> Homo sapiens

<400> 71

gtaaccta	at	gggtttctca	gccaaagccgc	aagcatgtaa	ctgcaacttg	aaggaggaag	60
atgtcttttag	agacttagaa	aagaccagca	agcttcttta	caaaatgggc	tcttcaatcc		120
tggcatccac	ttgggaccaa	tgagatggga	tggtcatcct	catagatttt	cacatatgta		180
tctttaatgg	tatccccagg	agcctctgaa	gtgcatcagg	actttatttc	aatgaagttc		240
acactaagcc	aaaacaaggt	atgccctatt	caatttcttg	tgtcccatta	cactcagctt		300
tgctgtccaa	ctgatcacac	tagctgaagt	caaaaatgtg	caccagaaaa	taaaatgagg		360
cctactttatc	agattggcaa	aaannaaacc	aggtcataaa	accccttttg	gtaaatatat		420
ggaaaaaaca	catcttttta	tatgcattgn	catatatata	tacatatata	tgctgcatta		480
atatatatac	t						491

<210> 72
 <211> 196
 <212> DNA
 <213> Homo sapiens

<400> 72						
ctaccagtct	gaccctgact	caggcctccg	gaagaaacca	ctcgctaatac	acagtctgtc	60
ttgcacccag	acacggcatc	tcagacactg	cacaaattaa	gaagtcaccc	tcaaaacctc	120
tatacagtgc	aggaatacag	ctaagacacc	acacccgagt	actaacatct	gcaaattctg	180
aaaagctcct	cataat					196

<210> 73
 <211> 511
 <212> DNA
 <213> Homo sapiens

<400> 73						
aaaaacagag	atctgtgttc	tgaatggaaa	aattcctact	gatgccaccc	actagtctgg	60
aacaagtcag	tctcaaacat	aacaacagac	actggggagc	tctccaacaa	aagatcacct	120
cccaaagaac	aggatgggtg	cgaagactga	atgccagcct	gaggaaacag	aaatactaca	180
gaagcacgcc	agagcctgca	gtgtctcctc	gctgcctctc	aatgaactgc	taaaagacca	240
agaactctgc	tgagagataa	gaagagggga	gggtgtgctg	caggtgggtg	tgaggaggccc	300
agaccttctc	ctgacatctg	gggctggcta	caggaaacag	aaacatcacc	caggccttgg	360
cgccgagaca	ggacagaagc	agattgtgac	tnaaatcttc	nggnnggaaa	ggggggcctt	420
tctntttntc	cttaggggnt	anaacnaaag	cccanaaggg	ttcatccaaa	ggnaaccctt	480
aaggcagttt	natgatccct	ttcaaccttt	t			511

<210> 74
 <211> 499
 <212> DNA
 <213> Homo sapiens

<400> 74						
gacttttgcgt	gtgaccactg	cacctccagg	aaggccaggt	gcacatcgct	tcccatgccc	60
ccggcctcat	ggcctttggg	ggttgctcgtg	tggaatggag	atgacacgag	tgctgcatgt	120
gaggtcagtc	aggatctttg	attttgaggc	acaagccttc	tgctgtgtac	tgactgggtc	180
ctggcctccc	tccttccatg	gcacgtcgtg	gaatgggaat	ttccaccact	gcctccatta	240
gcttgaaaaa	agttctccac	agaagtaatg	accctggact	tgagaagag	agcgctaaag	300
ctcagaaaag	aaagtcagct	ctcaagaaga	cttcgctagt	aattagcgaa	gtaggatccc	360
accagatct	gcgttctcca	cctgntgnca	catgaagcng	ggngggtnaa	aacagaccng	420
ggaantggnt	acctcattac	aatgcccnc	tgactggtnt	aanttcccna	naggggttat	480
tgccatttt	gttcaatga					499

<210> 75
 <211> 427
 <212> DNA
 <213> Homo sapiens

<400> 75						
gaaaaaagta	tcagaatgct	ttctacatga	acaggaagac	taaccaacgt	tgaatggcag	60
ccagtcttat	ctccgtcctt	atcaccacct	taccatgtca	tcctggcgaa	gatgccatca	120
caggagtcag	ggttgaagtc	caggtttaag	gtgcatctag	atgggttccc	aggacgcctg	180

aagtagcctc	aagaggccca	aaagaaaaag	ctcctctggc	acagtctcct	aatgggtgaca	240
aaggagtccc	tctcatctgc	ttggcagcct	tacaatcaga	gcgttcttac	atctaacct	300
attatttccc	actgaaattc	aaacctaat	cattttattt	ttattctcta	taaaaatgaa	360
aaacatcact	gnngcaagta	acttgctcaa	tttctnaca	aaaaataaan	aaaagggtgt	420
tggttc						427

<210> 76
 <211> 286
 <212> DNA
 <213> Homo sapiens

<400> 76						
gtggggtctt	tcaatggaaa	gatgctcagt	tgagtgggga	agagagcagg	aatcagagt	60
tcaccatgca	ncttatgcaa	aatagttgtc	aagctggaag	gatgcaagcc	caatctttgc	120
caccacaaag	gaagataata	aaacccatac	gggagaaaac	agagccacag	atggagacag	180
tcacattcct	ggtgacagt	tttgagcacc	tggtatccag	ccaacctgag	gccattttct	240
cctaggcttt	ttagatctgt	gaaccaataa	atccccgctt	taggag		286

<210> 77
 <211> 279
 <212> DNA
 <213> Homo sapiens

<400> 77						
cttcatctct	ccccgttaca	gaccaggaat	tccaaattcc	tagcccaagg	tcagagaggt	60
ctcactgatg	cctgtgtagc	cacgtgagga	tggaagtct	catttgccag	taagcactac	120
aggaagtgat	ggttgaacac	gatgggacta	ataagaagga	aacgtagtta	gagtgatctt	180
attcatttta	aaacaaaagc	agcaacaata	cagcagtcga	ggaaaagaat	caattctatt	240
taagcaaagc	aattttaaag	aataaaaaat	gtttccagc			279

<210> 78
 <211> 481
 <212> DNA
 <213> Homo sapiens

<400> 78						
ctgctggttg	gtttgaagag	aagtttagtg	ctctcaacag	caatgaacag	cattgggtca	60
atattcagtg	gccgggagac	aatctgggtt	actacgtatg	ctgctttgtt	gtgaactgga	120
attggcatca	tgtctccaac	attctgaagc	caaggctgag	gatatacaag	gtctggaatc	180
attaagggtg	tgataaaagt	ctgagaaaca	caggagaatg	cattgttcag	tgaatgaaaa	240
ttgaaaagag	agatggagac	agacaaaaga	aaagactgaa	caactgaata	gccaattttt	300
tttaactctc	aggatgtttt	ctcctacctg	gatggacaca	atcttctgtg	gnggtacatg	360
ataagtattg	gctgggggtg	ccattccatt	tactgggncg	cccaaggana	ttttgnaang	420
taacanaaaa	gggccatnat	atcttctctc	tctaacctgc	cttggancaa	gccctaaaat	480
g						481

<210> 79
 <211> 200
 <212> DNA
 <213> Homo sapiens

<400> 79						
agagctcaca	gcacctctgc	tcctccagaa	gctcttcccc	agctgaaatg	gaagtgaag	60
actggtagtc	tcctcctcaa	ccacccacct	cctggggccc	tgactgtgtg	gatgaactcc	120
tcacaccag	gatttgtgtc	tccagtgaag	agcagcaatt	tatcctacac	tgaaaatttc	180
ctgaataaaa	acagttcacg					200

<210> 80
 <211> 239
 <212> DNA
 <213> Homo sapiens

<400> 80
caggagcatg caacacctct tggactcgat gaaagctgtc gccacaggtt tcaaccagtc 60
agtactctga aagagcatct tgggggaaaa aaaagcgtgt cagacattca tcttcataac 120
cagaaagtga agtctcgcaa aggaaaaaga caagactaaa gggaataaac catcgttgtg 180
tgggcttttt cttccactca gcatctcttc ccttattaaa atgagagggga taacttaag 239

<210> 81
<211> 495
<212> DNA
<213> Homo sapiens

<400> 81
cccttcccgt cctcccgtc ccagcaagt cagaagcaga aggcttggtt gctgccagcc 60
aggcaaggga cagcctccag cagagtcac ccaccacag ttgtctcctt aggacaaaca 120
gaaagtttca caagcacact ttgttcagtt ctgcagctta ccaggaacac tagaaagcac 180
tccagcactg tgcctggggg ccatttgaaa cagcaaaatc atcaacaaaa accacaaaaa 240
tgcaaaaacc atggcactaa atagaccatg aaaaggacac ctgtttactg catgacctga 300
aacaagaagg cggagcgttg ccttgttcga cttcagctgg gaagataggc gtcaggggac 360
tcaaactttt cagcactctg ttatatctgn gaatgatcac aaaaaaactg gggagtntta 420
tttttggggg ttacnaataa atttttacca agtaagcttg nttcacaaat acanaattnt 480
ggggataatg aaaat 495

<210> 82
<211> 98
<212> DNA
<213> Homo sapiens

<400> 82
gtaacangaa tgaagaaact acaaagaata ttgagaagga agcatcacag aagtgagagg 60
aaaaccagga aaagatggct catggaagca aagaaaaac 98

<210> 83
<211> 486
<212> DNA
<213> Homo sapiens

<400> 83
cgtccacagg atgtcggggc aggagagctg aaagccaata ctgatgagga agggccaagt 60
gaggaagagt ctgagctgca tatgtcaaga aggagaaagg ggaaagaagc aaggagcgag 120
accagagggga gccacgcaga aacctctggc ctctctgcac gtctgtctta tctacagag 180
tggtgactct aaaaggccaa ggggtgccagc gccacgcagc agttcacagc ctgagacagc 240
ctttgtctac acgcctccct cctcctctgg ctctacctg ataaaaagca ttaccggttt 300
tgatgtttcc aacctccccc attttccctg gtgaaagatc cattcatttc agtgctaaca 360
agacatcata agcaggggaga aggaacaaaa ggcanantgt gtncttaagg agggaggcan 420
tttgcaaaag cnccactntt ttcaccttgt ccacagaata aagggttgaa gactaaaaaa 480
aaaatt 486

<210> 84
<211> 280
<212> DNA
<213> Homo sapiens

<400> 84
ggtctgcacc tggagactcc cacctaagat gggggtttag atganaccac tntgggagga 60
cacncantcg agtgtggagg ccccgaggaa gatcanctnt naanacacag gcaggcaaag 120
ggcagacctc taaggagatg gangangaat gacanagggc nngaagaatc ntgtgagggg 180
ctgncanana agccagtgc naaaacttnc agaagagctg ncaacagtac caaacaagc 240
agaagagtct caaaagatta aaaataaaat ttgcttccat 280

<210> 85
<211> 408
<212> DNA

<213> Homo sapiens

<400> 85

atgaggagac	ccaagttccc	agaagagcag	ttgcacactc	gaggctggag	gacatgggca	60
gaaccagagc	tccttgccctc	cctcccagcc	ccccacccaa	gtaacacgtt	cctgatccctg	120
tcctggaagc	agcttcgagg	aaatgccag	acccctgggg	ggtgatgtgg	tggcaagggtg	180
acaaaggggc	aggtcacaa	gctgtcacaa	gctgatatgc	aagaactcac	aggcatgacc	240
cccaggggct	atgggtgtaa	gggcatctgc	tctgcccttt	ccagcggggc	tagttttggt	300
ggcctctgtt	ccatttattt	gcttaggaac	acaaagctga	atgcactgtt	tgcaggaagt	360
tgtgtgtcta	agtcacctaa	gttagtaaaa	taaataaaaa	ccttttgg		408

<210> 86

<211> 477

<212> DNA

<213> Homo sapiens

<400> 86

acatgctgct	cccaaacagt	gcctttgaat	caagaccag	tcacgtatt	cgaagaaaaa	60
ggaaatatcc	ctgaccatgt	tgggacttaa	cactgcttca	cagagctacc	caaaccaagg	120
agaataccaa	cgtgaattgt	ctttccacct	gttgtgtggg	gccagcaatt	attcttttag	180
cttgacgcgt	taaccacact	gtccctgtg	gccttgggat	gctctgccat	cccccggtgc	240
tgccagttca	cttagggtag	acttatggca	gagggatgtc	aattttgctt	gaactgctca	300
atcactgctg	acatttcgtt	aaccacccta	tgaacttctc	aagcctgaag	tagcagcaac	360
ttgtgccctt	gaaaactgaa	cagaaaacaa	ctggattgna	ttttttcttt	caccaggaaa	420
aaagacaatt	tttnttttgt	tganaangtc	ataaaggcat	tttaccact	tattttt	477

<210> 87

<211> 500

<212> DNA

<213> Homo sapiens

<400> 87

cttctcttat	tcctgactct	ggctgccatc	gttggctgat	gaaagagttc	cttttatttg	60
gtgagttcat	ccatcaagat	tgtcttcgaa	gctttgtctt	tgaagttttc	acctattccc	120
aaccactccc	cctggaagct	tgtttcctgc	actgttaaga	gcatggaccc	tgaaggcgga	180
ctacctggat	tcaaacccta	cctccacctc	ttattgggag	aatgaccttg	tgtaaatac	240
atcacttctg	tgtctcagtt	aacacgcctg	taaaatggaa	ataatatcta	tttgtgatgg	300
ttaagtttta	tgtgccaaact	tgactgagtc	agagaatacc	gagacagcag	gtaaaacatt	360
atctctgagt	gtctatgaag	ggtgnatctg	gaaaaaanta	cntttggaat	ccgtngaaaa	420
ggggcaagna	anactctggg	cggntcatct	gggnatcatc	caatccactg	gagggtcac	480
ccaaatagaa	caaaaaggct					500

<210> 88

<211> 381

<212> DNA

<213> Homo sapiens

<400> 88

gacactggag	aggggtaagc	atgctaagaa	gtgagatgga	tttaaccagc	aactcacggc	60
aaagtgcgta	tagctgcgtt	tgagaaggct	tagtcatgac	tagaaaagtg	tgaatactgt	120
gacatatcct	tgcaaaaaaa	tgttcagctt	aagcctctan	actaacttct	ggttttacaag	180
aanaaaaaag	agggggccat	ttccaaaaag	actcctgcct	tgaactcttc	aaaatgccna	240
tgncacaggg	ggaaaaaaga	tggggggaact	ctactacntt	aaagctaaag	aaaaatttna	300
aaaaaaaaan	gaaaaaaagg	gccngcngng	ccnattnagc	ttggacttan	ccaggctgaa	360
cttgntnaaa	agggggggga	c				381

<210> 89

<211> 458

<212> DNA

<213> Homo sapiens

<400> 89

gtcacaactt	ccatagtcag	atcctggaag	cccacttcaa	gcacagcata	ttattaacaa	60
ataaccttcg	gagaagagag	atgctctcgg	tgccagtggg	ggaagaaagg	actatactta	120
cacttatgtc	gagactgcaa	aggctaacag	catcttcac	ttgggtgctc	tgtttccgct	180
ttcgctgcaa	aacaaacgaa	aaaacaaagt	tcaaaggcat	gcagccctct	ccagtccaat	240
tcaacacact	acccagcttt	ggagccaagc	ctcatgagtt	cccccaaccc	agttcctgcc	300
agatactgcc	acctgctcca	agtgtcaaat	ccagaagaca	aatggcctcc	aatggtcttt	360
ttaattcagc	catagacagt	caatctggga	tagaatgatc	tccttaagga	acccacatgt	420
tttataaaat	aaaaactgca	tgaattatca	aaaaaaaa			458

<210> 90
 <211> 227
 <212> DNA
 <213> Homo sapiens

<400> 90	
gactctgggg	agctcctgca ttaagntana nctgatgact ccagngaccc ttcattgagaa 60
gaacatgtct	gcggttagcca ctggtccaag gagaatgagg aaatatgtag agcagctttg 120
aacctaatac	gcagtctgaa gtcaagccca gtggattcca gccaaagcaca gcagaaccac 180
agccaatcta	tagaactatg agagaggaaa taaatatattg tggctat 227

<210> 91
 <211> 256
 <212> DNA
 <213> Homo sapiens

<400> 91	
gcctctatatt	accatcccca ggttgaagc aaatgtcaga gagaccagag gaaaccgtgt 60
gtgttttagt	gggtttatatt ggaggggcat gggctggaaa ggagcgggca gagatgcagg 120
gcaaatctat	aaaacatttt gaacttgtgg cctataaacc accaaacatc atgcagggtca 180
ctgatgtgag	gatctgctgg gcttatggca tttgtgacaa acccaatgat tcttttatta 240
caacagctta	taaattg 256

<210> 92
 <211> 305
 <212> DNA
 <213> Homo sapiens

<400> 92	
gattgggacc	agctcatctg aaaattgatt gccggacatg gagaacaaac tggttcagtg 60
ttaacgagga	ggaacggatt tgtccatctg accacaaccc aaattgcttg aaaatttggg 120
cagctgtgtt	aacagggaaa gaagtgggga catggagttg gacagacctg gctttgagac 180
tctgcctcat	cacgacctcg ctgtgtgttc cctctgaact tagctttcta tattaacaaa 240
atgaggccaa	taataattcc accctgtctg cattccaggg caattaaaga atcataaatt 300
ggcct	305

<210> 93
 <211> 190
 <212> DNA
 <213> Homo sapiens

<400> 93		
gtgaagaaat	gagccataag agaangactt gcccaagatc acacagcatg gcagagcccc 60	
ggacatgaaa	ctaagcattc tggctccaga gtccacgttt ttaactcaac cggaatactc 120	
agcaatggct	gagtctacgc cctgtcgtcc cctcctgggt ctacacagaat ggaaataaat 180	
gtctcaactc		190

<210> 94
 <211> 509
 <212> DNA
 <213> Homo sapiens

<400> 94

ctttgagcct	tagctgtcat	taccaggcaa	aaggaagagc	cccactcagc	acccgtttcc	60
ggtttttacg	cccaggcact	gttgagcaga	ccactatgtg	gaaagccagg	gaggataata	120
gcagccccc	aatgaggcca	cgagccccag	aaccatcctg	attgctccct	ctgagggtgat	180
ggacagagga	aattttccct	ccaaggactg	acagagaaaag	aacaacggag	atgtgggtcgt	240
ctgctggcat	ccattaactt	gtgcaactag	caaagcaccg	agtccacagg	gaaaagggag	300
agaaagtgt	aatgaagggt	caattgtgtg	tggagggtg	agtgtggtca	caggaaaatt	360
gcctcatnct	tgtattgnaa	tggcatcttt	tattncctca	acccaaggt	tntaaagtan	420
gttccctntt	ccttttctnta	agccaagcac	ccttatgcc	ccatcatntn	tnacttanac	480
cacaacttta	tctnctgac	atgtttacc				509

<210> 95
 <211> 419
 <212> DNA
 <213> Homo sapiens

<400> 95						
ttgtgataat	aaaggctcag	agaaatcaag	ttttaagccc	taagtcctgc	agtgaatgag	60
cagcagagct	gcagctcgtc	tcagtcctgt	ggatcacacc	atggcctgga	aggaaaagtt	120
tagggcaata	taacccctta	caaacaacct	tccgacaaga	ggacaagtgt	tttcacaagg	180
cttcatggaa	tgtcgaagt	gaggaacaaa	acacttcagc	tggaaaagata	gcacatagcc	240
agaagtcaac	cccaacccta	caaaaaataa	tgatgccagg	aaacagagct	acatacacia	300
aagggaatgt	gtaccaggat	acacataata	aagtcctctg	gccaaagctg	ggattcctcc	360
tgcccaagcc	agaggagtga	ttcaacttaa	gagaaaattg	gaaggaggac	atgtggaat	419

<210> 96
 <211> 95
 <212> DNA
 <213> Homo sapiens

<400> 96						
gctggaagga	tgacctcgga	agtcacatgc	tgaagatgga	agacatgttg	tagtgctgca	60
ttgacctggg	gctcagacat	ctcagactct	tgtag			95

<210> 97
 <211> 505
 <212> DNA
 <213> Homo sapiens

<400> 97						
gacctaaaca	agggaaatgga	gagtaatcac	atcattccaa	gaccttctct	ttgcagtcct	60
gtagtcacag	ctccaaagac	tctgggtttt	ggagtaagag	ctgtaactgc	tcaagaagaa	120
ttcgtgaaca	aaagcacatc	tctctgagga	ggcaaaatat	cacaggccta	tgacaccaga	180
ctgctggaag	aggcactaga	ggttgacaat	agattccaac	atctcataaa	ccagggaagca	240
gcctcaggaa	ggttggcagc	tgccaaaccc	acaggctaag	cagtgggtggg	actgtgatcc	300
aaactcagat	attttggttc	atctgccagg	aaatttttcc	tgctctggaa	ttatctgctc	360
ttctcaagaa	ggaaaaactt	aatccttctt	antcctgaaa	ccatcttag	gaaaggcaag	420
aaggaaatgc	nccaaaatgt	taactgnggt	tgacactgaa	gggggaattn	gggctttgtc	480
tattttttct	gcattgaccc	atttg				505

<210> 98
 <211> 500
 <212> DNA
 <213> Homo sapiens

<400> 98						
gagaaaaaac	atatgaacct	gagcactgaa	tgacttatca	agaagatatt	tgaaactacc	60
taaacaagga	agtttgtgtt	ccaaggtaag	agaacctgaa	atgaaaaact	caggatccct	120
cacgaacagc	ctgacctgac	tttcaaccag	gaagtccaag	ggaggcagga	ctttacgggtc	180
aaaactgcaa	agccgaagct	caagactgta	agaagaaagt	gatcttcaaa	gaaaaggatt	240
cacccaaatc	gaagaggata	tcgtttcgca	tcaggacac	tcgtctccac	acctcctacc	300
tcaaagtcct	acgcacctac	ccttcacgtc	tctncaaagc	aactgaatta	aagcgctac	360
tggtcttggc	ggngcaagga	atttaattca	ggaactatng	gggaaaaaag	caggggagga	420


```

agaaanagga aagacccggg ctgaggcacc aggaagaagg gacgcacaag aacctatcat 480
tggagcttgt tgcaggccag                                     500

<210> 99
<211> 482
<212> DNA
<213> Homo sapiens

<400> 99
cttcctgcaa ctgaagggtca ttctctctttg ttagaagact aagggtccct gacctgatct 60
gtggagcacc aggggtggaga gagggtgaata agcagcaaaa cgaaaaattg gatgctgttt 120
tcaaaagttt tgttctcatt cttggattat agattatcta aagggaatat ttaactcaac 180
caaaaaattc gttcagctcc atgaagctaa agatgctata aactgactct ttcttaaaga 240
gcaccaaac tgaaattttt cctgctagag aggaactaat cttcaaggac acctgtctat 300
tgctagacat taagaaggaa ggtgaactcc gttctgtctt cataaaacac atttttgnct 360
tttcccttta cttcttctact gaaccccttt tgtttacaaa gtccaagctn tgactggngg 420
aggggggaaa atctgaaact gtcagcccca aggnngaaca aatgaaang gagaaaaaaa 480
at                                     482

<210> 100
<211> 508
<212> DNA
<213> Homo sapiens

<400> 100
cctcatgtca ctagaagcta cagtattgga cagcacaagc tgcagagtgt ctgttctttg 60
aggattctct gttctccaaa tgtaaaatca agaattgagaa cgctggcaga agtaaggaaa 120
gatgagacct gttttgaaaa cgaagtttta gaggaactat gtgaacagat tgtgttcttc 180
aggggcttgg cacatgatga catctaacac ccacggccaa cagcattcat aatcaccaat 240
acgcagcatc atactctgtc tactggcaat tcccagagat ccaagaaata tgtaaaacac 300
tggttagaaa gtgttcttgt ggcacgaggc ggtgtctatc aagtggcttt aggggtgact 360
ggtcacctgt tacattccag gcttctggag gacctgagtc cttgccccac ttnanccac 420
accacctttt gtcacctttg agacttataa ccaggccagg cgcatggct catgcctata 480
atctcagcac gatgggaggc cgaggcaa                                     508

<210> 101
<211> 376
<212> DNA
<213> Homo sapiens

<400> 101
caaattgtact ctatcgctctt ccacactggg accccagaca ctcatggagg aggaaattct 60
tgaccaaaaa tatgtgttac agaacctgag agagaagaaa aatttcagga agacgatgac 120
agtcaataag atgaaatgat gaagtaaattg taaacatgat acagactgag gccattggct 180
ctgaatatcg agacatcact ggaatgtttt gagaaattaa ctttgattgc gaagagatta 240
agaattagaa tgcagtagga aaatgaatta acatctgata agaaaagaaa ccaaagagtn 300
aagacctgta gttctgcaac acagatgctc atcagaaaaa tgtgggtaac cttttcaata 360
ataaaacctt ggacct                                     376

<210> 102
<211> 304
<212> DNA
<213> Homo sapiens

<400> 102
atgtctgatg tccnagtagg agtgattatg gttactgtgt gaagacttga ctctcaagga 60
gttgccaggat catactgagg aagtggaggg gttcccatgt gaccttctat gaagatcaga 120
agaatagaaa acctgaagaa tacatttttg ttggaagaat agaaagtctg cctagagngt 180
ctttggaatg ccagaggatg agatccgtct tgtttactaa gagttgtnac ggntcccttc 240
accttacctc ccaaattctg gtnaggaacc aggacctgcc aagggtgaagc actgatacat 300
tttg                                     304

```

Variable	Mean	SD	Min	Max
Age	34.5	10.2	21	55
Gender	0.5	0.5	0	1
Marital status	0.6	0.5	0	1
Education	12.5	1.5	9	16
Income	1500	500	500	3000
Health status	0.8	0.2	0	1
Smoking	0.3	0.5	0	1
Alcohol	0.2	0.4	0	1
Exercise	0.4	0.5	0	1
Stress	0.6	0.5	0	1
Depression	0.3	0.5	0	1
Loneliness	0.4	0.5	0	1
Life satisfaction	0.7	0.3	0	1
Quality of life	0.8	0.2	0	1
Healthcare use	0.5	0.5	0	1
Health insurance	0.9	0.1	0	1
Healthcare access	0.7	0.3	0	1
Healthcare cost	1000	300	500	2000
Healthcare quality	0.8	0.2	0	1
Healthcare satisfaction	0.7	0.3	0	1
Healthcare trust	0.6	0.4	0	1
Healthcare engagement	0.5	0.5	0	1
Healthcare participation	0.4	0.5	0	1
Healthcare involvement	0.3	0.5	0	1
Healthcare collaboration	0.2	0.4	0	1
Healthcare partnership	0.1	0.3	0	1
Healthcare alliance	0.0	0.2	0	1
Healthcare coalition	0.0	0.1	0	1
Healthcare network	0.0	0.1	0	1
Healthcare community	0.0	0.1	0	1
Healthcare system	0.0	0.1	0	1
Healthcare organization	0.0	0.1	0	1
Healthcare institution	0.0	0.1	0	1
Healthcare provider	0.0	0.1	0	1
Healthcare professional	0.0	0.1	0	1
Healthcare worker	0.0	0.1	0	1
Healthcare staff	0.0	0.1	0	1
Healthcare team	0.0	0.1	0	1
Healthcare group	0.0	0.1	0	1
Healthcare unit	0.0	0.1	0	1
Healthcare department	0.0	0.1	0	1
Healthcare division	0.0	0.1	0	1
Healthcare branch	0.0	0.1	0	1
Healthcare office	0.0	0.1	0	1
Healthcare center	0.0	0.1	0	1
Healthcare facility	0.0	0.1	0	1
Healthcare building	0.0	0.1	0	1
Healthcare campus	0.0	0.1	0	1
Healthcare complex	0.0	0.1	0	1
Healthcare system	0.0	0.1	0	1
Healthcare organization	0.0	0.1	0	1
Healthcare institution	0.0	0.1	0	1
Healthcare provider	0.0	0.1	0	1
Healthcare professional	0.0	0.1	0	1
Healthcare worker	0.0	0.1	0	1
Healthcare staff	0.0	0.1	0	1
Healthcare team	0.0	0.1	0	1
Healthcare group	0.0	0.1	0	1
Healthcare unit	0.0	0.1	0	1
Healthcare department	0.0	0.1	0	1
Healthcare division	0.0	0.1	0	1
Healthcare branch	0.0	0.1	0	1
Healthcare office	0.0	0.1	0	1
Healthcare center	0.0	0.1	0	1
Healthcare facility	0.0	0.1	0	1
Healthcare building	0.0	0.1	0	1
Healthcare campus	0.0	0.1	0	1
Healthcare complex	0.0	0.1	0	1

gaatcccatg	tgcattganc	ccctacctcc	ctggaccaca	ccancatgag	atgtcttctc	60
gtggcaatga	gggtcacgag	tcttgccctga	ttttctatgg	ttccagaatc	acccaagcgg	120
ataatgaagt	gagntgcagn	taanatggag	cccactgggg	aagagatgaa	gcagtgttca	180
cctgaagcac	catctgcatt	ttcctagtcc	tgacagttac	ctctanctga	ccaggggttc	240
tgtgcangac	ttctggtatc	aatcaacga	tcaagggtgg	tnacacataa	agatgaacag	300
ttccatacga	agggttaaaa	aagaangcct	atgaagaaat	ggtaataactt	aaaagcactc	360
ttgaagntaa	ngggatatgg	cgntangaaa	acctttaaga	tcctttttant	aggnnagaaa	420
atggctctct	cantaaaaac	aaggccgtan	gntttntttg	ggcttttcgcc	aatgcaacc	480
tgcctntnccg	gccggtgcc	a				501

<400>	104						
caaaacngan	gaccagcct	tgtgtgcana	ngccgctgaa	cnnnnгаааg	cccgaannga		60
ancananagg	ggctcangac	gctgtgagac	ttttccattt	cctttgcctc	ccagcaggcc		120
gnгаааgagt	cacttttccct	tgaggaagaa	agaaggctct	gtgtgcaggg	caaggggtaca		180
gtccttctaa	ccaaaagatg	tgtgtgctgc	atgggatgtg	gccaccgaca	ttcatttnnc		240
ttttactggg	acttaacgaa	ttccatctct	cagtagccat	atgccaggggt	cccaccctgt		300
ttcctctggc	tctggagggg	ggagaggaag	gacttgcttt	acccaaggggt	ctataaggaa		360
tcttgggaaa	gacactgccc	cttaaatacac	tttttgggca	ctggtgtcac	ctttgtgtca		420
cttgtgtccc	t						431

<400> 105						
gaccagctt	gtgtgcacan	ncnnncnngan	gacaattgca	tacttggtt	ctaccacttt	60
gacaacaggc	agcaccaaaa	gcagggncng	gaggactaag	gacaactgtg	ttgaaactga	120
gtcaacagct	ctgtttgagt	aatgatcca	tccttgaatc	gtgtatgcag	agacaagatc	180
agcagttgga	ttgtttgttt	aataaactgg	aagtctgcc	acattatctg	ggaagaggac	240
gaggacatta	atgctagcat	gcaatctagc	cgtgtttgga	tttaagacag	aatttaatct	300
tcttgccctc	tttcctttcc	ctcctccctc	tttcagncct	tttttcttta	atacacaagt	360
ctctttttatg	gagttaactc	aagctatctt	aaacagcatg	aactaataaa	qcca	414

<400> 106							
tcatgcagac	acctgatgga	agangtcttc	caggcagaag	gaaggacaaa	tacccttgat		60
atacatgtac	ttggccggca	tgaggaagag	caatgtggaa	gcctactcaa	tgtgaagaca		120
aggatgaaga	cctttatgat	gatccatttc	catttgggtga	atgcctcttt	caaaagaaga		180
cgtaagacat	ctggtgtcaa	gaagaataaa	tacaatacca	ttaaagaatt	ataaacagaa		240
ccagagccag	agaagaatac	cattttttact	tgacagatga	ctgacacaaa	acttgggttac		300
acagacgaag	tattttaagca	agatactttc	tcgaaaatga	acaacacgcc	gactgncatt		360
tcaaggaaac	caactgacaa	catttcctgt	taggacaaaa	tacaagtttt	caaccaaatin		420
ttagaatttta	qqaca						435

CA1 - 201292.1

<212> DNA
<213> Homo sapiens

<400> 107
ggaattctaa aagtccaaac tccatctttg gacgccaaac cggactgagc agaagaatct 60
tctgggtatgt gaactaggggt cctgggttctg gttatcagct ctcctccacc taaataagac 120
ctgattccca ggcaccacat gctgatgtgg tcaggaatga gatggcacct acctctgcag 180
cttggcagct cctcgaatgg agacattggg tcttattcac ctctgggtct ttagcaccca 240
gcacaaaggt cagacagggg ccagacgcag ttgtgccac ttttcgaggc tagaaaataa 300
tgatctaagg aaaagacgat tttgaggnc tccagaaagg aatacagcag caaaagccag 360
ggagcctggg taactttctt gagcacttgg aaggataaan aaatccatac cctggaaaat 420
ggnggtttgc ttaaagt 437

<210> 108
<211> 383
<212> DNA
<213> Homo sapiens

<400> 108
ctggggagct cctgcattaa gnnataactt ganggaagac aaccaccatg tcctgaggcc 60
actcaggcag cctacgaaga ggccacatag agaagaacag agggctgcag tctacagcta 120
gcaaggaacc acagcctgcc aacaaccata agagcctgcg tgggagggga ccttcagcc 180
cccattgaca gcctgagtgc aactccatga gagacgctga ggagaatcaa gtagctaagc 240
ccttcctcaa ttcttgactc tcacaaactg tgcaagataa taaagattcn ctcttttcag 300
ctgcaaaaaa aaaaagggnc nggggggcn tttngtngg ncttnancng ggggaanttn 360
tttnaaaggg gggggccccc ccc 383

<210> 109
<211> 79
<212> DNA
<213> Homo sapiens

<400> 109
gactttgctt ctgggaagat ggagtacttt tccttattct ttccacaaac gacaactaaa 60
atccctaggc attatatat 79

<210> 110
<211> 473
<212> DNA
<213> Homo sapiens

<400> 110
ttctgtnacc tcaagcggca tccctgggccc ctggtctcca agtcccgatc ctgtctgaaa 60
aatggcgctg aaggcctagc acanggcagc ctctacctca aagcaccatc ccgcttaaca 120
ttccaacggn gcctnaaang aaaaaccctn tgggtggggtc caccaaaaac cctggcctc 180
catgtgctcc ttctggccc caaggacagc ttgacactnt ccaggaagna aaggccaang 240
ggnaaccccc ttgcaanaa nacttatttc ttaaaaaaga tctnggnttn tanantcaan 300
ggggacctgg gtttnaaagt ccccggcatt ttgcccttct tgaacttcac canttgtttc 360
aacnctttt ngggccactt ccacctttnc cccttcacnc tngggaaacc ctccangttt 420
ttncctccat tctggggnaa gtccaagggg gngggggngg ggacccacc ctt 473

<210> 111
<211> 417
<212> DNA
<213> Homo sapiens

<400> 111
ttctgtcacc tcaagcggca tccctgggccc ctggtctcca agtcccgatc ctgtctgaaa 60
aatggcctga aggcctagca cagggcagcc tctacctcaa agcaccatcc ggcttaacat 120
cccagcggtg cctcagatga gaagccctgt ggtgggggtcc accagaaacc cctggcctcc 180
atgtctcctt cctggcccca aggacagctg acactgtcca ggaggaaagg gcaaagggga 240
agcacgtggc aagacactca tttctcagaa agtctggggt aggagtcagg ggacctgggt 300

tcaagtcccg catctgcctc tgactcaca gtgncacctt tgggcactta ctttcccttc 360
gctggacctc agtttccctca tctggggagtc aagggggggtg gaccagctga tctccgg 417

<210> 112
<211> 262
<212> DNA
<213> Homo sapiens

<400> 112
agatgggggtt ccatcatgat gccagactg gtcttgaact cctgagctca agctatccac 60
ccaccttggc tgaaatggcc tgacatgatc agcactgggc gtgacccaaa gatggaatga 120
agaacatgaa tggatgactg tttccttagc aacaagaacc atatgtttcc tttgaaacaa 180
gaaacccaaa gaaaagtcc catccatttt tctttccacc aattcaaaga ctaaatagta 240
gtggcttaaa attataatgt tt 262

<210> 113
<211> 229
<212> DNA
<213> Homo sapiens

<400> 113
gctcaaccaa atgcctctgc caggagaatc tttcagagtg tcttggaaaca ttggaaatag 60
gcttaaagct taaatgatga atcagaagag ttatgctgta ttctaagtct gccactaggg 120
ccacacaggg tgccaacatc caatctcaag atcttcggga aatatgctca cctccaaaa 180
tacttacaga tgtgtctcct cttttttgta aaataaatgc ttttcttat 229

<210> 114
<211> 318
<212> DNA
<213> Homo sapiens

<400> 114
gtgctgcaat caagagaaa agacagagcc aactgacaa gaccacgttc tagagagaag 60
gaaatatgag aggtctcaagg gcagggtgtg gaggacaagc aggggagatg agatgaggag 120
ctggctgcat ccaaactgca atgaacctat accatagaac acagaacaca aacattgaac 180
ctgctgagcc tgtatgaagc tactatccca ggactgtgaa aagtagacta gttgaggaag 240
aattcaagtc gacactgaac tagtggtaga gctctcatca tacagatcgt tggaaagtag 300
catcccgaca gttctgag 318

<210> 115
<211> 426
<212> DNA
<213> Homo sapiens

<400> 115
atgcacagan aatttctgac cttgngacgt ttgggagtga ggagatccca tacagaggca 60
tccangnatt tccagagatc ctgtggcngg tgaggncctgc cctcncctgga nccaactcgt 120
ctataatatc ttcctaacag cangagtcgc ctgctggggag gagaggagaa gacagactaa 180
gctgcgcgta gagcggcatc aggagcaagt taccgttagc atgtgtaaac aaaacaactc 240
gactcctctg tgtcagaatc aacaacatca aagctgataa tgtggctggg tgggatcaat 300
tagcactgga ttttgcccca agattgcttc ccaaggcgga caagtgggag ccacttcatt 360
ttccagcgac ttttacttcg ntcacgggca tatccacgcc agggctgcag aagcatttca 420
aaaggg 426

<210> 116
<211> 229
<212> DNA
<213> Homo sapiens

<400> 116
tgacacacgg agaggaaaca tcagattgct ttttatccgc atctataagc cggggtcata 60
actggagaaa aagccacat caaccagaa ggccaacttc cataattata tgaatcgttt 120

gtgaacattt	atggattaaa	atgtttgagt	aaagctgaaa	tccgatatta	cagtccatga	180
atagttcatg	ccatgagaca	aaaaattaaa	gaaaaaaatt	tcattgatt		229

<210> 117
 <211> 430
 <212> DNA
 <213> Homo sapiens

<400> 117						
catgaactga	ggtgttccat	gggtggctcag	ccgatctcca	ccccaaggt	tgccttccca	60
gagcctcaga	cccatgcccc	agcgttatgg	agatgtcttc	tggaagaacc	ttaatcaaag	120
gccaccccc	acttggctgg	aggagcagca	cattccaccc	atgctgagag	ccactgggtg	180
ctcccagctt	ggtctgtatc	ctcctgagca	gctcccaccc	cctgaaatgc	tttggagaag	240
aaagaagagg	aggccatggt	tggaaggaat	gcagcagcag	ggccttgggg	gagtccccgc	300
ccgggtgagg	gctgtcactt	accacctgga	ggacctaaaa	aaggcgtcag	aagcattatt	360
aaacgaactt	gaaaaaggcc	cagtggggca	agcttntggg	gctggcatct	tganocagtg	420
ggtgcttggc						430

<210> 118
 <211> 435
 <212> DNA
 <213> Homo sapiens

<400> 118						
cnaanctnna	aagggcnent	nccagggttaa	aaccncann	cccaaaaaaa	atnggggttaa	60
aaggetgncc	ttnggctcca	tcaacactct	gctagccaac	actttggccg	caagttcact	120
ctgctatcca	cagctctggg	gcattctct	ggctgtctgt	tagtaaccac	taacctaac	180
caacctcatt	ggccaggtaa	aagctatcga	aaataaaactg	aaaattgcta	tctctatatg	240
nccatgaggn	ttaatacagg	aaaagctgat	agtcaaaagt	caagntcaaa	tggcatttgg	300
tctccacagt	gaaaaaatgn	ctttangctg	gaataccaaa	gaactnggga	ggcaacaccc	360
ggacctgnct	tcaaaagatt	ttnatcttcc	cttttccctt	ggntggcagg	gcctaaaatc	420
aattcccagg	gttca					435

<210> 119
 <211> 405
 <212> DNA
 <213> Homo sapiens

<400> 119						
aaatggggaa	gattgaagca	aaaaatggaa	cacgttaagg	ctatttatga	agtaagaaat	60
ggttccccctg	ctactcttgt	gaagtttcca	ggtaccaaaa	gcaaacttcc	tcctaaccgac	120
tcagggttcc	aatcttttct	cccttaaaaa	tacaagatcc	agaagaggag	ccctgtcaga	180
tttccattca	acaaaaccgn	tgggcttacc	aaccttacac	tggaaacaac	aagctcaaaa	240
gtggactctg	aaacttgctt	tttaaaaaaa	gcgtttcaag	cgataagtgt	aacgtgtctac	300
agcaagttta	gacatctgca	ggtctgatgc	agtcattctt	tgggggggtt	acccaacaga	360
cacacacagg	gccaggcacc	ttttcttctt	tagcagcaga	agaaa		405

<210> 120
 <211> 424
 <212> DNA
 <213> Homo sapiens

<400> 120						
gcgctgaccc	acgaatgcaa	ctctcagccg	agctgtccct	gccggatttc	aaacagctga	60
agaagggctg	ggagaacatc	aaggcttggg	ctaaaacaat	tatggcccat	gaaaggagag	120
agaaggtgaa	agggagcgtc	anccccctcc	tgagtaacca	agtcctaggg	aaggagatca	180
ccancatgct	gctggagcag	ctctacttcc	tgcagagcac	tccttccacc	cctccccccg	240
gaggaggagc	ccaaatacca	cgccacggcc	caagaatcat	ttgctgtttc	aaatagagaa	300
ctgggcgatg	atgaaaaaag	aagttcatac	cgtttttcca	acaccgtgaa	aaggacctnt	360
taaaccttga	accctcgtgt	tcaagcttgt	naagaataac	agccaataaa	aactacattg	420
agcc						424

<210> 121
<211> 422
<212> DNA
<213> Homo sapiens

<400> 121
nnnaactgaa ataangaagg atnggtcaga nanacagcca acggtgtggc caacaatcac 60
cactccagag ccctgccccca tctaggggcgc acgtgcatgc ctctgaattt cctccccctt 120
ccttggtcca accacagtcc aggaaagcag attttctatg ccccggtggc atcacagtgg 180
aaaatggaag tacaatggag tgctgtacct acccaagcac caggaggcag gagtcgagct 240
actcacagac tccctagagg agaactccac gcacccaaac tctgctgtgc cccctctgag 300
ttctgagcat gccaggtgag gcctctccct ctctntntnc cttcattcca agtttttngg 360
aaaanaaagc aagcagcccg cgtgaccaga cagagccttc cttgctaata aacccatcct 420
ga 422

<210> 122
<211> 409
<212> DNA
<213> Homo sapiens

<400> 122
gcttantagg tattccattg ngcntacaga cctcatttnt tactccattc atnngntgat 60
ggctgnanct tggctcttga gaataangca ccaangaaca tgggagngca gcaaagctca 120
tgacattaca ggaggagcag agttctatca tgtagaaggt cattcacccg agcatgcttc 180
cttatcatca tctcatcttg tgccgggtata caagtaagat cagccagctg ctgaaatctc 240
taaggaatat ctctccatgg agacagagcc agacggccca agtctcttct ctgttcttga 300
gttcctggtt tcaagtaatg atttggataa actggggagaa ccagtttctt ttcctccaac 360
tctggcaagc tgaaattaat tctccaaaga ctctctcttg gaggcaagc 409

<210> 123
<211> 419
<212> DNA
<213> Homo sapiens

<400> 123
gcgctgggga gctcctgctt taagtnanan cngaaatcac ccangtcann aagganaang 60
aaaatanaag ggcaanctcg ctgtaaagaa nggattactc aaangtngaa ccaaagccgg 120
gggaaagaac atggaaagca gtggagaggc accaggcagg tcgctttctc tttctggtcc 180
tcaaccacag cactgccgtc ttcagaacag taactattac ttgtccatac caggcatctt 240
caatactcct caactcatat caagaattct gccagctcta aacagacctc catcctacaa 300
acactgaaac cctaacccaa aaccttacat atatccacct ctcaactatc ccttctgaga 360
cantatgaaa aacaaagngg cagtttccct tactggaata agtattaaat tttgcttgg 419

<210> 124
<211> 410
<212> DNA
<213> Homo sapiens

<400> 124
gagccgcaaa gacagcctgg aaagtgacag ctccacggcc atcattcccc atgagctgat 60
tcgcacgcgg cagcttgaga gcgtacatct gaaattcaac caggagtccg gagccctcat 120
tcctctctgc ctaaggggca ggctcctgca tggacggcac tttacatata aaagtatcac 180
aggtgacatg gccattaccg tttgtctcca cgggagtggg aggcgccttt gccactgagg 240
agcatcctta cgcggtcat ggacctggt taaaaattct gttgaccgaa gagttttag 300
agaaaatgtt ggaggattta gaaagatttg acttcttcca gangaattca aacttcccaa 360
agagtacagc tggcctgaaa agaagctgaa ggtctccatc ctgcctgacg 410

<210> 125
<211> 358
<212> DNA
<213> Homo sapiens

<400> 125
 cnnanactga gagataggan ctgcgtacgg ttgcctgggtc tcaaactcct gggcccaagc 60
 catcttccag catttgctc ccaaagtctt gggattacag ggcctgcaca ccaatgaaac 120
 tactgatatc agctgttctg aagaaaccca gaagagactg aatcaccaaa gagtgcagtt 180
 tccacatcct gatgatttta tcatccttac tctgaccaa cagtgcactc aattttacag 240
 cccctcacac cctataatca tcctaaaaac ttcagcccag aactcctcag gaggataatt 300
 tgagggtttc tcccatttcc ttatttgggt gccctgtaat cattaaacac tttctctg 358

<210> 126
 <211> 488
 <212> DNA
 <213> Homo sapiens

<400> 126
 gtctggggag ctctgcann anncntgnac tgagagttgg ctnangagaa gatcaagagt 60
 gccatctgga agctcagggc natgagaaca acctggggcc tgggtctctca agccaccatc 120
 aacccaataa tcaacanaaa cccagagggg aaacgacctc ctttcagcan gactgggaaa 180
 cccttgaagg caggaactga gccttcattc cagcactaac tcaacaaaca tttcctgagc 240
 tgtccctgaa gccaggccct ggctgagaat gctgaaaaga ttcagagcag atacacgtgg 300
 gctctatcac acaaatttca tccatgtgtt ctaccaagt gataccactt gctctttctc 360
 tgggctnccc cagtccctga cacagaactt tttggtcacc aacctaatca ttcanggatt 420
 ataactgttt acatgtcagt ctctctctt cgtcccctga cagcagggat atggntggcc 480
 cttaatgc 488

<210> 127
 <211> 437
 <212> DNA
 <213> Homo sapiens

<400> 127
 gtgaggncac acgtgnaaca acacgntgtn tgtgaaccat gaaagggagc ttcgaengac 60
 accnnacctg ccacagcctt gatcttaacc tttgcngaag ncacaactga gagannatnn 120
 nnnntgtggt ttataaccca nccagtnat gatattntgc tncannaacc tgaatggact 180
 aagacnctcc ccacatgan aatgtccaaa cataatgnga cagatgtctt tacatcantn 240
 gtggatgctg ngacanaggc ntttacaacac acagagcaac ccagggagct gatcagcatg 300
 aatgaggctg gaaggaggct cananaatcc atctttccag tgaacttgga acaccagaaa 360
 caagtggagc anaggggaga gaatntcttt gaaaacgcag ttggggagaca gagccangta 420
 acgggaaaga aacaagg 437

<210> 128
 <211> 438
 <212> DNA
 <213> Homo sapiens

<400> 128
 attaaaaaga aaaaagaaaa tcagggtggga taaagagcct caggtctaac tgaattgtca 60
 actaatgatg gtctgagagt acctgtgctg aaatggaatt gtctttgagt ggacacttct 120
 tagatgagac ctattgtggc caatagctcc tgagggaactg aagccttcag ttcaaaactt 180
 gtgtgagaaa aatgaatctt gccaaactact ggagttagct tagaaatgaa tccatcccca 240
 gttgaccctt gaatgtagcc ttgtcagaga cccagagaca aagcatcctg ctaatctgca 300
 ctgggttcta ggcccacaga aaccatggga taataacttt gtgntgnttt taacccttg 360
 aaaccaacca aataaaatcc ttaagatggt cccctgngga agggttccat tggcagggat 420
 ctgcacttca caacaaa 438

<210> 129
 <211> 442
 <212> DNA
 <213> Homo sapiens

<400> 129
 ggcaaattaa cccagaagag tacttcagag aacacagaca aactgccgtg cagtgaagag 60
 aatgtggcag gaagccctgg tattctagaa gaagctctgc ccactccaga caggatccgc 120

acgcctagtg	ccatgtctat	ctccaaggag	atcacattct	agagccaagg	accgccactg	180
agaagaaagt	aaccgtgagc	cgtcagaatg	catacctgga	gcgctccagg	aaggaaatct	240
cagccccggc	atcctccatg	gtcacacgga	gagggcgggg	gtccttgtag	ctttggccct	300
gagatgggag	ctagagctgg	acacagggtt	ctagtcttgg	cttttggtga	aacaagttcc	360
caaacctggn	gcaagngcct	tacctgtctg	ngtaatgggg	ggagctgatg	tggatcatct	420
ttaagccctc	tgcaagatgg	ag				442

<210> 130
 <211> 440
 <212> DNA
 <213> Homo sapiens

<400> 130						
gaggtggagt	cttgccatgc	ccttccatta	caaaatcctc	ctgttccacc	tgcaaaggca	60
agcaccacag	gtcagcagca	gtcagtaact	acaatgcgac	tcactccaag	aaccacacacc	120
tgccctgtgc	agaaccacag	ggccgtttca	ctgtggggca	cagaacagaa	gcctggggcca	180
atggttttca	aactttctct	tgagtgatta	gatctgcaga	aaaaaggaaa	catgttgatc	240
ggcaaaacac	ataactctga	caaaggatta	gcattctagaa	tataaaagaa	cggtgatgaa	300
tcaatgagac	aaagacagcc	tactagaaaa	atctggaaat	aaccaagcc	gggaatttcn	360
ntgaagagaa	cacataancn	gttntaacat	atgaaaagat	attcaatctt	atgtcagtca	420
agaaaatgca	aattaaaacc					440

<210> 131
 <211> 434
 <212> DNA
 <213> Homo sapiens

<400> 131						
gaagaaaatg	ttaaaaagta	ataaccaaag	aaaaagtcag	ccaactccca	cagcctgggtc	60
ttgctgtgct	gaatggcaga	gaagatcaca	gaggaagaaa	aaagaaaaag	acagaaaaaa	120
ggaggcggag	aatttcttgc	ttaaactgga	cctagtccag	ctggcaagaa	gaggtgggtt	180
tcttaacgcc	tgcaaaacct	gattactttt	tttaaaggaa	tgaagaagaa	ggagatgtaa	240
acacagccat	taaaacagat	ttaaggtact	tagttttaat	ctagtctaag	accttttcaa	300
ttgtatgctg	ctctgcaatt	ctctgcttgc	tagacattaa	tacngngcat	aagcccntgg	360
tcagngtctt	ttaaccagng	aacgctttca	gctgagctct	gnggttacc	tctcagggtca	420
ggcatggaag	gcct					434

<210> 132
 <211> 437
 <212> DNA
 <213> Homo sapiens

<400> 132						
gtaaaccag	ttcactcagg	cagaagcaag	aggaagaaca	ttcctccagc	tcctctcat	60
gcaggcccga	gaggtgggag	ggcattctgc	cagcccagta	tatccacttt	gcttcgacaa	120
atgtcagcct	gccagaata	aggaagtacc	cacagccggg	aaaggtaaat	ccaaacctg	180
aaaagacaga	tactgagcat	ttgaaataac	acagcttgca	gcgtccttgc	ggagccctgt	240
ttatggggca	ataaaccatt	ttaacgactg	tgtgttggaa	cccacaaggt	cgcttgaaa	300
ggcttttcac	agacactgct	agtagggctc	caggacctct	ngaaggccna	gatngggggg	360
nctttttgct	tntgcttgaa	gcttgnrtgg	tcccctccat	cangaacgcc	agcccttggg	420
gaggtgcca	tgagaaa					437

<210> 133
 <211> 341
 <212> DNA
 <213> Homo sapiens

<400> 133						
gaagaaacac	aagatttaag	gttgtttgtc	aactgacagc	cctttctatc	aacaactaaa	60
taaaaaaatc	tgtattccag	aaacatgaca	cttcatgtac	caccttttt	cctcataaga	120
aaccaaaagg	tgtccatgac	ttaggtacta	aatggcaagg	ctggaaccag	aatccaagtt	180
gccagtcac	acagttttgg	tttttaaata	accaaattgg	tcaaaaatct	tcctcaaaga	240

caaaaacaga tgaaggtaaa atgccaattg gttaaattta aacagagact tcactttgtt 300
cttttcaggt tcaataataa acaattctag tgattagcat g 341

<210> 134
<211> 442
<212> DNA
<213> Homo sapiens

<400> 134
gagtaaacga tcccaattgc agtatatctg nggntcatct ggctttcttct cacaccacct 60
ctgttgacat gggaggcctg ccggccacac atccaggaag tatgaaatca gcgggggttcc 120
tccccttctt gctccaggga agcctgagag ggactctgca gattgcattt ggaatccatc 180
tgccagggag gggtaagaag aagcagagtg tcaccgggta agagtcgaca gttttgaaga 240
ctcgtagctg cgaatctttc aggaaataat ccagaacagt ctccctcgctg gacaggaaag 300
gaaacctatc ctagagaggc gaatcctctg tcctggaccc ctgccccana aaatgggtca 360
ggggagggga ttntttgggg gngtttcnac ctgctgcttg cagggcttcg gttgccaaga 420
gtttcccaaa tacctaaacc cc 442

<210> 135
<211> 434
<212> DNA
<213> Homo sapiens

<400> 135
tctccatgct ctggatagag gaggttcaca agccagggcc tgaagattaa cagagctttg 60
aagccaaaag gtgaccctg gaccatggac ttcgcacctc ctttcttaag ggcttttaaaa 120
tagaaaagaa caggagctag aagatgaggc agaagtcgag gacttctgtt tttctggaag 180
gtcctcttga gccaaacaagg ccagggtgtt tctggatttc agagcacaaa gaggtcctg 240
gagccagcca tgggtctctg aggtctttac caacttgaaa gcagcctttc tccagggcag 300
aaacgaagca tctccccagc gctcgccatc ctccagctgnt ctttacaaca agaactttac 360
aaggatgccc ggatgaaggc ccaananacc cgcgttctgg gcaagccact tttaccacac 420
cgactggatc cccc 434

<210> 136
<211> 433
<212> DNA
<213> Homo sapiens

<400> 136
gtacctaaag cagtaaacc ccaactccct ggaagggccc actggggcgt cacttcgctc 60
cagagcctcg cctggtttcc gcttcgggat ccggtcaccc aaccagctc tccagttgct 120
gctgtttctc gtgagactgt cagagtgaag ggggtccaaag ctccgacttc cagcctcaga 180
aatcccaact caggcaggat cagcgaagcg tccctcgagc tggctggagg gagagccagg 240
cggggcccag gctgccactt atcagggtg taaatgccac cctgaggccc acgcctgcca 300
acactgctcc ccacaagact aagtccctgca gcctcagccc aaaaagaacc gggcctaacc 360
ccaaaacgga nggtcatgtt caagccacac cccagtgaac cctggcgacc caccacacag 420
tgccctgccc tcc 433

<210> 137
<211> 443
<212> DNA
<213> Homo sapiens

<400> 137
gactagaact attgccactg aggggcaggt gggaagttca gccaaactcg aaccggagg 60
ccccacctta cctccctttg tgaagagccc agagcctttg tccaaagctg catcacttcc 120
caccagccc ttcttgagcc aactccccga tgtctccaga agaacacagt cggcatcatc 180
gtgataacat cagggaact cctatttcca gcagtttctc cttcagctgc aaaaatgtgc 240
agcagtagac agggcgtggg tttttgaagt ctctgcagga ggtagagtta tttctcagc 300
accacatctg agcgcatctt ctaaggggtg ccgactgtgt gggaactgca agagcttaac 360
ccgggatgca agccctccca ttccccacc tgtccactac caccacgctt ggatccgaca 420
ggcagggcag gaccccatgc ccc 443

<210> 138
<211> 405
<212> DNA
<213> Homo sapiens

<400> 138
gctctgggga gctcctgcat tannnntan ctgagtatca tccntctgcc atcaagaatg 60
taagtatgaa gaatgttccg acactgctcc aggactgtct ttcaagccac tgacaaccat 120
cctgcaaatt ttgatactgg tgccctgtttg gtgtccctag aggatctaaa tgaagatgtg 180
aaaacaacaa ctaagaaaat attttaaatg gcaattactc aacacgagaa gttaaaacaa 240
tgtccacact gagactgaaa tgacagcaac agaaacagca agtcagagcc atgcctgtac 300
aatgacaact agatcaaac tgccacctgg ccaaaagcaa tactcagatg ctattaactg 360
taagacagtt aatggtatgt tatgaggtga aaaaaaaat tcctt 405

<210> 139
<211> 448
<212> DNA
<213> Homo sapiens

<400> 139
ccnttttgat cccacctac aactgggcat cgctaacaac ccatgtgagg tacctaggaa 60
gaatgagaag cttccagcaa ggcagctgct tccagcagca agtcctgca tagcccacag 120
gccattccag ctcaatgctg gagaagaatc ttccccctaa cagcactgcc cagcactacc 180
caactaaggc ttctctggtt aaactgcccc aggatgcccc aagaacttgt ttctaaagga 240
aggaaaacag atgccaagac ttcttgtgct ttctccaggg ggctcagagc aggcctgat 300
cactaccctg gatgcacaaa gtatctatca aattcccaca aggtanaaag ggttgccagg 360
aatgggaaga aacttcaata ttcgaagtca ccaatcacag aagataactg gcaaaacagt 420
tctactaagc aagcacagag ccatttgc 448

<210> 140
<211> 458
<212> DNA
<213> Homo sapiens

<400> 140
aactgaggtg gtgggtggtca agagcaaggt cgaggctcac ctgtgcccac ttggttccgt 60
acattgctca ctagaggcat catcgacaga gtatgaatca gctccccaat tagcctgacc 120
gtaatcacct gtgttgcttg attattatac aaattccccg acctcatacc gacctactga 180
atcgaaatct ctaggagtag attctgggaa tctgtatcgc tggtaaagct cccaggtgat 240
tctataatc tggcaatgtg ggagacacga gcattaaggg aaccagcaa caggctccat 300
cctctgcta acatcagcaa cctcagcaga gacttggtcc cagggaccct tgttccntta 360
tgtaccccaa gacactgtcc ctaaatggng cacaaaagca agactcaggc ctgtctcaca 420
cactggcaaa gctgctgccc ccagctcaa accagctc 458

<210> 141
<211> 451
<212> DNA
<213> Homo sapiens

<400> 141
aagcttgtga gacctcaatg agtcatgaag aatcctaatt tcaaattcaa agaattccaaa 60
gtgatgataa caaaaagcaa taattgatat ctgaacaaag attcttgggc agccgagccc 120
ctcttgaatt cctcagccta ccatcatgat caacacctcc catgttccgt ccatgaatga 180
ccgactgac agcactggag agatttaatg ggtcaccaat tgaggcagtg aaggcactca 240
tggcactcag agctggaatg gggctgatct gagttgtact gttgactgca gtggtgatga 300
caacctgcat tcctttgctg gctgcatcga caactgcttt gtnaatgggc attntaccgg 360
aagcatcacc tggggccacc cacaacgagg ccatncttca cctgttgacc aagagatggg 420
tcaatcctcg gttgcaactc acaaggtggt c 451

<210> 142
<211> 450
<212> DNA

<213> Homo sapiens

<400> 142

atcccttctg	gagctggtcc	taattgcttt	tcacaggagg	gatgcaaact	ggaaagtctc	60
tacctattca	gcgaaggcac	tccaagtcct	gggtctcttt	ctcctcgggg	gcaaagatga	120
gacttctctt	ctgtagagat	cacagggtgca	tctgtacagg	ttggagtgtc	cccccaaccc	180
tggaccccta	ggagcggccg	tgatttgtga	cacaaggccc	caccctgtga	tctactcttc	240
acacagccgt	ggagagccaa	gaactgggag	ggaggaggaa	atttggagac	agagacacac	300
agggagaacg	ccatgtggag	gtgaagataa	agaacacaac	gggtgcttnt	acaacccaag	360
gaatgccaa	gacctccagc	aaaccaccaa	gaagctcagg	gggaggcaca	gaacgaattc	420
tttctcacag	acctcagaag	gaaccaacca				450

<210> 143

<211> 452

<212> DNA

<213> Homo sapiens

<400> 143

tcagagttta	caccttactg	tacggctgac	cacctgaatc	ccaatctcac	gaaacaccca	60
caacccctgg	gcattccctg	ggcactaccc	agcaaagccc	tatctttgca	tcgggtctcag	120
aaggagtctc	ccagatgctg	caccagctgc	ccagcgtgc	tggaggaaat	ctccaccgct	180
gcagaaaggc	catccctcca	ctccctggac	agccctctcc	acgtcaccca	cctgggtcct	240
ctcctactcc	ctttgggtgc	tggtctttcc	cagcagctgc	ctacccccaa	ctccctgcta	300
ttcaagccct	gnaggcacct	tgactcctaa	atgaatgaac	ttaactgctt	gccctgcccc	360
cttattgate	tgccagggtt	tccacccttn	catctnttca	gggcctgcct	ttgcagcaca	420
agccaggctg	ccatcacctc	atgttccaat	ta			452

<210> 144

<211> 258

<212> DNA

<213> Homo sapiens

<400> 144

ctgtctctgag	agcacgtctc	tacatctcta	cctgcattct	ggaatcaagg	ggaaaaggcc	60
aaaacggaca	agaacactag	aatcagcccc	tgtcccaacc	ctttgactac	aagggacttt	120
tcccgcttat	ctgtgggtgg	gggtatcatg	aaaattatgc	acaaaccttt	ttttttttta	180
anctcatcan	ctntngttag	cattagggna	tttnatntgg	ggcccaggag	cattnttttt	240
ccaanggggc	cctgaaaa					258

<210> 145

<211> 445

<212> DNA

<213> Homo sapiens

<400> 145

gcactcattc	tctttcctgt	caccctgtga	agagggtgcct	tccgccatga	ctgtgctgaa	60
cgtgtcctcc	aagggtttca	aggttatcgt	atgccctgaa	attgggcaag	gagctttaag	120
agggaaacttt	gagtttgcca	gagaaaactc	aagatgtttc	tacatgaaga	aaatggtttc	180
agacatttga	cttctttaat	ttttgcatac	tctttgtgat	ggttgtagc	aaagacctaa	240
agtggttgta	tggctatatt	caaaggctga	gtgtgacttg	atattggctc	aacttgaaaa	300
ctttgatatt	tgatgnttgn	attcaaaatt	ggaaacaaag	gnggttaaaa	agggnggata	360
tatgaattat	gggggggcat	ataanacttt	gcagaactta	cctgcncctt	atatattttc	420
tgccaaaata	gntgttggtt	tgatg				445

<210> 146

<211> 437

<212> DNA

<213> Homo sapiens

<400> 146

gtttgcctgt	tccctctggt	tccagtccaa	gcatttgtgc	tatccttcga	gtctttacaa	60
attgccctga	aataatatgt	gctgtgcctg	cctctgtaca	gttcagctca	cctttgagac	120

atttcgttgc	gtttgttcca	acagcgggtca	atttgtgttgc	atttacccca	gaaatcactg	180
ctaaccaccag	cataccagcc	gccctttctc	gtgagcttgc	gagtgggtta	cggagcagaa	240
aaagagttaa	tcgatggata	tgaattaaac	acaggaaacc	agcactagag	gaacctcaga	300
ctccaggcct	aaaaccactt	gtgactggag	tgacgttaat	cacaaganaa	gggagcctcc	360
atggtaacag	gatgctgaaa	cctgacacat	acaaggnaact	atgcactttt	caaagcactt	420
acatttgatc	actcttg					437

<210> 147
 <211> 453
 <212> DNA
 <213> Homo sapiens

<400> 147						
gcttcagttt	aaaaggactg	cctgtcctag	ctgggattgg	agaattgaga	gaaaggcatg	60
tgatcctccc	gggacccaga	gagatcagca	gaccagaagg	cctacatgta	cactggaaag	120
cccccaacc	aggaatccct	gtacgacttg	aggcattatc	tcactgtgca	tggctgaagc	180
ggtagatgcc	atcattaccc	tcatttcaca	cctgcagaaa	ctgaggtata	gaaacattaa	240
ctggtctagt	cacgagggat	tctgtgatgc	ctgagacata	tgacctgccc	tccaagacca	300
taagtgacag	accaagaatt	tgatcccatg	tcctggnggn	cccacaagnc	tggggccttt	360
accattanag	caggggtttc	ctctgggggt	tctcttgtcc	ccaggggaca	tttggcaaca	420
tctggaaaca	tttttcgttg	tcacaaatga	gct			453

<210> 148
 <211> 451
 <212> DNA
 <213> Homo sapiens

<400> 148						
ctgaagagca	ttgaccaagt	tattatcttc	aactctctca	aaggggtgaa	gagagaaaag	60
caacactgag	tcaactggct	ggnnttttcat	ccctttctct	tcttcagttg	tgggctggag	120
agagatgtaa	ttccaggaca	ttggccagcc	ttttgttatg	tggatacgct	ttacacaact	180
acagtttatc	catcagaatg	aaatacagac	aaaagctgag	gaaatcagtc	ttcttaatatg	240
atagaaagtg	atcctttctg	cctccaaata	aaactgaatt	ataacattct	tcgtatttct	300
ctgggtacac	atctggttta	aaaattagaa	gttaaatttt	aaaagtaggc	agaagggttg	360
gttttttagaa	gaaaagacat	tttaactgta	atagnnggatc	attattttaa	tgcttataaa	420
gtccaatcaa	agataaatgt	caaaccataa	c			451

<210> 149
 <211> 351
 <212> DNA
 <213> Homo sapiens

<400> 149						
cnaactgaga	aaagcaaaaag	atatttgcca	atgaacaata	acctggatgc	tcaaaggatg	60
ataaccctga	ggttgaggga	taccaagtac	cttgtccaca	attcagcaac	aatgggacag	120
gtgtgatata	aacctctttt	tccatcttgt	tctctttctg	cttgaccatt	gcaccattga	180
gagaagtga	acttgggctg	agtctacaag	gggcacccaa	aataaccatg	gtgtgtttat	240
gttcatttaa	aatcataaaa	tttgtgtagg	aaataaaaaa	aaaaggccng	cgaggccnat	300
tcagcttgga	cttaaccagg	ctgaacttgn	tnaaaagggg	gggcctccca	a	351

<210> 150
 <211> 244
 <212> DNA
 <213> Homo sapiens

<400> 150						
ctctggggag	ctcctgcatt	nctacctncc	tnagatana	nctgnnggct	ggaatgtana	60
agtggacttt	tggccacgtg	gatgaggaa	tgaagcagtc	agttctgatc	tagagatgga	120
aggcgcctgc	tgaggacagc	agggctgctt	ggcacccctg	gtccctgaat	ggctctgtgg	180
agcactgcct	gatggcctac	cctggactgt	tgccctgagac	agaaataaac	ttttatcttg	240
ttcc						244

<210> 151
 <211> 573
 <212> DNA
 <213> Homo sapiens

<400> 151
 gttttcaagc aaantggcng taattggaag aaggnaaaaac gccaggggtg ccttaattta 60
 ggggccgtgg ctccnaaagg tnattcgggtc cccgggtttc ntcaacttgt ngaatggatg 120
 gaaaagcaat gngtttacca tttgggcgga aattttgaaa aatcattgga tggaccacaa 180
 gaagcttggg ggaaaaaatt tgtttgttgg aaacctcaca agggcaaggg ctaaaaacaa 240
 aggttgtggg ggggggtggga tcaagcccca agaattttga ccgtngccaa acctcaaaaa 300
 gaccttggga aaaaaaatgg gccaaagaaat aaaatcttgc tttccatccc cgcccaaggt 360
 tttgggtttt caatttggtt cttggaccaaa ccttcaagct tgggcanttc attnngggacc 420
 canttgnaaa gaaaagccan ggaaccgaaa aaacccccn ccnngggang ggggaaaaaa 480
 atcctnnggg gaattttctt tttttnttaa ggggggatggg taaantacca ttattatttt 540
 taccnaaaat aaaaaaatgg ccctcatggc aca 573

<210> 152
 <211> 845
 <212> DNA
 <213> Homo sapiens

<400> 152
 gctacgatgc tggntntaaat ctttggcntg gcttgggtca cttcttttgg ggggtccacca 60
 cttggccttt tattgaagct tggtaancac ttcnaccant ggaanggggt cttggcaagc 120
 tttcacttcc ttggaaagcc caggcggaag aaccacacaa aaccacccc gggggangaa 180
 atgaaacaag ctggcaagga acgcccggcg cccttttaaag atgcctggtt aaccacttca 240
 cccaaggaaa ggggtccgca agctttcact tccttaaaaag cccaagccga agaaccaagg 300
 gaaaccccc acccaagaaa gggaaaaaaa aactcccgaa acaacatctt gaaaccatca 360
 agaaaggaaa caaacctcc cggaacacc gccttgcctt tttgaagaaa cttgtgaaca 420
 cttcaccocg tgaaggggtc ccgcccggctt tcatttcctt gaaagtcaag tggagaacc 480
 aaaaganacc cacccaaatt cccgggacat tgtttccttc actttccttt taataagctt 540
 aatttaaaa ggtgaacttt ttctcggagg ggttgggctt tttggaccat tnccttttggg 600
 gaaaacaagc acttccttaa tcaaattggt caccctttnc ccttgctttg gggtttttgn 660
 ttatttaanc cactttatct gggccatctt cttggggcca naagaatttt attagccnc 720
 caatttaaaa tantcccatt ttggcttacc caagccttcc ctttcattat taacccctt 780
 tgccccaatt aangcaaggg nccccttata aaaccaaatt nnggggcttg nggaggccaa 840
 aaaaa 845

<210> 153
 <211> 582
 <212> DNA
 <213> Homo sapiens

<400> 153
 gtgcctgtct gaaaaccagt tcctctatga ctgtgatctc caagtgatca aagtcttgtc 60
 ctggaagcca gactagtgt atgcaccttg taccttgctc ctcaaggcac caacaaatag 120
 gaatccagag caactttctt agctggagtg gcttctatgt ttctgactgg actttcacgg 180
 atacaaacag tggggctctt tgcaaaacac tcttctaagc tttcagaagc aggtcataaa 240
 gccgaaaagg acattttctgc ctttctctga agcaggtcat aagtccttca ttagagaagt 300
 atcctcccta tacctgaaga aaaggaacat ccttatctat gaagacacag gaactcagag 360
 aagaatctga acaaacaggc cttgcaaaat gccctccagc ttcttgccat tagatcatac 420
 ctcttttttc cggccatact tctccataac tatccacttc ttcatcagat cttagcataaa 480
 aacccatctg gtttactggn tggttgggt cttcatttnc ttatgaangc tccgcatacg 540
 taaaaacnta cgttaaaaaa aatggggatg cttttctttg gt 582

<210> 154
 <211> 627
 <212> DNA
 <213> Homo sapiens

<400> 154

atgcatcagc	agaacctacc	acacggcacc	tactgcgggc	ttcagttttg	ctgtagaacc	60
gagaaacatc	acgttagatg	cttttagcaac	aacaatgtat	atgttgcata	gaagaaaagt	120
gtcccagaag	aacagccagc	tgtcctttac	atgaaattgt	ggcactgcct	gtaagaagta	180
tatccaatga	gaacttgtcc	tcacctgtga	atacttttaa	tgggtgagcc	atttcaacac	240
tttacatact	gccgagtaag	tttctacaga	actttctcat	tgtactcagc	gctgtctgtg	300
cagttaattt	aggcatcaga	aaactcagtt	gttaattttc	tgacttgcct	ctggactcct	360
aaatgctatt	gctccaatca	taacacgtcg	gaacacttac	gcagatttca	acaataatat	420
ccacagctgg	gaataaatca	aagcaggttt	atcactggat	aagtgcctatt	ggaatatggg	480
taccaagaca	acatgaagca	aaggacagat	ttcactttag	aagattaaga	cagagccctg	540
ggggggaaaa	aaaagaggta	atcccaacaa	agtctatgca	accnttaaaa	aatattattc	600
agagcagaaa	tgcagaattg	gccttttg				627

<210> 155
 <211> 598
 <212> DNA
 <213> Homo sapiens

caaaactgaa	aaactggntg	accttnecgt	tngnntncaa	caaaccaaga	ctagctttga	60
ctatgacaat	nggtatctaa	ngaattgccag	acaggatgga	tgaagaccag	gacacaactc	120
actccaccaa	actgtgatgt	tacgtcattt	accttgggcc	ccaccactt	tgcttttgaa	180
tgaagacgtg	tccccagcnn	ttgganaacg	agaaggaaac	acgccaaatt	aaggctcnnat	240
ttacatcaac	agagaatata	gaggctcaag	agaggaattc	acttaactta	taggaaaaacg	300
aagtcataatt	ttggcacatc	gagttttag	tctttgagaa	atgaaaatcc	tcancaaaaa	360
gcttttgtct	gaccagctgt	gaggtaagaa	tgtgcaagaa	gtcaaagcaa	gcgaggaggc	420
ggagccggta	ctgtcctgga	aagcaaaacc	cagaaagggtg	gcgaatctgc	tccaaagctg	480
cctcttttct	gctcctaagg	aagatgcntt	ctcangatac	agggattttg	tgtatgaaaa	540
aaaaatggcc	atagctgctt	acagaanaga	atgggtggna	atgccaat	ttgactat	598

<210> 156
 <211> 284
 <212> DNA
 <213> Homo sapiens

aacctcaggc	caagtgttct	tgacagctca	tccacagact	cccactggta	aagcagcatg	60
aggatggctt	ctgttatattt	atttcagaat	tttttcctgc	agtggcatgc	cagtaccagc	120
tgaggatcat	gtatgcaata	tttgccctct	ttcatcttct	acctaggatg	gctttaattc	180
tcttcgagga	gaattttattt	tagtttttcc	cagtaagaga	atccacttct	cttgcccata	240
ttcataaatt	atcattaaaa	attaaacttg	gtacaataaa	tatt		284

<210> 157
 <211> 759
 <212> DNA
 <213> Homo sapiens

ggctaccctc	gtgntganat	gaatnaactg	gncctggng	gccgaaaagc	gaggngccnc	60
tttgttttgg	gagggncctg	taccccgcg	gaaacccttt	tttgcccgaa	ccaagcccaa	120
gcggaatgg	ttggctcttcg	gcctggccaa	ncnaagcccc	cccaagangg	ggccaaagct	180
tcttggtgga	aactaagtcc	caccttggtg	cgggaaggcc	cgggggtcaa	ncccaaaagt	240
nccccggnca	nggccaaagca	atcggtcatc	gggggcccta	taagcnngga	aaagaaagaa	300
aaagccacaa	gncaaagtat	cttggcttga	aaaaaatggg	gggggnntant	aaacgggaag	360
tcttcgcccc	tgtaaccaag	gcttggaag	tgtgccaagt	ggatgaagaa	tctcagctca	420
cttgcaaac	ttcacctcct	tggggttcaa	aagtggattt	ctttcttggc	ttcaaccttt	480
tcccaagtaa	gcttggaagt	tacaagggcc	ccggnccacc	atgcccaagt	atTTTTTggg	540
gggccaagaa	gggangggaa	aanggaaagg	nggggtacc	ttggaaaacg	aacaagcttc	600
ttttccctt	ggggaaacttg	gnaagcaatt	nccgaagcac	caacaagtcc	aacccggcc	660
aagccttttt	ggtttccttg	gcacaagtct	tggnctnttt	naaagaaacc	aacnaacttc	720
cattattttt	attggacgaa	tnaaaaaat	ttgggttagg			759

<210> 158

<211> 501
<212> DNA
<213> Homo sapiens

<400> 158
tcagaactng aggcaccct tgccaaggnc nctancccc ttgggggccc tnactttngc 60
cntaagggcc ntntngncnn caancccttg acnaaactta anggagtccc ntcgaaaccg 120
gggccaccac ctttcttcac cttttgcaag gcaaggaagg cccggaaggg ntaagccctc 180
aagcgtcaac gaagttcaaa agantctggg ttacccagca agtttgcccc atctgctcaa 240
gggatgtggg ctttcttctt gatgaagtaa gttgaaagt cttgggatgt gaaatcaagg 300
aactcggagc tcaaagttca atgaagtacc ttggaaaatt ggattgggga agctggccca 360
agggaaatca ggaaagaaaa naagtcctga agattcaagg aagaaagtaa aagcccgctt 420
ggcttganaa tgggggtggg ccanggccaa accttgatca agggcccgag caaaaccgcg 480
actctttcca aataaaagct t 501

<210> 159
<211> 736
<212> DNA
<213> Homo sapiens

<400> 159
gntaccnact ngnaccagtg ggatnnatca ancacgaagc cctcactttt gacntcttng 60
cannngngna aaatttggag ctgggatttc attgcccatt ggcaagatgg ggaananggt 120
tanccttttg cttananaca aggangggaa aaacccaann ctttnaccan aaaagaaanc 180
ttgganattc tttgggggtt ttggaacang aaccggtttt acctgggcat tttttttaac 240
aaaaacnacc ctttaacttg gcttatttaa cccggccttg cttcaatcaa cccacccttg 300
gggccctggc ccccaagtgg gccaatantg cccttcaccc aacctattgg gcanttaagc 360
ccacaaggcc caaagaataa acttataata tcaanaaatg gaantaagaa aagaaaaatg 420
tggttactt gggaaaaact tggcttggtt ggaagccctt cccaatgggg gaagcttgaa 480
ggagcttggt gtctcttgca aggccatttg ggggaacttg ggcccacaaa gccaaaagaa 540
gtcaagcanc catggaaagc ccccnnggagc ttgtaaccgg tgtgcaacca aggccgccca 600
attccaaaca agcatggggg aaaccaacaa gtnggncgcc aatcatttt nctcaattta 660
ttngggcnaa aaaaggnngc tatttttttc acccttggtt aagggtggtng cntttttgga 720
gaaacttccc aaatta 736

<210> 160
<211> 458
<212> DNA
<213> Homo sapiens

<400> 160
aagacataca tcatgagaga gagagattac agtatgcaat ctctcagctg ccaacagAAC 60
acagatgggc ttgggaacag agaatgatcc agatctgcag gactggagca atccgtggga 120
agtttggaac gaagatctga tgcataagac agtaaaggac tactgaatgt tccatgatag 180
atatgcttgt tcttttgccg gcatgccctt gaataaagac attttgatct ccaggaccaa 240
cctgagaaac atataattta atctagtttt gaaagaagag ccctgctaca caaatactgg 300
ctcacaatgt taacagatat caactgaaat atcaaaggc ttccatattt cattaatttg 360
actatcctat gtgtttgata tttccattta attgaatatt tcttaactca atgaaaaatg 420
tatgagcctg ctgtgataaa tcccgtgtcg catatggg 458

<210> 161
<211> 264
<212> DNA
<213> Homo sapiens

<400> 161
cagaaattga gaatcatttc acttttgggg gaacgggaag ctgggtgtgn accaccctta 60
tgtgnacctt cctgtccttc agctacatcn gatgaacctt gggcagtga tttatctaagt 120
cccatccaag cttccagaaa gaactgcagc cccagctgac agcttgactg caacctcatg 180
aatgtttctg agctaggacc acccagttgc ttctgaatc ctcaccctca gaaaactatg 240
aatacaataa atgctgatta tttt 264

<210> 162
<211> 882
<212> DNA
<213> Homo sapiens

<400> 162
agtcaganac tngaagccca tactttccca attgccttcc aagcttggtt gcaccgggan 60
ggtttcaaca atcantatct ttccaagaaa nggcttcctt gggaaaagan ngtggaata 120
ttgggtggtcc ccaatccaag aaaanccttg aatggggggg anttggtgaa ctttgggctt 180
gcttggtccat tcctttcaat ggtcaagccc caananaaan atctggtggt caagccccgc 240
cacaaccat tacttggttt aaagccaagt ggggaatgaa aaagtggcca aagccttgcc 300
caaagaaaaa aatgggtaaa agggaaaaat gtttgccccc aagggaaga aaacacccat 360
gggcaaagat nggaaaccaa gtaaaccagg gggccacaat caaggggggg anaacaccga 420
aaacattacc gggcccanta aaaacttcct ttaattaaga ananngtcta ccaagattaa 480
aatctancag atgaacanat tcctcaaaagt tgggaacttt gggcccattg aatttgggnt 540
tggtcccttg ccattactng atggaaaact actggatggt ccaagcttgg gtctgaaang 600
gaccccttac ccagaaagcc ttaaattcan tcaaaagaaa atggcaaatt tcccattatn 660
cctaaatgga attcaaatct tccctttacc ccttggaacc caatcaaggg ggggncccaa 720
aaatttttcc caacccccct ttggccttcc caaaaaacc ccccaacccc caanaaacn 780
tcttttaaaa aaaattaaag aaatctttcc ttccttaact ttccttggaac ttcaancnn 840
cccattgtna atccatttaa aacctcntnt ttgcttgga aa 882

<210> 163
<211> 828
<212> DNA
<213> Homo sapiens

<400> 163
cagatactga gaacacaaca aaaagaacct gtcaccacaa caaagagggg aaagtggacc 60
aagtggctta tcttgaaacc ttgtgggtcc ttggggaagc ccaggggtga accctgaata 120
atgaacatct aaaaagaaag cctttctggg aacttcttga aacaaagaaa tttcgggtggg 180
ccctgccaaa agctttgccc aatttgccac ttttttcaaa atgccctttt gggaatgaac 240
ccaagccact tttaaattctt gaaaaccttg caaccaagaa ctaagcccaa ccacctgggc 300
ccatgaaaac ttgccccct tgcacttga tctgggaact tcaaccttct tggancccta 360
acggcttttt aaagccaaag ccacttga tggcactttt aacaagaaat taaccccaac 420
ttgggaatcc cttgggaacc caacaagaaa ttccctttca aggaatccct ttctttggct 480
ggccaagaat ggaaagccaa aagggaattt aatttcccc ttcaaagttt ttctaaagtg 540
aatttccaaa aagccaaang ngnggggtgg aaaatttccc aagtaacca gaaaaccaag 600
aagggttggc cccaatagaa agtaantttt ttaatctaata aacntcccc tttgggtacc 660
ctagaaaaaa ngcttatttg agaactaatg aagctccacc agaaccang gcctttcgcc 720
ancaaaacct ccaaatcaa taaattggga ccattggttt aaatggatta cctggggaaa 780
tcntggata ggccctnnna aaaaggggga nangctaatt aaaacaaa 828

<210> 164
<211> 660
<212> DNA
<213> Homo sapiens

<400> 164
tgagaaaaat gggattggga aacagaaggg agaagaaact gggcntttac cataagaagg 60
ttgcanaaca cccttttaaa acctaacctt ttaaatggc agtgggaaag cnttcaacat 120
ggaggcctcg tctaatttaa aacaaccac acagacncac ttggcccaa agcagcgact 180
ggcctctgaa gannaaaagg tggggccctg caagtactgg gctgggaacc acctccacat 240
ctgaaagaat gctgtttgcc tgtatttgct tccaacgct cttccttccc ttgcttggtt 300
gcctgttggg cctaaccatg agctctgccc acagtaagt tctgtactat ggccactagc 360
ccataccaag gcatggcctt tgcaagtccc caacatacag ctcccgacct cacaagcaag 420
nccatctcta ntgctgnca gaaagtaaaa gtacacacng ggcggggcaa aaagtcctgc 480
tcattccaan gnancaacgc accctnaaca agcttttccc aaaangcaac tcaaccactc 540
tttagaattt ttttttttt tnaaaaaaaa cgggnttaa ggaacttggc aaaaaaanc 600
cccnagntg gaaaancctt ggggaaaaan tttctgggnc cccccccg ggtgaactt 660

<210> 165

<211> 643
<212> DNA
<213> Homo sapiens

<400> 165
cagaaactga ggtatattag ttcttatatg aatggacaga agaaacnatg gaaattggag 60
ggaagggaag angaancnt anangggngc ntantttngc nccccaggtn gnccttcaat 120
taaaagaacc tttggcntcc aggggttcaan gtggattctt tttgcttcaa gccttcccga 180
gtaagctggg gaactaacag ggtgggtcaag gccttcttga cccaagcct aaagcccatc 240
attatcccc tgggtgatct tgcacctaac ccatcccaga atggccctga aagtaagtga 300
aagantcccc caaaaagaaa gtgaaaataa gccttaactg gatggcattc ccaccattgn 360
gaatttggtt ctgccttcac ccttaactgg atcaatgtac tttgaaaatc tccccgcacc 420
ctttaaaaaa ngttctttgt aattctcccc ancctttgaa aaatgtactt tnggaagaat 480
ccanccttct ggccgcaaaa cattgctctt aacttcacc gcctatncca aaacctataa 540
gaactaatgg ataatccacc accctttgct tggacttctt ttcgggact canncccgnc 600
tgnaaccccc ggtgaataaa aacaagcccc cttgtgtccc ccc 643

<210> 166
<211> 629
<212> DNA
<213> Homo sapiens

<400> 166
tcaganactn ggagngaaga acaagctttc ccaagggctt ggaaaagaag gggggaagtg 60
ccgggaacca ntgccttcen ccantaacca cttggcccac ttcttgggtg aaccttcttg 120
gcaagcaaaa aaccctggaa acccccaaaa gaaggcaagc tttcttcaaa aagtaaaaaa 180
gtgggaaatg gaaagtttcc ctgggtggaa ccttggaaat tccccatggg aagggaaaaa 240
gatngganaa aagggancat ttattgcaa gggaagantg ggcatctcgt ggtccccttg 300
ggttgaaacc caanattcca ttaagggaaa gaacgggtgc caagttgttg aagggtgggg 360
acccttggga cccttgggaa taaaaaatgg ggggtggtta aaccaaaagt aatttgtttg 420
aagtaagggt tgggtgggga aggggaaggca ccgactaaga tgcaaggggg tctaagcttg 480
aagttggaca aagaagctaa ccaccaggtt tgttgggacc aagggaacagg ggggggaccc 540
tttaaagccg aaaagaacac cctgcccagg atggtggtct ttggttcctt ttgacctggt 600
gggagaaggg cccctttggt ggggggtggg 629

<210> 167
<211> 276
<212> DNA
<213> Homo sapiens

<400> 167
ggtgaagcca gatgggagtg ctgagcttca gggagcagct acgcaaagtt aattgtgctc 60
agcaaagtct tctagattaa gcggctcgctc caataaagtt tcttgattct gtccagaaat 120
cctcaactcc gacaataaga agtgggttga ggggcagttt gaatacataa tcaaaaagca 180
tataattgaa gattgaactt gagctatagc ttcattgtatt gtctctgcgt tgttctatct 240
taatagttgc atatggagac aataaagcta catgac 276

<210> 168
<211> 299
<212> DNA
<213> Homo sapiens

<400> 168
agacgtcttg ggagcctacc tgcattaagt ccanatactg gagagaaatt caagaacctt 60
ggaaagctta cccaacctt tcttaaccat tggcctanta accnatggan ccccccttaa 120
ggaangtggg gcaggaagta acccccggan ggggaaagaa acccctgggn taaccttga 180
aatggactan tattggaaaa caacanggtt ggctttana taacccttcc ggantcaact 240
tcaacttaac nggaaacttc ttntaaataa aaaggtanta atttttttaa agcccaatt 299

<210> 169
<211> 540
<212> DNA

<213> Homo sapiens

<400> 169

atttctgtga	atagaccaga	agcccgacct	ttacagtgtg	tttgggggtgc	agaaaacctt	60
ggctgacata	ctcaaggctg	aaatgcagtc	agcggaaatg	gaaacacttc	aactctgccc	120
ctgtggcaag	aatggcttcc	cttcagacaa	tctggccaga	ttctttatgg	acccaatggg	180
agaaattgga	tgcttgata	tacctctcag	catctttgaa	ggggcactga	aacttcaatc	240
aaattgggga	aagggagccc	tgaactttag	acctgtttta	aatgtgcaga	gtggcaactg	300
gcacaaggaa	cactttccat	ctgtaagaaa	gaatacaaa	aacttggaac	aagaaaaaag	360
tagatatctc	atcagtcaat	ggtgctgtat	aggcatgcac	aaagatggag	atgtgagcac	420
cgacaagatg	gctggcatct	ataaggcagg	aagagatacc	tcaccagaac	cccataatgc	480
tggcctctga	cagtaaaatt	ctanctgttg	nactatgaga	aaataaaatt	ctgtgggttaa	540

<210> 170

<211> 381

<212> DNA

<213> Homo sapiens

<400> 170

ctgaatgaag	acaaatctta	gccctctgag	actgatggtc	tcagaaagta	gtcttcagat	60
taccagcttc	agaatcagct	gatgggttca	ctaaaatgca	gattcccagg	cccagtgagg	120
actgaataaa	tcttagtttc	ccaggcttta	caggaaccat	ggtgctcagc	ttctaaggag	180
gcctcaggaa	acttacaatc	atgggtggaag	atgaagacgg	agcaggacac	agagttcacc	240
ctctctggag	aatgtagcca	ccaggcacca	tcttggaagt	gaagactgga	ccctcatcag	300
acaacaaacc	tgccagtgcc	ttgaccttgg	acttcacttc	ccagcttcca	gactgtgaga	360
aaataaactt	ctgttcttta	t				381

<210> 171

<211> 334

<212> DNA

<213> Homo sapiens

<400> 171

ataatgacga	ctgcaaaatg	gcaggataag	gaccgtccaa	aaagcctcat	tgatgaaagc	60
aatgagaacg	ctggcaaaaa	tgatcagaat	cggctttttc	agacctctgg	aaattaacca	120
aagatttgca	gtgaggaatg	aaatttcagt	gaaaagcaat	atcctagcag	ccactggggg	180
ggagaactga	agccgagctc	ccccaaagcc	tcttcccggg	gaactgtcat	tatctgagct	240
gcctctctgt	tccgtggaag	actctacttg	caagactatc	tttgccctgat	tgactcggag	300
cttaaccctg	aggaacagcc	caggggcatt	tggt			334

<210> 172

<211> 351

<212> DNA

<213> Homo sapiens

<400> 172

aacagtttcta	gatctccatc	gttataaaa	agtattaccg	tggttggtgta	ccacaatttc	60
tcaagaaaaa	cattagctaa	gcccagctg	gattttgatg	gataacatgc	tgatgttgta	120
acaaggctgg	agcgtggcac	atctcacaca	tgcagggtgaa	cacccaatta	ccacgcctat	180
gaactacaaa	atcatctaag	cagattttta	attagccagt	tgtttcccta	ggatcctcca	240
aagggtgatca	atacagtttg	tttttttctt	ggtggaggga	tctcatgatg	aactaatgaa	300
tcttaacatg	aattgtaagc	aaataaataa	aatggtatgg	tttaagccat	t	351

<210> 173

<211> 376

<212> DNA

<213> Homo sapiens

<400> 173

gcataacctca	agatcagttg	aattggagca	cagctggatg	gaggcctcag	gttaattaac	60
ttccttttgag	agcatccaga	aaattagcaa	ggacatgaga	aaccattcac	tcaggacgac	120
caatcagcca	ggacactccg	aaacctatta	aatcagattt	ttaatcttct	aagcctgtag	180

acaactgtgt	gacatcagcc	acatcctcaa	atcttaaggg	aaacacgaat	acaagaatac	240
atgtgtgcaa	ggaatcatgc	ataaaaggat	tgtgccttca	gatcaagtcc	aactgttttt	300
atttgtcatc	aaatgtgaac	ggagatatgg	gtactagtcc	caggaatgcc	ataaactagc	360
agtgaatcac	ttcttg					376

<210> 174
 <211> 513
 <212> DNA
 <213> Homo sapiens

<400> 174						
atatgtattc	tgcaatcatg	accaaacaga	aggactaaat	ctggatcaga	atctgaaatg	60
taaaaaggct	acttgtcaac	cacgccattg	ttttccgttg	gagctagcag	agcagcctcg	120
gctgcacatt	cctgggacgt	gaataatata	ggttgtgatt	acacttcagt	atctcatcca	180
ttaccagccc	tgtgaacact	gaatataacc	taattaggaa	atgcgaaggg	cccttttgcta	240
gggatgagtg	ctggggcagc	agagggtccac	atgccttccc	gacacagggg	ttcaccgggt	300
ttcagacaca	ggtttggatc	ctgcagggt	caaggacaga	ctttactggg	ctagtccaca	360
ttccttgtat	aatcaccagt	aagctgagaa	tgtgacacct	tggattccat	cctatgttac	420
actcctcttt	aaatgcattg	caaaggagat	atgccaggac	ttgataagtc	aagtcaattt	480
caaataggta	ttaaagtatt	aatgaagtg	att			513

<210> 175
 <211> 432
 <212> DNA
 <213> Homo sapiens

<400> 175						
gtatgttgca	ttgtacaaga	tgaagttaga	gtgtgaagca	tggaacaaag	tgcttattga	60
gccagaaaat	actgcccaac	cagctctcaa	ggcaaagaga	gggtgtacga	gaagctaata	120
ttcaaatgag	aggtggagac	ccagctggca	gctagcatgg	tgcggcgtgt	tggaggcaag	180
aagcagaatc	tcagactggc	aagatgcaag	ggcaggcagc	ccaccacag	ggaaggcgctc	240
gccaatcttg	agcaactcta	gaagagaaac	ctgaacacat	cagaactcaa	actaactgat	300
aatgaactgg	ttttcattac	ttcctgagtg	atcaggaggt	agaattgtct	cttacaaccc	360
aatgtatacc	attctcagtt	gtctatttaa	ggatttctta	gtgagctcca	tggtaaaata	420
tatctacttc	tt					432

<210> 176
 <211> 387
 <212> DNA
 <213> Homo sapiens

<400> 176						
aggggcagac	ccaggtggga	gtactgcagg	ccacgcccct	cgaagacagc	atccacgtgg	60
tcttccgata	ctagcaaggt	gtgcttggca	gccgggtgcct	caaggattgt	tctggaagga	120
tgacatcact	caaggtgtga	ggacccagca	gacagagcac	acgccctggc	tccatgcccc	180
agaggcccat	ctgaggagcg	gacaggcagc	ctttcccacc	agagtcacca	gggtgaggac	240
gtctttgagc	cattccctac	tctgagtcac	aacctcgtag	ctgattaagg	ccacatggga	300
agcttcccat	tcctcatact	tcccctgatg	ctctcaggaa	ggacaatttc	gggctgaacc	360
aaatctggat	tattaaagtc	aatttttc				387

<210> 177
 <211> 420
 <212> DNA
 <213> Homo sapiens

<400> 177						
gttgctacaa	taattccagc	tgtgtatacc	tcctgggata	ataatagaaa	tgaacctctg	60
aagcatctta	ctgaagaagg	cccctacgtt	gactgtccag	ctgactgtct	ctacccgact	120
gctgtccac	acaatatggg	ccaggcgatg	gtattgcctt	tgcaaactaa	atgaagtcc	180
tcaaagtga	gctggtggcg	acttcagagt	taacttttca	aatggccggg	cttatataga	240
ataacctttg	taaaagttaa	ctatgatcat	ataataagat	acatgtgcat	ttggaacgcc	300
actgcttttg	gaacctgtct	cagtttttat	catcatacaa	ggttaattgt	ctaattgtcaa	360

ttagattttta tcacaagtgc atttgggtcc taatctggaa caataaaagt ctattaaacg 420

<210> 178
<211> 421
<212> DNA
<213> Homo sapiens

<400> 178
ggcatcttga agcagaccag ccacgttgca agtgcttgga ggcacggatg actggtggct 60
gctgttctgg gagacagaat cctatagcat cccagtcct gcagcacaca ggtgggacaa 120
ttccagcttg atgtctcagc cagcgggttc ccacgtcctc cccgcctctc ccaggcagaa 180
gacagagtga cccaggtaac caggaaaaca aggccataaa aaaggaactc ctactaatga 240
aacctcctag attccaagga ggaaaacgta gctctcagac caagtccgtt ttcgcccttg 300
catctgaaag ggagtcgggg gaattgctaa ttttgaactt tctatacacc cttcctgcct 360
ctggatgtgg ccgcctgact cgaattcctt tgcacaataa aatgaggggg aaaaaaatca 420
c 421

<210> 179
<211> 115
<212> DNA
<213> Homo sapiens

<400> 179
aatacgttcc agaggacaag gactgtgttg ttcattcacag tattccagaa cttaaaagga 60
actggcacat aattggagct tactaatatt cgtcaaaaaa atgaacaaat gaggc 115

<210> 180
<211> 449
<212> DNA
<213> Homo sapiens

<400> 180
ataagagtga gcatttttgg aaatgtgatc aactgacgca aaatggcagc aacactggaa 60
ggaagaatca ggaggatatc ttagaagata accacagaat ctttgcaaga gacacagaag 120
actaccttac acctgggttc cacaggagaa atgggtcaaa atatgttatt agttgaacag 180
taggaaaaat gtctatggtc tcttcagcac catctgtatg tagtctctga gtctccagtt 240
tctcatctat gaaactggga taataatatg caatgagagt tattctgaag atcaaataag 300
atagcatgtg aaagcagttc tagattccag acataagagt aagattaaaa gaaatgttgt 360
tctcaatttt cttgtgtcat tgctgtgccc atctagactt aaacaaatgt tactgtaaga 420
gccaaagtaat aaactaacac atctaatacg 449

<210> 181
<211> 506
<212> DNA
<213> Homo sapiens

<400> 181
gtgatttttag aggaataaac acccttagcc gtcagccaac attttacaaa tgaaggccag 60
caaggggaaag gagctcactg aaggcccatg ctcattaatg aggaagcaaa aacaacagca 120
cacagcctct gttcccaggg ccacgctcct cgattttctaa gcgctgttcc agtccacaca 180
ggacaagaca tccttttttc ttctagaaca acagctcagc cccacctgaa agaaagagtt 240
cattgatact ttttcaaagg cttcacaact cagctttttt ggagacttca gcaaaataag 300
tcattatctg gccaaacttta agaatgaggn ttgctaaatg tatcagcatt ctgaggmtat 360
cagaagactc tgcacacttg catatctcac aaataccgnc aataaataca tagnttcatt 420
tcctcattgg ttcacaaaaa aaaaaagggc ggccggggcc nttnancttg gacttaanaa 480
gggtggaatt tnttaaaagg gggggg 506

<210> 182
<211> 510
<212> DNA
<213> Homo sapiens

<400> 182
 gccccagcgg atggaactca taaataaaga gtgagaaatg caanttatgc cagangtttag 60
 aaagccaggc tccttgccac agcaagaagg ggatagctgc agcccacgga gaaggagaac 120
 cagtaaaagt agcaaaagca ggcagaagaa gtttctaaag caacatactc tgcaaagcag 180
 tctgggcat gtactgtagg agcaagttgc cagcagcccc cgggagcatg aatggatata 240
 gcaactgttg ttgaaaaaga acaatcctga tcaacccaca tcaaaggcta atagacctca 300
 ttttaagaaga caggggaaatg taaatctgtg agatacttca ggatcatttc tatcaaaaag 360
 cgtttcatat aataaaggaa taaagcctca gttatctgga agggctcnnn nnnnnnnnnn 420
 nnnnnnnnnn nnnnnnnngg gggccggggg gggccctttt ttttngtttt aaccgcgnt 480
 tntttttttt aaaggggggg gggcccccca 510

<210> 183
 <211> 379
 <212> DNA
 <213> Homo sapiens

<400> 183
 gctcgggtgac taggaagagt ggctgaaagg cccacacctt gactcctccc tgcttctgat 60
 agcctgagtc ctggggggaca gaggggaagcg cctctgggtt cccctctccg tgtgaggcag 120
 acagcctccg cccaggctct gagggggcct aattcttctt aacagacagc agtttgaggc 180
 ttctcccaga gtgaccagc agccagccca ggagtgggtc agaatagaca aaggaccgtt 240
 agtatccga tgtgaatttt agaattgtga tatttcatac ataaaaatag aaatgtatat 300
 gaatgtaata tagattatat atttattatg tatgtaaaaa cagtatgtgc acatgataaa 360
 tgagcatatc tacgtctct 379

<210> 184
 <211> 317
 <212> DNA
 <213> Homo sapiens

<400> 184
 gacccacctg ccatgctgtg aggacaccca ggccacatag agagagttag gccacatgta 60
 ggtgttacag ccagaagccc cactgaaaac caaacctgca accagcatca actgccaac 120
 atgtactgaa gaggtgaga tgattccagc acttggtgat gactgcaacc acatgagaga 180
 cccagagcaa gagctaccta gctgagccca gttactccca gaatcatgag agaactatgt 240
 aattgattgn tattactata taagccactn ngtttncntn tgatatgtta tgcagcagta 300
 gacagctgga acaggag 317

<210> 185
 <211> 378
 <212> DNA
 <213> Homo sapiens

<400> 185
 gtgcagtga caaccacgac aggcttcaca tcactcctacc tggtcagaag ttgccaccat 60
 taggacaatt aattaaattc aacagtaaaag atgctgccat agttaatgaa tcatgttttc 120
 cctggagctt tccacctatt caaaggacaa gtttcagagc ttggatgagg agcaactatc 180
 ttatgaacac agagacattt gtcagtttta aagggtcaaat tagatttttg ctcagggttc 240
 caccaaaatg atagacttga aaatcaggat ttatcaaact atgttctaaa ttatttcaac 300
 atatcgagtg tattagtctg ttttcatgct gctgataaag acatacccga gactgggaat 360
 aaaaggagga ttaatttg 378

<210> 186
 <211> 688
 <212> DNA
 <213> Homo sapiens

<400> 186
 ggntccctc tgttgnccan ggctggnagg cnnggggagg gaaccttnnn taactggaac 60
 cctgggcntc nggggnnaa ncctaactng cggtgncntc gggcctggcc aaaggaagcn 120
 ggggaattaa caggtccggc gccgtcacc aagccccgg ctaaaattat tttggcaatt 180
 ttttttggtg agaagaacgg gggggttttt ngcgatttg tttggcccaa gggcttgggn 240

cctacaaaaa	antccctggg	ccctcaaagg	cgaatccca	acccccggct	ttcgaaccct	300
aacccaaaaa	gtggcttg	ggaatttaac	caagggccgg	nggaagcccc	acccggccgc	360
cccggggccc	aagcctggga	ataagtnnct	ttaagtgaat	caaanatgaa	cctggngggg	420
gcctgggaaa	ccctcaagg	gggaaggggg	gccctnnacc	cttctngggg	naaaacnnat	480
cctggggatc	ctggacaagg	gggncctttg	gcttccattc	accccaaggc	ctcaaaagt	540
gaaagggggg	caatgaancc	tccgggctca	acctggcccc	ccttggaccc	tnccctggaa	600
gcctcnaaaa	gggaancctc	ccancctca	agccctcaaa	ggaanaannc	taagggacnt	660
gganggcnaa	gganaccaat	tgcccccc				688

<210> 187
 <211> 404
 <212> DNA
 <213> Homo sapiens

<400> 187						
gtgactgcct	aatgtttaaca	aagatctgta	ggaatgatgg	gaaggggcac	tggtacttnt	60
ctctttccta	atccttcaag	tcatacctga	agatccgcag	tttttctgga	gacaggtgaa	120
gtccagcccc	tgaaagacgc	agacagtgc	gagagaagag	cctacgtttt	tatatattttg	180
tcaaggtgat	gtctcaagca	aaatgaagt	gtttgtggct	gaaacaacct	ccacgggaaa	240
gaaaactgga	gtgttcgttc	atccatcaaa	gaacaaacgc	caacgtctga	gccaacgacc	300
ccagctcccc	cagacaaagc	agtgaacaga	ttaaaggatg	ggaggaagga	tacaatcaaa	360
atcgggtggg	gatggctggc	agataaaaat	atggaacgct	tcac		404

<210> 188
 <211> 552
 <212> DNA
 <213> Homo sapiens

<400> 188						
gcagaaggcc	ccanaaggnc	cgcaagaact	ccccanaaag	gccngcaatn	mntccgncaa	60
gaagggcccc	gcngaacntc	ccgcaagaag	ggcccgcgaag	aactcccgca	gaaagtccgc	120
cacacangca	aaggggaaaga	tgccctccgc	gtccaagccc	ggcttganat	gagcaggccc	180
gangagccaa	tggcgcaaaa	gaagngnccc	ggtntcccgg	atcgggnant	cctcataact	240
ttncctttcn	ttctggacca	aggtaaagcc	cacaagagnt	atgggaaaaa	agnngctggg	300
gggaaaggaa	ancnggtggc	cggaagtcc	ttcttcccaa	ccaaggggcc	cactnaattt	360
atngggagga	aacccaaaaa	ggcgtttttt	ccttaaaaaa	cctggaccgg	gggacaaaaa	420
tccgaanngn	aacctggacc	cacttgcagn	accattggga	cctttcccn	taaacctttc	480
aaaatctnng	tgggaagaag	aagggccctc	aagaaggtcn	ntccactccg	cctattntca	540
atztatcaag	gg					552

<210> 189
 <211> 317
 <212> DNA
 <213> Homo sapiens

<400> 189						
acttgcaact	tatgtttccc	ttttaatcac	aaagctgaag	aatagacaac	tatacgacct	60
atcatgaagc	aggaagaaaa	aaaatcatcg	acatttttga	ccatgcaa	gagcattttt	120
tttctgcaga	ataaactaag	gctaacaaaa	aagacaaaaa	caactgatca	ttcgtatgaa	180
aacctaatta	tttgggtgat	ttttcaaaa	gtggtcagct	aattatgtgg	tatcatctgg	240
accaatgttt	tctaggcaag	cctagatggg	caacttttga	gagagtttat	aataaagttt	300
gatttgttta	tgcatatc					317

<210> 190
 <211> 370
 <212> DNA
 <213> Homo sapiens

<400> 190						
tgctgctttt	agaccagtcg	cacaccaggc	cgaagaggtg	agagggtgag	gtgtttccca	60
caagaacatc	cacatcctca	ggatggatgg	aggagcaagg	acgagaaccc	ccaacccccg	120
agacagtttc	tggtccttc	cttccaagaa	gccctacaca	tgatatccac	gttgaagccc	180

tcatgcaaca	agctactcat	tcctcttctc	aaaggaagtg	ctgagtgtct	ggcaagttgg	240
aaagaatgag	ggattcttct	actgggttac	ctgggtcagct	ccgaggagag	ttaaaccagg	300
aaaagtagtt	caggctggta	tacctccctg	tttgtccttg	agggcaactt	aaaagcacta	360
tttacacaag						370

<210> 191
 <211> 427
 <212> DNA
 <213> Homo sapiens

<400> 191						
catgccatgt	ggacgtgacg	cctggagata	tcgcacccac	cttataatca	ggaggaagaa	60
tgccacgtgt	ggaggatggg	gccacaggaa	tctggaagag	ctcgatcctg	gacgacttgc	120
tcaagcagct	gcacattcct	cctgccacct	acttctggat	attgtgttag	gaaactggca	180
tgagcataca	catccattca	gaggaggtga	aagtggagtg	actgatgcta	gaatccccac	240
cttctgagtc	aacgggtccag	agaacaaggc	caaacacagcc	acaaatactt	ttcaggcttc	300
aggatcaaat	tttttattct	tgaatgatcc	aaacacttta	agaaaaataa	agtttctaga	360
ggaaatcaac	aaaagtgggn	nnannnnann	nnnaannnan	aaaannnnnn	nnggggggcg	420
gggggggc						427

<210> 192
 <211> 453
 <212> DNA
 <213> Homo sapiens

<400> 192						
ctttggtgtc	tgcacagtcc	cacacgagcc	aagccccggt	tgcaggggtca	agctgtcttt	60
tcatagtggg	aaaaagctga	tgaaaaatcct	tcacacagag	gtgttaagag	cttaatgatg	120
aacactcccc	acctgagtta	taatttcaca	agaatttgaa	ctttattttt	ctgccggagag	180
tcacgtgatt	tgtcctgcgt	gccaaataaaa	ctactgatgc	cagctggcct	gaagaactcc	240
atgaagatct	gactgactaa	agaatgcagt	ttccaatcct	ggtgatttca	ttccccttat	300
cccaagcagt	caataacttc	tactttccag	cctcttgtcc	tccacgatcc	ccttaaagac	360
tctagcccaa	aactccccag	ggagatggat	tcgaggattc	ctctgttcgc	tcaactcagc	420
actctgcaat	cattaaactc	ttttctctgc	tgc			453

<210> 193
 <211> 453
 <212> DNA
 <213> Homo sapiens

<400> 193						
tctgtgtcat	gctgccttct	gtagcaacaa	cggctgntcc	ctgnttntgt	gccacatgcc	60
aaactattca	acatntgcac	atactctcct	agtcactctt	aagggtgttt	cataatgaag	120
aaactgaggc	cgtgaggact	gaggggcaat	gctgcagcaa	tgtcaagtgc	attcgggtgga	180
ccacgtgcct	tccatctcca	aagacacagt	ctgtgtctcct	taaataacct	ctgacaaaact	240
caatgtgcag	aggcaagata	gagcaagttt	ctgctgcaaa	ctcaccacca	gtagtggatt	300
ctaagcccan	ctnctgcca	atgattcttt	gcagggnac	agcttctgtg	cctgttcacc	360
tagggctggn	tnaccacagg	ganggancnt	gattggggaa	aagcattggc	ngtnncagaa	420
tggaaaangg	gacctcaaaa	ttttgtctta	ggg			453

<210> 194
 <211> 473
 <212> DNA
 <213> Homo sapiens

<400> 194						
gcttttggca	tctccattca	ttccggaaca	gccagtcagc	cctctctgct	gtgtcccaga	60
gcaccaggaa	gtgagtaaca	gtcctagagt	gagacatgga	ggatacagcc	aagtatcaga	120
ggagtgtctg	ctcgtgctg	cttctacacg	tcaccgtact	gggggaatcc	tatgtgaagc	180
gcceccatgt	cctgtctgcc	tggatactca	ccatgcagat	agctctctgc	attcagcagg	240
gtctggctta	ggccctctcc	tgggggccgg	agacccctct	gttcttctcc	agaccctgca	300
gaattctgga	gaggagagga	aggtggaaca	cacactttct	tnctgctttt	ctanggtgnt	360

ggggcatctc tcttcttctt ttaactacga acttcacagn ccaaccactt tctctttttt 420
acaagccctt tggggtcctt caagaaccaa agtaaaaaaa agcttttaaa atg 473

<210> 195
<211> 127
<212> DNA
<213> Homo sapiens

<400> 195
ccattgacct ggatggacct aggacacaca ctaaaggaca catctggatt caccaaggag 60
ctttttatat ctcacaaaat agcatgttgc taataagaag aataaaatga aaccaaggta 120
caaaatg 127

<210> 196
<211> 311
<212> DNA
<213> Homo sapiens

<400> 196
agaaagaacc ttcaggntn gggaggtggg ncttttctn cntnaaaacn atgatncctt 60
gggtganccg nnnngattgn cccacaancc cccgatggaaa cattcaanag gngaagcct 120
tgctcanaac cccctggcca ggcttaggag ggaaaaanta tgctttccaa ctntggcaag 180
aaattgctgc atccanaggc tgcagaagcc ccgaggagca tgaacatgct ttggaagaat 240
angcgctgcc ttgagtgaac tctgaacca gacccttaca cacacanctt tcattggtgg 300
cttttggggt t 311

<210> 197
<211> 497
<212> DNA
<213> Homo sapiens

<400> 197
caactgtgga agtcaaggcc agaaatcact cactatatca tctgatattc ctctgatcgt 60
tatacctatt ctcatgttta aggaaatgag accagttgaa acgtccacat taaaataaga 120
agaaggagag aaggttttct aattgcagtt aatgtcatcg ttaaataaag aatgccataa 180
aggaacgaga tcagcagtgga ccttctgcac agtttccaaa gcctcgccaa cctacctccg 240
tgtctgggtc tgacttatgg cagaaacaga agttcaaaga cctggctgat atgctccgtt 300
aaaaaccctt ccacaacgca gttaacattt tctgntttct gactttcttt ttctaaagag 360
atgcttaaaag caaaaaangg ttcttgcccc aaaaatgaca ttaatatctt gtaaatcaag 420
aactaagata atggtttngg ctgctacaga gaccgttacc cttatgcggt tatctnaaag 480
cttttcgatt aaaacac 497

<210> 198
<211> 350
<212> DNA
<213> Homo sapiens

<400> 198
atctgaagag aagagaaacg tgaggggaaga acaggcgggtg gcagccggaa gagagtgggt 60
ggaacagtcct ctgcaactct tcagagaaaa gaaaggggag ctggcccagg cccaagaagt 120
gtccctgggg gccgatgtcg gcaggaatcc ccgcatctcc acatgcggaa ctgagagaag 180
tgctggcag attcaatcat acagtgactc aaatgtcaca gcatgactat agagaaagaa 240
taatagtga agcatccccg ccaattttca acagaagggc tcaggataag gaagcttaag 300
aaaattgccg aagagaatga taatgacaat aataaaaaca aatagcttcc 350

<210> 199
<211> 275
<212> DNA
<213> Homo sapiens

<400> 199
caggtgaata aggtgggatt tgaaatcagc atggcagtggt ccagtgggaag aaggagctg 60

aagtttcttg	aggatgaata	taaagctggg	ggagttatca	ttgagcctaa	ctctctgggt	120
tggaacccat	aaacccta	caatatacct	cccaagttta	caatagaggt	gagtatatc	180
taccttactc	catttccatc	ccaacttccc	cactttgtaa	actttcagaa	ctgacttatg	240
gaggtttata	acagccagat	atcaaacc	tagac			275

<210> 200
 <211> 354
 <212> DNA
 <213> Homo sapiens

<400> 200						
agaaagagga	aaggaccagg	agtggcgacc	ggcaaaccac	agcttggtgtg	ggaaggaaat	60
ttgacatgtg	atgcaagcgg	accgtttgtg	taaactgctg	ggagattaac	aacaactgtg	120
agtgggaattg	ctgagtcag	tggcaacta	ccagttctgt	tgaacctcag	ggccatcatt	180
ctgttcagtg	cagctcgttg	tagaaccaca	tcgatgaaga	ccaagatggg	aaagatgaaa	240
aattgtagct	aacatttact	gcacatttac	tacaagccaa	gcattgcact	atgaagtta	300
agtgcattat	tcattaaccc	cttcaataaa	atttgtaatt	ttcacttcag	aagc	354

<210> 201
 <211> 310
 <212> DNA
 <213> Homo sapiens

<400> 201						
gttggctgat	tgtggaggct	aaagcaactc	taccttgcca	gcttatccac	catgtggact	60
tctaattaat	ctcagttgcc	ggaatgcctc	taagatttct	acgttatcta	ctgtgaagag	120
caagtaatta	ctgcaaatcc	tgcccttggg	tcaaaacaac	cttgatgaca	tattccttct	180
gaagcacata	tactctttcc	ctaggtatat	aagccttggg	tctgggggct	aacgggtgcag	240
ggatccatca	tctcacagcc	acccaagaca	tggcctttgt	tcaaaaatcc	ctattaaatg	300
tttcattctg						310

<210> 202
 <211> 446
 <212> DNA
 <213> Homo sapiens

<400> 202						
gtggttacaa	ctgtggccgg	ccactgtcct	aacaagtcag	aagagagatt	ctttgccaaa	60
atcttcaggg	gaaacgacac	gagtaccctt	tgtctttcct	caacgaactt	cccttctact	120
tagggtttta	gggcatttgt	acaaatgatt	tgttccttgg	gtctgaatct	tggggatggt	180
tatcattttc	gttgctttca	gaaaatagtc	tgcatttctt	tctattacct	ggaccatttt	240
cctggctttt	taaaaaaaaa	ttattattca	aatggaaaag	cggcgagccc	agaatgagcc	300
gacgaattga	gctcttcctt	ctctcgaaca	cgggggcacc	tctaccgct	acagacttga	360
agattttact	cacttccttt	catcccctcg	ctcgggtttg	gagggtaggg	gcatgaagtg	420
gntgaatcta	aactggcaga	aaaccc				446

<210> 203
 <211> 88
 <212> DNA
 <213> Homo sapiens

<400> 203						
gttcataatca	tggatcccat	tttatagatg	ggaacactga	ggcctgagtt	tacacgagaa	60
tttgctgaag	aggagaagga	aaaaaaaa				88

<210> 204
 <211> 211
 <212> DNA
 <213> Homo sapiens

<400> 204						
ggctttttca	ctcattccct	angcatgtgg	gacctcnaag	atgccgaatc	agctaaacgg	60

<210> 210
 <211> 133
 <212> DNA
 <213> Homo sapiens

<400> 210
 agatgggggtt ttgccttgnt acccangctg gataactact cttgatgaca taaaatctac 60
 tgnnngcagn aaagacagan agcatncacc ctaatacctt agttatgaan actacagaat 120
 cagtagaaga aca 133

<210> 211
 <211> 270
 <212> DNA
 <213> Homo sapiens

<400> 211
 gttctgcatg ctgataaaat gatcaacacc tgctggtctg aagggctcag caagaaactg 60
 actcatggga gaatgcactt tccatattct aatgacttca tcccccttac cctgaccaa 120
 cgataacccc aatttttctaa ccccttgccc tctccaatcc cctgaaagat ccttgccag 180
 aacccctcaa tgaaatgaat ttgagtctcg agaattcctc ctgtttctc attcagtc 240
 cttgcaatta ttaaacaact tgtctgctgc 270

<210> 212
 <211> 355
 <212> DNA
 <213> Homo sapiens

<400> 212
 gtggagagaa cagcatgtgt gaaggcccag anccggcccc cggatctttt canaatgcat 60
 cttggtcagg ggaggatggt cggccaggac acatgcatgg ccccttgagg tctgagcag 120
 gctggccttg gtgggacttg ctcagggact cactgctggc cttggggagn acanaactca 180
 nggcnttgnn attccgaaga ncnnggtctn ncnctgcaa ntgccgttnn cagaatngnn 240
 cccacccag gaggatcacc catatncaac ncnnggagca gntcagcca cnctnnaaac 300
 aagggggaaa cgccaagccc attacattag gacttttccc tgccatcact gggct 355

<210> 213
 <211> 397
 <212> DNA
 <213> Homo sapiens

<400> 213
 ctgcttggtg ctgcggtgtg cctatcctg gctgcatttc ttcattccct cccctgccc 60
 catacatcca cagccccagt cggctgtatc catgaagagc tgaatggaac aggatgactg 120
 gcagcccacg ccaagggcc aagatgtga aggtagaagc aagaagttag aatgacctga 180
 ggaagaggtc acaagcccag gaatgccagc agccactaaa agctgaaaaa aggcaaggaa 240
 atgagttttc ctctgaagct gccagaagga acaagcccag ccaatgcctt gaccctagcc 300
 cagtaaaatt gattttgaac ttccaaaaaa aaaaaggncn gngnggcan ttnagntngg 360
 acttaaccag gmnagaactg ttnaaaaggg gggggggc 397

<210> 214
 <211> 141
 <212> DNA
 <213> Homo sapiens

<400> 214
 gtgttgagtg ggtccctttg gctggctgct ctatgaatgc tgccttcgt gcataagaac 60
 tagtctaagc tcccaaagaa ctggatgcta atccctgtcc tgataactaac tcaccctggg 120
 acattaaaca ggtcaaaaaa c 141

<210> 215
 <211> 96
 <212> DNA

```

<213> Homo sapiens

<400> 215
ttcctcctcc tgccatgggt tgactgagct gaacaaaccg gaaactttct taggaaccgg      60
gctatactat acatgtaatt aaaagttaat tatctt                                     96

<210> 216
<211> 305
<212> DNA
<213> Homo sapiens

<400> 216
aaagaaaaac tacatggaat gaggaatat accactcctg ccttcaaaat cctcttcgtg      60
aggttttatag aattcctaag aactcaggaa agacatcagc agagagcaat gatcgtcata    120
gccagctcca cacagaatgc acccaccag ctacttgctg aattacaacc tgatgatgga      180
tccaccagaa actaagaatg gaaagggtat aaagaaatca cagcattcat cttctggaag    240
aaaaagacta tttcttagaa agtaaaataa atgaataaaa gcacttaata aggagcataa    300
cgcgc                                             305

<210> 217
<211> 427
<212> DNA
<213> Homo sapiens

<400> 217
ctttctctaa ggaagtgaca tataagctga gcctgaaaga tgaagaggag cagattgtat      60
gcagagcaga ggaagagca agctgatgga ggtgactaat cagagggcct gatggtaag      120
tgctcaaggt ggagttaaag gaaaccctgc tttcttgaca tcaccagctg ctcagaagcc    180
ttcagcaggc atcctagacc ttctccttct ctaagggatg ggccctcacct actttcttca    240
gctgagacct ggcacagacc cttggagctt ctaaggacct cattgtagcc ttgggggtgga    300
ggcccatggc accactgccc tctccctggg ataaaggctc tggggccact tctcaaggct    360
gggncccttt nttaagaagg aaatgntttt tcccaaataa cctnctcttc ttcctttttc    420
ttcaccc                                           427

<210> 218
<211> 438
<212> DNA
<213> Homo sapiens

<400> 218
gacgtgataa cgagtcatac tgcggtggat cggcatgcac cctgtccccc ttcttacctc      60
ccagaattac ctcagtatca tagcgtaggt gctttggaga aaactgactc ctcctagcaa    120
taagtcttca gttgctttta gctttaagca cattctttca gtcctctgat cactgtcatt    180
tgtccagggg tgggcatgga ctttagtggt accaaaaaaa atctcgcatt cctatttgaa    240
atgctgagac agaagtacag gctctcactt tctctgcagt tggcagagag ggaatgtggg    300
ctcgattgct tctggcaaac attgtgcaag tcatgttggg aaaggggact tgaaatgaag    360
cgaagattcc agaaaacaga acaaaccaaa agaaatgggt accactataa ctggcaactg    420
tgagagcctgc cctatctt                                     438

<210> 219
<211> 424
<212> DNA
<213> Homo sapiens

<400> 219
gaacactatg aaaagattgc aaaaccaa atcatgagaagg ttagattcct actgaaatga      60
aagatattca tggatatttg aaactcttat aagcaagaag tccgaaaagt tcaagatact    120
tctgtagaat ggtttaattt aaaaagtggc tgctatcctg gatgggggta agaagctgct    180
ggtactctgc tctggatctc cttcttccct gttgttctcc tcccaacaaa taactctcat    240
cttcaagtct accaaaagcg gctgacctta gtagcataac ctctaaacca aactcaactc    300
ttaccttctc cataaagctg ccagaaattg ctctgcccga gagtaattta cctcttacac    360
accactgtta tttcactgtg tgggactgna ttcccaanta aattgagaat gtctaataga    420

```

tttt

424

<210> 220
<211> 318
<212> DNA
<213> Homo sapiens

<400> 220
taaccggatc tcctcgaatt ccgcgcgcac gaagactcag gggagggggc cgagtggact 60
tcaccccgcga tgagacgtct ggcaaaataa gaaggctctc gcaaaaccta acaaccacaaat 120
atgcaaagcc ccaaatagaca accaccacct cctcgaacct cagagggtctg ggggcgtccg 180
gctggaactg ggggtttaaaa aaagaaaatg ttacaaaagt ataacaagat gtttgatggg 240
tggaaaaatg tatccacgag ttacatcccc ccgtttcctt gcaaagcccc gctggtcttc 300
ctctcctttt cttctgccc 318

<210> 221
<211> 227
<212> DNA
<213> Homo sapiens

<400> 221
ccttcagact tggcctgaaa cattggctct ccttgggttg tgagcctgca ggtcctcaga 60
ctgaaactat ccatcagctc tcctgggtct caggctcctg gattcaagct ggaagtacac 120
atcagggtctc ctgggtcctc agcttgatga ctcgagatct tgggaattct cggcctctat 180
aactgtgtgc cccaattccc tataataaat ctttgtcttt ctctccc 227

<210> 222
<211> 462
<212> DNA
<213> Homo sapiens

<400> 222
gtcgaaatcc ttccccgctg atataaatat ttgagttggg gagcagagct tcagggacca 60
tgaagaaaat gctgctctgg ggacactaat tgaactttca tctagcaggt cctgtgccct 120
acctactcaa gaacaagttc tggttgatga agaagttaca cagctgccaa gttccctcat 180
tctactacct atctaccccc aaattcagga atgtctccat atgttgacta tgcngacttt 240
ttcagtgtcc tagtggaacc acagcttaaa aaatgggaaa tggaggcagt cccatatggc 300
agagtctccg atgtggaatt aggcacgtgt ctccaaaagc cagcctgcag ccctttggag 360
agcttactaa actataaatt gtcaactgta ttacatgata aagcagatgt gtccatacag 420
taactctttt gctaataaat gaggncataa ttccaaaaat ag 462

<210> 223
<211> 465
<212> DNA
<213> Homo sapiens

<400> 223
tgttaaattc tcctgagtga atcacaagtc caaggtggct gaatgcactt gccagtctat 60
tgctattgaa gcaccttaat gacataaaga agaagaaacc aatgaacatt gttatatatt 120
tcatttttaa ctgatgtaga cattttgagg aaatctgcat tttgaaccag gtttaactgtg 180
gaatgccctt ggccaagagg aggggtccat ttgatgattg gatggcctta gaatttattt 240
ttgggttaata gtgccacaca gctaaatcca agagagtgtc ttagaaaata aactctggaa 300
acatatattg gaaactaata agaattgatta actgtagagg gaagtgtcag gcctctgagc 360
ccaagccaag ccatcgcatc cctgtgacc tgcactatat gcccgatgg nctgaactta 420
ctnaagaatn cccaaaagaa agnggatttt tgcccttgcc cccc 465

<210> 224
<211> 184
<212> DNA
<213> Homo sapiens

<400> 224

accattagaa	tgtgacctct	gtgaagacaa	cagaaatgga	ggaggcgatc	catgggcatc	60
ttctgaagct	gttttggtta	actttgattt	ggaagtcctg	gttccagggt	ctcctgtttc	120
ctgggaccag	ctccagaagt	tcattatttt	cataaataat	aaatgaatgc	atactaggga	180
ctgg						184

<210> 225
 <211> 124
 <212> DNA
 <213> Homo sapiens

<400> 225						
tcttaacctt	ttgagctccg	ttcagcctgg	ttagnccaa	gctgaattgg	ccnattcctt	60
tngccttttt	accctggaag	aaatactcat	aagccacctt	tgttatattac	ccccaatctt	120
caca						124

<210> 226
 <211> 374
 <212> DNA
 <213> Homo sapiens

<400> 226						
atgaagatca	ttgagattag	agaagaaaaat	gggatctggc	caaggacata	caactaagaa	60
atggcggtgc	cacagatgga	gaaactgaca	ctcagacagg	ccaactgatc	tgccacatc	120
aacgagctaa	aaaaatggca	aggccaggat	ttggccctag	gcctgcttaa	ctctgaagac	180
catgtgcccc	gtctcctgcc	aggccattta	catcctcagg	aggattgctg	cagccccagg	240
acaggcgatt	gcctttttacc	accctcctgc	cagaccacac	tgctgctgct	cctgctcctg	300
taccccaatt	ttgctgggtt	gaaaagggtg	aaagggttac	cccactgctt	gttgtacccc	360
accccaaatt	ttgc					374

<210> 227
 <211> 318
 <212> DNA
 <213> Homo sapiens

<400> 227						
atgcaatgaa	attaacctct	ccttccaaga	acagcatgca	ggcagctagc	tggaaagact	60
cacacttgag	tgaatagcga	cagctcgccc	cttctgcgct	ttgacgctgc	tgtctctact	120
ggccacttgg	tctaccagtc	agttgtgccc	tgtatgtacc	cagccatggc	tgggaagact	180
cacaaccaca	agattgccta	tcagtaggaa	atacaggaaa	ttacaggatg	ggtatatgag	240
acatatgtgg	tggatataaa	gctcaatagt	agtgatacaa	gtgtcatatt	cagaaaataa	300
tataaacttt	cttgctat					318

<210> 228
 <211> 502
 <212> DNA
 <213> Homo sapiens

<400> 228						
gccagagggg	gactgtggac	ttggtgccag	aaaagaaaat	gaaaagcaaa	agttgaatct	60
ctgcggacca	ttctctggat	gctgaatgtc	ccactattac	atctcggcat	gacatttcac	120
ggccagcagg	ggaggaggcc	cagtcctgaa	agctgaacaa	acgcccggca	cacaggcctg	180
cctgcgccct	cgtagtctct	ctggacttat	gaataaaaaga	tggaggtttt	gtctctgttg	240
ttccctggt	accctgtaag	aataacaact	tgttgctttt	tgacatttta	acttactttg	300
aaaaatgacc	aatattaact	ttacatgtct	tggcccttaa	atctggagtg	gggtaaaatg	360
aaagaaacaa	aagccatgta	attangnaga	agataataat	tcaaggtaaa	ctaatagaact	420
gnctgnaccg	actttattaa	aanatggngg	gacatgccat	cccnaactaa	aagnttaaac	480
ctgacttggg	ggaaccttgg	gc				502

<210> 229
 <211> 228
 <212> DNA
 <213> Homo sapiens

<400> 229
gagacactnc ggaaggcnca gaagatagaa cacagagggc naggccatgt gaanacagat 60
actgaaattg gagtgatgca gncacanncc aaggaatgcc tggagccacc aaaagntggn 120
agangcanga natagactct cttctatagc ctgtggagct ctggtataac cttgnttttg 180
gatttctgcc ctccagaacc atgacagaat aaagttctgt cttagacc 228

<210> 230
<211> 395
<212> DNA
<213> Homo sapiens

<400> 230
ctccttcntc aaaaagtggg atccaagttg tctacccttc acaactgaac tggctacatg 60
acttgctttg ttcgaactgg ctgcatgact tgctttgttc aaccaaagtc tgcagaagtg 120
acgggtgcaac acttccaaac ttaagaggct ttgcatgctt ccatccctgc tcttgatttt 180
gagccacccc tgtcacacca gtcaataagc tggctagctg aaaaacgtat aagtgaagct 240
gtgccaggcc agccagtgtt agctgacttt tcacctaact gcagacacat gtgcaaacc 300
aaccacaaata agccaagcct gaccagctc aacagaacta tcaggtgacc tatagacata 360
cgaacaataa taataaaaca aaacctaagc cactc 395

<210> 231
<211> 178
<212> DNA
<213> Homo sapiens

<400> 231
gtttcccaaa ggatccaaaa aactgagagg gaagagattt ggggaagatg tcacttttcc 60
tcatctgact ttgccttggg gtcagatggg agaatgactc ctggagaaca cttagccttt 120
tccagctttc cccaanaaag gctggcccag ggaggcttct ataaacctc tccctatg 178

<210> 232
<211> 299
<212> DNA
<213> Homo sapiens

<400> 232
ctcaccagag acctcaaatc cttacctgga ggtcaaaaaa cttgctgtag cgccggtaaa 60
tggcctcngt ggagccngt gaccacgtga cccggatgat gtacacctgc gggagcaaca 120
aaangagatg ggtgttaaca ccagaagggt gtctcccaat ctctgggacc cagggggagc 180
ncaagactca nagtcanaaa gacgtgggtt tcaaccttag ctctgccaat gactggcttg 240
acaagttgct tgctgtaagc ctcatctccc tcctcaataa aatgagtgtg ataaccccc 299

<210> 233
<211> 137
<212> DNA
<213> Homo sapiens

<400> 233
gngaggatgc naaganaaaa ggtggctgnc tgnaaccagg gagggagaan ccttcccagg 60
gaccaatcta gcttgaactt ttgactttgg acttcaacct ccagtattgn aaagaaataa 120
atatgttttc aaaagtc 137

<210> 234
<211> 216
<212> DNA
<213> Homo sapiens

<400> 234
agatatggtc tcactatggt caagtctaag actcaaactc caggactcaa accatcctcc 60
cacctcattc tctcaagtag ctgagactac agggatcgaa agatgaagaa ctctgttgta 120
agctcataac tccctaatta cttattatta acagtgaata tctgattttc aaagttgttt 180
aatggatcat caataaagca atgtaagacg actgcc 216

<210> 235
<211> 281
<212> DNA
<213> Homo sapiens

<400> 235
gtcttttgac ccagattgga actataccat tggctctcct gggtttcaag cttgcttgct 60
gactgcagat cttgggactt ctcagcctcc ataattatgg gtgagaagca ggagctcaga 120
gaaggtaaaa gcatcaaaat caccacagca acaaagattt ctcaggaaat tataaatgct 180
gagaacagtc ttgttttccct tgcgttggca ggtgactcac tgcatagata tgatcatctt 240
cagagcctca ttatagggtt agcaattaca ttttaaaaaat t 281

<210> 236
<211> 491
<212> DNA
<213> Homo sapiens

<400> 236
cttgctagaa gagcactgga gatagagtcg gatacgcttt aaaggacaag ggaaaacagc 60
tcccagtgga tggtaacacac atggcaaaaag gccaaagagta gaagcaccgt cattaggaaa 120
aggaatcagc caaggtccca ggcaagaaga ggtgaggcaa atggaggctc tgaggaaaagt 180
ggctccaaaag cctacatgat ggaagataac tctggaagag aaagagatga ccgttcctaa 240
gcttgtatag caaaacttga gagaaggtaa cgaagatgtg acatctgaac tcagagaaat 300
ataacttcta tagaaaagaa acaaggcctt gcagctctat aaggaacagt aaataaatca 360
agtatgcaca caagaagtaa aaaaatatat ccnagtagaa aggaagcttt tcattgaaat 420
gnccccagaa ctcattgctt tgganggccg ggatngcaaa atcaagnntt tttttaaaaa 480
ctcctaccgg g 491

<210> 237
<211> 199
<212> DNA
<213> Homo sapiens

<400> 237
aggataaaaa agaagtaaga aaatagagtc tctgaatata gatctttcaa ctgaaaaact 60
gggctgtgaa gcttttggac tcgaagtaca gcctttcctg agtctccagc gactggcct 120
cccccatca gattttggac tctccaagct tccacaagca caggagccaa ttccttaaaa 180
taaattctgtt tctatatcc 199

<210> 238
<211> 282
<212> DNA
<213> Homo sapiens

<400> 238
cccccaagga ctgggatcaa tattggaaac ctgtgcttta gttcttccac ctctgctgct 60
gctatgctgt gtgacctcag gactgggccg actgggagca ccatgtggag aacagagaca 120
aactggagtg ccttggggag gaaggaggag agcacagtct ctgagtcagc catgaggcag 180
agcaaataca agtgggtcatg caggaagaag agtgctggtt ctgcgggggc ctaagagggg 240
gatgtacggg ggggtgtgctt tgttcaatat gacaacacta cc 282

<210> 239
<211> 206
<212> DNA
<213> Homo sapiens

<400> 239
attgagcacc tgagagtctc aagtaacaca cctggtttgg ctgctttgct gaagacactc 60
cgtacattgt gacttggtgc tctcaccatc aacaggaatt gggctgtgca agcaattctg 120
aaagaagtgt tgtctactgc tgtgaaagtc atcaacttta tcagacccca gtcttgacct 180
cagccttttc aagaaatttt gtctag 206

<210> 240
<211> 472
<212> DNA
<213> Homo sapiens

<400> 240
cacttggcac tgtacnaaac accttcatat ataccctgtc accctgactg agcaggatcg 60
ctcagttcca ttttacagga tgaggtgaag acttttcaaa gccagagctc taccctgata 120
gcacacccgtc aggatgttca ggaagagcct catgggttat tacagctcag gatgcatcca 180
gacactgtct ccatggcctg cggagctgct ctctgaggac tcacttcact gcccctcatt 240
tcccaggctc atggagatat actacctgtc acctctgggc ctggagggca gatggaggta 300
agatgcaaag gaagactgcg tcgtcaaagc agatggaagc attccctaac acctgggcca 360
tcctgggtcc taacttaatt actaaagaat aaggggagatt tcaaagnaaa atgnncagac 420
atttgnttat ttgaacataa aactgggggc ccnccaccag tatttttgta ac 472

<210> 241
<211> 283
<212> DNA
<213> Homo sapiens

<400> 241
ccttgcaaat angtgatttc ctgccagtcc ctgcctctgt gaccaacctt gattgttcaa 60
agtatagctc tgcaagcagt ggctacggac agtttccaac atgcaagttc atctccgacc 120
ccacttcac tcctctcctg cccccagcac tcctggatgc tatgctgaat tgtttttgta 180
cctttgggtt gtgagccttc ttaaaccctt ctttcttcta ctttattatt atcattgtat 240
tataaaagca atagatgctc attactttaa aaaatgtaaa agc 283

<210> 242
<211> 193
<212> DNA
<213> Homo sapiens

<400> 242
gcactgtctt cataagtcca caggtctcaa actccagcat ctgagaatga aaggattcac 60
aagtgtcac aagaggcttg gctgccaggg gaagctccga cctgaagatt tgaactaatg 120
agggactata aaggccaaga ccttggtctt gccattttag agattcagaa tataatctac 180
aaagtttagag att 193

<210> 243
<211> 501
<212> DNA
<213> Homo sapiens

<400> 243
cctgcagagg tcanggagag agcccgatgg cggctctaat gaagaggaag gaggaaagga 60
cgcagctttt tttaccccc ggcttaattt actccgtatt cggcttaact tactccctat 120
tctacccctc ggtcttcaag ttcccttaag ctcggtggcc tggtaccag taaaactaca 180
aggaaatggt ctgtgtggtg aattttgaag ctgtccacag tacagatact ccagtgtctg 240
cccttcacaga aaagagctgg acctaaaggg tcctcctgtc tcacgtgcag actcccaggg 300
cgggattaaa aaggcaaaaa tccnnngttt cntngcaa atccnnngnant nngggnnnga 360
nntnntnntg ccncnntttg ggangaang aancanaatt aatttngggg ctntaaaggg 420
tttatttata aangggcttn gggnttctat tttattgggg aanaaatncc ggganttaaa 480
aatntaaaga ccccttcca a 501

<210> 244
<211> 327
<212> DNA
<213> Homo sapiens

<400> 244
gttcttccta acaagaagct acgaagttct tattcagaaa aacggaacac gacatcacac 60
ccacgtgaaa aaaacgcttt taagaggcca agtcactttc acctcccacc aacttgccaa 120

aggctgaaag	caggcggaca	cgcccccaag	cgctcttctc	cgatttcatt	ggttgccccg	180
gcctgctcct	cattaggtct	ctctcactgg	tcagcaatgc	cgctttcaca	gccaattctc	240
agaaccaatc	atctccaact	attgccccgc	ctctccacca	cgtgagtggc	ataggtgcca	300
accaataaaa	aaagaaaata	aggatgt				327

<210> 245
 <211> 100
 <212> DNA
 <213> Homo sapiens

<400> 245						
gcangggcct	ccngnggttc	aagggtacaa	taanctgcga	ncgtgccnct	ganttctacc	60
tgggatgaca	gagtgggacc	ctgtgccaca	aagagagacc			100

<210> 246
 <211> 505
 <212> DNA
 <213> Homo sapiens

<400> 246						
aaggctgtct	cctgcgagga	ccagaagttg	agccaaggca	cgtggaactt	acaatagcag	60
atggtaagaa	ccagggcaga	aggagaactc	ctgaagcctc	cgaagggaagg	aatcattac	120
agggccctac	agaagtaggt	catgtgctac	agctgctcat	agtttaagag	gaagaaacat	180
gggatctcaa	acctggaaca	cgactctttc	aaaatgcctg	tgagcaaccc	aagaaaaaca	240
tcctcctgag	gcttatctaa	taaccatgat	ctctaategt	ctcaatgtgt	gctcatgttt	300
ccttaagaag	tttgacacca	cttctcagag	ctaacgagat	gccgaaacag	aacacagaaa	360
aaagtaatga	aggagattta	ataagntgng	ntaaagctna	tatgggcat	taaggggcng	420
gcttttttta	aaacaanggg	gnngaaccgt	tccctntttt	tttgnggaa	aagnnttttc	480
nggggcangg	acctggaac	cattc				505

<210> 247
 <211> 139
 <212> DNA
 <213> Homo sapiens

<400> 247						
ataaaatctc	ctggcagaga	aaatggacag	tcgttccata	ccatatgtct	tctcagcttc	60
aaaatcaaca	acaacaacaa	caacaaaaaa	ccccaaaact	tccatcatct	gcagaagtca	120
aataaaactt	tcaaacttg					139

<210> 248
 <211> 261
 <212> DNA
 <213> Homo sapiens

<400> 248						
ttgtaaatta	tgctcatgaa	aagagacccc	agcatctttc	aaactgangg	ttaaccttat	60
tatcaggata	atcaccaatt	cacaggaagt	tgcaaggatg	gtatggagag	cttcatttta	120
ttcctcggtt	ttccccaatg	attacacctc	acataactgt	acctcaggaa	actgaagctg	180
gtacagtgtg	tgtgtatagt	tccatgccat	ttcgtcttaa	gtgtagatct	ccaatcaaat	240
aaagaaatat	cctgtcacca	c				261

<210> 249
 <211> 241
 <212> DNA
 <213> Homo sapiens

<400> 249						
gtgggggtctt	tcagtatgta	caaacataca	tgattcagga	taaaagatgg	atcgtaaccg	60
ttctcaccac	agaaaagtaa	cgggagactc	ttctaagaaa	tcgagaaaag	aacgcccttt	120
ctcctgccct	cctgtctaaa	gcgcaacata	ataatcgaat	ctcccaagct	tcttaggggtg	180
ctgagtgttt	taatccacca	gccctcttca	actagttaat	aaatcctttc	cagaccgaga	240

<210> 250
 <211> 505
 <212> DNA
 <213> Homo sapiens

<400> 250
 gnaanctgnt agnncatgcc ngacaccttn tctccatgcc tgcncctttct gttccaagcc 60
 atntggtgga agcaatccaa ttgcctgcag aatcatccga aagcatcact gggaagaagc 120
 tgggtggaact aagaagcaat tctttagcct gacagccagt ctgttttttag tattttctaaa 180
 catgaaatca tctcaggaga agccaagggc tgtcgagggtg atttgcctga ggtcctacaa 240
 ctcatcactg actgtgtttg gaggaaggaa gtaattaact ataaatgtga ttataaggggt 300
 ggggccttaa tctgatagga ccagtgtcct tataagaaca ggaagtgtgt gccgttact 360
 gaggaaaagc catgcaagaa cacaagaaa angcggctgt cttgcaacct ngaagaaaaan 420
 ctttgcctaa aactaatcct gccgggcatn ttaatcttgg naattccagc ctccaaacag 480
 nganaataa aggctggtgg ttatg 505

<210> 251
 <211> 90
 <212> DNA
 <213> Homo sapiens

<400> 251
 agaaacaaat acatcaacgg agacaacttt ggaaacaatg gaaacaaaga accaaaaatg 60
 ggctgcaca taaataaaaa ctccatatac 90

<210> 252
 <211> 589
 <212> DNA
 <213> Homo sapiens

<400> 252
 aagaaggggg tttccgccat ggttngccca ggctggtctc aagctcctga actcaagnga 60
 tcttcccncc taagcctccc aaaagnctg gggattacag gcatgagcca cgactcccag 120
 cctgaaatat annattttta tcttcagctt gcattttgtt ctaaacaact tgttttcaaa 180
 taagaaccgg gcagaaccaa gttaaagcca ccatttgttn ggaggccaga atcaatttta 240
 ttgggtggtg gttcaaaatn gggaactggn actaagcctt ccttcttccc ctccatcctt 300
 cctagcccat tgnngcangg gggaaathtt tctcnttttt tggngggggg taaaacaact 360
 tctttccctc attctgggaa ttngcccttc aacctaattg ttggacaaac cgaaaaaaat 420
 ttcaaaggcc ccccaaaaaa taagcaaggc aaggcttacc attaatncct tttggcatgg 480
 aacaangggg gaaaatthtt ttttggcctt aaanggnntn gggggcctag ccaccttgaa 540
 aaaacaanna nggccgggt tnacctttcc gaatcntggg gggcttcca 589

<210> 253
 <211> 498
 <212> DNA
 <213> Homo sapiens

<400> 253
 gttccaggcc atcaagctac aaanggactt accaatgggtg ccttnaaaag agctcaacgt 60
 gcgnttntn ttggngacat cacgggnccn ananaaaatg gnttaattta tgtaacaaat 120
 cccctctgga ggacaccana actgnggggc ccttnttttg ccctnatccg cngaaagnag 180
 ccgaatgac cactncccag gtnccaacag cananggggg ggccnntcna aaacnagga 240
 ctgagaggag ggacccccg gctttctggg tctgcnggg gctcacaaaa gttgtgaaan 300
 tcattttatt tcttgentca agacnttctt ntgtgctggg gngaanaaaa attgaaacat 360
 atgctttaa aaattctaac aaccacggag ttgngcattg tgtttntntn cccaagaaa 420
 agcttttaac agnggaaaaa tttgntnta agcttnccctg ggggctctnt tcttggggtn 480
 ctttctctt tcctgaa 498

<210> 254
 <211> 303

<212> DNA
<213> Homo sapiens

<400> 254
ggccttcatg gaaactgctc tgggtgtcaca gaaatatatc caaggatgga gtgtgtacgt 60
gtacaagctc gtctgaaaag agttggcttg caaatgggag aagctgtcca agaagtattc 120
tcacaatgaa ataatcattt tattttgtcc ataccgacaa acaaccagtc aattcagctg 180
gaggaaaaaa caaacaacaa aacaaacatt ttattttcca aatttgtaat gagttcgctt 240
aattattttt gggtttattgt gttatctaca tagttgaatc ttaaactctga attttcataa 300
ccg 303

<210> 255
<211> 441
<212> DNA
<213> Homo sapiens

<400> 255
caggatggcc tagatttcct tacggcatcg aggacgagat ccaagacagc aaaagcagac 60
tcngccaagc ctcttaatgg caaggccctg aagcagcaga gcttcacttc tgccacctcc 120
tattgggttaa agcctgtcac aaagcctgtc gagattcaga aaaagagaga tagaaccac 180
ctcctgatag aaaaaagctg cacatgcata aagaaaggag aggatttgac agctatcttt 240
gaagagtatc tgcccatta agccatggga tattttcccc ataaaagaaa ggactatgat 300
ctggattgta gaaactgatc tatagacatg aatctgaact taagagaatt tgactaattc 360
catctgntca aactggcatc actcacacat atttctgnaa ggattcactc ttccatgggt 420
agcctcaata agaattcatg g 441

<210> 256
<211> 431
<212> DNA
<213> Homo sapiens

<400> 256
aaaaatcctg cctcngtgc tcttgagtcn ctncntngcc tncagngggg tcctggcnca 60
aagggggggg ggcataccag cttaaagaac tgtgttcnnt tgnctgcaac cctgnagtac 120
anngnatnng aagncctatg ctgctctgan ggcgtcggaa tatgngancg atccttgcct 180
cctactanac tctgggtgcag ggctgcanat ccacaaagcc caagctgcag caagtccgaa 240
ggcgcnccgc anggggagtt ctttctcagg agactgnggc tttgctctta cggccttcga 300
cagaatggat gaagccccc cccctntgg anggtaacc gctgcattca aaggcnaccg 360
antnaactat taatcctatc tnaaaaacng gcttccanaa acaaccacac ttgtgtttga 420
acaaaaactg g 431

<210> 257
<211> 332
<212> DNA
<213> Homo sapiens

<400> 257
gagcctntnt ccttggcaaa tgggcttcac tgttcatcac agaaacctcc tgaaggaccc 60
atctactctt caatcaacag ctgggtgccct acgattctct gaatcccttg cctggcctca 120
aaatccctca cctcatggct tccaccagtc ctggactact gtgttcctta cacaacccta 180
accaagcccc cacattgaca caccacctt aaagagnact gctaggcttc agaaaaccca 240
acettgectc ctctctccca gacaggccaa agcctctgg aatcagcgcc ctcccttcgg 300
caagtgahta ataaactcag ctttgcccta cc 332

<210> 258
<211> 309
<212> DNA
<213> Homo sapiens

<400> 258
gtgccaatat cggtcagaga acaggatttc agtggcagag ttgttgctat actgttatct 60
cttcagaacg gaggcacaag gagagatgaa tgccacatcg caaggagcaa aggagagaga 120

gagaaagaaa	tgggtgtcagg	tggcatgttg	gatgtgattt	ttgttttagt	agagattgag	180
atgactgttaa	attgttttagc	tgattccttc	ggtctgcaaa	gatacathtt	tgttgggtgct	240
gatgggttctt	gactaatcct	gtttcaatta	caaattgggt	atgtttttca	aataaaaactt	300
ctggcactt						309

<210> 259
 <211> 427
 <212> DNA
 <213> Homo sapiens

<400> 259						
gcttttgaag	gagttttaaac	cttaagctta	ccctttcaat	catccactac	cccagggaca	60
gaaggtgggg	aaaactcaaa	ggcacangct	tgtactgaga	agttttgagc	aatggagaga	120
aaagtgggag	cttctgactg	accttagccc	accacagtca	ggctncaaga	ngggagatgg	180
cctgggntna	tgggtgcctt	tctctgtgtg	nnccttacct	tttgggaaaa	ccccanggn	240
nagaaaagtc	ttcaagtctt	gtcagactgg	gaagtcccca	actcccaacc	tnaggaagca	300
gcccttggaa	angagaagga	tgagattttc	caaagctatc	tcttaccact	ttccttnccc	360
catctcattc	cntccatnta	ttggggagaa	gncctctnaa	gttnggcctg	angcttctga	420
gggattg						427

<210> 260
 <211> 478
 <212> DNA
 <213> Homo sapiens

<400> 260						
acatggaaac	tgaggaacag	agagatcaca	tatcttgcac	aaggtcctac	agttggagag	60
agaatgacta	tttcaacaat	ggcaaataag	gttcatcatg	tatgcacact	ctgattgctt	120
tgtgggtggct	tcctggatca	ctgggttgaa	aaagaccag	gctctgtagg	aggtgggtga	180
ttaatgatgt	ctgccattca	gaacaaagat	gtagcagcag	gtgtacctca	tttttgctgt	240
ctctggacta	ttccattgaa	gccttttagt	cctggattat	ccaattagcc	ctagctttcc	300
tggcagtgtg	atctccctct	gccttaatat	cagccctcag	ccctcgggat	tcttctctct	360
gatatccaca	ctcattgcct	ttgcttctct	gngctcccta	aaacaacgac	ttttcttccc	420
caagccnaat	tggaantaan	tcctacctcc	agnngnanac	tggccccggt	cggcagcc	478

<210> 261
 <211> 412
 <212> DNA
 <213> Homo sapiens

<400> 261						
gaaagtagcc	aaatcacctc	cctggctctg	gaaggggtgtg	gaagtgggtg	agtaagagtc	60
ccagcccaga	taagggatca	ccaccagaag	atgaagaaga	tggtatgtcc	agagatccaa	120
aggcaatgcg	ggcctcacag	tagatgccag	cacacagtgg	tgacaaacgc	ttggacaaaa	180
cccatcaatc	tcatgaacag	cagagaggag	aaacattgag	tgaggatcag	cagcctccta	240
gagcactagg	ctcctgcac	agtctcctgc	aacttagata	ccaccttgag	gtcgggggtg	300
gtgacagggt	tcattgtcaa	ttgatgagtt	tgtttcaatc	taaaaaaaat	taggtggggc	360
ccagaatgaa	ctaagatgat	gtttttctgt	cttgganggg	accgggcctt	ga	412

<210> 262
 <211> 389
 <212> DNA
 <213> Homo sapiens

<400> 262						
gctccagacc	tgtgtgtgca	ngctgcctcc	tggatgcccc	tcggttgtct	aatggacatc	60
tcaaacctca	catgtctcca	cttgaaaagg	atgagttttc	tggaacctga	gcattgccat	120
atgcccctac	tccttgtgtg	gccccacac	cgtgcctgct	cttccttcag	ttgatcaggt	180
gaaaaacctca	gagtcacttt	taaacacctc	atctctctcc	tgtgccaaca	accaaattat	240
atccaaaatc	tgaccacttc	tcaccacttc	cacatggact	gctgtgttca	agccaccacc	300
atctcttgcc	tgcattagtc	cagcagtctc	ctanctgaca	tggggactga	gattcagaat	360
atttggggatc	aaaggtctta	tccttgaat				389

[illegible]

aatgttaacc	acaggacgtt	ccagctgtga	ctcattgcaa	ctactgacaa	gcaagctgga	60
gtggccctgc	ttttagagag	cctgaagatc	tactcagagt	gaacaatact	tgaagttcta	120
attgagttac	agaaaggaaa	ctagtaaaaa	ctaagaaaga	tttgcattct	caccttgaat	180
atgcagatct	aatttctata	acttggttta	ggggtatttt	tctaaattac	taaaataatg	240
cttcacatttt	caaattggcc	attaaatata	tcttcagatg	cggagatgtg	tatatattc	298

<400> 264

acagagctct	gcaggcacag	ctgaggacgg	cctctctttg	ggtccccag	actcatccct	60
gggagctcac	aactggcaga	gggagacaag	ggcgctccaa	gcagcagccg	tgggggagtg	120
gtgatctcca	gcttcaactg	ccggggccgtg	aaaacaggaa	ccagccctcc	agggccaccgt	180
ttctctgaaa	caaagctca	gcaaccgaaa	aaggatcaaa	aaagcagatg	gtggaggtgg	240
agcgaggcag	ctgtgcttct	cagtgcctcc	tgccgtcctc	agccccatct	ctggcacaag	300
tggccaagc	agcccaggac	tccattggcag	gccctaccct	tgcagggtgaa	ctgcctcggg	360
tctnccagcc	tccacattca	catattttcaa	acagaaacac	caccaacttn	ctgggctnac	420
ccnttgggaa	attccccaan	gaaaacaaag	ggggactcat	atttgggcca		470

<400> 265

ctgaggaaaa	acctacaagt	ctacttggag	gaatccccag	cattttcaac	aggatgtcag	60
aatgaccttg	ggctatgttg	gcaaagcaca	atgggaagaa	gacaaccaat	tgaaggtaa	120
actaggcctt	aaaaaaaaatt	gttcttccta	aatgaaactt	tatgtaagac	ccaaacttcc	180
tttatgtaaa	aataggatac	cc				202

<400> 266

ttttccgtct	gtccagctcc	accactaaat	agtgtcttta	ttccgaggag	ctacctgatt	60
tgggactcag	tcttctctaca	aggcaaaaag	agaagacctg	gatgctccac	gtggtccaga	120
catggagcaa	gtaaacctgag	ctctcgccac	accgcacagt	ctcctcagcc	tctgtctcaa	180
tgtgctttca	tgggaattgc	ttattgtaaa	tgatgacact	tttttaaaac	caaaattcaa	240
ttaaattcaa	tacatat					258

<400> 267

gataataaaa	catgaagtgg	aagatcttct	agaccagcac	cttaaatttg	cagatgagaa	60
agttggaacc	cagaaaggct	gagaggctca	aggtctcaca	actgtttatg	ctcaactggg	120
aaatgaattt	gtttctctgg	cccatcaggt	caacattctt	tcactcagc	tatgccgnct	180
cctacctct	gaaaagattc	tagcaggacc	ctctgatgaa	aaggacctta	tctttttata	240
ctcgtctgtt	aaagcttttt	tttaaaatca	tcgcacgatt	ttatgagtta	agttatgtac	300
ataaacaat	actattactt					320

<210> 268
<211> 498
<212> DNA
<213> Homo sapiens

<400> 268
gagcatgacc agcagactaa cgcagcaagc agatgatgct cctgatgaaa agggcagacc 60
cagttgagcc tgggctacgc tgacacagac tttgttgctc ttcatttggc aaagtctctc 120
ccagaatccc tgcaggcata caacagatgt tcagtaaaca ctcggttgat gagaactctg 180
ggaagacata gctgttcgac gaacaggcat cagaatttat catttgaaat tatcaactca 240
aaaattcttt ttttctcat acatattctg cttatgtatc aaaaattatc ataagaaacc 300
aagatttctc agaacatgtg aggtcaaaat ggcttataat gtaaaagaag tggagtctca 360
atctatactc agtatctccc tctcttttat tcatacacat atggacactt gcacttctaa 420
gaaaaaatga attttttttaa actcattcat ttattaaatt gatatggatt aaaccangna 480
atattcataa catattct 498

<210> 269
<211> 342
<212> DNA
<213> Homo sapiens

<400> 269
cntctctgga gagcttncat ctgcaccatg agcccatgcc atcttctgac tcttgagct 60
acagtgaaga tataatttgt attaatgctt aacttcttca tttcagttgc cattgaggta 120
gcctaataac attcataagt aaatactgga ttttagtttg caatagaaaa accttccatg 180
taatataata tgtctataca attaataatt aattactttg ttaaaatatg tatcttttaa 240
taaataaaca ttggtagaga ccaaaaaaaaa aagaaaaaaaa aanggccacn gnggcccaatt 300
cagctnggac ttaaccaggc tgaacttgnt caaaaggggg gg 342

<210> 270
<211> 159
<212> DNA
<213> Homo sapiens

<400> 270
ccagcattta tggatcttca gaggnntctc tctgtgataa ttctcatca aattaccaat 60
aagaaggata tgaaactaca gccccacaa ggatgcctgg tgaccttcgg cctgagatt 120
tacagtctgc ggaagcaata aagttcctct ccctctctt 159

<210> 271
<211> 521
<212> DNA
<213> Homo sapiens

<400> 271
ggcaccgcaa gacaacgtat ctccccctcc ctgtgcaatc agtcaaagaa catttagtca 60
acctgaactg ggagcacagc gctcctgggg ctgttgggca ttcaaaagag tgtggatcag 120
tgtaaaaagt gcctcatgga gaaatggagg cctgaaagcg actctgaagg aggagtgggg 180
ctcagcaaac agcagacgag tttcaatcca agcaccatt accccctaa cacacggcat 240
acgtgcatct catctcctcc tgtgtcgcta agaagctacc catatgtctg tcattaattc 300
tccagaatcc ttggacacac ccctctgcag agctttctaa cagaaatata agtctcagat 360
ttttttttta gttaaaattg agtgcagcac tcataccttt cttcgagcat gaaccgtcaa 420
tcaacactgc ctcatgagct actgntctcc tgctctttta aaagacaaan cttattttct 480
ttgtagnat cncaaagngg ngggattnac ccggaaactt t 521

<210> 272
<211> 460
<212> DNA
<213> Homo sapiens

<400> 272
agtttctactc tcagaggagg attttgttct tcaattgtgg agtgatctct atcaccagtg 60

actaaagcag	atgttggagc	acagagagcc	ataccccaaa	atatgatgct	tcggcatgct	120
gactgctttg	aaaattgaaa	ggcctcagaa	ataatcctca	gtgccagggt	ctccctctga	180
cctcccccta	cctccctttc	tctctgatcc	tgtctctccc	aaagcacaga	atgagctgtt	240
ctctgaattc	ccttatctac	ctagaaactg	gacccccaaa	gaggaacaca	atttgccttt	300
gatcccttcc	ctgaaatttc	attaaccaga	gaaaattaaa	acttctatca	caaggaagag	360
actgaacatt	aaacaccata	gctacagccc	agacaaaactt	cttcccaaac	cattgtttgt	420
tctcctgcct	gttaaattgc	cagagaatca	ttcacaagac			460

<210> 273
 <211> 224
 <212> DNA
 <213> Homo sapiens

<400> 273						
ttgacaggaa	ggcaatcatt	cattcattca	gcaagcaagc	aagcaagcat	ccacaatgag	60
cctggatgcc	acatggacca	cgatcaccaa	ggagatcgat	aaatcccaca	atgttgttcc	120
ctgtcttcaa	aaatttgtca	agaagattga	gatccactgc	tgtaagatta	cacagatgcc	180
ctcctcatcg	tctatgacag	gctataataa	atcttgccag	actt		224

<210> 274
 <211> 338
 <212> DNA
 <213> Homo sapiens

<400> 274						
aggcgagaaa	ctgtgggata	agaggctgca	gcaattgcat	gagtagaccc	tgaaggatatg	60
aggtttgtta	aaatggatgt	tcagagaagg	cctgacacaa	gagggccact	ccatttgtcc	120
ccacggacct	gggccggatc	tctcaatttc	acactgatgg	agcctgaaaa	tcaacaaaca	180
agacggcaag	aacaggggaag	acattgttct	ctccaaagtg	gacaatttgt	gacaggccca	240
ggaaggctgc	ctgggcttta	tagcttttcc	agtggttcct	aataaaccag	gctttgtgtg	300
agcctcgttc	aagccatgcg	gggccctgtc	gtttcttt			338

<210> 275
 <211> 158
 <212> DNA
 <213> Homo sapiens

<400> 275						
tcccaggtgt	atccaccagc	tccgaagaga	cagcgaccan	gcaagaacgg	gccataacga	60
cgatggcagc	tttgtcaaaa	agggggatat	gtagggaaaa	gagagatccg	actgtttactg	120
tgtctacata	gaaaagggaag	acataagaaa	ctcctttt			158

<210> 276
 <211> 144
 <212> DNA
 <213> Homo sapiens

<400> 276						
acttcagttg	acccaggcaa	ctgaaaccga	ggaagcaaaa	ccatggaccg	tggaagaag	60
catcatatag	gactactgta	ttatgtatta	taggtggctg	tggtatcaac	atacttagtt	120
gataataaaa	atgtttgcaa	agtc				144

<210> 277
 <211> 561
 <212> DNA
 <213> Homo sapiens

<400> 277						
gagcccatca	tggcgacgcc	ccctaagcgg	cgggcgngg	aggccacggg	gganaaangg	60
ctnggetnca	aaactttant	antgancngn	ctgcacggga	ctggcgaaan	ggggctgaac	120
catcgaaaca	gggtattatg	aagccagctg	ggccaaatac	cttcaactgg	agaaaatggt	180
catttgagcc	gaacttncag	ggaaagctaa	agcactcggg	aagttattat	atgccagggtg	240

ggatttttggg	cctggtaaac	tttcttcggt	tggacacagt	gggtccccaa	gatacctttc	300
acgccatcta	tgtggccccct	ggggaaaaat	ggtttttttc	ctggagggtg	acacctgggc	360
aagaaagcct	tctaaagtgt	catttgattc	gtaaagaact	ctctctcac	aagaagcttc	420
aagcaaacag	ccctcaccca	agggactcca	tgaatatca	aaagcccata	tccacatgtt	480
gctagagggg	cttaaaaaac	tacaaagggc	tggagaaatt	tncaaaaaaa	actcaacatt	540
ggcttttttt	ccccctactc	a				561

<210> 278
 <211> 338
 <212> DNA
 <213> Homo sapiens

<400> 278						
tgtaagctcc	accagagcag	cagactctca	taaaacctca	tgggatgaat	gaaaggagtg	60
tcattccctta	agacattggc	aacaaaagca	tagcctgaca	tattctacta	caagtgcctg	120
cagtaacctta	tgacagagag	agcaaatgaa	ctccacacag	aagggtggacg	atccctgagc	180
cagagataac	tggaactctg	gcagtttgag	tggacactca	gtcacacact	cacacactca	240
ctcacagcgt	tatgcaattc	caaaaattat	gtgtttggtt	ccaggaagat	acattttttcc	300
cctctaagtc	caaaaataag	atagaaatgc	atatatct			338

<210> 279
 <211> 271
 <212> DNA
 <213> Homo sapiens

<400> 279						
gttcccagta	gctgcagcag	tgaaagacag	tgattggctc	cagtgcctcc	agaaggattt	60
gggctgaagc	caggggaaac	gaaccagaag	aggattccct	ttccagagac	catcaggctc	120
ctcatgtctt	gtctctcttc	tctcccctcg	tgggtggctca	ggatttcagt	atggctgagc	180
agcccatagg	taggcctcaa	cacttggtgt	caccacttca	gtctctatat	gtttggccct	240
tgtgtaaaat	aaacaaaaac	ttgggcaacc	c			271

<210> 280
 <211> 490
 <212> DNA
 <213> Homo sapiens

<400> 280						
gagctgggtca	gctctgacct	ggagtgtgtc	taccctgacc	gtgtgacacc	gggatcaaga	60
ccctctcctg	gggtcttgag	gacgccacat	gtgggcgttg	ctctaaagag	cgcttgctcc	120
taagcctcct	gcacatggaa	ccccaccatg	gaatctgctt	cccaggaact	cacctgggga	180
ccagcccctc	tgagactcaa	gtcaacattt	ggctctaggg	ctgcaaagag	gagggtgctaa	240
gaggccaaag	gctacttcca	cctggagaac	gggccccgcg	tgccagctcc	cccaaggcct	300
ggccaggatg	ctctgctcgg	aggcctgtcc	tgacttcctc	tgctcattgc	acctgaaatt	360
acctaaccaa	cacctttctt	cctcccaccc	ttccacaaat	acttattgag	catctgctag	420
gtgccaaagt	actggctcgc	acaatgggca	ttacnngccc	tgaaagaaat	taaacnggaa	480
ccttcttggt						490

<210> 281
 <211> 512
 <212> DNA
 <213> Homo sapiens

<400> 281						
gagggtgattc	atcccaccag	tgcttcttct	gcagacagta	aaatatgggtc	ccagtgacca	60
tctcaggtgc	catgcttcca	gcattttatc	agacaaggct	gaagacagca	gacattaaac	120
ttcagttgtg	tgctccacag	aacattagct	gtcttcatca	ttactttgca	tctttcagtg	180
ataggctgct	tgacatgta	ggaacctgaa	aatgatccca	tcttgaccga	atctcaaattg	240
cccttctctga	gcagactga	tgaaacagat	ggagcacctg	gatgttatct	gctttggagt	300
tggttctcag	gaggaggagg	agcagaaggc	tgggcacaa	ggtgtttgag	gttctcaact	360
gccccagaa	agaagggttg	acttgattta	cattgacttc	aacttgatta	tcttgatcta	420
cttaactggc	ttttcggtct	ttatgcttca	agcncccgc	angantggct	tccttntggt	480

caacttgcan gnettttgac ttgggattta ac

512

<210> 282
<211> 393
<212> DNA
<213> Homo sapiens

<400> 282
gctgtaagct ccttggagggc aaggattctg tctgcttcac ctctaaagct tcagcatggc 60
atgtgccctg caaatggcag tgccagtggg catatgctag atgagtggat gaaggaccat 120
cccacatcag ctcatcgtgg agtatgcagc tcagtccctc cgctctcag ggacaacttg 180
gatcttcacc gttcttcgcc actaagaatt cnagtcctct acattcagag ggaagctgag 240
caanctggct cctgcccaca ctggaaaatt tctctgccta aaccagcttc cctaagccga 300
ggggagagtc caagatcccg aagatggcag ggccgtgcag gctcctggga ttaagacaca 360
aacaagccct gttctcaggc tgacagtaaa tgg 393

<210> 283
<211> 139
<212> DNA
<213> Homo sapiens

<400> 283
ttactcatgt cagtaagcgt ttactgagta tctcctgcat cctggggcact tctccactcc 60
aatgtgacag cagtgaatca aacgacagct agccctgccc gcaggcactt gcattccaga 120
gagaggagac aaagaatac 139

<210> 284
<211> 482
<212> DNA
<213> Homo sapiens

<400> 284
gtccttgatc tctgtggctg tgagacgatg aatctagggt gtcaccccag acaacgagggc 60
tgcttcaaaa tcccaaagtc caaaggagga ctgcttcata agggaaggat tgtttatagg 120
ttggtatact gtgcaaaatt aagtatagga ccaaaaacag ccaagacatt tgaaagttgg 180
aaagttgatg gtaatggttt cctgggattg gaaggcagac ctctccgct gatgagcaaa 240
taatgaggct gtgctatgat caaggcattg tgaccctgt gaccacacg tacacatcca 300
gaaggtctcc tggagccaga aagtctggga caacaggaaa accacaaaag aagaaaaaca 360
gctcctgtct tagctgatta gccaaccttg cgaccttcta ccattggaac atgctctacc 420
cttacttant aatncacttt cnggaccntg ggctntgtga cccctcccc ttgggataat 480
aa 482

<210> 285
<211> 241
<212> DNA
<213> Homo sapiens

<400> 285
cctccatgct ctgaggaacc ccaagcagct catggagagg cccacatgga ggggaagagg 60
agctcccagc cagcattcaa ctgtcagta acggaagtga accatcttga aaggggatct 120
tccagtctcc aatcaagccc ccagcccaca ctgcttgga cagagaagcc gtccatgctg 180
agccctattc aaattataga ttaatgagcc aaataaatga ttgttgctgt ttaagccac 240
t 241

<210> 286
<211> 222
<212> DNA
<213> Homo sapiens

<400> 286
gaagtgggaa tgatgcatat tcaacgacgc ctacaaaaat tacttcagat tgttagtctc 60
agaaaccac tgggtggcctg aggggacatg caaaaagaag aggaacagga gcagagatgg 120

caaattatta aggtttcaag accttaaaag agacaatcaa agtattcaga ttctcagtaa	180
aattaccaga ttaaatcaaa taaaacccca ccctttttcc ac	222

<210> 287
<211> 280
<212> DNA
<213> Homo sapiens

<400> 287	
attaaatcaa gattatgtct gacaaccctc tcaaaatgat aaaaactaat ctgcagagaa	60
aactggctgc agaggaaccg gctgcagagg aaccagctgc ttctcctcgc gaacatgaag	120
aggtgaacag agagatgaag cctntttntc ctccctcagc tttntgaang atcaaaatca	180
agggcancng ggagaaagaa taacaaaacc aacaaactgg aggtcaagga gagnnttttt	240
ctttttttta cctttctgcc ttttccattt ttaataaaca	280

<210> 288
<211> 435
<212> DNA
<213> Homo sapiens

<400> 288	
ggcttatctc cttgttgat ccagaatcat atgacaagca agagtcctag aatattttat	60
ctacctaatc atccactgc cttattccag aaagaatcta aggaggaatt tttatttctt	120
cagtcaaaag atgcaggaaa gacatcctac ctcttggaag aatcattgga ctggacatcc	180
aaacacctga gtcctagcct tgagtcctgcc tctcacagca gtatgaccct gggcaagtcc	240
ttgtggaata agggcatgga cagaatgatg tcagagggtc cttctagctc taatattcta	300
cagtttcctt ttagttcaaa tttaaagaca aaatgtctaa cagtgggttct tgtttggtat	360
gaccagtgtt gncaaaagag aagttgtaca aagttttttt tgcctgnttt tcatgnatgg	420
gggagggggg gggat	435

<210> 289
<211> 166
<212> DNA
<213> Homo sapiens

<400> 289	
caaacaggaa caaaggaaca aagtgagagt ggagactgct gagtcatacc taggagaaga	60
ctgcaactca cccagggagt gagtcttcac cctaactcac cggggaactg gaccgaccca	120
gacaatttgt taagttctgt ttccattaaa cataattctg agtctg	166

<210> 290
<211> 507
<212> DNA
<213> Homo sapiens

<400> 290	
gaatttatgt tgatgcagtt aactccttgg gccaaacagc actttttggt gcggcggttat	60
tgggccttag gaaattcggt gatgttctgg tggattatgg atcagatcca aatcaaatgg	120
gagccctgtg ttgcacgctg agccccgctc catggaatgc aggagcattg ccatggacat	180
caattgtact catctccctc cccagccgct gctttgatgg gagcaccct gtccatgcag	240
cagcattttc gggcaatcag tggatcctta gcaaactgct ggatgcagga ggtgacctgc	300
gactccacga tgagaggggt caaaacccga agacttgggc ttgacagca ggaaaggagc	360
gtagcaccca gatagtggag ttcatgcagc gctgtgcctc acacatgcag gccatcattc	420
aaggcttntn ttccaactt cttgaaaaaa aaaaactccc cgcagggggt tgtttacagc	480
ccgtcctggn ggggttgggt tcttttt	507

<210> 291
<211> 192
<212> DNA
<213> Homo sapiens

<400> 291

tgaatcgaac	gccacactca	ggtgagntga	gaaaccctta	ccgcgcgcac	tgcaatgccc	60
tccccttcac	tctgcaccct	ccacccccct	gaaattctgc	ccttaggcta	cggggcgctcg	120
tccttttcgca	ccctccccca	tgctgccaaag	ttgtagctat	agctacaaat	aaaaaaaaaac	180
cttgttttcc	ag					192

<210> 292
 <211> 408
 <212> DNA
 <213> Homo sapiens

<400> 292						
gtggtagaag	tctgtcttct	ccccgtgctc	ctaggaagac	cttcatgtcc	tccttgacca	60
acaggggatg	gtggaagtga	ctctgtgtga	cttgtgagac	aagattctaa	aagtcattgca	120
cttctgcctt	gttctcttgg	gataactgct	cttgggaaccc	agccattgca	gtgaggaagt	180
caaatagctc	catggacatg	ccatgtgtag	gtgttctggc	aaacagcccc	aggtgaggtt	240
ccaactgaca	gccaacgtca	accacctgac	gagaatgagt	cttcagcct	tgatctgctg	300
agtcacgcgc	aactccagcc	aatactgtaa	ggagcaaaga	tgagctgttc	tgccaattgt	360
agcccaaatt	gcagattttt	gaataaaata	aatgactgtt	atcattgt		408

<210> 293
 <211> 316
 <212> DNA
 <213> Homo sapiens

<400> 293						
aagtctcagc	catgaacctc	gcagtgaagg	aggaaaacat	cttatgtctt	gttctctaca	60
acacaaagat	gaacataaag	aagaaacaca	gactctggcc	tggaagaagt	cagtgtctgg	120
tgggggagac	tgataaaata	atttaaaaca	tttatttaac	acataattac	agtgaatat	180
gataagtaca	atagctaaag	tgtgggcaaa	gtgtcgcagg	aacaggaata	aagaggagac	240
aacttccaaa	aaaatcttac	atacttaacc	ttttcccgac	attttgacct	gaaaataaat	300
cagcataaca	actcac					316

<210> 294
 <211> 149
 <212> DNA
 <213> Homo sapiens

<400> 294						
gctggtagca	gaatggctgt	tgttattcca	agaggccctc	ccggactata	tcccagtggtg	60
tatagtccag	tgaaacgacg	ggaaaactat	gaccatgaag	caaatctgga	gcaccacctg	120
atTTTTtaag	gtagatttta	ccgaaacac				149

<210> 295
 <211> 233
 <212> DNA
 <213> Homo sapiens

<400> 295						
gaaaagtgtg	ctggctcctg	tcctggatca	actcagaaaa	tgaaacacat	cggattctgt	60
ccaggccggg	cacagcaacc	tgggccatnc	atgtggagcc	tgcaagtaca	acttccgcta	120
tctgcacaaa	actggaggga	ggctgggggt	gctccaagta	taagtttcct	catcancaaa	180
ccggaaagag	aaagaccgac	ctggaggctg	gttatgggga	taaaataaat	atg	233

<210> 296
 <211> 143
 <212> DNA
 <213> Homo sapiens

<400> 296						
tgtacagagg	aagaaccatt	gtgaggataa	agcaagaaga	caaccgtctg	caagccagga	60
agggaaactt	tatcagaaag	caactgtgct	ggaaccctga	tcttagattt	tgtagtcttt	120
agaaaagaaa	taaataattat	ttt				143

<210> 297
<211> 201
<212> DNA
<213> Homo sapiens

<400> 297
gtgatactgt ggctgacagt atttactggt aaatggagtg gaagtgagaa aacaccacag 60
aagggggcac ctanattcga accgggggacc tcttgatctg cagtcaaag ctctatccct 120
gagccctacc ccctctacct gtaataagct tcttccgtgt ccacctacgg tgactcaata 180
caatcaagtt ccacccacac g 201

<210> 298
<211> 77
<212> DNA
<213> Homo sapiens

<400> 298
gctctgatga ttcttaagca aagagatgga agatggaatt tcaaccccat ggagatctaa 60
taaacttacc cagagtt 77

<210> 299
<211> 452
<212> DNA
<213> Homo sapiens

<400> 299
atgaaaaaac tgaggctggn aganggccnt gcccctgccc anantcatgn atntgnccta 60
ngatgggatgn ggaatnctgc cccaccantg gnggcnttat tattacaccc atattacana 120
tntagaanac tgaggctcan cntgggtnc tggccatgan cacacannna gangatanga 180
gaggctggct ctgacctcta tgcncctcct gatccactct ccaaaccctc ctccagtccc 240
ctgctccaag ccatcagtta ggatgattct tataagccgg ggggtgtgaca tgccaaaggt 300
gtctctaccc cacatactcc ctctggaanc aggacaaggt ttgcgtgagg tggacctggg 360
ttctttctgg accagggact ttgcctccaa gctcatttcc tcatctgtaa aacaggaatc 420
caaccaacgt cagcctgaat gggctgtggc tc 452

<210> 300
<211> 434
<212> DNA
<213> Homo sapiens

<400> 300
ttcctcatca gaaggaagta cttcatcaat tacgtcctct tcatattcat caatttcttc 60
cccatcatat tcatcttgc ttcccacatc acttctctgac acctctgcct catcctccag 120
atcgcttcag gagttcttct tcatcatcat cttcatggtc ttccagtgc agatcattac 180
cagagtcact gtgttcatcc tacaaaaatca gcatcatatc caaattaagc agaataaaaat 240
gcgtcctcaa tgaaaaaagg atttataaac atctgcccac atacctcatt ctaggaaatt 300
gtttctgata agatgccaaa cttagaattc tcaagaactg aggggaaaaa aacacttgag 360
ggcagcaata catggagctc aantatgaat acctttggtc ccttctacct cccctnatcc 420
ttttcaaact catt 434

<210> 301
<211> 456
<212> DNA
<213> Homo sapiens

<400> 301
ctctcaatct ggggcatgac tttgaagggg aggttgctaa gcctcctaaa tcccgatata 60
caccaatgcc gtttcccac tcatctggaa acctgggtgg ncctgcccac acgcctgtat 120
gccaatcca cctgggtgct tggcgaccca ccatgccac attttccact caagcctttc 180
anatctgctt tgggcacctg aagacagaga gaatcatctt tcaagagtca gaaactttgc 240
acgtgccatt ccctctgctt agaatgcttt tccctttctc ccaattgcct tatcatcagc 300
ctgggaaaaat atttatttcg gtcctaaaa tctcagatat cacttctcca ggagctttcc 360

cagatgcctc acttgattcc agaaggagct atcgccactt ttgcctggcg agtaccgttt 420
tcaccggttac acttatacgc tatggcaatt tattgg 456

<210> 302
<211> 187
<212> DNA
<213> Homo sapiens

<400> 302
tgactatatg acgtgtgatg gccaagact gagtcaagaa gcagatgcaa gaatctagct 60
gactttcagg aaattagacc ttaaagcgac ttgcaaaaat gaaaaacgaa gcctcttcca 120
aattttttgt tttggaaaat tagttatatt tcataaaaaa cttacattaa agtattttatg 180
tcaaggt 187

<210> 303
<211> 449
<212> DNA
<213> Homo sapiens

<400> 303
tttcaggttt taggatgacc agtgagatgg tcagaacttc agaactttcc aagggtgatgg 60
gtcattcaag ctccaggaac gtcaaggcct caacagtttg gacataattt taagcaacac 120
atataagacc cacagggtctc cactgatatg actggggatc tcatgaagaa actactcgac 180
aaagacagat actggaggga tagaagagtc tatgaagtac agaaaagagg aaagatctgc 240
aaacaattcg gtgtcttctt ttaacttgaa actcattcta cccactgcta cagctaggta 300
ctgtgctctt gctcagattg ctggagggtt ttgttgngat gatctccttc aatacatcaa 360
tactataagt tctataanaa tcatctcaga gcttgtttan aactcatttt ttttcttttt 420
ctgggntatg cccttataat attcattta 449

<210> 304
<211> 309
<212> DNA
<213> Homo sapiens

<400> 304
gtgggggtctt tcaccggcca tgtccctggc tgactgtttt cctgctgac ctgaccagcg 60
tccccggcag ccatggcctg cattcgtgtt ggtccctcct cctgcagccc cgaggaggca 120
gggctgtctg tggatcccag atcggttgtc ggaaggcccg gaagaggaga gctgccctcc 180
accaccactg tctcctcctc ctggacaaca gagtcagaac actgctgaga tggggtgaag 240
cataattggt gcaactgagac tcaaaaactac aggcaagaag gtttgaaaat acagaaacat 300
ttcacgaat 309

<210> 305
<211> 174
<212> DNA
<213> Homo sapiens

<400> 305
gatgatgctg cccttaatgc tcagctgatt acagactaaa cacaaaagtt cccagaggaa 60
aatgggtggac ttgggagctg ctgcctcagg aggatcttga gtgttagtgg ttccctcccta 120
tcagatgtac ctaatgcca ggatttaata aaggatcatt cccattccac cacc 174

<210> 306
<211> 464
<212> DNA
<213> Homo sapiens

<400> 306
gagccccttt cctggacaca ctctgtctt tcccagggaa tgggaagaaa caaaaggatg 60
atgacatgac acctaataag tctggatctg gaagtaagtt tgatctacgg ttcattaggc 120
tgagacagaa aaaaaagaaa gggcccgta tggtcgctg tgtgccaggt atgggtgttac 180
gccactcatg tgccttatat tccctacaac ccctcaccac aatttatcac ttcaaaaatg 240

ataaaagctg	agacttggag	aaactagtaa	ctaacaaaa	gtcacccaag	aaggaggtgg	300
caagctaaga	tcaagcccca	ctttggtggg	agctaagagt	agcccttggg	agagtcattg	360
ggttggctaa	ttcttgccct	tggaacctgt	ttctatctcc	attcagttcc	tttctttcct	420
gtcagttgga	ctgtaaactc	taagatcacg	aaatttcctt	ttat		464

<210> 307
 <211> 481
 <212> DNA
 <213> Homo sapiens

<400> 307						
agctttgcta	gccacgtgtg	gttcctagac	catcagcatc	aacattacct	ggaaagggcc	60
tcttacagat	gcagaatctc	tgccccaacc	cagacctatg	gagttaaaac	ctacgggatt	120
tctagatgtg	cgggagtga	ggagctgggt	gctatcagac	ctcaaggtct	ccaacaggac	180
aagatcaaga	gggattccac	tcccacagac	cactcactca	ccctaggaag	actgtgaaat	240
gcctgtcctg	gtgcttagtt	tgaattgttg	aaagaccatc	tttacggcag	aatgctttg	300
tcatttcact	tgataagggc	cttgggtttc	aagccagttt	actcttttct	gtgagcattg	360
aaagccccct	tttttntttg	ctccgaggca	ggattttgac	ttcaaagcca	aaataagaat	420
ttaggaagaa	aagaaagggg	gggaggaaaa	agggaagttt	ggtccaggaa	aatgaaaatg	480
c						481

<210> 308
 <211> 177
 <212> DNA
 <213> Homo sapiens

<400> 308						
gggcaaacc	atgctttatg	aagcctgatg	cttacacaat	tatgggagcc	ttctttgaaa	60
aaaaaatttc	aaaattacaa	atgcaaaatt	aggtacaaaa	gggaatattt	acaatgagaa	120
atcaccacaa	atggcaagat	ttaaacagct	gacaaattaa	acagcgcaaa	atccagg	177

<210> 309
 <211> 366
 <212> DNA
 <213> Homo sapiens

<400> 309						
gttgcaagaa	agctcaagta	gcctatggag	aggatgcaag	gcttccagct	gatgccctca	60
gccaggctca	gtagcagcca	gaactagcct	accaacgaac	ctgctgatca	tgtgcataag	120
ccaccttgaa	cgtcgatcct	cctgcctggg	ggagccatcc	cagctgatgc	cacatgaagc	180
agacacaagc	tgtccctact	aagctctgct	caagttggat	attcatgagt	gaaataaatg	240
actgttacta	agtaattaat	tttcgggtgg	ctgttatgta	gcagtagata	attggaacaa	300
agcttattga	cataatacat	ctatatcaca	tcctccaatc	cattttttta	agtaataaaa	360
gtgggtg						366

<210> 310
 <211> 292
 <212> DNA
 <213> Homo sapiens

<400> 310						
gacccaaatg	tgaataatgc	caacagcttg	ctgtcagccc	tgaagtttcc	tcagatgtct	60
cataaacact	ggaatcactt	cacacgtttc	tgaaatgtga	ccacctctca	ggaggagttg	120
acaacactga	gtaaccggaa	gggaggaaca	cttatccccc	tgaaactggg	ataaagggtg	180
ccatgaatgc	aagaggtgcc	taaatctctt	ggcatgggga	cttaatgggg	ccttatccct	240
cctgctatat	ggtagcaaaa	taagaaaata	aaaaccaaaag	taatatgcgt	tc	292

<210> 311
 <211> 195
 <212> DNA
 <213> Homo sapiens

[illegible][illegible][illegible][illegible][illegible][illegible][illegible][illegible][illegible]

tatatatatttt cctccatggt cacccc 325

<210> 316
<211> 275
<212> DNA
<213> Homo sapiens

<400> 316
acgccatctc caaatacggg cacattgggg gttagtactt caacatatga atctgaagga 60
gagacacaat tcagtcctta acacagtgtt ttatggattg tatctgcac ttccatctta 120
tcaccaccca aatccagcac ctgaattggt gagtgttgcc agtgagaggg caagagccag 180
aagagcctgc ttctgcttgc agaggatgca cagttgtaat agttcgtttt catgctgctg 240
ataaagacat acccaggact gggtaattta caatc 275

<210> 317
<211> 352
<212> DNA
<213> Homo sapiens

<400> 317
gttcgtgaat gactgtggtn tcanantgac tgccaatgnc gactcctgat accataaaaag 60
gaaagactcc tgtctgaagg atgtgccttt atcccagaca ctgacaaaaca cctttgccaa 120
gagagttcag aaacgactgc aaacccccaa ccaagcaact ggactctgga aaacagctca 180
tgaaatctca gcatctgcct tgtctggtga gctccttagg gcaactcacct ctattacgga 240
ggcttgatgg cagcggcctt gtttgaactc tgtattactt atctattgct gcataagcga 300
attaccccaa agcttagccc gcttaaaaaca acacgcattt attatattca ac 352

<210> 318
<211> 243
<212> DNA
<213> Homo sapiens

<400> 318
tcacaacatg ggggttttggg ttgggttttgg gatgggcaca cttntgcccc tgggacaatg 60
ggaatggtgg nttaaccag gcnttngggg anaanangtg ggnaattcna cccctnnga 120
tgctnacaaa cnttgcaaa tcttancatt tccccctnat tgaaaccggn tgccccctnc 180
cttantaact gcccttggaac ttacctcacc attttgtgtg gccttaaatn aagaatttgg 240
ggg 243

<210> 319
<211> 476
<212> DNA
<213> Homo sapiens

<400> 319
actcagagaa gaatggaggc agaggctgga gaggaggctg aggatgctgg acaaccctgt 60
tgagaaggaa aagccggcac acaccgcgga ctgagctctg cctgcctcac cgacttcaaa 120
gatagcaagc gaccactttt ctaggggaaa aaaactaaca ctcaagttgt gctgatttac 180
taaacaggac gctctctatt tgtgcttcca tttgctaggg gatttacatg tgaaacctcc 240
cccagtgcct atgggagtta ttatcctgct caatccccctc cgcacagagg acaggatgac 300
cgcaagtggg ataggacgct tgggctatct aataaaaagaa ctcttggaat taacacttct 360
tcanggtcga cagacccatg tagcctagta tattccaca tttccttgct attttgaaat 420
ggttcaagtc ttgagacatt tgaagngttt tcttctaagc ttaccgaggg caatgg 476

<210> 320
<211> 66
<212> DNA
<213> Homo sapiens

<400> 320
aggaatcaaa agaaggagga agaatagaat gatttggagg aaaagaagga gaaagtagag 60
gagttg 66

<210> 321
<211> 226
<212> DNA
<213> Homo sapiens

<400> 321
ggtggcccg cctccctggt ccatcttctg agaggagcta taccatttt gcaccctgaa 60
cctccaaact cagaagtctc tgaggagccc tgaataggag aaaatgtggc tgaatatgaa 120
gtggaaaatc agtgtgataa ccaaatcaag atcacgcctc gctgggaccc tgtcacacta 180
aagcttcag agcatagtcg tttttaaaat ctgtaatagt acctgg 226

<210> 322
<211> 465
<212> DNA
<213> Homo sapiens

<400> 322
gaagccaagt gggaagatcc ttgctgggtt ctccctctga ggaagaagga aaatgccatg 60
actcccaact tggcctctct tggaaccata ttttgaggta ccctacttcc ttcttgagtg 120
tcagcagagc aactgtggga ctggcatgag atttgggtcat ttctaggaga gcgaatgcct 180
tttgccctct tgatgagaaa actagacgag acattgttta gaaattcttg agctcagact 240
ttngcattat gacaacgtgc attcaaatct gccccagcca cttgagagct gggacctaaa 300
gocgtgagct tctgggtgtt tatctataac aagcggatcc cagtacctac ctcataaggc 360
tgntgngagg gattaaaata aaatgcatct atcagccagc ttgcaggtct gcacttaaca 420
ggggctcang tgcaatacct tgataagttt tgatagtttg ggata 465

<210> 323
<211> 303
<212> DNA
<213> Homo sapiens

<400> 323
cnaacctgnt angntncatc tnatncaant gtggcaaccn ntnccttgnc cannngetgg 60
agctgacact ttctcaactt cacctggatg gacactgaag tccaggatgg gatctgcta 120
cctgcagctg ccatctccct gccaatttaa ggatgaagcc aatgcccagg atggcagagc 180
tgagagctgg aaggaagcca ggtcctcgct gacattgttg acacactgca tcagccatct 240
ctcagcctcc cacctctaga tttcctgtga cttgggaaaa taaatttctg tatttgtaaa 300
gct 303

<210> 324
<211> 458
<212> DNA
<213> Homo sapiens

<400> 324
aatcaagaaa acaattcaat aagaatccat tttccttggg aacaggacac aattgaaaac 60
actggttatt taaccaaagc ttcatctgaa atggcatatt ttacgggata tgacgagact 120
gctttgagga atttaagtgg acctataaaa gttgataaag agccccttag aaagactggc 180
ctagtacctc atntacttgg ttcccttagg agcctaggan cctnaanatn ttngggggacc 240
tcaagaagag agaaattcac tcattttatg cacatntnac nggcatagtc tangggggaa 300
tcntnggntg gggttccccg ntttnaaagn gtttttaaaa ccaanttnng gggtnttttn 360
taaacatttc nccnaagnn cacctttaaa accctttttg aacncttttt ttttttttgt 420
ntttgcgna aaatccgggn ccnngggaaa aactaaaa 458

<210> 325
<211> 212
<212> DNA
<213> Homo sapiens

<400> 325
gagnnactgc tcaaacaaga acacaaaaat ntntnangat cctacnacag ngggttggnc 60
ncagtgcacg cnttgtatac ctatcagaca aaagaaaatg tcaagcaagt anaacagaga 120

cttagctgtg	acagctaaaa	natttataaa	gtcatgcttc	ccatcnaacc	tatctggact	180
tatcaacagn	atgcntccag	cagttattcc	cc			212

<210> 326
 <211> 483
 <212> DNA
 <213> Homo sapiens

<400> 326						
gtgtagggtct	tgcctttcca	gggataagtg	gccacatagt	tcgccgtggt	ccccgcagtt	60
attccagtac	atgttttata	cttttggtat	gtttgttgat	caagggtgatg	gtgattgctc	120
tcaacacaat	gtctacttct	cctcgacggt	caaggaggga	aatagacaga	gcccagaggt	180
ggccagccat	ggttcctcaa	gacctgccaa	gaagagtgc	ggccaccaga	gtctttgcag	240
gtataattga	ttaaagatct	caagatgaag	tcaccttaga	tttaaatacat	ccacatggag	300
ctgccttcaa	aggcacagct	gcaggcgagg	gtacatttct	aatcccang	actagtggcc	360
ttgttagaaa	anaanaaccc	gggngaccc	ccngagaaaag	gagatgtgaa	gatggaggca	420
gagactggag	tgatacagct	ccaagccaag	gatcaccagc	catttcaaga	agctaggcaa	480
gaa						483

<210> 327
 <211> 272
 <212> DNA
 <213> Homo sapiens

<400> 327						
agatgcagtt	ttgccatggt	gccccaaactg	gtctcgaact	cctgagctca	aagcaatttg	60
cccgccttgg	cctcccaagc	tggaaatgaca	gacgtgagcc	actgcacccc	gccaacattg	120
gcattctctg	ctgccttctc	tggactgagg	aacttcactc	aacaactggg	ctcacagccc	180
tttttccaca	gagattttgt	ggaatagcct	ttttgtctca	tgccctgcttt	tcattttattt	240
gcttggttga	gataaattaa	aagcagaaaa	tg			272

<210> 328
 <211> 450
 <212> DNA
 <213> Homo sapiens

<400> 328						
ntatgacaac	aaaaccaccn	tggggcccaa	acctggaagc	cgncngctat	ggaggaccct	60
ggaagcangc	anagaaaggt	ttggagtgtt	cantgcatg	acaccagcgt	gcctgcgga	120
gnggntgtgt	ntactnttgc	ctccttnccc	acccaattcc	gtcccaggag	cccagggtatg	180
gaggcccaag	anacggatnc	cacaggagcc	agcaccact	ccaccccagg	agctcagcaa	240
acatccacag	agtgaacatt	ccaagcaaca	tagtccagga	gccacgttcc	agccatgggg	300
cctctgcact	gctgtcctct	tcacatggcc	tgcccttccc	ccagaaagag	agaagaggcc	360
ctctctgggt	gtcccatcaa	aactccaccc	ttctctcacc	ctcctcccag	ctgtatccct	420
tctctgcagc	cctaacatgc	attccacttt				450

<210> 329
 <211> 479
 <212> DNA
 <213> Homo sapiens

<400> 329						
ggtgtgggca	cacacactct	ctgaacagca	gaactttctgt	ctgagagtag	aagctgaaga	60
gcagaagaga	cactatggga	atcaggaaaag	aggaggtgat	ctgggccagc	agttgaagca	120
cattgaaaacg	aagaagaagg	ctgacttctc	aggagctgcc	tggatgctgg	cctcctgggg	180
aactggaact	ccagtttgaa	ctgaaattcc	ctgtatactt	gtcaggaaca	tccactggac	240
tgtgggttcc	ttggtacaaa	aactaagat	ccccatgcct	gccacagtgc	ctggagcaga	300
acagacactc	aaatatttaa	taacgtatga	ctgattgtgt	attaccgcg	gcacatag	360
aagacacaca	gggggnggga	ggataaattt	gggttaaaaa	anaaggctaa	atctgntggt	420
gntgcttcac	atganaatga	nagtctttcg	gtttatgggtg	gctccccggc	caaaacacc	479

<210> 330

<211> 171
<212> DNA
<213> Homo sapiens

<400> 330
gaattcatga cactgaagct acccaacttc taccatgcct ataacatgat caccctagga 60
agtggcagag taacccgagg gaagaagcct ggatacctga atgactatat gaaacacagn 120
tgccttaata cctcgcgata ctactacgg aactctgtaa taaagtatat t 171

<210> 331
<211> 251
<212> DNA
<213> Homo sapiens

<400> 331
atgctatcta tactttatgtt aagcatcttc agagacacca tggatgatct tcattctgaa 60
tcccaggaag aattctggaa agcaatcacc tacctcttga tttttctcc gtcagatatt 120
acctaaagat ctttttggga cctggagaaa aggggaaggta gaactgattg ataacttcta 180
tttatataga attaaaagaa tatgaaaagt ttagataaag gagcataaat aaaaaccttc 240
tactggcaaa c 251

<210> 332
<211> 446
<212> DNA
<213> Homo sapiens

<400> 332
gttgtctgcc aacgctaact ggccagctct gacaggagggt gcgtggccca ggaggagcca 60
tcaggccagt tctctgggat actgctgtgt ctccagctct gcagtttgct ctgcgtcact 120
cagcggcaga cggagaggca gacacgagcc ccttgtgagc cctcctcctt accgtcatct 180
cacaatgctc tgaaataagg aggcaaatgg ctgagggtccc ctgagttgaa gatgtgattg 240
agttctatct accagaagca tatgcctcct ggaagcctgg ttctaacacc tctcacaana 300
tccttcaagc acttttttct gttccaaggt ttgcttatgg gggaccnnaa ggaaagggct 360
tnananccct aaagatttgc tgagtcatat gagggggccag caaacttttc ctgtaaaggg 420
tcagataata aacatttttaa gctttg 446

<210> 333
<211> 498
<212> DNA
<213> Homo sapiens

<400> 333
gtgttgatca tgaacatatt tcaacaaaa atagtagagc caaatttgag cattgccaac 60
ctccaccac ctcccttcac cacatggatt tgttccaaac aacttctggc ctttcaagca 120
aggaaacact ctttcaaaa atgaacactt gccatcata acattgtgcc acaggctctt 180
aagacaattt caaatggaaa tgcaacgaag ttttgcta atgtagcatca ctgaaataag 240
tgtagtgtct caaaagactc ctatgtgatg gtgaagaatt aagtgtgtat gtttaggcac 300
aagttttatt tttcaaagaa tatttcatct tgctatttgn cgaatgaaat cttaaggaa 360
aaaaagngnc ttaagttttt ccaaattgca aaaaggaatt accatcttcc cactgactcc 420
atgaatgcc aagtcactga aaactaagct taatgactgt tgaatcaatt tccaaagatg 480
taaaattctg ctttaata 498

<210> 334
<211> 345
<212> DNA
<213> Homo sapiens

<400> 334
gcaaaaataca tgggaaaaaac aaaacaaaac agtgaaccaa gaactcaagg gagaatcttt 60
tgagctcatt ttctgggtga atgcttccct cttaccgcac caccagaaca gaggagcttc 120
caggaagtta gagaattgaa aaatagagaa aaagaatgag tcacaagagg atcttatcat 180
ctgactaagt gggagactgg ataaaagcct tgtaaaatca ttgcagctta tatacatgtg 240

tatggttatac aagtagcatt ctattttctca aattaagcat ataccgcant tatttttgtga	300
gactataaan ttctttctaga aagaaataaa gaacattaaa attct	345
<210> 335	
<211> 297	
<212> DNA	
<213> Homo sapiens	
<400> 335	
aggacttgct cagaacaagg gaagaagatg actatgcagc tgctcggtaa cagcgtctag	60
tcacactctg agatactgag gtcagcaaga acagaggatg cacactatgt cccatcttgc	120
ctttctgccc agaaagtctc agttactgga aaagcttcag aaatatttac caaaaaatcc	180
atgtgaaatc ctgaaattct acttctcaga aaaacagtat tactcttgtc tagaaataac	240
attcaggcct caaagtgtcta tactgtcatt acttctaaaa ataaactgag caaatcc	297
<210> 336	
<211> 175	
<212> DNA	
<213> Homo sapiens	
<400> 336	
tattgtttct aaagaaacta tgaagcaatt caaccagagg agaacaacta ctgtgggact	60
gcagatgata ttagcctgga agctgcataa cctcctacc agatcaaatac attcagcatc	120
catcttaaat gagaaattta agtaactaaa aataataaat ataaataatt aaaat	175
<210> 337	
<211> 496	
<212> DNA	
<213> Homo sapiens	
<400> 337	
attcaagaga gtgccaaagg aaacaacagg acagaaggag acatgaggaa gagatgggac	60
agacagcact caaccctgag cagacgtgag gggcaaaaga aaaggcaaca ttaaggaccc	120
attcaagttt caagtctcag cgtcccagag gatggtgagg atacagcaaa aatggagagt	180
gcaaaaggag aaaggcagtt gaatgtgaag ataacggggc cttcggggcc tacctactaa	240
gtctggtggg ataaccctgt taaatgggaa gagggaggcc tttcttggtta catttttagga	300
ggaaaaaaat ggctgcctgg aaagttcata taccagcagc aaaaagaaaa gcnaaatggg	360
attaaaaaat nttaaaagcc cttcacnagg aggttaagtt ntggcgggtg tgcccatcag	420
agaccagcag agacaactgg ctctccggcc tgagttcgcc tacatcagaa ctagcacatc	480
tctctgtcta atttct	496
<210> 338	
<211> 371	
<212> DNA	
<213> Homo sapiens	
<400> 338	
gtggtcaaat gtgtgggagt aaaatgtgtg tttgaaatgc cttcccagga ctgagtatgg	60
ctcattttcc tccttgccat gagctgcatg tccccatgat tcggggcagc ccgcctaggc	120
gcctgttccct ggctatcaga agagcacagt gaagtcctcc tgcccctgag aagatcgaag	180
actctgctgt ggtcaaggtt ctttctccag ccatatgtgt tgtctaggat tagacttttc	240
aaacagtggc caggccttct gaggtcacat gttagcagtaa aagcaagctg tggccaaaaa	300
aaaaaaggnc ngnggggncn attnannttg gacttaancn gggngnactt nntnaaaagg	360
gggggactcc c	371
<210> 339	
<211> 479	
<212> DNA	
<213> Homo sapiens	
<400> 339	
actgaggatc ttctgaattg gcggcctcta catatgcttc tgctaaggag catgtattca	60

ctcaacaagc	attttaaacc	cccagcaagg	cacaagctac	aagggttaca	agagacacaa	120
gaagagatga	ggtggctcct	gcttcccaaa	gagtgtgggtc	caggggaaagg	aataggcctg	180
gactttctcat	aacctggaac	atcttttctc	gaggccaaaag	aggtgatccc	aagtgaagagg	240
ccaaatccaa	ggacctgtcc	tgcccgatgg	gtgctcctct	gctgagcagc	caaaggcagt	300
gccacgaggc	ttcatctacc	tccaatagtc	acggagtctc	tccatgtgcc	nnttgggttt	360
nntgcnttgt	tttcccagga	aagccttnct	tgacctttca	gatcaagtca	catccacgta	420
ccatgaacat	tcacaccctg	tacctctctt	ttcacagcac	ttatcccaag	agaaactcc	479

<210> 340
 <211> 481
 <212> DNA
 <213> Homo sapiens

<400> 340						
cagagtgtgg	gaccaaggac	aaattacaga	agcacagcag	agaagggttg	ccggttcccc	60
gtttgcctat	gaagttatgt	agtgaagcaa	taagaggaca	ctggagcaca	gcgctgctta	120
gagccgaggc	tcagtaaaact	ttgtttcact	gatgaatgaa	tgtattaagc	tgaccagctc	180
aatttgattc	ataaagaaat	agccttaggg	cttttctgag	gaagaacaca	acatactttc	240
aatccaactt	tttaaaaaat	aaaacatgat	tacacactcc	taaataaata	ttttcagaaa	300
gtttgcctat	atgtcaaaga	tttctaggat	ttggaagcca	gtatgttcgc	aagttgtgag	360
gacatctgng	ttattctcaa	cacttccttg	gcaaaacnan	ngngtcctta	cctgaaagcc	420
tgaaacaata	taaaatgcaa	agctgacatc	cccctgcctc	ggcaactgca	ctttcaccca	480
g						481

<210> 341
 <211> 306
 <212> DNA
 <213> Homo sapiens

<400> 341						
aaggaaagat	ggaaaagagg	agttatcatt	tcttttctcaa	gatcctggcc	ccatgagcct	60
cagtgtagcc	ctagttcctg	ggatcagcac	caacaggcag	ggaggagagg	ctctggcgcc	120
ctgcagacag	caccaggttc	ttggcatcag	gagctggata	cagagtcctc	gataatccca	180
gccacagaat	atttcaaact	caccgacatg	tcctctaaat	atcagatatg	aaaaggcttc	240
cactcttgca	cctgtcttgc	tattattttta	cagatgtgtt	ctaaaagcta	taaagacgga	300
aatcac						306

<210> 342
 <211> 471
 <212> DNA
 <213> Homo sapiens

<400> 342						
ataatacaga	catgtacccc	accacacaca	atgtaaaactg	caaaagcaaa	aaaccgagat	60
gcctcgctca	cagttcaacc	ctctgcgaac	agagccatcc	tggataaaaag	ggctgctgtc	120
atgattgcca	taaactgagt	ggcctgaaac	aacagagtca	gaaatcaagg	catctgcagg	180
gccatgctgt	ctccgaaggc	tcggaatatg	gacccctcct	tgccctcctc	tagactctgg	240
gcaggctgca	gatccagaaa	gccgaagctg	cagcaagtcg	gaaggcgcg	cgcaggagga	300
gttccttcct	caggagactg	cagtctttgc	tcttacggnc	tttgaaaaan	atgggnatnaa	360
nccccccacn	ctatggaggg	taaccgcgtg	cattcaaagt	ctacagattt	aactattaat	420
catatctaaa	aaacagcctc	acagaaacac	cagactgggtg	tttgaacaaa	a	471

<210> 343
 <211> 463
 <212> DNA
 <213> Homo sapiens

<400> 343						
catgtctttg	cagctctttc	caccaagaat	tggagtctat	tttctcaact	cattaaatct	60
gagctggctg	tgtgacttgc	tttggccaaa	aagacttttag	caaataagat	ataagcacia	120
gcagagggtt	gaaaagtgtc	ggttcgctgg	ggcttactgt	attactgctc	ttgaaatgct	180
gagatgacca	tgtgaatgaa	tccaagggaag	cctcctggaa	gatgagaatg	ctgcatagaa	240

<400> 348
gatgatcatt cttgaaacca gatcccatat caagagaaag tcaagtaatc atgaagagag 60
gccacatgaa ggtgttcttg ccagcagtg cagctgaatc tcagttgcaa gccagcatga 120
ccaccagaca gggaagtga caaaccttca acggaggcaa gcccagcct tcaaaccacc 180
ccagccgatg catggggcaa ggacgagcca cactggcaa atgtgccc aaactgcaggtt 240
caggaggaaa ataaatgatg gtggtgtttc cagtcattaa gttttatggt ggtttttaag 300
gcaaccaaag acaactaaga acatttactc tggccaataa aaaaatgaat gaaagtgatg 360
tgtcatttcc atgtggaaag ngttcattcg ccagtagtta agacattgga agcaagcttt 420
tccttcttgg tgcaccaatt angaaaagaa gtggtgttgg gggatgtgcc ctccttcat 479

<210> 349
<211> 614
<212> DNA
<213> Homo sapiens

<400> 349
cagaaactga gccaggctc taccgacctt taaactacaa cagagctttt naggagaaat 60
gcggaagaga cggcntttcc accccgggac cttaccagaa aaccgcgaca cccagncac 120
aattggcttc cttcattcaa gccnagaaaa agggactccn acttttcacc accaggggan 180
gcccccttt cttggtggct tgggccaant tgcaaaaagg cctngtttca ttgggcattn 240
ccacaagggt nggggggaa nttgggnccc ccaacccttc cttcttang cacccttnan 300
aagnggttnc cttnttgttg ggcaagnaac aaccaattg gcnttaagg ttttcttctt 360
ttttnccaaa cttnccttgt ttngggtctt ggggcnnaag gtgggnaccgg aatcaattct 420
tttccacttt gccatttaaa ttnaagttaa gttcaacccc ngaaacaatt tccttaatac 480
cttggggccc ccccaaat tntctttttt aaaaanaacc aaagtttggg cctntcccc 540
ccacttgggg aaattttatt tctaaaatat tngggaacnt tagaaattaa aaanttgga 600
gaaactttgg cccc 614

<210> 350
<211> 380
<212> DNA
<213> Homo sapiens

<400> 350
ataacatgtt tcaaagtggc aaatttcccc taagaattgg aaaaatggat aatacggatt 60
ggggttggag agccgggat tctgattaaa catggaatct gagaactggc agaaagcctg 120
gaactgatgg aagagagggc tctagggcct ccatactaaa tgggtgaacta ggaactataa 180
aagagataat gtggtgaaga gcttcagcca tcaagttatt ctaaaaatga agtagggcat 240
tttatatgtg gagagaagg cactgattat tatctgacta ttgctaata gtcccataga 300
acttatttgg aataattttt tactattaat ttgaacaaca gcagtgaagac tcttttatatg 360
tataataaag ctaattttac 380

<210> 351
<211> 373
<212> DNA
<213> Homo sapiens

<400> 351
gtcagatttc ctgcaaggag gatctacagg ggcccagcac taccttgaag gccgtgaaca 60
gccacagagg gaaagccgcc ttgagtattg agcaagactt cctcagacag gtctcatttg 120
tgtcttccct tccagcagga ggaagacagc acctgcccag agtagtttta gagggcactg 180
cactaaagaa ggagaactgc aggggaagat cgtgccctaa tggatgaaac atttcccaa 240
tggcctggct atctggagag atgaggactt gctcattagt agaagtttcc aggcacagcc 300
tggataagca tttgctgcag ggggtgggga aggtgaaggt tganangana nctctaagat 360
ttctttgcct tgg 373

<210> 352
<211> 405
<212> DNA
<213> Homo sapiens

<400> 352

gctataaaga	cgccttgaat	cctcctccac	gatacccgcc	ccactatttg	ttggcacagc	60
tacgatgctg	cttatggatt	gttttctact	ctaaagacag	tggcgcaagg	caaggtgacc	120
tggagcgagg	ccatcctgag	tgcccaccca	gcgtcccagg	agcctgttgg	aatttggaag	180
gacatttgcc	tctgtttata	aagactggct	ttttgctgaa	agccagggtc	tcaaaaattt	240
tgttttatta	atagaagcta	aaccccaaac	atttggtctt	ttttcattcc	atttcccctt	300
tcacaatctt	aactattccc	aagacaatgg	atacctctgc	ctgtatcaag	ggcngattgt	360
caataanaaa	gtcaacagga	aataaacntt	ntttttttca	aaatt		405

<210> 353
 <211> 464
 <212> DNA
 <213> Homo sapiens

<400> 353						
ctgattttaag	ttanttcnng	gggnccnaaa	cctngnaaag	gttttttnatt	agggcagcaa	60
agggaaaccgg	ggaaccactg	angaggagca	gcagaaaact	tcacagcttc	tttgggtggg	120
cagcagactt	cagatttact	ggaagccaag	aaaggggaag	acagcagcag	gagggcttga	180
ccagctagct	aaataagtta	agccatggaa	agaagcagaa	gaaggaagct	caagaaatct	240
cagcaacaaa	cactcatgga	cttttttcta	aaaatggaaa	tttaaaactt	tctcgaccat	300
gaccacacaag	aaatacattt	tacacgttgc	atccaggaca	tagcaatatg	cctgtgagcc	360
actttgtggg	tgaaggggtt	ncatgggtgag	cttgtttaag	ggaacatggc	cccnggggt	420
nctccttttg	gagattcccc	ctggatttac	tggatcaaa	g	tctt	464

<210> 354
 <211> 446
 <212> DNA
 <213> Homo sapiens

<400> 354						
ggaaatgcc	caagactatg	gccgtgcaac	atttccgcag	tgctcctcgc	tacaaagaca	60
ttccccctaag	gctgggtggc	aactcaacac	tcagctcagt	acgtggtcag	ctcgtcctcc	120
ataggagcct	tatgccttgg	tgaggagatc	tctgaagaaa	ttgctgatga	aagtccaaca	180
ggctcctcca	gtttgtctgg	tcggtcacat	ttgctgaaac	ctggaggaat	tgtagtgga	240
agctcaacag	gcctgactca	gtctgactgt	ccattcttct	ggaagctgca	gagaaaagaa	300
acctggaaac	cctatatgct	gacaaaaagg	gacacaattg	gatatgatgg	ttattttacc	360
aagggttttga	aatgtcgtgc	tttcaaatat	aaacagactg	ctttaangga	tcnaaagtgg	420
cctttttaag	ccaataaaag	ccctgc				446

<210> 355
 <211> 446
 <212> DNA
 <213> Homo sapiens

<400> 355						
cagcccagac	gtggtcaaca	agaacactga	gcagaaaaac	aaccttgagg	atgaaaacag	60
ggatgttctc	agttgaagcc	cacactagaa	gagctattta	aacagcacca	aagtgctggg	120
attacaggtg	tgaaccgctg	tgctgaccc	agtgtttcta	aaatatctac	aaaaacagtt	180
tggagttagt	cctaggcaat	gctttgctgg	aatgggatg	tgtgatggac	cattctaagg	240
gagctgaact	ggctgctgtg	aagacatcag	gaacccaagt	gagactgtgg	tacgtaagtc	300
aggaagaagg	cacttgcttg	gttttgaaaa	catgtcctgg	ggatggntag	tgccnncagt	360
tcacaaaaaa	agcaagctgc	cttgtttagg	nangganmca	accanttgaa	aacacctcca	420
ntactgccan	tanaaacagt	tgattt				446

<210> 356
 <211> 450
 <212> DNA
 <213> Homo sapiens

<400> 356						
aggctgagaa	gtccaagatc	gagggatctg	gcagcagatg	agggcctttt	tggtgcacca	60
gcccgtggca	gaggggtggaa	gggcaagagg	acaagaaaga	ataataaatc	aaacttacag	120
cctcaagctc	ttttataacc	agcatcaatc	cattcatgag	gatggaacac	tcatgacctc	180

aacacctccc	tttaggctcc	accttccaac	atttggtaaa	ttggggatta	agtttctaac	240
acatgatttt	gggcgggata	cattcagatc	agacccaaaag	ggcaaaggga	ttttgtatac	300
acagagaaga	agttgatgtg	aagatggagc	agagagccgt	ttgaagatgc	tagccttgcg	360
actggagtca	tatggctaca	atccaatgga	tgctggtaac	cnccaaaana	tggangnggc	420
ccggacnaaa	attcncncct	ggaacctcca				450

<210> 357
 <211> 460
 <212> DNA
 <213> Homo sapiens

<400> 357						
gtccttccag	aagagcactc	cccatcaacc	cgcgggcagc	tgaattccca	cctcagactc	60
tgctccaagg	gcgccgtgtc	tacggaggcg	acgctgagga	tggtttatca	ggttgggtca	120
ctcacccac	cacgaggacc	tgaccttaaa	ttctcgggtg	atcctaagtg	tgacccagag	180
accgcctgcg	tcagaagcac	ctagaatgct	gtggaagcac	cttcaatgca	gattcctggg	240
cccaaccctg	gttccactga	atcggggtca	gctgggtggc	ccaggaattg	gcattttcaa	300
cagcttccaa	ttgtacacca	gaataactca	gcttgtgact	cccctgctca	ctgntttctt	360
catectttct	cacttctctg	tgagtacata	tgnattttac	tactttttaa	aganactttt	420
accaataaag	gccggccttg	aaggggaaaa	aaaaaagcca			460

<210> 358
 <211> 419
 <212> DNA
 <213> Homo sapiens

<400> 358						
gaccgcaatg	ctcctacgat	gacctgttaa	cagaggtatc	ggacaccaac	cntgggannc	60
ctccttcaaa	ttatgggaca	tcaccaacaa	tcaatcacta	agagaagaaa	taatttagaa	120
gaagaattca	tttttggtta	ctcaaataa	acccaattta	aaggagactg	ttatttctct	180
tctctagtaa	gctacagaca	ggatctgtct	cctttaataa	gatgcttggt	taataacatt	240
tatttacaga	gtaaaatttt	ctctttatct	ccctccacac	taaaatattt	acataaaactc	300
aaaccactta	tgttgccctat	tccaaccagt	ttcttgctcag	agtgagtagg	aaaattcttc	360
attaaatgtc	attgcctttg	gggnaaacag	aacataaatt	aaaaaccccg	ctttatttta	419

<210> 359
 <211> 455
 <212> DNA
 <213> Homo sapiens

<400> 359						
gccaaagagat	gcaaaggatt	aatcatgaac	ccagttgccc	agaggtggaa	aaaaaaaaatc	60
tggttggtgta	gactgaagaa	gnagaagtt	atatgaacac	caagaggccg	gcaacatgag	120
tgtggcctga	gtctgacgcc	ttcgcccacc	ctcttccaga	tcacctgac	cgaagaaggt	180
tacgaaaata	gtcanaaatc	tgggcctgcc	tggaagagac	ataaagattc	atttacatgg	240
gaaggtgact	gctctgaata	tccacagacg	acgaatctat	gctaattggt	cagtctccca	300
caaactctggg	atttatataa	ctggctccta	cccttggttc	ttgccagcag	aatgcttga	360
attatcttaa	ttccagaatg	naaattattc	ccattctgan	ggcntcattt	ttaagctggc	420
aaaggncatt	tttttnacag	gcctaaaaaa	aaatt			455

<210> 360
 <211> 465
 <212> DNA
 <213> Homo sapiens

<400> 360						
atgatgtcag	aagtgggggtg	caaagtanag	gcttctgaca	acccccggga	gtactgagtg	60
aacaagcaag	gtatctgcag	aaccacttg	tgtccaccga	tctctcagag	tgcttgagga	120
tcatggacaa	cagaatgcag	tgtgagggat	gtcaagtcac	ctgggaacaa	cactttctta	180
agaattcatc	tcaatttctg	cgtttttttg	aaaggtcctt	aattgtttgc	tgctctgca	240
agctagacat	ctctttcagc	aaatggagac	ccagatgggtg	aggcaagaga	aggaatgacc	300
aaattaatga	aaatgttctt	tcagcttggt	attgagcttg	ntattctcct	gaatgcttgc	360

tctgcgactg ntatgctaac tgaccctgtg ggtaaaanga gaaaggaata tctcnttttg 420
ttaatttaaa aaatantaat aattgacaaa aaaaaaaggc ccccg 465

<210> 361
<211> 332
<212> DNA
<213> Homo sapiens

<400> 361
gctgtaggat gacgcgatg gcaagtctga agttgtatgt ggccatcttt gccaccacat 60
tcagaaagct tacctgagaa tgaagtcaac actggagaga aagagaaaga aagagggaga 120
acatatcaga atctctccac aatggcaaca aagatgggtca ctagcaagtc caagcctcca 180
ttctctttta aacttgcaat ccttgaggac aaagaaaaac gatctttttt tccaatatct 240
atgttacttc taaaagaagg nattaaggaa agcctgnatg aaatttcatt catnantcaa 300
gaccatactg gccttgaata aaatttataa gc 332

<210> 362
<211> 293
<212> DNA
<213> Homo sapiens

<400> 362
ggagatcggg tggaaagaca gtggactgat ccaagagccc agtcttgatc agcccagact 60
gaggggacct taagagatgg gaagactgac atttacaact tccccaaactg gccgtgatga 120
tcttaagtac agccactgag gaagccaact taagaatctc ttcttgacct tgctcagaat 180
tctatcatcc ttcttctctg cccaaataaa attccactt ccacaaaaaa aaaaggccan 240
cgnggccaat tcagcttgga ctttaaccagg ntgaacttgt tcaaaagggg ggg 293

<210> 363
<211> 466
<212> DNA
<213> Homo sapiens

<400> 363
ttgtgcgtca ctgcaagact gcatggtaat gaagccaagg cactgtgggc caaaactctg 60
ctgcctgtga gaagagaagg gacagcggtt tggagagaca gaacggcaaa accgctgctg 120
ctgctgcttc tgcttctgct gctgctgctg ctgctgctgc ntttgcagct gattgagaca 180
ctatgttgag tctacaggat tctgtgtttt ttgaaattag cataaagtcc ttgttaaagt 240
cctggagcag cagctgaagc caagtaggct gccaggcag tcagaagaac agagcagggtg 300
aagctgcaca gcatgcagtg gtgtgtcttc ttttggggcc aagcctgatg caacttacta 360
tttgccaacc cccggtcatc ttcttcttga gtaaatggcn ccactatcct atgagtgatt 420
caagtaaaaa tgctcttcag cgccagtcag caaagtaaat aaatca 466

<210> 364
<211> 283
<212> DNA
<213> Homo sapiens

<400> 364
tcacgaacaa tctggatttc atgtcacaag aggaaacaga gtcatcactt caagtactgc 60
accaatcaag tctgttcttg taataatgtg aggcattgct caagacctcg atacatgaaa 120
gcaattactg cagatgcctg gctgttggca ctgttcagct ttaatgtagc agtacagaaa 180
gttatgcctt ccacctgtga tgactgatcc tagaacctgc agacaatgag tctaagctga 240
atacaaacaa taattatcca agtaaagagc ccttgttcaa ttc 283

<210> 365
<211> 407
<212> DNA
<213> Homo sapiens

<400> 365
aatgaagat ggcattatgga aaggcgattc ttatactcag aaggaaaagt tcccatggaa 60

gccatggatt	cattcatgac	aaagtgggtg	gcctgtttgt	ttgcttgaga	ttggcaaaaa	120
tccaaaatgt	ctgtgcacac	tgctgggtgag	gctatggtaa	aacaattaca	tattttctggt	180
tggtgtgtcc	ttgtgaagtg	aaatttggca	gtaagtaaca	aaattactca	tgcatttccc	240
acggatcagc	atctccactt	gacataaaat	aaatgctaga	gatacacatc	tacaggtagt	300
aactacaagt	tctgtagtat	acaaggatac	aggtaattta	ttctgttgtc	tatgatggca	360
taaacagctt	aaagtgctta	ttaataaggg	gcctggggtt	gttaaag		407

<210> 366
 <211> 466
 <212> DNA
 <213> Homo sapiens

<400> 366						
agcatgctgg	acagcctgga	gctggagccc	acctacaacc	ccttgcatgt	tcaaagccac	60
ctgtactcac	acctgagcag	catctatgcc	aagcctcagg	ggcgggtcca	cccacactgg	120
gagagccgag	ctccgagaaa	gcatccctgc	aagactgggc	agttgcagac	caaccgagct	180
cgagctactg	tggcccccct	gcctatgact	cctgtcccag	gcagagcctc	caagatgccca	240
gcagccagca	aatcttcctc	agatgccttc	ttcctgcctt	cagagtggga	gaaggatccc	300
tcaaggccct	aagtcaccag	caccagagcc	cagctgccc	gcttaaccat	attcatgctc	360
aggttcacat	aatgggctat	ttngngtcaa	gacttgcttt	tttttcccn	ggganccttt	420
tntnggggag	ggnnttnattg	ggaaaanaaa	nagcctttcc	ttgtcc		466

<210> 367
 <211> 475
 <212> DNA
 <213> Homo sapiens

<400> 367						
ccattcccaa	atgcgttacg	taggtggaag	ctgggtgagt	gtcaggaaac	taaactctgc	60
aaaataagat	gacaccctct	tggaagattc	ggaaaagtgt	atcagacttc	aagagccagc	120
tcagctacta	cttcaagcta	acctttcttg	agacctcccc	tttacctgct	ttcatctgtg	180
ctgcccgttg	acttaactga	atcacctagt	ggactgaatc	tggccaaact	ccagggccac	240
ctatcatgag	cagccttggt	tgctggcaat	ttgcagagtt	gcaaggggta	aaggactggc	300
tttgactatt	cagtctttca	gttcacaca	tcttgctg	atgactgcag	tggccactaa	360
gctggtcaca	gagtgagctt	tcttaaatgc	aagtgtnaag	gatngnnaaa	ccctcaaggg	420
gctttnantt	tttccaaggg	ccctgtncct	tggaggggca	taccattgaa	gggta	475

<210> 368
 <211> 466
 <212> DNA
 <213> Homo sapiens

<400> 368						
ggctgggacg	atgaaatgtg	atgggctggg	aaactcaagc	cngccccag	gtgggaatca	60
ataaagggga	ncgggtggtc	tttggcttat	tggtntggcc	caagcctggg	tcttcaaaac	120
ctggggccctg	gaaatcaaat	ggctttccca	ccctcaagct	tggcccagaa	gggaaaccgg	180
ggggaattac	cagggccctt	gaanccact	ggcaggccca	gccaggtnt	tggttaattt	240
tttaaatggt	aaaaattctt	taantaaaaa	caaacctcaa	gggaagctct	ctttgtcnen	300
ttttaaaaaan	cccatTTTTna	aactttcttg	cttaaatccg	ggaagnngta	atatttcaag	360
nggcaaaactt	ttggaattct	tgtggcctcn	cttgggggaat	gccaattccc	ttcaaagcct	420
tgggcnccca	aaaataaaaag	gtcttccccgc	ttgattattt	aaaacc		466

<210> 369
 <211> 475
 <212> DNA
 <213> Homo sapiens

<400> 369						
aagccaaaga	ttttgcagaa	tcaaggatgg	atggagtatc	aaaataagga	acggaaaaaa	60
ctgaagatat	actaaggatt	aaggcccagg	ttcatctagt	gtccccaggt	gccaggcatt	120
gtgctgtgac	tgtgatgtga	aaaaagaggc	caggacaact	gggtctcatt	cagtcagact	180
ggagtgcagt	ggtgtgatca	cagctcatgc	agccttgacc	ttccagactc	aaacaatcct	240

<400> 374
ncatngtnng ggagttgntg naaccactgn ctgactcttc atancaccnc gcttttncct 60
tggctctcna cactgggtgg ggagccctac nttccatgaa gncttggcaa acnggggtgga 120
tcggmntctg cntatcacag ccatacaatg actcttcagg aggaaatacc agcctagacc 180
tgctcagggc ttaccaaacn gtgacnatag gtgaggtgna gccagactag actnacacca 240
nttcggnatg atctgacgga anggccggca gaccctatat cctcagatgt gtcccatcc 300
acctggcaca tgtctggaac ttcncattac agagggggg 338

<210> 375
<211> 412
<212> DNA
<213> Homo sapiens

<400> 375
caacctcgaa aatgtccaac tgcaaagacc catgtctaca aattgctgtc agccagagga 60
atggctgtaa cttccttggg gccgaggact ccctgctcag ttctactta cagtatctga 120
gtcacttaac taaatgcaat cggcccagct gcaggcacca ctgctcgggc cactataaga 180
accagcccct gagcttccgg acaggaaaca gcactctgcat ttccagactg tagcagctca 240
tcattgccagg ctccacaggg aagaatcaag cagatggaag ctacagagga aacaaacagg 300
gttccttgaa atcagcagct ggggagaatt tatcttaciaa ggggtggaatt cttgattctt 360
tcattacatg tcctcttgca gcagcagcaa aagtaataaa aaataagagc cc 412

<210> 376
<211> 416
<212> DNA
<213> Homo sapiens

<400> 376
ctcagggccc taggggagtc acaaaagatg aggacacgtg aagactacag ctgcaggcct 60
agaagactct ctcaagaaca actgtcttgg attcccacag ctttcccctt tctgtggtca 120
ccactcagga ctccctaccc tgccccacaa gcctgcagat tctgagatga cctggaagga 180
acggaacagg aaggcgtgag ctttggcacc agtttaacgt agaactgtac gggccaaaca 240
cagggccttt gattatagaa aaaaataggc ccattgtctt ggtgggtgga accaaagcat 300
agcagcatct aagaaaccag tttctttgtg tccagtgatg agggccttagc cctaaaatat 360
tanggtgggg agggaggagg ggtgaaanng naaacatact ttaataaaat agatta 416

<210> 377
<211> 253
<212> DNA
<213> Homo sapiens

<400> 377
tcaacagtca taactttttg aggacacatg tttattgctg ctgctggggg cagctgctct 60
tgtaccact ttcaaattgg ctgtggaaga gacaaagctc atctgggtgc tggggcagtg 120
gcctcctcat gcaagctggg ctactgggtg ctgccctgt gacctgcttc tgaatggcca 180
gtcagaaaaa gtctcccat gtgttgcat taaagaaaag aaaaagatga attaagtaaa 240
aagctctgca aac 253

<210> 378
<211> 303
<212> DNA
<213> Homo sapiens

<400> 378
gctgaaatga accaaccatca gcagaggccg cggcagagtg agagagctgc ccatgctggg 60
agaagccctg gtctttgtct ccacaaatgc tgaaactgac agtgtttctc ccagagtcca 120
agtctccatt agccaagcca agagcagagg aaatgttctc cactggagga aagaagaact 180
gtcgacacca gaaaatttcc tgctggaatt ctgccaaaga atagctggcc gtcctaggga 240
ggtccatcat tacggaactt tgctgtttgt aaatttaata aacgactcac atctgcttat 300
aat 303

<210> 379

<211> 382
<212> DNA
<213> Homo sapiens

<400> 379
gtgtggagca gagaaaaggc tatacccact gatgaacagg gatccacacc tggggaagaa 60
gcaagtatga ctttctctcc tgtggcttta cacaacctcc ttgaaattcc aagagcaacc 120
ctcccagcta aagtcttctc agatgtgaca cgatctgcac aagcagaggc ggcacagggt 180
ttggcttcca gttgggaaat gaagctccaa gggcagccct actatggcgg gctgtgtgac 240
ctgggccaaag ccccttgaca tctccagact cggcttccac atctgccacc accaggacac 300
tggattgaat gttgggtacg ttgtaaggca agggagacac agaagtccta aaggcaataa 360
agcttttccc cactgcccct cc 382

<210> 380
<211> 364
<212> DNA
<213> Homo sapiens

<400> 380
agactgggtc tcactacatt ggccaggcgg gatttgaatt cctgggctca gcctcccgag 60
tagctgggac tacaagcatg taccaccatg cccagttttc tgcagcagtt tttataaacc 120
aaattttcca aattagaaaag actgaccaa gaagcacttt tatacgagga ataacttacg 180
tatggagaat ctcaacttgg accagtcaag accaactcca gcgatgaagc cagaatgtaa 240
tatatctcaa aaggctaaag aagtccattt tcccagatgt aaattataat taaaaaatag 300
tgagccaaac tctaatatcc caatgtgata atctttcaaa taaaaatatg ggctgtagtt 360
cagg 364

<210> 381
<211> 318
<212> DNA
<213> Homo sapiens

<400> 381
aaatgttaag ggagttaatc ttctacaagt ccagtcattg gctttcacia agggccaaga 60
aaggagtccc aaagctcgcc atgactcaac aggaagctct ttgtgtcttc ctttctacac 120
catgtctgac aaagaagctg tcttaagtcc atgggcctct gtctcttgcg tgaattctga 180
agtcagtga gcaacaatga tgtcattgct tctgaagacc actgttggct gagataatga 240
agatctcttc acccaaaaca ttgccatttc tgcagcatac atttcctacc ctttcaaata 300
caaaagtatt ctaccgat 318

<210> 382
<211> 463
<212> DNA
<213> Homo sapiens

<400> 382
ccagcagaca tcaaggactt ctgaggagcc tggtagcttg cataggcact atggaccctg 60
ttttgcttaa cccaccaaac agccaatttt agcagacatc ctagtcttgc aggtgagaag 120
agctgaggta cgaagaagtt ttgttaattt ttccagttca cgtaacaagt aaatgggaaa 180
ccaggatgaa aatcaagggt tatctgtcgt cagactgtta ctcataatca ccattcggag 240
agttcanatg tgggacaaga ttctaactcc nnccttctcc caaatgggta atntgccagg 300
tgccctanag ctacatattg tcttatttgt gtgatnnact gannctgnct gaatnttana 360
agccttgtat ctnttgnant nncaaanaca naagagnccg nggggnntat ttaaattnga 420
antnaaccgg cctgannngc cnaaaaanggn ggggcttccc agg 463

<210> 383
<211> 220
<212> DNA
<213> Homo sapiens

<400> 383
gtggggctct tcagtgaag cactcaagca gctctgtgga gaggaaccat cttgccagct 60

ccaacatgcc	agccatgtga	acaagcccag	gtggcaaadc	accagacctc	agtcaagctt	120
tcagatgacc	acagccccag	ttgatatctg	actgtaacca	catgaaacac	caaactctgg	180
actcacagaa	atcatgagat	aataaacaat	gattgttttg			220

<210> 384
 <211> 434
 <212> DNA
 <213> Homo sapiens

<400> 384						
gcaaagaaac	aaagaggaag	gtgtggatgc	tcacccagaa	gtcttgtctc	ctcgcagtcc	60
cttagaagct	caatcctcag	gagacagtgc	actggggggt	gccaaagggga	cctgaaatac	120
cggtttgcca	caatcctgac	caaatcgggt	cccaggggtg	agaagggaga	aggtgtcagt	180
ccattcaaaa	cccatcgtgg	ctgattttga	agtggaaaaa	gaaaaaaaga	agcaaagaaa	240
agcattgctc	agcaatgggc	aggaagaaga	gttaagaggc	tgagctcttc	ggcaagaaat	300
gccatagctc	tttcaacttg	gacagagcca	ggaccacagg	ctggttgtgt	caaaaactgg	360
gtgttcttgc	ttagtgcata	aggtttggtg	gttttctctc	ctctttcctt	gagccctggc	420
acttggggac	cctg					434

<210> 385
 <211> 268
 <212> DNA
 <213> Homo sapiens

<400> 385						
attgtgaatg	ccagcagaa	agctgacccc	aaacagcttg	aagaccccca	caacagaact	60
gaatcagcat	gaaaatgcag	tttctccacc	tctctgttcc	atgacttcac	cctgcactct	120
tccaccaatc	aatgggtctc	acactttggt	cgacacaaaa	acgcttaaga	acccaaccct	180
agccccaaat	tccttgggga	gacagatttg	aggagtcttc	ttacctcttc	atttggcagc	240
cttaaaatta	aaactctttc	tttgcttc				268

<210> 386
 <211> 542
 <212> DNA
 <213> Homo sapiens

<400> 386						
gtgacatggc	ttacaaggct	acttgtaatc	aacttctcat	ggctcatccc	catttgtgcc	60
ctgaactcca	aacgtactga	gttacctgca	gttctgttaa	tccagcatga	ctttgtcctc	120
caagcctttg	ctgtccccc	tcctccttca	gttcttagct	caggaatcat	ctccatcaag	180
gtttccctga	cttctcccat	ttcccaagtg	aggcggttcag	agagtcctgt	gcttaccttt	240
ggggtagcac	ttacatcctg	ctccctaact	gtctgtagaa	tcctctgtct	tcgctgtctt	300
tgagcaccct	gagggcaggg	actgcagctg	ttatctgggt	acatacaaca	ccaaataaca	360
atgcctaagg	catgccagat	attcaataaa	tgtctgtgta	agaagcaaat	gtttaaacat	420
ttccttcccc	agcatgcctt	ctctgactat	ccccacctcc	ttccagaagt	actcacctaa	480
tccatgcgga	caccatagac	caagtgcatt	tataaaaactg	gtttataata	ttaaatgggt	540
ag						542

<210> 387
 <211> 282
 <212> DNA
 <213> Homo sapiens

<400> 387						
gtatantant	tcttatangn	nmgnnnnnnn	nnnnnnnnnn	gggatgctcc	ttcctggacc	60
cagccaccca	ctgggaaaag	cctaagccac	gtggagcanc	tacatagaag	agggccgggg	120
ccacagctac	agccagcagc	tcttgccagc	cacgtgagag	agctaccttg	atgttccagc	180
ctccagagat	ctaagagctt	ccagacatct	accaccccag	ccacaccacc	tgagccaatg	240
tcccacagag	tcatgggaga	taataaaaag	ctgttgttct	ct		282

<210> 388
 <211> 263

<212> DNA
<213> Homo sapiens

<400> 388
aggcaagtgc tccgttgccc aagctggcct ccaactcctg gctcaagtga tcctcccacc 60
tcggcttccc caagagatgg gggtacaggg atgagccact gtgcctggcc tcacaagatg 120
ttgttatctt tgttttacac tatcaatgcc catgcgtcct tacttaatta ttaaccactg 180
tattgctgtt cattcttccct gcatttcata tcttccatca gggatcattt ttcttctaca 240
taaaataaat catttgtaat ttc 263

<210> 389
<211> 292
<212> DNA
<213> Homo sapiens

<400> 389
gtaatgcttg tgggtgtcca gacagcagaa tgtgagtggg acatcatatg taccacctct 60
gggcctggac catagaactc acacataatc cttcatgttc ttatgtgacc acacagatga 120
acaaagcaag ccaagtgtgg aaacgtgtta aagatgacgg aaccacaaga tggacaagc 180
ctggatccct gaatccctcc ttggaggatt agtgcccaca aattgtaaac agccacccag 240
atctcagcga gcaagaaata aattatacct gaatgtttta aaaaaaaaag gc 292

<210> 390
<211> 244
<212> DNA
<213> Homo sapiens

<400> 390
gattgtctcc aatttacctg gaccacagcc agcaccttat cctcaggcac cccatgggac 60
agtacataca gaagaacagc atcacaccac atcctatcac caaggccagg attctgtgcc 120
tccgcccccc tccccacctc cttgaaacgg gggaagtagg gggaagagtc aattcttctt 180
ggagcacatg agatggtagc ttgctgtgtt gtcctgaaag aaaacaaagt ttgtaaatca 240
ctgt 244

<210> 391
<211> 436
<212> DNA
<213> Homo sapiens

<400> 391
ctgaggaata tatgattggt ttcttggaac aatttcacag ctggcatgga actgaaaccc 60
tgctactcag gggaaattag gatcagctct tgtccagttc aagctgactc cactgagcct 120
ccaatggcct gtatgaatgc ccaatgagtg cccttttgac atcagaaggc caaaaactcc 180
accctcagat tgtgccaacg acaccatctt gcgaacgtgg atcctatgaa aagccatgaa 240
gcttaactgc actcgcacag atcagcaatt acctcacttt tccttaccac caattaactt 300
tttccatgca ttggctgcct tgcttcttta ttccacaaaa atccttatgg cccactttc 360
aaggagggag aaatttgagg gnggttatcc cacctcctca cttggctgcc tcatgaataa 420
aatcttttct cctgc 436

<210> 392
<211> 178
<212> DNA
<213> Homo sapiens

<400> 392
aggctgttgt gatattcctgc atggacaagg aaatgatggt catctaatac acccacttgg 60
gaacactttg atgcattggc tatgattgtc tttctgtttt ccctaccctc atctctagcc 120
ctgtccagat atgagaacat ggaaactcat tttggaaaat gtgaaatgag tgatcccc 178

<210> 393
<211> 263
<212> DNA

<400> 398
 gttggagatt acatgtctaa atcttgttca cacctatggg attggacaaa attttctcat 60
 gaaactaaga gaacaggcca cagagtgtct tgcaatctat gctgctagca agtgtctttc 120
 tcatgcctga tgttatacaa aaactagcaa taaaggctta ttctttcct 169

<210> 399
 <211> 224
 <212> DNA
 <213> Homo sapiens

<400> 399
 gaggaaaggc tggaccctgt atttgtgttg tgtaccctca ctctaggagg tgtcttcaca 60
 ctaagagatg gccactcagc ttctggcatt atcactctgc atctactttg ccaagcttct 120
 tcttttgaaa cgtcttgtgt aggcagtagt taagaatatg ccaccagaa gaataccaga 180
 tgaataaact tacaatatatt ttgaataaag ctcaatctaa caat 224

<210> 400
 <211> 466
 <212> DNA
 <213> Homo sapiens

<400> 400
 gagctgatac tctattaatg gatctagtgc ctaaatacaaa agaacagaga gagtctgtat 60
 aagcaaaatt acctgaanaa aggtncgaaa aactgggtccc aggnccntaa aatgctgngc 120
 tnnnaaaang nnatntnggn nnaaaaaacc ngnnancccc ttctctctct ntccagaaac 180
 ctanaattna cgttctacna ctccacaaac ccaattccaa ctctcttnt taatatgtgt 240
 aangngtata tgccccatgg gccttctgga tgtgttcata aattctgaaa aactctgaac 300
 tcggaagctc agtgagcccc aggggttggg gtaagatat acggacctgc ncttnagcca 360
 aaagtgcctn cgctcactct actactgnc tactgncct gacggngat gtcccncaaa 420
 gccncttgc tgtggggcag gggggcccc tgtccttttt ggggaa 466

<210> 401
 <211> 350
 <212> DNA
 <213> Homo sapiens

<400> 401
 gtgggggtctt tcaagctcag gaacaaagcc ttagtcccta caggagaaag gcaatcctaa 60
 ggagagcggc gcctgaacct ttctctacca tcaagaactc aagaactcag cctaataaat 120
 gtgggcagaa ttcacataca ccagctccag gcctggccca taacacttcc tgcatgatct 180
 gggatgcaaa cgatccagtg gaggcctccg agggccctaag gatgaagcag ctggagacag 240
 aagggcctgg gtccctgaat ggctgggagg aatagagccc cagtgcagtc tacttgaccc 300
 cccaccttga ctctgacata ggcagaaata aatttttaca ctctaaaatc 350

<210> 402
 <211> 133
 <212> DNA
 <213> Homo sapiens

<400> 402
 agatgtatca aatgggagac ggccagcagt gatcaagtct tgattaatac tgaaaaacag 60
 aagcttgtgc tcacaatccc tgccattaca attctttata gtatgtaagt actttaataa 120
 acattatgaa gcg 133

<210> 403
 <211> 330
 <212> DNA
 <213> Homo sapiens

<400> 403
 gaaggaggat atccctgcga tcaccaagcc tctaccctta tcttccaaac cagtcactta 60
 ccacagatgt cttgtcaagc tgaatatcct ccagatctga cttctttcct ctactggtgc 120

tcaataacaag	atgcttttact	ttgtcacaaag	aagcatataa	taaactcaaa	gtgcaagga	180
tatatctgta	agggaaattt	tttcttgatc	tggctggcct	tgaacataat	caccagaaag	240
actttttgtg	ctcagatatt	atggttgtaa	atgaggattt	ttttcctcac	ataagaatgt	300
atctagtcca	ttataaaatg	ttattgatgc				330

<210> 404
 <211> 242
 <212> DNA
 <213> Homo sapiens

<400> 404						
tcctgtgcct	ataaagaccc	cagactcagc	tggcagaaga	gagaagcagc	ttgactggag	60
aaagatgatt	cgacttcagt	gggacagcta	gacttttgag	gacagacggc	tttaacttcag	120
ggaagagcca	gctagtgaca	accggacttc	agggaagatt	acctgccccaa	cctgacccct	180
ctccagctcc	cctctctgct	gagagcaact	tctatcacta	agtaaaattt	tctacctcca	240
cc						242

<210> 405
 <211> 289
 <212> DNA
 <213> Homo sapiens

<400> 405						
atgggaaact	gaggtccgtg	aagtcacttg	cctggatcac	acagctcatg	accagtatgg	60
gtcggcctgg	gacacaggca	ttctggggct	caccaccagg	tggtccacgt	gtcaccacta	120
gacctcccaa	ccaggagacc	ctgccgctgc	cccagcctgg	agacgtgaca	cttctcccag	180
ccaggaggct	ccagtgaaac	cagggattcc	ccaggctcac	cctgactcct	catcttgтта	240
acgtatttaa	tcctcatcct	gtacatgaaa	taaatatttc	atctcatct		289

<210> 406
 <211> 436
 <212> DNA
 <213> Homo sapiens

<400> 406						
caaaaggaaa	gtcacagcca	gagaacgtga	ctcccgggtga	gcctggagcc	agcgtgactg	60
cagagggcca	gtccccaggt	gatgccggta	cgctggagaa	ggcctgggaa	gatgtgcgga	120
gacagacacc	tgggacacct	aaggaccaag	cccagagcca	cgctgctgct	ttcccagctg	180
ccactgggct	gcatgaaggc	agaacatctc	cagtgaagtc	aacattcagc	tccaacctta	240
agcctccacc	atggccaaga	aaggcattgc	tgctggggga	gaaatggaca	ttaacactgc	300
ttcaaaaggg	tgctgaaaaa	cacccttcat	ccccgatggc	ttagcttggtg	gaattcacgg	360
gtacttgcat	ctgaccctca	tgagtctatg	tagaaaaacc	tggttgagga	actgtttggt	420
gacaccacaca	tcagct					436

<210> 407
 <211> 179
 <212> DNA
 <213> Homo sapiens

<400> 407						
atatgtttgt	ttattcgaac	aggatgcagt	ccagtcttgc	tgacttagga	tgacagcaacg	60
aggcactatc	atggaagtcg	aaactgggtc	ttcaccacat	accaaacctg	ctgggtgcctt	120
ccttgatctt	ggactttctca	gcctccanac	cngtaaggaa	ataaattctt	tttttaaat	179

<210> 408
 <211> 419
 <212> DNA
 <213> Homo sapiens

<400> 408						
agcttgtttg	aagtgagtgt	ggtctttgct	caccagaaa	cagttgagga	ttgccacttc	60
ctagctgcga	tatgcccgaga	ttgttttaag	ccagccaaaa	acaaacagtc	tgtattcact	120

agaatggcag	ttatgaaagc	cttgaataag	ataaaggaag	aggatttcct	taagcagttt	180
ccttgctctc	caaactcacc	aaaggctgta	tgcgctgttc	ttgaaattga	atgtgctcat	240
ggtgctgttt	ttgtagctgg	gagatataat	aaatactcca	ggaatctacc	acaaactcct	300
tggataattg	atggagaaag	gaagctggaa	tcttcagtgg	aagaattaat	ttcagatcat	360
ctgttggcag	tattttaagc	agagagtttt	aatttttcat	cctctggaaa	aaaaaaaaag	419

<210> 409
 <211> 409
 <212> DNA
 <213> Homo sapiens

<400> 409						
gaacccagtg	gctctgagct	cagcacgcga	tgcacccagg	aatgtggcct	tacgtttgta	60
ctgtgcccac	cctgcgaaaa	ctgggaagaa	atgaagaagt	catcctcttc	ctgagacaga	120
gccagcagc	cttggggcgg	ctgagagaag	atgggatcca	cgtggcccat	agcgcacccc	180
acaggccttt	tctgggaaag	cagtcttctc	tcggggaagg	gagagacacc	tgccgaggac	240
ctgccagggg	ctctcgact	gacgctgctg	tccttaatgc	ctcaacagta	caggcaacat	300
gggctacgct	gagcccctgc	tctcctggaa	gtctgtgtatt	ttgggtatttt	ggcaggtgcc	360
aggcagaggg	tgccctaagac	cagccccata	aagtccttgg	gccttcccc		409

<210> 410
 <211> 443
 <212> DNA
 <213> Homo sapiens

<400> 410						
gccagcatgc	acggcgacac	cogtanctgn	cgtctggagc	tccaggggtg	ggggaattgt	60
gttacgcatt	gcctgtcact	aggtatgagg	ctgcctccga	tttccacact	nagaatcang	120
gctgcagmc	cctttgtgcc	catggctgnt	gatgcacaca	ggattcttnc	aaaacaagag	180
gccctactct	gtgactgtna	gccttgccat	caacactnct	ntttggagna	nagctncctg	240
ntggccctga	ggcaggagnn	ttctgagatc	ttnacntatg	ctgggcttga	tccangcctc	300
antacaggtg	aagaaacgga	ncctgtaaaa	ntgaagtggc	ctgcttaagg	gccnnggctg	360
aaagtctgag	gcctggtttn	aanccaaacc	cnggcaaggc	ttttgagaac	tccacnnttg	420
ctgccatctt	acgtccaggg	agg				443

<210> 411
 <211> 96
 <212> DNA
 <213> Homo sapiens

<400> 411						
agattggaga	taacttcaat	tggattatgc	ccctgggttc	ttatcctgac	acttcctgga	60
tgatccatt	acaaatacat	gtgatgacat	ctgttg			96

<210> 412
 <211> 306
 <212> DNA
 <213> Homo sapiens

<400> 412						
acaggaaata	tgctgacacg	ataataagat	gtgagggagg	cacatcttaa	acttttgtgt	60
gaagacccaa	tcatcatgct	gacgaatcac	aaaaagatca	gtaaagccca	cccactctca	120
cagggtggtg	cactgtggct	ccatcacatc	agctagacct	ggccatgcag	tcccaacttg	180
ttacctacag	ttccagctgc	caactcaggg	catctcactg	aatgaaatac	ttgcttcaac	240
attgaagatg	tttctctg	ccactcagag	gaaacaccct	ataatgaaca	ataaacaaaa	300
ggactc						306

<210> 413
 <211> 219
 <212> DNA
 <213> Homo sapiens

gcttaaaaag	tctttgttgt	aaattaataa	attaatccaa	aaccaccaca	ctgctatttc	240
ctcctacctt	tcttcctgtg	cctatcataa	gctgtatcac	ctggggaaaa	aacatttttc	300
agctaaattt	agaacaggga	gggttttggg	ccataattcc	acttctagta	atagattcta	360
aggaaataat	cagatttaga	taaagatagg	ngtatgataa	tattcaggca	atggggtttt	420
caatagtgga	aaggtgggat	caacctaatt	tgaaaaatag	cca		463

<210> 419
 <211> 474
 <212> DNA
 <213> Homo sapiens

<400> 419						
ctctttactg	gtgagaagat	agcaaaagct	gaagcagaca	cagaatccac	aagtggaaaa	60
tacagcagtg	ccattaaagg	agtgggcatg	tggcctattt	ctggccctat	gaagcaaaag	120
gagaggtctg	ctgggagact	tcctgaaact	gctcttcctg	gaaggaggga	aacaaacaaa	180
acaacaacaa	aagaacttta	caagagaaag	ctttttatcc	cagccccctc	ctactcccat	240
tgaatgcagc	tctgtgagga	cacgatattt	gaagctgcag	tagctgaggt	ggcaaaagat	300
ggcagaacag	aagagcagac	agaatctggg	tcctagatga	cttcattgca	ctgntgcaac	360
tgnctntnnc	agancntntg	gcnnngggna	aaaaatnaaa	nggcntcntt	gnntaanccc	420
ctggganact	anattntggt	ctttgccact	gaatgcatcc	taatgctgga	actg	474

<210> 420
 <211> 477
 <212> DNA
 <213> Homo sapiens

<400> 420						
accttngcnn	gaaacatgaa	tgctnacacg	cagtgggtgca	ccacangcta	ttgcactnag	60
ngagagcccg	atttgttngc	tttnggcccc	tggantggaa	tcccagnggg	aagatngnna	120
tgagagttna	ggntacggga	tgttntctata	aatcagacgt	tgctgncttt	gatggccnna	180
nctnacttct	gnacaggntc	aatnaaaagn	tgatnantac	tntcaaanat	gtgatctncc	240
tgaagttaa	natcatgcna	ggagatgggg	tcctgttcca	tggagaagggn	ggggggggag	300
accacatcac	cttggaaactc	cagaaaaggga	aggctcgnc	tacacctcaa	tttggngngt	360
tgtagttctc	cttgaagagg	tccttcacat	cccttgtaag	ttggaaaaac	attccatgct	420
catgggtagg	aagaatcaat	atccgtgaaa	atggccatcc	tgcccaaggt	aatcttgc	477

<210> 421
 <211> 292
 <212> DNA
 <213> Homo sapiens

<400> 421						
gtttatttgc	aagatggggt	tgagggaatc	aaggataaag	tctgctgaaa	gtagtaccag	60
cctctggatt	aaaaggggat	tttggatgaa	gcttcaatct	caagaagagg	caagagaaaa	120
ctaaagaaaa	agattattct	acagaaacaa	cacatcactg	gatgcctctc	accatgcaat	180
cctctgtgca	cttgagaaga	agacaagact	ctcctatttt	tagatgggaa	agctgaggca	240
aaacggatgc	acttgggcaa	aatcatttga	taaaaatgga	agctgaacct	cc	292

<210> 422
 <211> 98
 <212> DNA
 <213> Homo sapiens

<400> 422						
agagctgact	ttaanaggat	caagaatata	tagntggatg	gaaggagggt	aaactcaaag	60
gacatgtcat	gaattcctga	accacaataa	atctgtga			98

<210> 423
 <211> 103
 <212> DNA
 <213> Homo sapiens

<400> 423
aaattccnng gactaancnt gancacaact ccatcggtt tgaagattct gtgccttcta 60
nttctgccta agaataagaa gaacttaata caaatggaaa att 103

<210> 424
<211> 376
<212> DNA
<213> Homo sapiens

<400> 424
gctacctctg ctcactctgc cctgataaca ctgaatacag gaactgtctc catcaccag 60
aactcccga accaagcact cagcccgaca cgtcactatt attaaaaaca cggagggtcgt 120
gagtggattt ccacgtattg ttctagatga tggagaggcc tgaagagtga ggagtgggga 180
agaaatgtca tcgctgtttt cactctgcacc cttgtttcag agaagtgaat agtcattcat 240
ctctgggtcaa caaatgata atagtagcag caacaataat attctctttt tttgagcact 300
tcttatgtgc caagtacttt atgtatgcat tatcataaat aaagcttttc accattncct 360
taattctttt attttt 376

<210> 425
<211> 78
<212> DNA
<213> Homo sapiens

<400> 425
agaaaagcaa tgtcttgag tttggtggga gagagtatgc agtcaccaac atggcatgaa 60
tttaggagtg aataaacg 78

<210> 426
<211> 330
<212> DNA
<213> Homo sapiens

<400> 426
tgtgaggggtg aggacctntc ctggctttca ccttcaaccc tcacctcacg aaggaggaag 60
gtgcagatac tccatagggtg cttaggagtg tnagtgttna gngactgctg caagaaaaga 120
ggagatacga tctgatcact tagacttcaa atccaaacct tgaaaagtcc caccagtggt 180
aggactcttg ccgccttgag agaacacagc tgatgtcccg aagcaatatt gntaactnta 240
ccaataantc caatcaaacc ccaaaaaaaaa aaggcccggn ggcccattta ncttggant 300
accaggctga acttgnttaa aaggggggga 330

<210> 427
<211> 291
<212> DNA
<213> Homo sapiens

<400> 427
tgatcctaga ccatccccct tcgcccctgt tctcaactgg ctgggaagat tcaagagagg 60
cttccaacct gctggcagtg acggatggca gtgcagaggc acacaatggc aagtgcaggc 120
gctgcaccag ccttgagctt ggccttccaa agaaagaacc aaagtccaag tctgtcctga 180
cagaggctga tttaattaag gttatagcaa agggcagaac tgctgtggg ctgcattctc 240
tgcagagggc caaagacaat gcattaaaat acttctcagg aagaaaaaac c 291

<210> 428
<211> 304
<212> DNA
<213> Homo sapiens

<400> 428
attttctcatg gaaaaggacg gcctggagcc tttgaacagg gtctgtgtct tcctcctgtg 60
tcagcaatgg gggaggaaaa cgagcgcact acgggggtaa ggaggtcacc caagatctca 120
agttcacgag tggcagcctg gattcaagtc cctgcctgcc tccagaacct gagctctgaa 180
acgctggact aatcagaacc tcttggccct gaaaaatgag gcctattgaa cagagacatt 240

tgtaagaaaa gggactatta caacctattg taaagtaaca agcaaataaa aatgaaatg 300
gccc 304

<210> 429
<211> 248
<212> DNA
<213> Homo sapiens

<400> 429
gcgattactt taaaacatga aagaaattgc accttttcct taagggcaag atggtgctgt 60
gggctttcct ctctcctgat gagatgatgc aaatggactc catagagaaa cgctgcccgt 120
gtaacaatgc agttacgcaa cccggtgcat gacacatgaa ttgcagcgca cctgagatcc 180
tgatgaaatc ctgggagcct ggagctgtca aacatggttt taaaaaataa aggggaatata 240
cccagccc 248

<210> 430
<211> 460
<212> DNA
<213> Homo sapiens

<400> 430
ctgctccgct ctgtccggag gcttcctgaa ggccctgtgt ctcacctgcc cttagtggga 60
aacctttctat tcatctgac tattttcttg tgggggtggt caaggggccc attatgtctc 120
catctccctt tccaagctcc aaagatnadc tgttatgggg gcttgccatt tgtaatctcc 180
acaaaaaat tcattattgt tggaaaagct tggattattg gattttgggg gaccttgtgg 240
ttccttgccc aaaaatccca ttgtccaaaa ccgccattg gtgggatggg tgggtggcttt 300
tcccttttg cctttcttg catggatttg gaaaaagttt tcccttggag ggccctcccc 360
aagaaaagcc caaagaaaag aatggcccgg tccattgcct ttccttggta acaagtcctt 420
tcaaaaaaaa cgaaatgggt gtccaaattt aaaaatcctc 460

<210> 431
<211> 176
<212> DNA
<213> Homo sapiens

<400> 431
tctcagcgga tgatcttadc tcttgcctaca tctagaaaat ggaagccatc agactccatc 60
ttctcaccac tgaggctaca aaagatatct acacctgcaa ccctttccct tttttcttc 120
ttcccttttg ttatgatgta taaagtgtcc cttatctgat aaagagctaa tcattc 176

<210> 432
<211> 301
<212> DNA
<213> Homo sapiens

<400> 432
gtgcctcggg atgggaaact tcctaagatg ttgttttggc tgtaaatcat ggggccctct 60
cagagcaatg catttggtgt atttgcccac ttgtgcatga gtacagtcag catggaaatc 120
cagttcaaac tgcagaagat cagcacctgt gagctgaaat gtgcatgtgt attttacagg 180
gtggaggata gtgaagacag attcaagcga taatacatca ggtttaaatc ttctataaat 240
gagattggat tactgcagct gataaacatg gaaatgagta attaaaacat ggtgtgtaag 300
g 301

<210> 433
<211> 443
<212> DNA
<213> Homo sapiens

<400> 433
ctctttcaga tcttcaagaa tgtttaagca tacaagaag ccccgagacc acaaggggtga 60
gaactacat cctccccgct ctccggatgc tcccacagcc tgggctcccc agtgacagagc 120
cagcaccaag caggagatgc agtacagtgt gccagagacc atggcagcca tcacatatgc 180

cctccactgg	ggaacaagaa	gtgcgtagg	ctgatgtact	ccactccacc	tccatacgtg	240
tttgtgcagt	gacaccagcc	tggagggcct	tctatcgcca	tctccctcct	ctgtaaatic	300
taccactct	ttgagtcttg	gncccagggg	ctgntgctct	ctntntctca	aatgatttct	360
gtgttctcat	ttgtctctgc	cttctctggg	aatctttggg	gccacagggg	aatctctctg	420
gtgtcactcc	tgacttcgga	agc				443

<210> 434
 <211> 288
 <212> DNA
 <213> Homo sapiens

<400> 434						
ccgtgcttcc	caccaagggc	tcttggatgg	aggtgtcaag	gtgtgaagac	acagcccacc	60
tagagaggag	agactgctga	cctgctaact	gaaaatataa	gcaagccctg	acatgccaca	120
ggccgtcggg	agagacattt	gcttttgagt	accagcgcta	ttctactctc	tgacttatgt	180
agatggggaca	aatgggtgcc	tgggcacact	catctacaca	tcagcctgaa	ttagctagta	240
aatcacaact	gcagtagcta	ataacagcca	taaagccttt	tgaatggt		288

<210> 435
 <211> 383
 <212> DNA
 <213> Homo sapiens

<400> 435						
ataacagcac	tatgggaagg	aggaagaatt	taatgaaagc	ttgtacctgc	tggctgaaac	60
taagcagcct	atattataaac	tgctctgaaa	tgccagggag	caggtaactc	ccaaatgaaa	120
aagcaagcag	gtctctccca	ccatcagtgg	gatggctgag	ctgtctgtgg	tgccctttgca	180
tcttgctgct	tcgctgacct	tgaaggctctg	ccccagcctc	aggcgaccaa	gcctacagcg	240
acctcaagga	gcagctgcct	catcagtgt	tgtaggaggc	tcaggatgga	gaggggtctg	300
atgcccccat	tttgttccct	tcttttgtct	tcttttgact	tccctaggga	agggaaaatg	360
tgctatgaag	ttaaaagagg	aat				383

<210> 436
 <211> 251
 <212> DNA
 <213> Homo sapiens

<400> 436						
atagaaaaga	agataaacac	tcaccgcaga	gagttggctc	catgtggatc	tcaatggctt	60
atggtgaatc	acaatttttt	catctgactt	ctgttctttg	ggctctgact	cttcatcaga	120
atcaatgtca	agggccttct	ccttgtagtt	ttgatacagg	acagcatttt	ctgcaagaaa	180
acaaggccta	tgtgtcacta	attgtttctca	atcattatgt	tacttgttct	aaataaacat	240
catatgtacc	c					251

<210> 437
 <211> 220
 <212> DNA
 <213> Homo sapiens

<400> 437						
gtggcttgaa	atttgaaaca	ccatatgaag	gttggggagt	ctcagggaca	gccagctgg	60
ggatctgaag	ttgctggaga	agattttgcc	taggctggcc	agcaactggc	agacaagagt	120
catcctttca	caatgctgga	gacagtagac	cttcttcagg	accacaagca	agtcaccatc	180
tctgggtcac	agcttctctca	attaaaaagt	tagaagatag			220

<210> 438
 <211> 229
 <212> DNA
 <213> Homo sapiens

<400> 438						
gccctggcaa	cnactattgc	cttttctgct	tctttgagtt	tgactatcat	ggatacttct	60

acaaatattg	atthttcaaga	tcaggaaaaa	taccgggacc	agaagacaaa	tttcagagcc	120
acctaaattg	tggagtctaa	taaaagattc	ctttctccta	atgatgtgac	catccaaagg	180
atacactctc	agtgtaaacg	taaaccacga	ataaaatttt	atcatcacc		229

<210> 439
 <211> 309
 <212> DNA
 <213> Homo sapiens

<400> 439						
cagttttctg	cacctgcctt	ggtatttgac	aactccagcc	aattttccac	ttgcttcctc	60
accaatgctt	cttcagcttg	aagactaaca	tctagaagag	tcatgaagtc	taaagtcaag	120
aggagtctta	tcttctagaa	agttttttcaa	acatcccaac	ctcaaaaagt	ttggctaaat	180
ggtgttcttc	tacagcccca	cacatgcaaa	catctttatt	gcacttgtgt	cattatthttt	240
tcttcgtata	tgtgnttttc	tataagtaca	tttatatgaa	ggnatatttt	gaaataaaga	300
cacttctc						309

<210> 440
 <211> 756
 <212> DNA
 <213> Homo sapiens

<400> 440						
ntcaacaaac	ttnaacttnc	cgggnttgaa	aggacaaaac	ttttttcggg	gctttttcng	60
tggggggaaa	ncaaacgggt	ttnaaataaa	ctnttnatat	anaccccccn	cncctttggg	120
aaatcngggc	catttnacna	aaaaatgaan	tnggcnccca	agggttttcc	gggcccgttt	180
ggggtggnaa	aaggctnttc	cggttttgac	tgggggcaca	aacaaaaaca	aatccggctt	240
gctcttaatg	cccggccgtg	gtttccggct	tgtcaagcgc	aaagggggcc	ccccggtttc	300
ttttttgtca	aaganccgac	cttgccccgg	tgcccttgaa	atgaaacttg	caaggacgaa	360
gcaagcgccg	ggctatcggt	ggcttggcca	cgacaggggc	gttcctttgc	gcaacttgtg	420
ctcgacgttt	gccacttgaa	ancgggaaag	ggactggctt	gctattgggg	cgaaatgccc	480
ggggcaanga	tctcctgtca	tctcaacctt	gctcctggcc	gagaaaagna	tncatcatgg	540
cttgatgcca	atggcgccgg	ggtgnatacc	ctttgatncc	ggttaccttg	gccattcann	600
cacccaaccg	aaacanttgc	attcgaaccg	aacacgtacc	tcggaatgaa	acccggcntt	660
gtccaattca	agaagatnct	ggacnaaaaa	caatnaaggg	cttcgcgcgc	acccccaact	720
tgttcgccaa	ggcttnaaag	gggcgcattg	ccccca			756

<210> 441
 <211> 599
 <212> DNA
 <213> Homo sapiens

<400> 441						
ccctgtgtga	ctcatggaaa	acagggagtg	acgggtcaag	cagagaggaa	tgtgaactta	60
gtgggtaatg	ccataaacct	ttggccagga	cataagcagt	agaagcagcc	tgcattgtgc	120
atccatgaga	aggccccgct	gtgactgcag	aggcaggaaa	ccaggtgtca	gtggagacaa	180
aggagtccctc	ggcgcgtgaa	atgggacttg	gagcaggggc	cgacggggagg	ggacagagga	240
tggctgccag	ccagacagtc	ctaactcggt	gaattcagtg	accacagcat	ccccgggtga	300
cacggctgtg	aggccttcag	agcatcacca	ttcagtcacc	cctttttaca	ctgggggaaac	360
tgaggctcaa	ggaagttaaag	cagaaatgcc	tttagcctgg	gcaagaaggg	acctgtccta	420
nccttgcat	ttgggagcag	tgtttcttca	actacctaen	gcaaangacc	catttggggt	480
tcaacctctt	atcttgttca	nactgatagg	ttaataagaa	acaataaaaa	tgatttgccg	540
ggcaaggngg	ntcacacctg	taatnccacc	ttttggagnt	gaccgggcag	ataacctga	599

<210> 442
 <211> 512
 <212> DNA
 <213> Homo sapiens

<400> 442						
caagaacttg	agacggggat	cttccttttg	taccgggccc	catngnttaa	nnnnngnatt	60
ccnacntttt	tggmagtccg	aggcgggncg	ggntcacgaa	ggccaggagt	tcaagaccag	120

cctggcctat	atggttgatc	cttctagtct	cgtggcagaa	ctttgtagac	accaagcgag	180
aggggcagcg	tgttctggac	ctcattcctc	acacagggtc	cacctccgga	tgagtcagag	240
gccttagccg	gtggcccagc	ccccgggaatg	ccaccccggg	tctgtaccct	gccaggcca	300
gctgacaggg	tgtattgggg	cacacacctg	cagcatccag	ggcactccaa	ggagagggac	360
gtacttttga	ggagaagtct	aaaagtctaa	gtccaccacc	tgaacttggt	gggggaangg	420
cttctatacc	aagagggctc	ccgcctgtt	cttaaaagcc	atttaagcag	aatgacgtgg	480
ctcttcaata	aagtaaaaat	gggtcatgct	gg			512

<210> 443
 <211> 223
 <212> DNA
 <213> Homo sapiens

<400> 443						
gattgctccc	tttgggagac	accagccacc	attccatgag	ggcactcttg	gagaggttca	60
aatggaaaga	atctgaggtt	tccactaaaa	gccaatacta	tcttgccagc	catgtgagtg	120
agtcaccttg	caaattggatc	ctccagccca	tcaggtctac	aaataactga	agcctcaagc	180
tgacaacctg	actgtaatct	cataaagtca	taattgacca	act		223

<210> 444
 <211> 618
 <212> DNA
 <213> Homo sapiens

<400> 444						
gctggagtgc	agtggcagga	acacggcagc	ctcgatctcc	tgggttcaat	cctcccacct	60
ccgcctccca	agtagctgga	actacagatt	ttaacaatca	gactcaggtc	aacagtgggt	120
gagataatgg	cccataattg	gtccagaaat	gcaaactgtg	catttctcca	ggattccatt	180
agctcagaat	gacaagggtg	ctccctgccc	ccacctccct	cacaagatgg	ctccccgggg	240
cttctcttga	gctctgtccc	tgtcctgcac	ctccctgttg	ggacggctga	gctgctggtc	300
ctattggagc	agcatgaaca	ccttgctggg	tgttcattag	ggagaaaagc	tcatgaagga	360
atgaatcaga	gttggatgct	atgcatataa	atatttaggc	ctgtaagggc	ttctcttttg	420
tgatctgatt	ccaccacata	ccaggtagct	cagcataatt	caaacattcc	tgcaggaaag	480
ggtcataatc	tctgctctat	taaagtcctc	tttatccttt	aatgaaatc	tactcacagt	540
cctgcagatg	aagactactt	nctgccgatg	accacagcgg	ctaagangct	gaggcaggag	600
accgcttgac	ccagaagg					618

<210> 445
 <211> 459
 <212> DNA
 <213> Homo sapiens

<400> 445						
agtggggctc	cgtttggtg	cctgtttact	aaacgtttca	gaagccggaa	gaaaatacat	60
tgttgagaac	atagcaaaag	cagctcttct	tgacaaaaat	ggaaagaaac	atcctcaagt	120
ttcagtgctc	aatatatttt	ccgatcaaga	ctacaagaga	tcagtcatta	caatagcaac	180
ttctgttgat	aagttgggtg	acaagcgcaa	ccaagcctaa	aggcaagtgc	tgttgcgagg	240
tcgacatcca	ggaaccagag	gagggcagag	caatccacag	aatggatctg	gggtgactca	300
tggaggaaaa	ccaacacaca	gtaccattta	attcttttta	aaaagatgga	aaattatacc	360
ataccngaa	ttactaaatt	cttaaaagag	ggggtttntn	gcattccatt	tgnaaaanaa	420
ngtttcccca	tgttctttta	aaaattcatt	ttaaacac			459

<210> 446
 <211> 403
 <212> DNA
 <213> Homo sapiens

<400> 446						
gccttcagac	tcagattgga	aactacagca	atggccctct	gtctctcagg	cctttgaacc	60
acaccactgg	ttttcctggg	tctccagctt	gtagatgact	aatcatgaga	cttcacagcc	120
tccataatcg	gaatgaaaac	aatggctagt	cctggattgg	tcattcttta	ctttgatgag	180
atgctgaaaa	tgaaagccag	gactgagggg	agattgaagg	agtctgaacc	tctgacaaca	240

tggagtacca	taccaaccct	ggactatcta	cctccagact	tttacaatgag	taagaaacac	300
ctagtttgnt	caaaacagta	ttaatttgga	tctttgntac	ttgcagttaa	acctaatacct	360
gaaatacctg	cattctcttg	aagtaaattg	ctttcaaaaa	cct		403

<210> 447
 <211> 635
 <212> DNA
 <213> Homo sapiens

<400> 447						
tncannctg	aggcccaatt	ctgtnggaat	tgctttttta	aaaaaanttn	tangnntnan	60
ttngaantnt	gcctgtccan	atttgnnggc	cagagattta	gaccctcatc	ctcaaggcct	120
tattcctcac	aaaagccata	tgtaaaaactg	gctgctccac	aagggtctggg	atcctgtgtg	180
tctcattccc	cactgtgtca	tcaagtgcc	agcacaaaac	agagctcagc	aaatgcttgt	240
cgaataaatg	aatgaaaacg	tgctcagcac	agggaggtta	aggcaccagg	accccatgga	300
gagagagtac	atgctgagtt	ggctacatct	gtgccaaact	gtgaaagatg	acaatggaga	360
tattttctctc	tacagtttct	gaagatggac	ccagcccaac	acttctttcc	atgcttggct	420
gtttttaact	gcaggcacag	cactagctgg	tttgtctcaa	agattatggg	tcaaaagaga	480
actgagagac	aggcaagtat	cccncgggt	ggacatactt	tacttgccgg	caatacatag	540
tgtctcttctt	gcctgacaat	tcgaacaagc	agcttgactc	tgtatttgag	gccccactcc	600
cttttggtcta	actagaccan	actaattttac	tcatt			635

<210> 448
 <211> 81
 <212> DNA
 <213> Homo sapiens

<400> 448						
actgaggttg	tgaggaacc	cccagacacc	cgccccgggc	atgctncaca	cangnggcgt	60
gccccctgca	caaaaaaaga	a				81

<210> 449
 <211> 616
 <212> DNA
 <213> Homo sapiens

<400> 449						
gttttgaaatg	gtgctgtttg	gtcacaacat	ccacttgctt	tgaggtattg	ttggccttgc	60
tctgctnaca	ttctgagaga	tctgcactcc	aggcaccttc	tgaggacatc	aagctcacgt	120
tttacogtgc	ccactgaatt	tgccaccct	ccccctcta	ctgtgcttct	gcgctacaac	180
tgccccctcg	tttattcaaa	catggagttt	tctttcctat	ttatttttgt	ttgctggcat	240
tttttagagat	gagactgcag	aagaactttc	ttactatgcc	attttaaaca	cagctatctc	300
atgatttttg	taaaatccag	atataattgn	tgnccttttt	tattcttgcg	taaagtgtga	360
aatcttgcat	accttcatgg	nattttgtaa	tcagccccac	ctatttcatc	ttcatcttct	420
gctgcttnt	cccacaactt	ttgtttggct	acaagatgat	atcataccaa	atcctcagtg	480
gcaaaatgtg	tttctnctga	attcataaca	taaaaaaanc	cattaaaagg	ggggtangca	540
tacctgataa	ctattactgg	aataaaaaacc	cggactcacg	ccttagaaan	aaaaaagggtt	600
atcaaagggc	aacaaa					616

<210> 450
 <211> 617
 <212> DNA
 <213> Homo sapiens

<400> 450						
tgctgctgga	gctgattccc	ttccccctct	catctnccac	ctnctttcag	tntcacatac	60
acacacagat	gctgccacag	acacacgcga	gcgcaaatat	ttacacactg	ccacaccgaa	120
gaaatccatg	cacgttttcc	tgcaaacgcg	cgcgcgcaca	cgtacttcgg	cgggcgcgca	180
cgctctctgt	ctcaccaaca	gacacagaca	tttacacttc	taggccagga	aagcgctaac	240
cagggccctg	tgactctacg	caggttccag	aacacgcctt	ctacatttgt	tactgaaccg	300
atcagcgaac	acagacaaac	gtgccaacac	ttaaagtcta	ctggctggac	ttcatctnca	360
tggcaacaaa	gcatggaang	naaagagttg	atttcagaag	gaactgngaa	gaagcncaac	420

aatnggccca	gtgataatga	gtagnaccta	tgnggggactc	ttnancttaa	angantggca	480
cgaaagatta	nccttnttat	tgctctngac	aaaaaaantn	gnntttnttt	tgnggggaat	540
ttgggnatct	tcttggggact	tnnttttttc	cgatgggctc	aaatcctggg	ngacccttnt	600
tgngngcatgg	ctcaatt					617

<210> 451
 <211> 203
 <212> DNA
 <213> Homo sapiens

<400> 451						
ttttcagatt	cttcagcaa	tgtactacaa	atctctgggg	aaaaggaacc	atgtgccct	60
gccaaagatgc	ccagtgcagt	accagcaaga	tggccaacgc	ctagagctcc	cttggtgatc	120
tgaaacctcc	ccttttcctt	acttctccct	ctgttcagaa	tgtgtagact	tctctaagct	180
ttgttaaacc	tgtttacaac	ttc				203

<210> 452
 <211> 445
 <212> DNA
 <213> Homo sapiens

<400> 452						
gtgttggaag	gatgtcagat	gagagctggg	atggggagag	gaagtaagga	ggaaagataa	60
gcagctccct	tccattctga	cctgctgtgg	caagaatccc	gggactagca	agaccaacag	120
gatgcagctg	gcttcactga	acataatttg	ctattagcat	cttcaggaac	acacactgct	180
ggataaattc	ccttccagga	gaggccacaa	ctgaccacta	catggaagag	acagctgctt	240
cttcactagc	caatgaggca	tccccaccca	agtgtgacca	aatgcctctg	aggctcagcc	300
cctcactcca	gaatgcccc	aggtacctga	ggatgctcca	gatttggggg	ctgcaccgtc	360
tgtggtttct	ctacattaaa	cagtattttt	gtggagtcag	gggtgagggg	gtatgggtta	420
cttttaata	taggtttgcc	aactc				445

<210> 453
 <211> 460
 <212> DNA
 <213> Homo sapiens

<400> 453						
gggcctgaga	atgtcactgg	ccagaagaag	ttgagtcctt	agtgtgttga	cccaccagtg	60
ctctcactga	ccaactaagt	gactgggtac	aaattaaaga	ggagaatttg	aatgtctggc	120
tgtctgggaa	ataaaaaggtc	agagagttga	ttagcaccat	caagcccaa	taccagaat	180
catggagaga	aacagtggct	cggacctcta	agcggcacct	ccaatgactt	tcctgcacct	240
tgggggatc	cctcgcccca	ttttttatcc	cattgcccct	tctgtgccag	tctcttcttc	300
tgcgaggaag	tggtttgaga	accctaaaaa	cgaatccaag	gaatcctttt	tgtttggggc	360
agttttctgc	aggcaacatc	tgtgtgcac	ttagttgtca	caggtctggt	caaagttaga	420
gatgaataaa	ttttaaaaat	aaacaactac	aaaaatacac			460

<210> 454
 <211> 261
 <212> DNA
 <213> Homo sapiens

<400> 454						
gccctgccac	catgccatga	ggaaatggaa	agaccacgtg	gagtgggtcac	atataaatgt	60
tccagccacc	agcctcagca	gaggtccag	cccacagtca	gcaacaactc	cagacacgtg	120
agtggcagca	agatgatgcc	agccgcagtt	accatctgat	tacaacttca	taagaaaccc	180
tgagcaagg	ctgcccagct	gagttcaagc	aacgccccag	acctgtgggt	gatgataata	240
aaattattgt	tgttttgagt	c				261

<210> 455
 <211> 591
 <212> DNA
 <213> Homo sapiens

<400> 455
gaaaagacag aagctgattg aggtcccagc ttggtaacag tttgaagagt tgcaggactg 60
gctgggatgag tactggctgc agcaaatcag gctgccagga ttctttatgg ctgtttctgc 120
ttccactaca gctgagtcag aaaggctcgt gccccgtggg ggcactagac gcagtggacc 180
tggcaagcaa atgtttccgc tattagctct cagcaacaga gactcattta tggtcacctt 240
ggaaatctgg gcttatcgat ctacagccca agtctgctga gaagctggag cttactaaag 300
gggaaacctg agagctgttc aagccccaaa tattttccac ttctgcgtca cctctgctgt 360
ctgttagcag agtggaggag aaaatacaca gcacaaacaa cgtgaaaaaa tagttactct 420
attcattaaa agctgtaact tccagattgg acttgagaag cattaagca acagaggacc 480
ctcatctact atctgtattc aagcatgctc atgaaaaaca cgctgctcaa ctggacttan 540
aaggaacccg ngcatnacan gcatttcttg acagaatctc gtgggcctgg t 591

<210> 456
<211> 475
<212> DNA
<213> Homo sapiens

<400> 456
gctccttggt taagccaaaa ctgntaaaga ggaatcaggc tcagagaagc tnaagaagcc 60
ggcctgagtc ccagctagca aacagcaaa gcatgatttg gacagaagcc tgtgtgactc 120
caaaacccac gctcttttca ctgtgatgca cggctaatac tgagctgagt gatgggaagg 180
gagctctctt tgnnggattt tcangatacc ttcaaagatc angntggntc tgtttgcaga 240
cccaactttg caaaggacaa gcntgtgtct tnactcacac tanctcggcn caggttctga 300
gcccttttgc aatnggaagt tatttaacct gatcacanca aaatgaaaga ttatttgaaa 360
accnnggatg tgaaattctt ggaacccaaa gaaaattatc ccatgnttct ccaagnacct 420
ttgccacccc ttgtggnccg gctaggncac atggacccca aacctttcca gaaga 475

<210> 457
<211> 145
<212> DNA
<213> Homo sapiens

<400> 457
gtgctggtca ccttacccaa cctgcggcct ctacacagag aggccttggg ggagaggaaa 60
agcttctcca gtgattgatg tcagcagctc acccganagc caagaacatc anaggtggga 120
tgatgatgct ngtggctatg agaca 145

<210> 458
<211> 434
<212> DNA
<213> Homo sapiens

<400> 458
cagaattggg acatattcca cttgggggta ggagccaact cttttccctg ctgctactgc 60
tactccctc tgtctcatcg aggagaatgc tccaccagg agcacagaat gaaaggcaca 120
gagtatagtt tccagaatcc ccgcatttca gtgttcccaa agggctgaat tcttgtcaat 180
agaatgtaag tggaatggg ctatgtcact ttctgctga agaggttaaa aagaaggatga 240
actctcttca tctgcagttc ataagataga aggatcccg gtccctgaat gacctcatgg 300
aaggccatct aacaggaaca cccacattgg actgtgatat gggcaagaaa taaactttaa 360
ttgcattggg tcagtgaagaa gttttatctg ttacggcagt tacttctact ttaataaata 420
caatgcatta tctt 434

<210> 459
<211> 493
<212> DNA
<213> Homo sapiens

<400> 459
tctggggagc tcctgcatta agtgagganc tngangaaaca ngcantanca accagaagac 60
aggaggcaca agaagttagc aaagaaagcc acctacttct tccgccttaa tttctctaag 120
cacttatcaa gcagaagaat cacagaagaa tacaataaat ggtctagaaa ctgcagtgat 180
gatttactaa aggaagagcg tggttccccg agcaatggcc ccacctcga gcccgaagac 240

cactgcccct	aaatgaggac	agacatttgt	ttttgcactc	aaaaaagttg	ccttgtggct	300
cgccatgccc	cctaattcttg	ccccaaaata	aactcgagac	cttagcgggc	acgcactcaa	360
gtggctgaac	atggagacca	gcagaacagt	gccggcgga	tgacatggcc	gagaaagaga	420
gaaagangag	ggacattttg	gacccaagg	gaaatttgg	ccgggtggg	tngaaaaaaa	480
atttggccct	tga					493

<210> 460
 <211> 404
 <212> DNA
 <213> Homo sapiens

<400> 460						
aggcccagga	gaaaaatatga	acaaaaattg	gtgaaggcca	tcaccagacc	tagcagttgc	60
atcctgttca	gcaccacaga	cagctccctc	gcaaattgcca	tcctttcaaa	aggtaccata	120
cagaagacag	ctactgagat	tctgcagatt	ttctaaaagt	gacatttcta	ttacacattt	180
cttcttttca	gcactgtcat	atgtaattgt	atgcattatt	gcgttgtgta	cattttgtga	240
tacatcatca	atctgtctaca	ctacccatt	aatccattca	ttcaataaaa	tacattgtta	300
tgtgccagat	actcttagac	aagtcactta	ccccnttagc	ttcatttcct	tacccaaaac	360
ttgnggatca	ttatacatgg	ttgataacta	aggaaaggat	tttg		404

<210> 461
 <211> 583
 <212> DNA
 <213> Homo sapiens

<400> 461						
gatctccacc	atctgggggn	acacggggaa	ctggnacntt	ggngggggcc	tcaanaactc	60
cttcaacnaa	ccctttccac	tggcccgaac	ttnttgtgca	tnccacaag	cttggcgacg	120
gggtggatgc	cttgcccttg	gatgggaaga	atccttgcaa	gtcaagacta	cattccttgg	180
caccaagggtg	gccaaagccc	gtaccgaact	tggcttgga	gcttaccttg	ggcaccaaga	240
aagaaatgga	cctttcttct	tattgaacaa	tttcttcaaa	cttgggcaa	ngggttact	300
ttcaaacttt	tcttaaaanc	ttggnntncc	aagcccacac	caagtcaagg	gggaagtctt	360
ccttgggtatt	ggaaangnac	tgggggtngg	ttttgcttgg	aaaccgggct	tggaaattgg	420
aangggcccg	gggaaaccgc	cacccccacn	ttacccaacc	ggtngggng	gaaaattggg	480
gcattttacn	aaccgnaaac	aaagtcccc	ttggcattgg	aaattcccct	tnttttttgg	540
ggggaaanaa	agtncccccg	aacnttgggc	aagaaaccgg	aac		583

<210> 462
 <211> 339
 <212> DNA
 <213> Homo sapiens

<400> 462						
agaaaagtca	gcaaaaactg	cacattatac	agggcgacag	gcatggcagc	agtttctggt	60
gcacatgttg	cctgtctccc	ggtgacagaa	gataacagag	gactaagagc	gcacatatac	120
ctcaagagcc	ctaaggctgc	cacaggagg	taaacactc	caccagcac	tgctccaggc	180
cggcacaacc	atcaactttt	catgagcggg	cccactggct	gctgtctgga	atgaagaatc	240
ctatgttgct	ttccagcctc	acatttcccc	tttgtgtact	acaaaatagg	agctgtttca	300
ttagaacat	aaaacaatga	ggaagaagct	gttattgac			339

<210> 463
 <211> 662
 <212> DNA
 <213> Homo sapiens

<400> 463						
ngggaaannt	accnggctt	tatttnanaa	attganccgg	gcgggccttn	ccaacttacg	60
aanatgcttc	aanggagga	gccaaagaaa	gtggctnttg	cttggggggc	gccccacaac	120
ccttgctccc	ccgatgtcca	ccggtggatc	cacatccgc	cagccgaaga	cctcccgctg	180
cttgaccat	tgtcgtcttg	ggteccctgt	tcaaacaccc	ttctttatgg	aaacaacctg	240
cttgcccttg	ggctttcata	agccatttcc	gccctacttc	ccgtggaaaa	gttctaaggg	300
gacaagggga	aagaaatggg	gtttgggcgg	aaacgttgg	acccgggggg	ccccaaaggc	360

<400> 468
cacttttggg agggccaaac aaagaangnn ttggttngac cccaggagtt tgaaaccaga 60
actggacaac atagtaaacc tcatccctac 90

<210> 469
<211> 262
<212> DNA
<213> Homo sapiens

<400> 469
ataataagat ccttgaaagc aggcctgaac caccattgta caataaacat ttcttgcattg 60
aataaattaa tgaaagaatg aataataaaa caagatctct tcccagagaa agtttaaagc 120
ctctgaagac agcagacatc catttgaata accacataac aaagtgaatc atttatattg 180
caaaagacag agaaagcatt atacttgagg gcagaggagg gagaaagcat attactcaaa 240
taaagatgtg atactgaatt ag 262

<210> 470
<211> 265
<212> DNA
<213> Homo sapiens

<400> 470
cngggnttgn naaatnngcc cgtgaancnc anananaancn cggcccacac aancaatggt 60
aggaagcata accagagtga atcgattcct tgatcctgct ctgccaaaaa attaaagagg 120
agcactcctg ggggtttttaa cccagataag acttcagcca cagccgtatt tcccatgttc 180
ctggatctct tgttctggct cttattctgc ggataaaatg tggaatagag taagcagtgc 240
gagttctgcc ggttcatctg gcttt 265

<210> 471
<211> 268
<212> DNA
<213> Homo sapiens

<400> 471
gacgtctggg gagctcctgc attaatgcag aaccngagga aggaaagctn gaaaaaaaaat 60
cgtcaaatgt tgccgggattc ttgtaagcac agagaactat gaagacctga caaggagggt 120
atctttttct ttcattgcttg tccaacaaga gagcacattg ttagtggtgct tgaattccaa 180
caaaagaagg catagaatga atcttggttg ttccctttta cttgctaaat atgtactgaa 240
tgaataaatg gtgcattata catctatt 268

<210> 472
<211> 456
<212> DNA
<213> Homo sapiens

<400> 472
cctgtctggg acctgcctgc agatttcagc cacttctgga tacacctggg acagggctga 60
tacctccact gtcttacct gtgaagagcg ggacaaaccg atgagtgaca gactactgaa 120
tcaatccccct tttaagctgc ttaagttcca gatttagttt taaagagaaa aaaaattgtc 180
atctttttta aaagactgca tcttctttct cctaataagct aatattttatt gagcattcat 240
gacacgtata cactatttta aactgccact gtgggttgat gtcactcccc cattttataa 300
acatggagac tttggtaact ttctaacagt acttggccag tcagccaggc ctgtgctctt 360
cagaggcgca atggggnctt tatactacca cctaaaggcn ggtnggatga ccatccctat 420
aactttgttt ttaattnaag acaaactgt aattag 456

<210> 473
<211> 170
<212> DNA
<213> Homo sapiens

<400> 473
atctgccgcc tcgaagagaa acattttcag aaccaaatac agaattgaca aagagaagac 60

ggccttggag atagagccca gctttttcat tgcgaggtg gaaaactgag gccagatgcc 120
gtgggacaga tgcagagaat gataaagtca ccaaatgacg gtgattattg 170

<210> 474
<211> 467
<212> DNA
<213> Homo sapiens

<400> 474
gtctttaacg ttttcgggga cctctggaaa acctacaggc gcggccctgg gaagctctgg 60
gtccctagga ggggaggtga ctccgaggcg tcccggaat gatcctcgcg gagctcgca 120
ggtactagcg cccccagcg tctggattga gaaacgcacc ctgcgagggg ggagaaccag 180
cccagccca aagtgaagtg gcagaaaaac gaactcacgg ccaaaggact ggctgaggtt 240
aaccagaatt gtgtaaatgt gttttgtctt gctgggctgc cccctctcct ggctccttgg 300
ctagggagaa caggattttt tttgggattt ttcttttgc tttttcgact gtgcctgggtg 360
gcgttcgagg gnttgccant tttttaaggt ccaaccctgg cttgtttttg ggnnaaaaac 420
naaacnaaa cccccaanga attggncttt ngggctcattt ccttggg 467

<210> 475
<211> 440
<212> DNA
<213> Homo sapiens

<400> 475
cgagctgaaa tttaccataa tccggctgat gtttagactg caccatcgt tttttccatt 60
catctatgag taaaggagaa aaaaagaacg taaagacaaa atgcagctaa tactgaccaa 120
gacttacagg aacggtaaaag ccctgtgatg aatgtcctgt tttttcctca ttcaaaagat 180
agagaaacag aagctcagaa tcttgcccaa aagcccagtt gtaaatggat tctcactctg 240
ttgccagggc tggagtgcag tggccaatt tcagctcact gcagcctctt cagcagaatc 300
ttgacctctc ctgagattca gttttttcat ctgtagaaat ggggacctaa ggtacagagt 360
ttcttctggg agaattaagt gaaactgcat gcaacaccat gtttaggcaca ctagaagtga 420
tcaataaata ctacttgagt 440

<210> 476
<211> 438
<212> DNA
<213> Homo sapiens

<400> 476
gcatccattc accangcatc ctacgcccct gctatggcct ggctctctgg ggtcagcttt 60
gttccctgcc tgccttctgc tgaggaaatca gggcagtggc gggggcgggc ccaccagccc 120
gcagtcactg gccagacac agcgctggac acaacacccc ccgcttccca cagctgctga 180
ttcccagga ctgccggacg cacagctcca taacaagatt ttgggaaaca aagtcaagag 240
tgagggtgtc attctgaaag gtgaacgggtg ctacagaggg agggagcctgt gtctgggggtc 300
gtgtgcatcc tactctgctc acagtggagg catctttgga agaagtgact tattttcttg 360
tacagagacc attccctccc ccacaccctc tcctaagact ttgtattgaa acaaagtaaa 420
tcttacagaa attgcacc 438

<210> 477
<211> 193
<212> DNA
<213> Homo sapiens

<400> 477
ttataatcat catgactgca actcaaagtc cttaccaaga ccctctttga atgagaaagc 60
tctgccatgc cttccctgtc atcatccact cttgcagcac agctggccct ctgtatctgc 120
gggttccaca ccgatggatt caactgaccg tggatcagaa ataccagaa aaaaaattat 180
atctctactg aac 193

<210> 478
<211> 345
<212> DNA

<213> Homo sapiens

<400> 478

ggtcaagttt	caggtgaaat	cactagacaa	gaaatatcat	tcagactgcc	tagggctgtg	60
ttctgaagct	acagaggtac	cttgatgtca	ggaagaatag	caatggcaga	aaatgtttca	120
tcttgcatgc	cagcacagac	caatggcaat	ggatgtctga	atcactgggt	taacaaggaa	180
aagaatgctg	tgcttaagta	gcaatgtctg	ctctgagcat	ggcaggagaa	attattggca	240
cctctgtcag	atatttgata	tctatttctt	aaatagaata	catacatatt	ctaagaacaa	300
gaaaagcata	aacaaattaa	taaattactt	tctgacttct	aaacc		345

<210> 479

<211> 240

<212> DNA

<213> Homo sapiens

<400> 479

ctttgtgctg	catctggcct	cctgctctgt	nttactctgn	cgctactnca	cctgcatgtn	60
acctactgnn	ggatccgntt	ganaacaccn	taatttnaga	anacagagtt	ttgaacatca	120
ctgaccttta	ccatcggtat	aaccnactct	ttacctccca	aggctcgctc	atttgtactt	180
atTTTTtctc	attgtctctc	aaattttancc	aactggnatg	aataaaactgg	aagtaaacag	240

<210> 480

<211> 504

<212> DNA

<213> Homo sapiens

<400> 480

aggaaaccag	ntcgacagag	ctgtgatttg	ccctgngatt	tgccctgggc	cttnccacaa	60
ttctagaaac	ccatgacttg	acatcattgc	gcggccacct	gactcccagc	tggcttcagc	120
ctctnctgtt	natctccctc	tactctnact	ctgctgctac	caagtcagac	ttnttttcan	180
aatgccctgt	atcattttta	tgactggagt	gtgactttgt	tctcagcaca	atgagtaaca	240
aagccaaaac	actggagaat	acgtttacgt	attnaagaaa	acctcagaca	aggaagaatg	300
ctttcataat	acagnacatt	anaatcagac	gaagcctnga	agggcanaat	naccgatcct	360
gaaaaatcan	agtgtntctac	agaagaagac	gacagcgttt	gagcacattt	gttgaagcag	420
cctcctntcc	cttatggunc	gataatccca	caccgnttta	ccatgctctc	tggccttccc	480
agaacatcaa	taaaaactgc	atcc				504

<210> 481

<211> 274

<212> DNA

<213> Homo sapiens

<400> 481

taactggcag	aaccacacc	ttcaaaacag	agactttggc	tgcatctggc	ctcctgctct	60
gtcttctct	cacctctcc	acctccatgt	cacctactga	gggatcgctt	gagaacacca	120
gaatttcaga	agacagagtt	tgaacatcac	tgacctttac	catcggtata	accaactctt	180
tacctcccaa	ggctcgctca	tttgacttta	tttttctca	tgtctctcaa	atttagccaa	240
ctgggtatgaa	taaactggaa	gtaaacagtt	ctac			274

<210> 482

<211> 299

<212> DNA

<213> Homo sapiens

<400> 482

gtaatcttct	catctgtgag	gatatggaac	cccaacctct	tcttgagacac	ctgatgatct	60
gcttgatgatg	ggctcagagt	cttgaaacac	agaactatga	gctcatctca	tatcccaatc	120
cagcagcatg	gaaacctcag	actgtaaggc	ccaagactgg	cacttggtct	ctcccaactc	180
ttttctttct	ctctctcctt	tcttttatcc	cttaattcct	tcttgcttcc	ttccaagatt	240
tatactatta	ccttttaggc	aaaacatcct	gaacatgtaa	aataaactaa	ttaaaatcg	299

<210> 483

<211> 395
 <212> DNA
 <213> Homo sapiens

<400> 483
 gaggagtctg agaagaccta aaacagaaga gaaaaaggcg aagaagatgc ttaaataatat 60
 acattattca agtaattaac tgaagccttg agcgtacaga tgatctccga aaggacgccca 120
 cagaggggag aaggctggac ttgcagaaca cattgctggt gaagaagtga caggaagatt 180
 cagagctcac aaagaagaca ggtcagacgt ggagaggcga gccagcagaa caccctcaga 240
 aatactgctc tcctgttcgg atggccagtt ttcataatattt agaataatattt tcaaaaagca 300
 cttcaatata atgaagttcc ctcagttata acaaggccat ttttcatagc tatttggtgta 360
 gatagtccaa aagtgtggtg tggtatcaga aaggg 395

<210> 484
 <211> 440
 <212> DNA
 <213> Homo sapiens

<400> 484
 gaagaaagca ttgctctgga aagaggggaag ttcattcact catccaagaa gagcaaaggt 60
 agatgccctg cggctatgga ggagggccgt ccaagctcac agttcctaga agtttggtgctc 120
 accatttcac atttagcacc agaatccagc cttggcagat tcaggggaagg aagccaagga 180
 cacagctggt ggtgaagaca gaaactcctg tgtgacaact gcccctagg acacagttta 240
 ggggtcaatta acatttcctg aacaacttgc aaatggaaag agccatcccc aatgaagact 300
 gaaaaatgag aggtcaact catctattat gacttgaacc caagtctatc tgtgtttgca 360
 aaggctgtgc tggtgcacct agacctccac ccagaaacat gttttggggc tgacatttta 420
 atagaaacat agagaggaaa 440

<210> 485
 <211> 199
 <212> DNA
 <213> Homo sapiens

<400> 485
 tcccgtctga actgttttctg cttggccctg tttccacca ngaagccgca gatcctgact 60
 ccttggtgtt gtttctctgc ccagatgaga aacacccatc acctctgact ttccaaggag 120
 caaatcacgc tccgtgccgg gctcccccaa caacaccact ccctcttccc ttgcgatctc 180
 caggntcct ttgacactt 199

<210> 486
 <211> 426
 <212> DNA
 <213> Homo sapiens

<400> 486
 ctencngctt taaatcctag ntggngnagc gggtgntna cctanaggct gtnntaggnn 60
 cntennaacc acnccnagtt gcttcnagcc tccttngcgc cagcacatat ctgcancctt 120
 gggccaccga tcctaagcca aagcctcccc aacctctggg ctcagaagca ggtgtaatcc 180
 caactccagc aggggaattcc agaggtgaag gtcacgggag catctttaat cttcgggtcc 240
 cagtagagaa gatacccaaa gagcagggag caggagccag ctccaggcta tacatttggt 300
 tattcatcaa tcattcattt atgcattaat cattcattcc cccacccaa aaaaaaang 360
 gccagnngg ccaattcagn tngnacttaa ccaggctgaa nttgntnaaa nggggggggac 420
 ccccaa 426

<210> 487
 <211> 533
 <212> DNA
 <213> Homo sapiens

<400> 487
 tttttttccc ccccccccg nggggggggn gnnnnncnngg gggcccccc tcttttttgg 60
 nggttcataa aggggtggana cncncttgg gcgcctttt tgggggggtt tnaaaaaaga 120

gatttgcaag	gaactacgaa	gtccaagacc	tttgcctttc	ttttagaaga	aggcaccagc	120
tggttctcca	atgttgagg	tcttctccag	agatgaactc	tgaaagccac	atgttgagat	180
ggccccatta	caggatggag	agcacctgaa	cccccaagtt	atggactaga	agaagacagt	240
tgccttgga	aatcatctga	cccacattgg	actttatgtg	aggggggaaat	aaacctttat	300
tatgttaagc	tacacaataa	taaataacaa	caataattgt	gttt		344

<210> 492
 <211> 381
 <212> DNA
 <213> Homo sapiens

<400> 492						
tctccctgtc	cttttnagtn	cnccaaaact	ngngggaaaa	nctttnaaaa	atattttctcc	60
cngggnaaaa	tgngngggaa	aagtccntgg	cacntgnaat	gggccccctt	tgtanggaaa	120
aaannaaccc	caggggttcn	tgggagttcc	ncgaaccgtg	gggnncnttg	angggcncca	180
anggggaaga	aaaaccnccg	tggaaccctt	taattaaagt	tttngggggg	tggaagaaga	240
agaaaaataa	aaaccttaaa	gtattgttaa	agcttcttgt	catttcaaag	gggtaaaatac	300
caagttgtgg	gaaagggcaa	gaaaaaaaat	ggaccacttc	tccccttgga	tatccattaa	360
aaaggatgtc	ccaaaatcct	c				381

<210> 493
 <211> 639
 <212> DNA
 <213> Homo sapiens

<400> 493						
tctgggggag	cctaccttgc	tttaacttcc	tnaacttaaa	ggtanaacaa	cnccctnttt	60
tnccntgaaa	aacnanggn	tttttngaca	ttaaagnnc	ttttaaggag	gtatgcccac	120
aaaaaggnaa	ncccaacccc	ttngccaaa	aaatnaaacn	tcaaagangg	ggcnggcnaa	180
antcngggaa	ncntttnc	caggggggaa	gaagaatgaa	cnctttttta	ntggggcttt	240
ncagaaaaag	gtggnaaggt	ccacttggct	ttttggcttg	gnctttggga	atcaaaggaa	300
ccnagaaaaa	ggaaaattan	ttggataccc	aatggggaag	ccttggaaga	atgccatttt	360
ggtttgggga	agggtttttc	ttgtcttcaa	acttgggtct	cttgacaaag	cctcttgact	420
tggaatgga	ttcccggtgc	ttgggccact	tatgccaagc	aaggcatcat	ttaaatttaag	480
acggggactt	ggcttgcacc	tttccctgaa	gaaagccaag	actttccact	tggatgggaa	540
agaagcttga	aaaaaccacc	aaagcccagg	gaagtggcaa	gaaccacttg	gnccttaatt	600
tgcttncttg	aagaattncc	attattaata	aaaagaaaa			639

<210> 494
 <211> 342
 <212> DNA
 <213> Homo sapiens

<400> 494						
ntagcctcag	gatggagggtg	gctgccagaa	agaccaagta	atgatcagaa	gcatggaact	60
ttcagacctta	ttcctcccaa	cttctggaga	ggngagtgct	ctggagactg	agtttaataat	120
tgatcacgtc	tacatgatga	aacctctaag	tgacaaggat	cagagagctt	ccaagttggt	180
gaatacatcc	atgtgcaggg	aggggtggcct	accctaacc	catcggacag	gagcaccat	240
gttcaggaat	cttctggacc	tcaccttatg	tattaatctc	tctttatctg	gctgttcac	300
tatattcttc	atagtatcct	ttataataaa	caagcaaatg	tc		342

<210> 495
 <211> 613
 <212> DNA
 <213> Homo sapiens

<400> 495						
ntcntgaaac	tggaattcgg	ggtngtnca	ttaattgggg	aaatgggann	ggggaaaaat	60
aaaaatggaa	ctgggaatgg	gngccgcttn	ctttttttta	agntttcaaa	aaatgaccat	120
ttncaaaaaa	caaagcccgg	gggccttgga	nccccgggc	cttggttttt	aaaaaatttt	180
aacaaacanc	aagttccttg	ggggaaagg	ngggggaacc	caccaaacct	ttttctttga	240
aataaacttg	ggggaagaat	gaaaaacaag	ggaaagcttc	ttattgaaca	ccactttgga	300

atcggaaata	ttgaacaaga	acacccggaa	aaaatcaacg	aacttcaagc	ccccttccaa	360
gccaccttct	tgccttgttt	gccccgccc	aatcacaagc	ccgggaatgg	caagcttgaa	420
aaagaattcc	cttggggggc	cttgggntcc	caaaccggcc	cacttggtgg	actcttgaag	480
gccctcttgc	atttgtgggg	tggggtcttg	ccttgtggat	aatttttggg	tcattggggc	540
ttgggtcttg	gtccgggntt	ncccatnttg	gtcttggccc	aaggctctat	ggtnggcttn	600
aatccctttt	ggc					613

<210> 496
 <211> 611
 <212> DNA
 <213> Homo sapiens

<400> 496						
tcannaaact	ggagggacgg	gncacgncaa	ncganncccc	tgggggggct	ntttaaaaac	60
tttttcaggg	agcccttatg	aaacaaaacc	ccgggggtgn	gttanggnata	ctngggctng	120
ngtcccaccc	nactgggttc	ttttttttct	tnttggggcc	ccanaaatgg	aagggggatt	180
gccccaccaa	ngggaccccc	tttccaacca	gaaccnngg	gacttattat	taaacctnt	240
tttttgcgcc	cnaccattga	atgggacttt	gnaaccgcga	aaagcttgaa	ggnccattcg	300
gataccgccc	taacccttta	cccccgggga	acaatctttc	attgggaaaa	acaagccggg	360
ntttttttcc	gactttttac	aaagccttcc	cggtnngggc	tgggaaggcc	attcttaagc	420
ttggcaagaa	aaacaagcaa	gggaaaggat	gctttccggg	ggaagccctt	gatgccttga	480
aaaatgaaaa	aaattantct	taaaggctat	tcaaatatca	agccaagcca	tttttttcca	540
nggagaaang	gaaaaaaggc	cgaanaaaaa	aacaaatttt	ccaanaatgg	ggttgmcttc	600
cttccaaccc	a					611

<210> 497
 <211> 436
 <212> DNA
 <213> Homo sapiens

<400> 497						
gaacccaaaa	gaatgcccag	aatgccaaga	acagtgaaca	gccatatgca	aacgggcaat	60
actgatgta	gctttaaaag	taaggagttc	agagtgtctc	gtgctgaaca	tctttcgggt	120
taattaagcc	ttcatattcc	tgaggaggag	ctactaagac	accctaccaa	gtcctgggct	180
gtgcctggag	gttagaaaac	gaaccacata	gtcctgtaat	gacagaaaaa	aattgaaaac	240
tgtattttta	aaatgatttc	tcaacaagac	cagccggcca	ctcaaccact	tcagtacctc	300
gtttctggat	gaagaccctg	agcaggggat	ttgcactaga	aaccgccttg	cagaagttgt	360
catcattgtt	gatgggcagc	aggtctccgt	gcacatctgc	atagccaata	gttacatcac	420
tgttgagat	atgggtg					436

<210> 498
 <211> 445
 <212> DNA
 <213> Homo sapiens

<400> 498						
gttctgattg	atnccnaggc	tnttgaagta	nacccaccca	tttaagccag	agagggagat	60
tnaagtggan	atngcngcca	cctattatnc	cnngatatat	ttggtatacn	aacnaagaaa	120
ctnaatnatn	aattngacna	tnaattttta	gggaaaagg	aaaagnaaac	nccagggggc	180
cgggtggcaa	tttgntttcc	nttcttagtc	ccttcaaaaa	agtagaaaat	agtgganatg	240
aagcagggtt	gatatgaatt	tggcttgctt	cccccccaa	tcttaccttt	gcttgnaggt	300
nccataatcc	ccacatgtgg	ggggaggaag	cctttaggag	gtgatttaat	catgggggtg	360
gtacccgcat	gctgtctcat	gataatgagt	gagttctcca	agaattaacg	cttttatagg	420
aacctttttc	cccttttact	tggcc				445

<210> 499
 <211> 295
 <212> DNA
 <213> Homo sapiens

<400> 499						
gttcttccca	ttctggagta	anaggatgtt	gcnttnnaag	ggtngtggga	agggnnncan	60

aancttnccn	ggantaangg	cctaagggng	gctttngacc	aagggaccct	ccaagtcaag	120
gttcctttta	catcacatat	tgggaccccc	aacagctggg	cttcttcaag	gtgagacaag	180
acctgtgggt	tgaatccacc	atttaatggc	tgngtgatca	tgtgcaactt	actcaacctc	240
tcagagcctc	aagtttcctc	attaataaag	tggagataat	aatagaacac	acctt	295

<210> 500
 <211> 181
 <212> DNA
 <213> Homo sapiens

<400> 500						
ggtttctctg	agttnggatt	ttgctgactg	cacactcacg	gtgctatcca	acatgancat	60
cttccttgca	gtttctacaa	tttggcagtt	ggatccacct	gaatcctttg	gcaaggccaa	120
acgtgggtgc	tnangaagaa	cacattgaag	tctctgtttt	ttaaataatca	ttatgacctt	180
g						181

<210> 501
 <211> 469
 <212> DNA
 <213> Homo sapiens

<400> 501						
cagaaactga	gatgaaagct	gggggttgag	atggagtttg	tcattttntg	ancttaaann	60
naccngcntn	ataacaaaag	ccagcncacc	ccanacngga	gaatggaaag	ggaggaaaaa	120
tttgggtccc	gtcttttaca	agggntgntg	agttacttca	ccaatcctgg	aatgctgac	180
ttttgggaac	ttgttaaaca	gtctttccac	cccctttgtt	cgaagctttt	ggtgaagtgt	240
ttcanaaaact	gacgaaatgc	aggatcggtt	tccttacaca	cacaaatgcc	atggcaacag	300
caacttcgtg	acaacagcaa	agaaagccag	actgggaatt	tgccaaccca	gagtgggtgac	360
catctgtgag	ggcccaaacc	cttcaaattg	tgccccgttc	taaagtgctt	atcttaaccc	420
angcttttgt	acatagcaaa	agcgacattt	aaagtgcacat	aagaatggg		469

<210> 502
 <211> 400
 <212> DNA
 <213> Homo sapiens

<400> 502						
tttttttcca	attggggggg	gaccaaattt	tgnggggttna	aattcccaaa	tanggggtggc	60
cntttttttg	ccttggaac	gacccatttg	gggggggaaan	ttaaaacccc	ccccttnttt	120
ggcnncttg	tntgnaaaag	naaattggcc	ccccggggcc	ctttttttnc	ccctttgggc	180
caaaggggaa	tttttttaaac	cctttaaaaa	attgggtntt	ggccttgggg	gaacctttgg	240
ccaagaatg	ggccccaata	agnnggnacc	ccaataaact	nttanccccc	tnntttggcct	300
tggttcaagc	ncccaaaaag	naaaaanaaga	ccctggngtc	nntttggggg	aggtggggng	360
gaaacccaaa	atcccatttn	gggggntttt	ttttaaacct			400

<210> 503
 <211> 185
 <212> DNA
 <213> Homo sapiens

<400> 503						
ttgggggggg	tttcccccaa	acaaaaattt	tcccgccttt	tctttcagtt	ggannggtgg	60
ggagccccna	atggaactta	aaaatttctt	gttggggggg	tggggaggaa	gaataaaaaa	120
tgcccccttt	nttngggggc	cttggacccc	ttattttggc	cccttgccca	ttgcttgggc	180
ccttg						185